<html lang="en"><head><!-- Shady DOM styles for custom-style --><!-- Shady DOM styles for dom-template --><!-- Shady DOM styles for dom-repeat --><!-- Shady DOM styles for array-selector --><!-- Shady DOM styles for dom-if --><!-- Shady DOM styles for state-modifier --><style scope="state-modifier">a[inherit].state-modifier {
  color: inherit;
}</style><!-- Shady DOM styles for browser-ui --><!-- Shady DOM styles for outlined-text-field --><style scope="outlined-text-field">outlined-text-field {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: column;
}

outlined-text-field span.outlined-text-field {
  display: flex;
  flex-direction: row;
  align-items: center;
}

outlined-text-field input.outlined-text-field {
  height: 40px;
  padding: 0 33px 0 16px;
  
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  flex-grow: 1;
}

outlined-text-field[orig] input.outlined-text-field {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-text-field[dense] input.outlined-text-field {
  height: 32px;
}

outlined-text-field[uppercase] input.outlined-text-field {
  text-transform: uppercase;
}

outlined-text-field:not([wizard-focused]):hover input.outlined-text-field {
  border-color: #737375;
  color: #414447;
}

outlined-text-field:not([wizard-focused]):focus-within input.outlined-text-field,outlined-text-field[wizard-focused] input.outlined-text-field {
  border-color: #3574e0;
  caret-color: #80a5f1;
}

outlined-text-field[wizard-focused] input.outlined-text-field {
  border-width: 2px;
}

outlined-text-field input.outlined-text-field::placeholder {
  color: #65686c;
}

outlined-text-field[uppercase] input.outlined-text-field::placeholder {
  text-transform: none;
}</style><!-- Shady DOM styles for mat-keyword-editor --><!-- Shady DOM styles for mat-chips-input --><!-- Shady DOM styles for mat-input-chip --><!-- Shady DOM styles for pat-dialog --><style scope="pat-dialog">pat-dialog {
  background: white;
  position: absolute;
  border-radius: 8px;
  
  box-shadow: 0 24px 38px 3px rgb(0 0 0 / 14%),
              0 9px 46px 8px rgb(0 0 0 / 12%),
              0 11px 15px -7px rgb(0 0 0 / 20%);
  z-index: 1;
  display: flex;
  flex-direction: column;
}

pat-dialog:not([open]) {
  display: none;
}</style><!-- Shady DOM styles for mat-tabs --><!-- Shady DOM styles for filter-chip --><style scope="filter-chip">filter-chip {
  align-items: center;
  background-color: #fff;
  border-color: #dadce0;
  border-radius: 8px;
  border-style: solid;
  border-width: 1px;
  color: #606368;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 32px;
  letter-spacing: 0.2px;
  padding: 0 16px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

filter-chip[disabled] {
  background-color: #e8e8e8;
  border-color: #e8e8e8;
  color: #a9abad;
  cursor: auto;
}

filter-chip svg.filter-chip {
  visibility: collapse;
  font-size: 18px;
  width: 0;
  height: 18px;
}

filter-chip[selected] svg.filter-chip {
  visibility: visible;
  margin: 0 8px;
  width: 18px;
}

filter-chip[selected] svg.filter-chip path.filter-chip {
  fill: #4577d1;
}

filter-chip:not([disabled]):hover {
  background-color: #f7f8f8;
  border-color: #d7d9dc;
  color: #454649;
}

filter-chip:not([disabled]):hover:active {
  background-color: #eff0f0;
  border-color: #d2d5d8;
  color: #222326;
}

filter-chip:not([disabled]):focus {
  background-color: #e7e8e8;
  border-color: #232528;
  color: #202124;
}

filter-chip:not([disabled])[selected] {
  background-color: #e9f0fd;
  border-color: #e9f0fd;
  color: #4577d1;
  padding-left: 0;
}

filter-chip:not([disabled]):focus[selected] {
  background-color: #d5e1fb;
  border-color: #d5e1fb;
  color: #2550a0;
}

filter-chip:not([disabled]):hover[selected] {
  box-shadow: rgba(0, 0, 0, 0.2) 0px 3px 1px -2px,
    rgba(0, 0, 0, 0.14) 0px 2px 2px 0px, rgba(0, 0, 0, 0.12) 0px 1px 5px 0px;
}

filter-chip:not([disabled]):hover:active[selected] {
  background-color: #abc8f2;
  border-color: #abc8f2;
  color: #2a54a3;
}</style><!-- Shady DOM styles for figure-callout --><!-- Shady DOM styles for mat-button --><style scope="mat-button-0">.mat-button-0 {
  ;
  align-items: center;
  border-radius: 4px;
  color: hsl(217 4% 39%); 
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: 0.2px;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

.mat-button-0[filled] {
  background-color: hsl(217 73% 54%); 
  color: white;
}

.mat-button-0[filled]:hover {
  background-color: hsl(217 60% 47%);
}

.mat-button-0[filled]:focus {
  background-color: hsl(217 59% 44%);
}

.mat-button-0[filled]:active {
  background-color: hsl(217 59% 45%);
}

.mat-button-0[filled][disabled] {
  background-color: hsl(217 2% 90%); 
  color: hsl(217 1% 65%);
}</style><!-- Shady DOM styles for search-term-wizard --><style scope="search-term-wizard">search-term-wizard:not([open]) {
  display: none;
}

search-term-wizard .header.search-term-wizard {
  border-bottom: 1px solid #e5e5e5;
  padding: 24px;
  padding-bottom: 0;
}

search-term-wizard .title.search-term-wizard {
  color: #3c4043;
  font-family: Google Sans,Roboto,Arial,sans-serif;
  font-size: 22px;
  user-select: none;
  margin: 0 48px;
}

search-term-wizard #panels.search-term-wizard > *.search-term-wizard:not([selected]) {
  display: none;
}</style><!-- Shady DOM styles for outlined-textarea --><style scope="outlined-textarea">outlined-textarea {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: row;
  
  position: relative;
}

outlined-textarea span.outlined-textarea {
  display: flex;
  flex-direction: column;
  flex-grow: 1;
  justify-content: center;
}

outlined-textarea span.right-button-container.outlined-textarea {
  position: absolute;
  right: 0;
  height: 100%;
}

outlined-textarea textarea.outlined-textarea {
  padding: 16px 16px 0 16px;
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  resize: none;
}

outlined-textarea[dense] textarea.outlined-textarea {
  padding: 8px;
}

outlined-textarea[has-icon] textarea.outlined-textarea {
  padding-right: 38px;
}

outlined-textarea[orig] textarea.outlined-textarea {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-textarea:not([rows]) textarea.outlined-textarea {
  height: 40px;
}

outlined-textarea textarea.resizable.outlined-textarea {
  resize: vertical;
}

outlined-textarea textarea.outlined-textarea:focus,outlined-textarea[wizard-focused] textarea.outlined-textarea,outlined-textarea textarea.outlined-textarea:focus:hover {
  border-color: #3574e0 !important;
  
  outline: none !important;
}

outlined-textarea textarea.outlined-textarea:hover {
  border-color: #202124;
  color: #414447;
}

outlined-textarea.hasValue textarea.outlined-textarea {
  border-color: #888d91;
  color: #45474a;
}

outlined-textarea #helperText.outlined-textarea {
  color: #6a6c71;
  font-size: 12px;
  letter-spacing: 0.3px;
  margin-left: 17px;
  margin-top: 6px;
  user-select: none;
}

outlined-textarea:not([helper-text]) #helperText.outlined-textarea {
  display: none;
}

outlined-textarea[error] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
  color: #3d4043;
}

outlined-textarea textarea.outlined-textarea::placeholder {
  font-size: 14px;
  font-weight: 400;
}

outlined-textarea:not([error]):not([disabled]) textarea.outlined-textarea::placeholder {
  color: #6a6c71;
}

outlined-textarea[error] textarea.outlined-textarea::placeholder {
  color: #c84132;
}

outlined-textarea[error] #helperText.outlined-textarea {
  color: #cd5648;
}

outlined-textarea[error] textarea.outlined-textarea:focus {
  border-color: #c84031;
  border-width: 2px;
  outline: none !important;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover {
  border-color: #97231b;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover::placeholder,outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover + #helperText.outlined-textarea {
  color: #a94945;
}

outlined-textarea[disabled] textarea.outlined-textarea {
  border-color: #e9e9e9;
  color: #b5b6b8;
}

outlined-textarea[disabled] #helperText.outlined-textarea {
  color: #c4c6c7;
}

outlined-textarea[error][disabled] {
  opacity: 50%;
}

outlined-textarea[error][disabled] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
}

outlined-textarea[error][disabled] #helperText.outlined-textarea,outlined-textarea[error][disabled] textarea.outlined-textarea {
  color: #a94945;
}

outlined-textarea[error][disabled] textarea.outlined-textarea::placeholder {
  color: #c84132;
}</style><!-- Shady DOM styles for chemistry-search-term-wizard --><style scope="chemistry-search-term-wizard">chemistry-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

chemistry-search-term-wizard .suggestions.chemistry-search-term-wizard {
  margin-top: 4px;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard svg.chemistry-search-term-wizard {
  margin-right: 24px;
}

chemistry-search-term-wizard path.chemistry-search-term-wizard {
  fill: #5f6368;
}

chemistry-search-term-wizard .help.chemistry-search-term-wizard {
  margin-left: 12px;
  margin-right: 0;
  cursor: pointer;
}

chemistry-search-term-wizard outlined-text-field.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard mat-button.chemistry-search-term-wizard {
  margin-left: 48px;
}

chemistry-search-term-wizard filter-chip.chemistry-search-term-wizard {
  margin-right: 4px;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard outlined-text-field[batchMode].chemistry-search-term-wizard {
  display: none;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard:not([batchMode]) {
  display: none;
}</style><!-- Shady DOM styles for text-search-term-wizard --><style scope="text-search-term-wizard">text-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

text-search-term-wizard > span.text-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

text-search-term-wizard > span.text-search-term-wizard svg.text-search-term-wizard {
  margin-right: 24px;
}

text-search-term-wizard path.text-search-term-wizard {
  fill: #5f6368;
}

text-search-term-wizard outlined-text-field.text-search-term-wizard {
  flex-grow: 1;
}

text-search-term-wizard mat-button.text-search-term-wizard {
  margin-left: 48px;
}

text-search-term-wizard filter-chip.text-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for classification-wizard --><style scope="classification-wizard">classification-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

classification-wizard > span.classification-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

classification-wizard .suggestions.classification-wizard {
  margin-top: 4px;
}

classification-wizard > span.classification-wizard svg.classification-wizard {
  margin-right: 24px;
}

classification-wizard path.classification-wizard {
  fill: #5f6368;
}

classification-wizard outlined-text-field.classification-wizard {
  flex-grow: 1;
}

classification-wizard mat-button.classification-wizard {
  margin-left: 48px;
}

classification-wizard filter-chip.classification-wizard {
  margin-right: 4px;
}

classification-wizard .no-matches.classification-wizard {
  margin-left: 64px;
}

classification-wizard .table-container.classification-wizard {
  max-height: 300px;
  overflow: scroll;
  margin-top: 8px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar {
  -webkit-appearance: none;
  width: 10px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar-thumb {
  border-radius: 5px;
  background-color: #5f636880;
  -webkit-box-shadow: 0 0 1px rgba(255,255,255,.5);
}

classification-wizard table.classification-wizard {
  margin-left: 51px;
  max-width: 575px;
}

classification-wizard tr.classification-wizard {
  margin-top: 4px;
}

classification-wizard tr.classification-wizard suggestive-chip.classification-wizard {
  margin-right: 8px;
}

classification-wizard #spinner.classification-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}</style><!-- Shady DOM styles for suggestive-chip --><!-- Shady DOM styles for mat-checkbox --><!-- Shady DOM styles for measure-search-term-wizard --><style scope="measure-search-term-wizard">measure-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

measure-search-term-wizard > span.measure-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

measure-search-term-wizard .suggestions.measure-search-term-wizard {
  margin-top: 4px;
}

measure-search-term-wizard > span.measure-search-term-wizard svg.measure-search-term-wizard {
  margin-right: 24px;
}

measure-search-term-wizard path.measure-search-term-wizard {
  fill: #5f6368;
}

measure-search-term-wizard outlined-text-field.measure-search-term-wizard {
  flex-grow: 1;
}

measure-search-term-wizard mat-button.measure-search-term-wizard {
  margin-left: 48px;
}

measure-search-term-wizard filter-chip.measure-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for numerical-search-term-wizard --><style scope="numerical-search-term-wizard">numerical-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

numerical-search-term-wizard .suggestions.numerical-search-term-wizard {
  margin-top: 4px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard svg.numerical-search-term-wizard {
  margin-right: 24px;
}

numerical-search-term-wizard path.numerical-search-term-wizard {
  fill: #5f6368;
}

numerical-search-term-wizard outlined-text-field.numerical-search-term-wizard,numerical-search-term-wizard outlined-textarea.numerical-search-term-wizard {
  flex-grow: 1;
}

numerical-search-term-wizard mat-button.numerical-search-term-wizard {
  margin-left: 48px;
}

numerical-search-term-wizard filter-chip.numerical-search-term-wizard {
  margin-right: 4px;
}

numerical-search-term-wizard #spinner.numerical-search-term-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}

numerical-search-term-wizard #suggestions.numerical-search-term-wizard {
  margin-left: 58px;
  display: flex;
  flex-direction: column;
  align-items: flex-start;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard mat-checkbox.numerical-search-term-wizard {
  margin-right: 8px;
}</style><!-- Shady DOM styles for text-button --><style scope="text-button">text-button {
  align-items: center;
  border-radius: 4px;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: .25px;
  margin: 6px 0;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
  line-height: 36px;
  text-decoration: none;
  text-transform: none;
  color: #5f6368;
}

text-button:hover {
  background-color: #f8f9fa;
}

text-button:active {
  background-color: #d5e2fa;
}

text-button[selected] {
  background-color: #e8f0fe;
  color: #1967d2;
}

text-button[selected]:active {
  background-color: #d2e3fc;
}</style><!-- Shady DOM styles for mat-spinner --><!-- Shady DOM styles for requery-tile --><style scope="requery-tile">requery-tile {
  display: flex;
  justify-content: space-between;
  align-items: center;
  box-sizing: border-box;
  min-height: 40px;
  padding: 8px 12px 8px 8px;
  gap: 8px;

  border-radius: 16px;
  background: #f7f8f9;
  color: #1f1f1f;
}

requery-tile:hover {
  background: #d7d8d9;
}

requery-tile > [slot="image"] {
  flex-shrink: 0;

  border-radius: 8px;

  background: #fff;
}

.label.requery-tile {
  flex-grow: 999;

  font: 16px/20px "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
}

.search-icon.requery-tile {
  flex-shrink: 0;

  width: 24px;
  height: 24px;
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/search/default/24px.svg');
}</style><!-- Shady DOM styles for s-more-inline --><style scope="s-more-inline">s-more-inline {
  display: block;
  margin-top: 24px;
  padding: 16px;
  padding-top: 0;
  position: relative;

  line-height: 18px;
  text-overflow: ellipsis;
  white-space: nowrap;
  cursor: pointer;
}

hr.s-more-inline {
  background-color: #dadce0;
  margin-top: 18px;
  position: absolute;
  border: 0;
  height: 1px;
  left: 0;
  width: 100%;
}

.button.s-more-inline {
  display: flex;
  align-items: center;
  justify-content: center;

  position: relative; 
  margin: 0 auto;

  font: 400 14px Roboto, arial, sans-serif;
  height: 36px;
  width: 300px;
  border-radius: 18px;
  background-color: #f1f3f4;
}

.button.s-more-inline:hover {
  background-color: #d8d7dc;
}

.button.s-more-inline > [slot] {
  padding-right: 8px;
}

.expand.s-more-inline {
  display: inline-block;
  width: 20px;
  height: 20px;
}

.expand.less.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_less/default/20px.svg');
}

.expand.more.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_more/default/20px.svg');
}</style><!-- Shady DOM styles for workspace-ui-search --><!-- Shady DOM styles for keyword-wizard --><style scope="keyword-wizard">keyword-wizard {
  display: inline-block;
}

iron-icon.keyword-wizard {
  height: 20px;
    width: 20px;
    color: #999;
    cursor: pointer;
}

iron-icon[active].keyword-wizard {
  color: #4285f4 !important;
}

iron-icon.keyword-wizard:hover {
  color: #ccc;
}

#wizardIcon.keyword-wizard {
  padding-left: 1px;
    height: 16px;
    width: 16px;
    margin: 4px 1px 1px 1px;
}

#wizard.keyword-wizard {
  padding: 0;
    left: 0;
    top: 37px;
    position: absolute;
    background-color: white;
    z-index: 2;
    overflow: hidden;
}

.wizard-header.keyword-wizard {
  display: block;
    width: 100%;
    color: #737373;
    text-transform: uppercase;
    font-size: 13px;
    margin: 16px 0 6px 12px;
}

.filter-chips.keyword-wizard {
  margin-left: 20px;
}

.chip.keyword-wizard {
  background-color: #ebebeb;
    color: #6a6a6a;
    display: inline-block;
    font-size: 13px;
    font-family: inherit;
    border-radius: 12px;
    padding: 6px 12px;
}

.chip.keyword-wizard:hover {
  cursor: pointer;
}

.chip[selected].keyword-wizard {
  background-color: #4285f4;
    color: white;
}

.input-label.keyword-wizard {
  display: inline-block;
    font-size: 13px;
    font-family: inherit;
}

.keyword-input.keyword-wizard {
  display: inline-block;
    border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    padding: 3px;
}

.keyword-input.keyword-wizard::placeholder {
  font-style: italic;
}

.keyword-input.keyword-wizard:hover,.keyword-input.keyword-wizard:focus {
  border-color: #4284f4;
    border-width: 1px;
    outline: none;
}

.cpc-field.keyword-wizard {
  display: inline-block;
    margin: 6px 0 0 24px;
}

#checkboxCPC.keyword-wizard:hover {
  cursor: pointer;
}

.checkbox-label.keyword-wizard {
  font-size: 13px;
    font-style: italic;
    color: #737373;
}

.chemistry-field.keyword-wizard {
  display: block;
}

#inputChem.input-batch.keyword-wizard {
  height: 150px;
    border: 1px solid #dfe1e5;
    padding: 6px;
}

#inputChem.keyword-wizard {
  resize: none;
    height: 15px;
    vertical-align: text-top;
    font-size: 13px;
    font-family: inherit;
    padding: 2px;
}

.chem-type-label.keyword-wizard {
  display: inline;
    font-size: 13px;
    margin-left: 12px;
    margin-right: 4px;
}

#chemType.keyword-wizard {
  border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    margin: 6px;
    padding: 2px;
    outline: none;
    font-family: inherit;
    font-size: 13px;
}

.import.keyword-wizard {
  font-size: 13px;
    font-family: inherit;
}

.import-text.keyword-wizard {
  vertical-align: middle;
    display: inline-block;
}

.import-button.keyword-wizard {
  margin: 6px 0 0 24px;
}

.import-button.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.import-button.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard {
  float: right;
    padding: 12px;
}

.wizard-buttons.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    margin: 2px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
}

@media screen and (max-width: 700px) {
#wizard.keyword-wizard {
  width: 275px;
}

.chip.keyword-wizard {
  margin: 4px 2px;
}

.keyword-input.keyword-wizard {
  width: 82%;
      margin: 4px 12px 12px 24px;
}

.search-within.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 225px;
      margin: 12px 0 6px 0;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  margin-top: 6px;
}

#inputChem.keyword-wizard {
  width: 82%;
      padding: 2px;
      margin: 8px 12px 12px 24px;
}

#inputChem.input-batch.keyword-wizard {
  width: 220px;
      padding: 4px;
}

#chemType.keyword-wizard {
  width: 150px;
}

.import-text.keyword-wizard {
  margin: 6px 12px 6px 24px;
      width: 220px;
}

iron-icon.help-header.keyword-wizard {
  display: none;
}

}

@media screen and (min-width: 700px) {
#wizard.keyword-wizard {
  width: 540px;
}

.chip.keyword-wizard {
  margin: 0 2px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 240px;
      margin: 12px 16px 6px 6px;
}

.cpc-inputs.keyword-wizard {
  display: inline;
}

.find-patents.keyword-wizard .keyword-input.keyword-wizard {
  width: 53%;
      margin: 4px 10px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard::placeholder,#inputAnd.keyword-wizard::placeholder,#inputExact.keyword-wizard::placeholder,#inputOr.keyword-wizard::placeholder,#inputMinus.keyword-wizard::placeholder {
  color: white;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  width: 35%;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  width: 42%;
      margin: 6px 4px;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

#inputChem.keyword-wizard {
  width: 290px;
      margin: 2px 12px 2px 6px;
}

#inputChem.input-batch.keyword-wizard {
  width: 280px;
      padding: 6px;
}

.import-text.keyword-wizard {
  margin: 6px 12px;
      width: 415px;
}

#chemType.keyword-wizard {
  width: 105px;
}

iron-icon.keyword-wizard:hover.help-header {
  cursor: default;
}

iron-icon.help-header.keyword-wizard {
  height: 16px;
      padding: 0 2px 2px 2px;
      color: #a3a3a3;
}

.help.keyword-wizard p.keyword-wizard {
  margin: 0 0 8px 0
}

.help.keyword-wizard .q.keyword-wizard {
  font-family: monospace;
      color: #0b8043;
      white-space: nowrap;
}

.help.keyword-wizard {
  z-index: 4;
      position: absolute;
      right: 10px;
      padding: 12px;
      border-radius: 2px;
      border: 1px solid #e0e0e0;
      box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.2), 0 6px 10px 0 rgba(0, 0, 0, 0.3);
      background: white;
      font-size: 13px;
      line-height: 20px;
      width: 450px;
      max-height: 400px;
      overflow: auto;
}

#withinHelp.keyword-wizard {
  top: 75px;
}

#chemHelp.keyword-wizard {
  top: 0;
}

#searchBooleanHelp.keyword-wizard {
  top: 140px;
}

}</style><!-- Shady DOM styles for bottom-bar --><style scope="bottom-bar">.fixed.bottom-bar {
  display: block;
  position: fixed;
  height: 46px;
  bottom: 0;
}

.fixed[medium].bottom-bar {
  height: 280px;
}

.fixed[large].bottom-bar {
  height: 480px;
}

.shadow.bottom-bar {
  background: white;
  padding: 16px;
  border-radius: 8px 8px 0px 0px;
  box-shadow: 0px 8px 10px 1px rgba(0,0,0,.14), 0px 3px 14px 2px rgba(0,0,0,.12), 0px 5px 5px -3px rgba(0,0,0,.2);
}

.oneline.bottom-bar {
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
  cursor: pointer;
}

.button.bottom-bar {
  cursor: pointer;
}

.buttonAlign.bottom-bar {
  margin-top: -4px;
}

.header.bottom-bar {
  height: 30px;
  font-family: 'Google Sans';
  font-size: 18px;
  padding-bottom: 8px;
}

.list.bottom-bar {
  overflow-y: auto;
  line-height: 20px;
}

.definition.bottom-bar {
  padding: 0px 0px 4px 0px;
  cursor: pointer;
}

[medium].bottom-bar .content.bottom-bar {
  height: 230px;
}

[large].bottom-bar .content.bottom-bar {
  height: 430px;
}

[medium].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 200px;
}

[large].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 400px;
}

[hidden].bottom-bar {
  display: none;
}

.label.bottom-bar {
  font-family: 'Google Sans';
  font-size: 12px;
  line-height: 16px;
  font-weight: 400;
  padding: 6px 0px 4px 0px;
  color: #1f1f1f;
}

[pad].bottom-bar {
  margin-left: 16px;
}

.layout.vertical.bottom-bar {
  display: flex;
  flex-direction: column;
}

.layout.horizontal.bottom-bar {
  display: flex;
  flex-direction: row;
}

.flex.bottom-bar {
  flex: 1;
  flex-basis: 0.000000001px;
}

.layout.start.bottom-bar {
  align-items: flex-start;
}

.layout.center.bottom-bar {
  align-items: center;
}

.layout.end.bottom-bar {
  align-items: flex-end;
}

.flex-2.bottom-bar {
  flex: 2;
}

.flex-3.bottom-bar {
  flex: 3;
}

.flex-4.bottom-bar {
  flex: 4;
}

.flex-5.bottom-bar {
  flex: 5;
}

.flex-6.bottom-bar {
  flex: 6;
}

.flex-7.bottom-bar {
  flex: 7;
}

.flex-8.bottom-bar {
  flex: 8;
}

.flex-9.bottom-bar {
  flex: 9;
}

.flex-10.bottom-bar {
  flex: 10;
}

.flex-11.bottom-bar {
  flex: 11;
}

.flex-12.bottom-bar {
  flex: 12;
}</style><!-- Shady DOM styles for landscape-link --><!-- Shady DOM styles for landscape-summary-box --><!-- Shady DOM styles for search-state --><!-- Shady DOM styles for iron-overlay-backdrop --><!-- Shady DOM styles for opaque-animation --><!-- Shady DOM styles for iron-dropdown --><!-- Shady DOM styles for iron-meta --><!-- Shady DOM styles for iron-icon --><style scope="iron-icon-0">.iron-icon-0 {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;-ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;-ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
        position: relative;

        vertical-align: middle;

        fill: currentcolor;
        stroke: none;

        width: 24px;
        height: 24px;;
}

.iron-icon-0[hidden] {
  display: none;
}</style><!-- Shady DOM styles for iron-iconset-svg --><!-- Shady DOM styles for iron-list --><!-- Shady DOM styles for paper-icon-item --><!-- Shady DOM styles for paper-item-body --><!-- Shady DOM styles for paper-item --><!-- Shady DOM styles for dropdown-menu --><!-- Shady DOM styles for chips-input --><!-- Shady DOM styles for input-chip --><!-- Shady DOM styles for keyword-editor --><!-- Shady DOM styles for paper-ripple --><!-- Shady DOM styles for paper-button --><!-- Shady DOM styles for date-editor --><!-- Shady DOM styles for metadata-editor --><!-- Shady DOM styles for restrict-editor --><!-- Shady DOM styles for overlay-tooltip --><style scope="overlay-tooltip">overlay-tooltip {
  display: none;
        color: #fff;
        background-color: #000;
        padding: 10px 12px;
        border-radius: 3px;
        font-size: 13px;
        font-weight: normal;
        line-height: normal;
        position: fixed;
        z-index: 100;
}

#arrow.overlay-tooltip {
  width: 0;
        height: 0;
        border-style: solid;
        border-width: 0 6px 8px 6px;
        border-color: transparent transparent #000 transparent;
        position: absolute;
        top: -8px;
        left: calc(50% - 6px);
}</style><!-- Shady DOM styles for query-renderer --><!-- Shady DOM styles for result-nav --><style scope="result-nav">result-nav {
  display: block;
        white-space: nowrap;
        padding: 0 30px;
        line-height: 30px;
        height: 30px;
        margin-top: 17px;
        font-weight: 500;
        font-size: 15px;
}

state-modifier.result-nav {
  color: #333;
}

state-modifier[disabled].result-nav {
  pointer-events: none;
        color: #ccc;
}</style><!-- Shady DOM styles for raw-html --><!-- Shady DOM styles for paper-material --><style scope="paper-material-0">.paper-material-0 {
  display: block;
        position: relative;
}

.paper-material-0[elevation="1"] {
  box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.14),
                    0 1px 5px 0 rgba(0, 0, 0, 0.12),
                    0 3px 1px -2px rgba(0, 0, 0, 0.2);
}

.paper-material-0[elevation="2"] {
  box-shadow: 0 4px 5px 0 rgba(0, 0, 0, 0.14),
                    0 1px 10px 0 rgba(0, 0, 0, 0.12),
                    0 2px 4px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="3"] {
  box-shadow: 0 6px 10px 0 rgba(0, 0, 0, 0.14),
                    0 1px 18px 0 rgba(0, 0, 0, 0.12),
                    0 3px 5px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="4"] {
  box-shadow: 0 8px 10px 1px rgba(0, 0, 0, 0.14),
                    0 3px 14px 2px rgba(0, 0, 0, 0.12),
                    0 5px 5px -3px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="5"] {
  box-shadow: 0 16px 24px 2px rgba(0, 0, 0, 0.14),
                    0  6px 30px 5px rgba(0, 0, 0, 0.12),
                    0  8px 10px -5px rgba(0, 0, 0, 0.4);
}

.paper-material-0[animated] {
  transition: box-shadow 0.28s cubic-bezier(0.4, 0, 0.2, 1);
}

.paper-material-0 {
  ;
}</style><!-- Shady DOM styles for search-box --><style scope="search-box">.layout.horizontal.search-box,.layout.vertical.search-box {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-box {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-box {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-box {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-box {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-box {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-box,.layout.center-center.search-box {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-box,.layout.center-center.search-box {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-box {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-box {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-box {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.inputbox.search-box {
  border: 1px solid #ccc;
        padding: 0 12px;
        background: white;
}

.inputbox[focused].search-box {
  border: 1px solid #4285f4 !important;
}

.inputbox.search-box:hover {
  border: 1px solid #999;
}

#searchInput.search-box {
  font-family: inherit;
        font-size: 16px;
        padding: 8px 0;
        outline: none;
        border-right: none;
        width: 100%;
        margin-right: 0;
        border: 0;
}

#searchButton.search-box {
  cursor: pointer;
        background-color: #4285f4;
        border: none;
        color: #fff;
        vertical-align: top;
        width: 70px;
        height: 37px;
        outline: none;
}

.suggest-bg.search-box {
  display: inline-block;
        min-width: 0;
        white-space: nowrap;
}

#suggestMenu.search-box {
  position: absolute;
        margin-top: 38px;
        width: 100%;
        background: white;
        z-index: 1;
}

#suggestMenu.search-box .row.search-box {
  font-size: 13px;
        line-height: 28px;
        white-space: nowrap;
        overflow: hidden;
        text-overflow: ellipsis;
        padding: 4px 2px;
        cursor: pointer;
}

.row[selected].search-box {
  background: rgba(0, 0, 0, 0.05);
}

.suggest-icon.search-box {
  height: 20px;
        width: 20px;
        padding: 0 12px 0 6px;
        transition: transform .15s linear;
        transform: scale(1);
}

.suggest-icon[hide].search-box {
  transform: scale(0);
}

#corpora.search-box {
  padding: 6px 0;
        user-select: none;
}

#corpora.search-box iron-icon.search-box {
  height: 20px;
        width: 20px;
        color: #ccc;
        cursor: pointer;
}

#corpora.search-box iron-icon[active].search-box {
  color: #4285f4 !important;
}

#corpora.search-box iron-icon.search-box:hover {
  color: #999;
}</style><!-- Shady DOM styles for iron-media-query --><!-- Shady DOM styles for paper-header-panel --><!-- Shady DOM styles for iron-a11y-announcer --><style scope="iron-a11y-announcer">iron-a11y-announcer {
  display: inline-block;
        position: fixed;
        clip: rect(0px,0px,0px,0px);
}</style><!-- Shady DOM styles for iron-autogrow-textarea --><!-- Shady DOM styles for iron-input --><!-- Shady DOM styles for paper-input-char-counter --><!-- Shady DOM styles for paper-input-container --><!-- Shady DOM styles for paper-input-error --><!-- Shady DOM styles for paper-input --><!-- Shady DOM styles for paper-textarea --><!-- Shady DOM styles for paper-toast --><style scope="paper-toast-0">.paper-toast-0 {
  display: block;
        position: fixed;
        background-color: #323232;
        color: #f1f1f1;
        min-height: 48px;
        min-width: 288px;
        padding: 16px 24px;
        box-sizing: border-box;
        box-shadow: 0 2px 5px 0 rgba(0, 0, 0, 0.26);
        border-radius: 2px;
        margin: 12px;
        font-size: 14px;
        cursor: default;
        -webkit-transition: -webkit-transform 0.3s, opacity 0.3s;
        transition: transform 0.3s, opacity 0.3s;
        opacity: 0;
        -webkit-transform: translateY(100px);
        transform: translateY(100px);font-family: 'Roboto', 'Noto', sans-serif;
        -webkit-font-smoothing: antialiased;
}

.paper-toast-0.capsule {
  border-radius: 24px;
}

.paper-toast-0.fit-bottom {
  width: 100%;
        min-width: 0;
        border-radius: 0;
        margin: 0;
}

.paper-toast-0.paper-toast-open {
  opacity: 1;
        -webkit-transform: translateY(0px);
        transform: translateY(0px);
}</style><!-- Shady DOM styles for paper-toolbar --><!-- Shady DOM styles for search-footer --><style scope="search-footer">#footer.search-footer {
  font-size: 13px;
        margin-top: 10px;
        background: #fafafa;
        padding: 20px 10px;
        align-items: center;
        border-top: 1px solid #ebebeb;
}

#footer.search-footer .links.search-footer > *.search-footer {
  display: inline-block;
        margin: 0 12px;
}

.layout.horizontal.search-footer,.layout.vertical.search-footer {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-footer {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-footer {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-footer {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-footer {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-footer {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-footer {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-footer {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-footer {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-footer {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-footer {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-footer {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-footer {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-footer {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-footer {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-footer {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-footer {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-footer {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-footer {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-footer {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-footer {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-footer {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-footer {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-footer {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-footer {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-footer {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-header --><style scope="search-header">search-header {
  display: block;
}

.lockup-logo.search-header,.lockup-text.search-header {
  display: inline-block;
}

.lockup-logo.search-header {
  width: 74px;
        height: 24px;
        background-image: url('https://www.gstatic.com/images/branding/googlelogo/1x/googlelogo_color_74x24dp.png');
        background-size: 74px 24px;
}

.lockup-text.search-header {
  font-family: "Product Sans", Arial, Helvetica, sans-serif;

        
        font-size: 22.1px;

        
        text-rendering: optimizeLegibility;

        
        position: relative;
        top: -6px;
        left: -5px;

        
        -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
}

.lockup-brand.search-header {
  opacity: 0.54;
}

@media (-webkit-min-device-pixel-ratio: 1.5), (min-resolution: 144dpi) {
.lockup-logo.search-header {
  background-image: url('https://www.gstatic.com/images/branding/googlelogo/2x/googlelogo_color_74x24dp.png');
}

.lockup-text.search-header {
  font-size: 21.3px;
          left: -7px;
}

}

header.search-header {
  background-color: #fafafa;
        border-bottom: 1px solid #ebebeb;
        color: #333;
        height: 60px;
        width: 100%;
        z-index: 1;
        display: block;
}

[latestStyle].search-header header.search-header {
  background-color: transparent;
}

.headerpad.search-header {
  margin-left: 16px;
}

[wide].search-header .headerpad.search-header {
  margin-left: 32px;
}

.leftheader.search-header {
  width: 322px;
}

header.search-header h1.search-header {
  display: none;
}

header.search-header h1.search-header state-modifier.search-header {
  color: #777;
        text-decoration: none;
        display: inline-block;
}

[wide].search-header header.search-header h1.search-header {
  box-sizing: border-box;
        margin: 0;
        padding: 20px 0 10px;
        font-size: 20px;
        font-weight: 400;
        white-space: nowrap;
        display: block;
}

search-box.search-header {
  height: 37px;
        padding: 0 16px;
        width: 900px;
        align-self: center;
}

.layout.horizontal.search-header,.layout.vertical.search-header {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-header {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-header {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-header {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-header {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-header {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-header {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-header {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-header {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-header {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-header {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-header {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-header {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-header {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-header {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-header {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-header {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-header {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-header {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-header {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-header {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-header {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-header {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-header {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-header {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-header {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-ui --><style scope="search-ui-0">.search-ui-0 paper-button.search-ui {
  display: inline-block;
        text-align: center;
        font-family: inherit;
}

.search-ui-0 .layout.horizontal.search-ui,.search-ui-0 .layout.vertical.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.search-ui-0 .layout.inline.search-ui {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.search-ui-0 .layout.horizontal.search-ui {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.search-ui-0 .layout.vertical.search-ui {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.search-ui-0 .layout.wrap.search-ui {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.search-ui-0 .layout.no-wrap.search-ui {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .flex.search-ui {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.search-ui-0 .flex-auto.search-ui {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.search-ui-0 .flex-none.search-ui {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.search-ui-0 .layout.start.search-ui {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.end.search-ui {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.search-ui-0 .layout.baseline.search-ui {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.search-ui-0 .layout.start-justified.search-ui {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .layout.end-justified.search-ui {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.search-ui-0 .layout.around-justified.search-ui {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.search-ui-0 .layout.justified.search-ui {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.search-ui-0 .self-start.search-ui {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.search-ui-0 .self-center.search-ui {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.search-ui-0 .self-end.search-ui {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.search-ui-0 .self-stretch.search-ui {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.search-ui-0 .self-baseline.search-ui {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.search-ui-0 .layout.start-aligned.search-ui {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.search-ui-0 .layout.end-aligned.search-ui {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.search-ui-0 .layout.center-aligned.search-ui {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.search-ui-0 .layout.between-aligned.search-ui {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.search-ui-0 .layout.around-aligned.search-ui {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.search-ui-0 {
  display: block;
        min-width: 350px;
        height: 100%;
}

.search-ui-0 #content.search-ui {
  height: 100%;
}

.search-ui-0 #leftBarOverflow.search-ui {
  padding-right: 16px;
}

.search-ui-0 [wide].search-ui #leftBarOverflow.search-ui {
  overflow: auto;
}

.search-ui-0 #leftBar.search-ui {
  box-sizing: border-box;
        color: #666;
        font-size: 13px;
        padding: 16px 0 16px 16px;
        border-bottom: 1px solid #e5e5e5;
}

.search-ui-0 [wide].search-ui #leftBar.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;

        -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
        position: relative;
        width: 350px;
        margin-bottom: 0;
        padding-bottom: 0;
        border-bottom: none;
}

@media print {
.search-ui-0 #leftBar.search-ui {
  display: none !important;
}

}

.search-ui-0 #leftBar.search-ui h3.search-ui {
  text-transform: uppercase;
        font-size: 13px;
        font-weight: normal;
        margin-top: 6px;
        margin-bottom: 6px;
        cursor: default;
        display: inline-block;
        color: #a3a3a3;
}

.search-ui-0 #closeButton.search-ui {
  position: absolute;
        right: 0;
}

.search-ui-0 #searchTermsHeader.search-ui {
  position: relative;
}

.search-ui-0 #searchTermsQ.search-ui iron-icon.search-ui {
  height: 16px;
        padding: 0 2px 2px 2px;
        color: #a3a3a3;
}

.search-ui-0 #searchTermsHeader.search-ui:hover iron-icon.search-ui {
  color: #4285f4;
}

.search-ui-0 #closeLeftBar.search-ui {
  height: 16px;
        width: 16px;
        padding: 0 0 8px 0;
        cursor: pointer;
}

.search-ui-0 #compactQuery.search-ui iron-icon.search-ui {
  height: 20px;
}

.search-ui-0 #backToResultsButton.search-ui {
  color: #fff;
        background: #4285f4;
        margin-top: 20px;
        text-align: center;
}

.search-ui-0 #main.search-ui {
  display: block;
        min-height: calc(100vh - 127px);
}

@media print {
.search-ui-0 [wide].search-ui main.search-ui {
  margin-left: 0;
}

}</style><!-- Shady DOM styles for import-list --><!-- Shady DOM styles for iron-request --><!-- Shady DOM styles for iron-ajax --><!-- Shady DOM styles for paper-dialog --><!-- Shady DOM styles for coverage-stats --><!-- Shady DOM styles for iron-image --><!-- Shady DOM styles for iron-selector --><!-- Shady DOM styles for paper-card --><!-- Shady DOM styles for paper-checkbox --><!-- Shady DOM styles for landing-page --><!-- Shady DOM styles for remote-fetch --><!-- Shady DOM styles for paper-spinner --><style scope="paper-spinner-0">.paper-spinner-0 {
  display: inline-block;
        position: relative;
        width: 28px;
        height: 28px;
}

.paper-spinner-0 #spinnerContainer.paper-spinner {
  width: 100%;
        height: 100%;

        
        direction: ltr;
}

.paper-spinner-0 #spinnerContainer.active.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite;
        animation: container-rotate-paper-spinner-0 1568ms linear infinite;
}

@-webkit-keyframes container-rotate-paper-spinner-0 {
to {
  -webkit-transform: rotate(360deg)
}

}

@keyframes container-rotate-paper-spinner-0 {
to {
  transform: rotate(360deg)
}

}

.paper-spinner-0 .spinner-layer.paper-spinner {
  position: absolute;
        width: 100%;
        height: 100%;
        opacity: 0;
        white-space: nowrap;
        color: #4285f4;
}

.paper-spinner-0 .layer-1.paper-spinner {
  color: #4285f4;
}

.paper-spinner-0 .layer-2.paper-spinner {
  color: #db4437;
}

.paper-spinner-0 .layer-3.paper-spinner {
  color: #f4b400;
}

.paper-spinner-0 .layer-4.paper-spinner {
  color: #0f9d58;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0;
        -webkit-animation-duration: 5332ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-name: fill-unfill-rotate-paper-spinner-0;
        animation-duration: 5332ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
        opacity: 1;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-1.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-2.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-3.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-4.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
}

@-webkit-keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  -webkit-transform: rotate(135deg)
}

25% {
  -webkit-transform: rotate(270deg)
}

37.5% {
  -webkit-transform: rotate(405deg)
}

50% {
  -webkit-transform: rotate(540deg)
}

62.5% {
  -webkit-transform: rotate(675deg)
}

75% {
  -webkit-transform: rotate(810deg)
}

87.5% {
  -webkit-transform: rotate(945deg)
}

to {
  -webkit-transform: rotate(1080deg)
}

}

@keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  transform: rotate(135deg)
}

25% {
  transform: rotate(270deg)
}

37.5% {
  transform: rotate(405deg)
}

50% {
  transform: rotate(540deg)
}

62.5% {
  transform: rotate(675deg)
}

75% {
  transform: rotate(810deg)
}

87.5% {
  transform: rotate(945deg)
}

to {
  transform: rotate(1080deg)
}

}

@-webkit-keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@-webkit-keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

.paper-spinner-0 .circle-clipper.paper-spinner {
  display: inline-block;
        position: relative;
        width: 50%;
        height: 100%;
        overflow: hidden;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after {
  left: 45%;
        width: 10%;
        border-top-style: solid;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after,.paper-spinner-0 .circle-clipper.paper-spinner::after {
  content: '';
        box-sizing: border-box;
        position: absolute;
        top: 0;
        border-width: 3px;
        border-radius: 50%;
}

.paper-spinner-0 .circle-clipper.paper-spinner::after {
  bottom: 0;
        width: 200%;
        border-style: solid;
        border-bottom-color: transparent !important;
}

.paper-spinner-0 .circle-clipper.left.paper-spinner::after {
  left: 0;
        border-right-color: transparent !important;
        -webkit-transform: rotate(129deg);
        transform: rotate(129deg);
}

.paper-spinner-0 .circle-clipper.right.paper-spinner::after {
  left: -100%;
        border-left-color: transparent !important;
        -webkit-transform: rotate(-129deg);
        transform: rotate(-129deg);
}

.paper-spinner-0 .active.paper-spinner .gap-patch.paper-spinner::after,.paper-spinner-0 .active.paper-spinner .circle-clipper.paper-spinner::after {
  -webkit-animation-duration: 1333ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-duration: 1333ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.left.paper-spinner::after {
  -webkit-animation-name: left-spin-paper-spinner-0;
        animation-name: left-spin-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.right.paper-spinner::after {
  -webkit-animation-name: right-spin-paper-spinner-0;
        animation-name: right-spin-paper-spinner-0;
}

@-webkit-keyframes left-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(130deg)
}

50% {
  -webkit-transform: rotate(-5deg)
}

to {
  -webkit-transform: rotate(130deg)
}

}

@keyframes left-spin-paper-spinner-0 {
0% {
  transform: rotate(130deg)
}

50% {
  transform: rotate(-5deg)
}

to {
  transform: rotate(130deg)
}

}

@-webkit-keyframes right-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(-130deg)
}

50% {
  -webkit-transform: rotate(5deg)
}

to {
  -webkit-transform: rotate(-130deg)
}

}

@keyframes right-spin-paper-spinner-0 {
0% {
  transform: rotate(-130deg)
}

50% {
  transform: rotate(5deg)
}

to {
  transform: rotate(-130deg)
}

}

.paper-spinner-0 #spinnerContainer.cooldown.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
        animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
}

@-webkit-keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}</style><!-- Shady DOM styles for paper-spinner-lite --><!-- Shady DOM styles for concept-card --><!-- Shady DOM styles for concept-mention --><style scope="concept-mention">.block.concept-mention {
  display: block;
}

[hidden].concept-mention {
  display: none !important;
}

.invisible.concept-mention {
  visibility: hidden !important;
}

.relative.concept-mention {
  position: relative;
}

.fit.concept-mention {
  position: absolute;
        top: 0;
        right: 0;
        bottom: 0;
        left: 0;
}

body.fullbleed.concept-mention {
  margin: 0;
        height: 100vh;
}

.scroll.concept-mention {
  -webkit-overflow-scrolling: touch;
        overflow: auto;
}

.fixed-bottom.concept-mention,.fixed-left.concept-mention,.fixed-right.concept-mention,.fixed-top.concept-mention {
  position: fixed;
}

.fixed-top.concept-mention {
  top: 0;
        left: 0;
        right: 0;
}

.fixed-right.concept-mention {
  top: 0;
        right: 0;
        bottom: 0;
}

.fixed-bottom.concept-mention {
  right: 0;
        bottom: 0;
        left: 0;
}

.fixed-left.concept-mention {
  top: 0;
        bottom: 0;
        left: 0;
}

#target.concept-mention:hover {
  background-color: #e8f0fe;
}

#target[noicon].concept-mention {
  padding: 1px;
}

#target.concept-mention:hover[noicon] {
  border: 1px solid #e8f0fe;
        padding: 0;
}

#target.concept-mention {
  display: inline-block;
}

.inline-icon.concept-mention {
  cursor: pointer;
        height: 12px;
        width: 12px;
        padding-left: 4px;
        color: #5e6368;
}

concept-card.concept-mention {
  z-index: 1;
        position: absolute;
}</style><!-- Shady DOM styles for fterm-concept-card --><!-- Shady DOM styles for fterm-concept-mention --><!-- Shady DOM styles for paper-fab --><!-- Shady DOM styles for paper-icon-button --><!-- Shady DOM styles for paper-icon-button-light --><!-- Shady DOM styles for classification-tree --><style scope="classification-tree">.layout.horizontal.classification-tree,.layout.vertical.classification-tree {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.classification-tree {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.classification-tree {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.classification-tree {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.classification-tree {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.classification-tree {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.classification-tree {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.classification-tree {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.classification-tree {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

classification-tree {
  display: block;
        line-height: 20px;
}

.wrap.classification-tree {
  padding: 6px 12px;
}

.wrap.classification-tree:hover {
  background: #fafafa;
}

.description.classification-tree {
  padding-left: 4px;
}

iron-icon.classification-tree {
  color: #eaeaea;
}

.code[first].classification-tree {
  font-weight: 500;
}

.code[additional].classification-tree {
  font-style: italic;
}</style><!-- Shady DOM styles for classification-viewer --><style scope="classification-viewer">.table.classification-viewer {
  border: 1px solid #eaeaea;
        display: block;
}

.more.classification-viewer {
  padding: 6px 12px;
        cursor: pointer;
        font-style: italic;
        color: #aaa;
}

.more.classification-viewer:hover {
  background: #fafafa;
}

.chip.classification-viewer {
  display: inline-block;
        padding: 4px 6px;
        border-radius: 2px;
}

.chip[additional].classification-viewer {
  font-style: italic;
}</style><!-- Shady DOM styles for image-carousel --><!-- Shady DOM styles for image-viewer --><!-- Shady DOM styles for patent-result --><style scope="patent-result">#wrapper.patent-result {
  padding: 20px;
        max-width: 1050px;
        outline: 0;
}

.scroll-target.patent-result:before {
  display: block;
        content: '';
        visibility: hidden;
}

h1.patent-result {
  font-weight: 500;
        font-size: 20px;
        margin: 0 0 20px 0;
}

h3.patent-result {
  font-size: 15px;
        font-weight: 500;
        margin: 28px 0 18px 0;
}

dl.patent-result {
  line-height: 1.5;
        font-size: 0;
}

dt.patent-result,dd.patent-result {
  display: inline;
        font-size: 13px;
        margin: 0;
}

dt.patent-result {
  font-weight: 500;
        color: #000;
}

dt.patent-result::after {
  content: ': ';
}

dd.patent-result {
  color: #aaa;
}

dd.patent-result ~ dd.patent-result::before {
  content: ', ';
}

dt.patent-result + dd.patent-result::before {
  content: '';
}

dd.patent-result ~ dt.patent-result::before {
  display: block;
        content: '';
        margin-top: 8px;
}

dd.patent-result core-icon.patent-result {
  width: 14px;
        height: 14px;
        vertical-align: top;
        color: inherit;
}

.table.patent-result {
  display: table;
        border-collapse: collapse;
        border-spacing: 0;
        border: 1px solid #eaeaea;
        width: 100%;
        box-sizing: border-box;
}

.tr.patent-result {
  display: table-row;
        border-bottom: 1px solid #eaeaea;
}

.th.patent-result,.td.patent-result {
  display: table-cell;
        padding: 10px 12px;
}

.thead.patent-result {
  display: table-header-group;
}

.tbody.patent-result {
  display: table-row-group;
}

.th.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.td.patent-result {
  vertical-align: top;
}

.td.patent-result > p.patent-result {
  margin-top: 0;
}

.nowrap.patent-result {
  white-space: nowrap;
}

.knowledge-card.patent-result {
  border: 1px solid #e5e5e5;
        border-radius: 2px;
}

.knowledge-card.patent-result > header.patent-result {
  -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
        background: #4285f4;
        color: #fff;
        padding: 20px 12px;
}

.knowledge-card.patent-result > header.patent-result state-modifier.patent-result,.knowledge-card.patent-result > header.patent-result a.patent-result {
  color: inherit;
        margin: 0 12px 0 0;
        display: inline-block;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result,.knowledge-card.patent-result > header.patent-result .tagline.patent-result {
  margin: 0;
        font-weight: normal;
        padding-top: 4px;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result {
  font-size: 20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result {
  background: #3367d6;
        padding: 10px 12px;
        margin: 20px -12px -20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result core-icon.patent-result {
  margin-right: 12px;
        width: 24px;
        height: 24px;
}

.knowledge-card.patent-result dl.patent-result {
  padding: 16px 12px;
}

.knowledge-card.patent-result hr.patent-result {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 0;
}

.main-link.patent-result {
  margin: 14px;
        font-weight: 500;
}

.footer.patent-result h3.patent-result state-modifier.patent-result,.footer.patent-result h3.patent-result a.patent-result {
  float: right;
        font-weight: 400;
        font-size: 13px;
        line-height: 24px;
}

.footer.patent-result dl.patent-result {
  margin-left: 30px;
}

.footer.patent-result > ul.patent-result > li.patent-result {
  margin-bottom: 8px;
}

h3.patent-result .righthead.patent-result {
  color: #aaa;
        font-weight: 400;
        font-size: 13px;
        cursor: help;
}

.tooltip-hint.patent-result {
  border-bottom: 1px dotted #ccc;
}

[marginRight].patent-result {
  margin-right: 60px;
}

.flex-width.patent-result {
  min-width: 0;
        word-break: break-word;
}

.responsive-table.patent-result {
  width: 100%;
        overflow-x: auto;
        overflow-y: hidden;
}

.layout.horizontal.patent-result,.layout.vertical.patent-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.flex.patent-result,.flex-1.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-2.patent-result {
  -ms-flex: 2;
        -webkit-flex: 2;
        flex: 2;
}

.flex-3.patent-result {
  -ms-flex: 3;
        -webkit-flex: 3;
        flex: 3;
}

.flex-4.patent-result {
  -ms-flex: 4;
        -webkit-flex: 4;
        flex: 4;
}

.flex-5.patent-result {
  -ms-flex: 5;
        -webkit-flex: 5;
        flex: 5;
}

.flex-6.patent-result {
  -ms-flex: 6;
        -webkit-flex: 6;
        flex: 6;
}

.flex-7.patent-result {
  -ms-flex: 7;
        -webkit-flex: 7;
        flex: 7;
}

.flex-8.patent-result {
  -ms-flex: 8;
        -webkit-flex: 8;
        flex: 8;
}

.flex-9.patent-result {
  -ms-flex: 9;
        -webkit-flex: 9;
        flex: 9;
}

.flex-10.patent-result {
  -ms-flex: 10;
        -webkit-flex: 10;
        flex: 10;
}

.flex-11.patent-result {
  -ms-flex: 11;
        -webkit-flex: 11;
        flex: 11;
}

.flex-12.patent-result {
  -ms-flex: 12;
        -webkit-flex: 12;
        flex: 12;
}

@media print {
#text.patent-result {
  flex-direction: column-reverse !important;
}

}

patent-result-ref-list.patent-result {
  width: 100%;
}

patent-result-ref-list.patent-result + patent-result-ref-list.patent-result {
  margin-left: 10px;
}

[narrow].patent-result {
  flex-direction: column-reverse !important;
}

.famheader.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.collapse.patent-result {
  color: #616161;
        font-size: 13px;
        cursor: pointer;
}

#imageDrag.patent-result {
  position: fixed;
        cursor: col-resize;
}

#imageDrag.patent-result div.patent-result {
  width: 4px;
        height: 100%;
        margin: 0 4px;
        background: #eee;
}

#imageDrag.patent-result:hover {
  background: #eee;
}

#imageDrag.patent-result:hover div.patent-result {
  background: #ccc;
}

.imageWrapper.patent-result {
  position: fixed;
        top: 60px;
        background: white;
        margin-left: 12px;
}

#notices.patent-result {
  padding: 20px;
}

#figures.patent-result {
  background: #efefef;
}

.headerButton.patent-result {
  color: #3c80f6;
        cursor: pointer;
        display: inline-block;
        padding: 0 14px;
        line-height: 27px;
}

.headerButton.patent-result iron-icon.patent-result {
  width: 16px;
        height: 16px;
}

.tr.conceptDomain.patent-result {
  display: table-row;
}

.responsive-grid.patent-result {
  display: grid;
        gap: 8px;
        grid-template-columns: none;
}</style><!-- Shady DOM styles for family-viewer --><!-- Shady DOM styles for app-row --><!-- Shady DOM styles for application-timeline --><style scope="application-timeline">.layout.horizontal.application-timeline,.layout.vertical.application-timeline {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.application-timeline {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.application-timeline {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.application-timeline {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.application-timeline {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.application-timeline {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.application-timeline {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.application-timeline {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.application-timeline {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.wrap.application-timeline {
  padding: 16px 12px;
}

.event.application-timeline {
  padding: 3px 0;
}

[date].application-timeline {
  color: #5f6368;
        font-size: 13px;
        padding: 3px 0;
        width: 70px;
        line-height: 16px;
}

[critical].application-timeline [date].application-timeline {
  color: #202124;
        font-weight: 500;
        line-height: 18px;
}

.line.application-timeline {
  margin: 9px 6px;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
}

.dot.application-timeline {
  margin: 3px 0;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
        display: inline-block;
}

[critical].application-timeline .line.application-timeline {
  background: #4285f4;
}

[current].application-timeline .line.application-timeline {
  background: #81c995;
}

[current][critical].application-timeline .line.application-timeline {
  background: #81c995;
}

.title.application-timeline {
  font-size: 13px;
        padding: 3px 0;
        line-height: 16px;
}

.title-text.application-timeline {
  color: #5f6368;
}

.description-item.application-timeline {
  font-size: 12px;
        padding: 6px 0;
        max-width: 300px;
}

#legal.application-timeline {
  height: 14px;
        width: 14px;
        padding: 0 3px 1px 3px;
        vertical-align: text-bottom;
}

#icon.application-timeline {
  height: 12px;
        width: 12px;
        padding: 0 3px 3px 3px;
        vertical-align: text-bottom;
}

.unknown.application-timeline {
  font-style: italic;
}

.not_active.application-timeline {
  text-decoration: line-through;
}

.active.application-timeline {
  font-weight: 500;
}

#cc[this].application-timeline {
  color: #202124 !important;
        text-decoration: underline;
}

#cc[this].not_active.application-timeline {
  text-decoration: line-through underline;
}

hr.application-timeline {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 10px 0 16px 0;
}

.header.application-timeline {
  font-size: 13px;
        line-height: 20px;
        font-weight: 500;
        color: #202124;
        padding-bottom: 8px;
}

.block.application-timeline {
  padding: 0 6px 0 0;
}

.year.application-timeline {
  color: #5f6368;
        font-size: 13px;
        font-weight: 500;
        padding: 3px 1px;
        width: 70px;
}

.expand.application-timeline {
  cursor: pointer;
        padding: 6px 0 3px 0;
}</style><!-- Shady DOM styles for patent-text --><style scope="patent-text">.layout.horizontal.patent-text,.layout.vertical.patent-text {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-text {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-text {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-text {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-text {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-text {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-text {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-text {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-text {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-text {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-text {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-text {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-text {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-text {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-text {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-text {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-text {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-text {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-text {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-text {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-text {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-text {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-text {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-text {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-text {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-text {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

patent-text {
  display: block;
}

#text.patent-text {
  line-height: 20px;
        min-width: 0;
}

#margin.patent-text {
  width: 16px;
}

#createHighlight.patent-text {
  position: relative;
        width: 16px;
        height: 16px;
        cursor: pointer;
}

.notranslate.patent-text > .google-src-text.patent-text {
  display: none;
}

.notranslate.patent-text:hover,mark.patent-text {
  background-color: #fbfcae;
}

.description-paragraph.patent-text {
  margin-block-start: 1em;
        margin-block-end: 1em;
}

.claim-text.patent-text {
  margin: 14px 0 0 20px;
}

.claim-dependent.patent-text {
  margin-left: 40px;
        color: #888;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim-text.patent-text {
  height: 0;
        width: 0;
        visibility: hidden;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim.patent-text:after {
  content: "…"
}

.patent-full-image.patent-text {
  max-width: 100%;
        height: auto;
}

.small-patent-image.patent-text {
  display: inline;
}

ul.patent-text {
  padding: 0 0 0 50px;
}

li.patent-text {
  list-style-type: none;
        position: relative;
}

ol.claims.patent-text li.patent-text {
  list-style-type: decimal;
        font-weight: bold;
}

ol.claims.patent-text li.patent-text > *.patent-text {
  font-weight: normal;
}

li.patent-text > para-num.patent-text {
  position: absolute;
        left: -45px;
        color: #888;
}

mark.patent-text {
  background: #fff59d;
}

mark.searchText.patent-text {
  background: #80deea;
}

.searchTextHeader.patent-text {
  font-weight: 500;
}

pre.patent-text {
  white-space: pre-wrap;
}

heading.patent-text {
  display: block;
        font-weight: 500;
        font-size: 13px;
}

#comment.patent-text {
  width: 16px;
        height: 16px;
}

[has-search][no-results].patent-text {
  display: none;
}

.highlight.patent-text {
  background-color: #fef7e0;
}</style><!-- Shady DOM styles for para-num --><!-- Shady DOM styles for result-container --><style scope="result-container">paper-spinner.result-container {
  position: absolute;
        
        top: calc(50%  + 56px - 16px);
        left: calc(50% + 175px - 16px);
}</style><!-- Shady DOM styles for scholar-result --><!-- Shady DOM styles for search-result --><style scope="search-result">.layout.horizontal.search-result,.layout.vertical.search-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

search-result {
  display: block;
        font-size: 13px;
}

#mainContainer.search-result {
  min-height: calc(100vh - 127px);
        color: #333;
}

#compactQuery.search-result {
  padding: 18px 20px 10px 20px;
        cursor: pointer;
}

#compactQuery.search-result > span.search-result {
  padding: 0 14px 0 0;
}

#compactQuery.search-result iron-icon.search-result {
  padding-right: 6px;
        height: 16px;
        width: 16px;
}</style><!-- Shady DOM styles for webdoc-result --><!-- Shady DOM styles for iron-pages --><!-- Shady DOM styles for paper-tab --><!-- Shady DOM styles for paper-tabs --><!-- Shady DOM styles for debug-info --><!-- Shady DOM styles for search-paging --><!-- Shady DOM styles for search-result-item --><!-- Shady DOM styles for search-result-image --><!-- Shady DOM styles for search-result-entities --><!-- Shady DOM styles for search-result-measures --><!-- Shady DOM styles for search-results --><!-- Shady DOM styles for summary-box --><!-- Shady DOM styles for timeline-page --><!-- Shady DOM styles for iron-localstorage --><!-- Shady DOM styles for search-app --><style scope="search-app">search-app {
  display: block;
        height: 100%;
}

#toast.search-app {
  min-height: 64px;
        min-width: 742px;
}</style><style>body {transition: opacity ease-in 0.2s; } 
body[unresolved] {opacity: 0; display: block; overflow: hidden; position: relative; } 
</style>
    <title>BRPI0815564B1 - 
  ANTIBODIES THAT INHIBIT THE DIMERIZATION OF c-MET AND USES OF THE SAME, MURINO HYBRIDOMA, ANTIBODY, ISOLATED NUCLEIC ACID, VECTOR, METHOD FOR THE PRODUCTION OF ANTIBODY, COMPOSITION, USE AND METHOD OF DIAGNOSIS INTO DETERMINATION OF DEPRESSION AND DETERMINATION DE c-MET
 
      - Google Patents</title>

    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta charset="UTF-8">
    <meta name="referrer" content="origin-when-crossorigin">
    <link rel="canonical" href="https://patents.google.com/patent/BRPI0815564B1/en">
    <meta name="description" content="
   
    antibodies that inhibit c-met dimerization and uses thereof, murine hybridoma, antibody, isolated nucleic acid, vector, method for antibody production, composition, use and in vitro diagnostic method of diseases induced by overexpression or underexpression of c-met receptor the present invention relates to a process for the selection of anti-c-met antibodies capable of inhibiting ligand-dependent and ligand-independent activation of c-met. more particularly, said process is based on the inhibition of c-met dimerization. in another aspect, the present invention relates to such antibodies and compositions comprising such antibodies for the preparation of a medicament for treating cancer. diagnostic process and kits are also part of the invention.
   
 
   ">
    <meta name="DC.type" content="patent">
    <meta name="DC.title" content="
  ANTIBODIES THAT INHIBIT THE DIMERIZATION OF c-MET AND USES OF THE SAME, MURINO HYBRIDOMA, ANTIBODY, ISOLATED NUCLEIC ACID, VECTOR, METHOD FOR THE PRODUCTION OF ANTIBODY, COMPOSITION, USE AND METHOD OF DIAGNOSIS INTO DETERMINATION OF DEPRESSION AND DETERMINATION DE c-MET
 
     ">
    <meta name="DC.date" content="2008-07-10" scheme="dateSubmitted">
    <meta name="DC.description" content="
   
    antibodies that inhibit c-met dimerization and uses thereof, murine hybridoma, antibody, isolated nucleic acid, vector, method for antibody production, composition, use and in vitro diagnostic method of diseases induced by overexpression or underexpression of c-met receptor the present invention relates to a process for the selection of anti-c-met antibodies capable of inhibiting ligand-dependent and ligand-independent activation of c-met. more particularly, said process is based on the inhibition of c-met dimerization. in another aspect, the present invention relates to such antibodies and compositions comprising such antibodies for the preparation of a medicament for treating cancer. diagnostic process and kits are also part of the invention.
   
 
   ">
    <meta name="citation_patent_application_number" content="BR:PI0815564A">
    <meta name="citation_pdf_url" content="https://patentimages.storage.googleapis.com/67/cb/aa/b116b52bad5922/BRPI0815564B1.pdf">
    <meta name="citation_patent_publication_number" content="BR:PI0815564:B1">
    <meta name="DC.date" content="2020-01-21">
    <meta name="DC.contributor" content="Goetsch Liliane" scheme="inventor">
    <meta name="DC.contributor" content="Pf Medicament" scheme="assignee">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,400italic,500,500italic,700">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Product+Sans">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700">

    <style>
      body { transition: none; }
    </style>

    <script src="https://apis.google.com/_/scs/abc-static/_/js/k=gapi.lb.en.IKZeRvoAYNY.O/m=client/rt=j/sv=1/d=1/ed=1/am=AAAQ/rs=AHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw/cb=gapi.loaded_0?le=scs" async=""></script><script>
      window.version = 'patent-search.search_20240531_RC00';

      function sendFeedback() {
        userfeedback.api.startFeedback({
          'productId': '713680',
          'bucket': 'patent-search-web',
          'productVersion': window.version,
        });
      }

      window.experiments = {};
      window.experiments.patentCountries = "ae,ag,al,am,ao,ap,ar,at,au,aw,az,ba,bb,bd,be,bf,bg,bh,bj,bn,bo,br,bw,bx,by,bz,ca,cf,cg,ch,ci,cl,cm,cn,co,cr,cs,cu,cy,cz,dd,de,dj,dk,dm,do,dz,ea,ec,ee,eg,em,ep,es,fi,fr,ga,gb,gc,gd,ge,gh,gm,gn,gq,gr,gt,gw,hk,hn,hr,hu,ib,id,ie,il,in,ir,is,it,jo,jp,ke,kg,kh,km,kn,kp,kr,kw,kz,la,lc,li,lk,lr,ls,lt,lu,lv,ly,ma,mc,md,me,mg,mk,ml,mn,mo,mr,mt,mw,mx,my,mz,na,ne,ng,ni,nl,no,nz,oa,om,pa,pe,pg,ph,pl,pt,py,qa,ro,rs,ru,rw,sa,sc,sd,se,sg,si,sk,sl,sm,sn,st,su,sv,sy,sz,td,tg,th,tj,tm,tn,tr,tt,tw,tz,ua,ug,us,uy,uz,vc,ve,vn,wo,yu,za,zm,zw";
      
      
      window.experiments.keywordWizard = true;
      
      
      
      window.experiments.definitions = true;

      window.Polymer = {
        dom: 'shady',
        lazyRegister: true,
      };
    </script>

    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/webcomponentsjs/webcomponents-lite.min.js"></script>
    <style>[hidden]:not([style-scope]):not(.style-scope) {
  display: none !important;
}

</style><style></style><style></style><style></style><style></style><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,300,300italic,400italic,500,500italic,700,700italic"><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto+Mono:400,700"><style></style><style></style><style>
  html, body {
    min-width: 100%;
    width: 100%;
    min-height: 100%;
    height: 100%;
  }

  body {
    background-color: #fff;
    font-family: 'Roboto', sans-serif;
    color: #333;
    margin: 0;
    padding: 0;
    /*
     * Turn off https://github.com/WICG/ScrollAnchoring/blob/master/explainer.md
     * https://memegen.googleplex.com/5230756293246976
     */
    overflow-anchor: none;
  }

  body h1, body h2, body h3 {
    -webkit-font-smoothing: antialiased;
    -moz-osx-font-smoothing: grayscale;
  }

  body a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  body a:visited {
    color: #3c80f6;
  }

  body a[open-result]:visited {
    color: #7e57c2;
  }

  /* For Firefox */
  a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  a:visited {
    color: #3c80f6;
  }

  a[open-result]:visited {
    color: #7e57c2;
  }

  ::selection , body ::selection {
    background-color: #c6dafc;
    color: #333;
  }
</style><link rel="import" href="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.html">
  <style>[hidden] { display: none !important; }</style><script type="text/javascript" charset="UTF-8" src="https://apis.google.com/js/client.js" gapi_processed="true"></script></head>
  <body>
    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.js"></script><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span>
    <search-app>
    
    <remote-fetch class="style-scope search-app"></remote-fetch>
    <search-state class="style-scope search-app"></search-state>
    <browser-ui class="style-scope search-app"></browser-ui>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    
      <search-result id="result" class="style-scope search-app">
    
    
    <search-ui mode="result" class="style-scope search-result x-scope search-ui-0">
    
    
    
    <div id="content" class="style-scope search-ui" wide="">
      <search-header show-search="" class="style-scope search-ui">
    
    
    <div class="style-scope search-header" wide="">
      <header class="style-scope search-header">
        <div class="layout horizontal headerpad style-scope search-header">
          <div class="layout horizontal leftheader style-scope search-header">
            <h1 class="style-scope search-header">
              <state-modifier inherit="" act="{&quot;type&quot;: &quot;HOME&quot;}" class="style-scope search-header"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                <div class="lockup style-scope search-header">
                  <span class="lockup-logo style-scope search-header"></span>
                  <span class="lockup-text style-scope search-header">
                    <span class="lockup-brand style-scope search-header">&nbsp;Patents</span>
                  </span>
                </div>
              </a></state-modifier>
            </h1>
          </div>
          
            <search-box class="style-scope search-header">
    
    <div class="layout horizontal style-scope search-box" style="position: relative;">
      <div class="inputbox flex layout horizontal style-scope search-box">
        <div class="suggest-bg flex style-scope search-box">
          <input name="q" id="searchInput" data-proto="SEARCH_INPUT" autocomplete="off" class="style-scope search-box">
        </div>
        <div id="corpora" class="style-scope search-box">
          <iron-icon icon="icons:lightbulb-outline" id="patentIcon" class="style-scope search-box x-scope iron-icon-0" active=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M9 21c0 .55.45 1 1 1h4c.55 0 1-.45 1-1v-1H9v1zm3-19C8.14 2 5 5.14 5 9c0 2.38 1.19 4.47 3 5.74V17c0 .55.45 1 1 1h6c.55 0 1-.45 1-1v-2.26c1.81-1.27 3-3.36 3-5.74 0-3.86-3.14-7-7-7zm2.85 11.1l-.85.6V16h-4v-2.3l-.85-.6C7.8 12.16 7 10.63 7 9c0-2.76 2.24-5 5-5s5 2.24 5 5c0 1.63-.8 3.16-2.15 4.1z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#patentIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include patents
    </div>
  </overlay-tooltip>
          <iron-icon icon="social:school" id="nplIcon" class="style-scope search-box x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M5 13.18v4L12 21l7-3.82v-4L12 17l-7-3.82zM12 3L1 9l11 6 9-4.91V17h2V9L12 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#nplIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include non-patent literature
    </div>
  </overlay-tooltip>
          <keyword-wizard id="wizardIcon" class="style-scope search-box">


<div id="wizardContainer" class="style-scope keyword-wizard">
  <iron-icon icon="image:tune" id="wizardIcon" class="style-scope keyword-wizard x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M3 17v2h6v-2H3zM3 5v2h10V5H3zm10 16v-2h8v-2h-8v-2h-2v6h2zM7 9v2H3v2h4v2h2V9H7zm14 4v-2H11v2h10zm-6-4h2V7h4V5h-4V3h-2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
  <paper-material elevation="2" id="wizard" class="style-scope keyword-wizard x-scope paper-material-0" hidden="">
    
    

    
    
    <div class="search-within style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Search within
        <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="within"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="withinHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search within the title, abstract, claims, or full patent document</b>: You can
          restrict your search to a specific field using field names.</p>
        <p class="style-scope keyword-wizard">Use <span class="q style-scope keyword-wizard">TI=</span> to search in the title, <span class="q style-scope keyword-wizard">AB=</span> for the
          abstract, <span class="q style-scope keyword-wizard">CL=</span> for the claims, or <span class="q style-scope keyword-wizard">TAC=</span> for
          all three. For example, <span class="q style-scope keyword-wizard">TI=(safety belt)</span>.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search by Cooperative Patent Classifications (CPCs)</b>: These are commonly used to
          represent ideas in place of keywords, and can also be entered in a search term box. If
          you're searching for<span class="q style-scope keyword-wizard">seat belts</span>, you could also search for
          <span class="q style-scope keyword-wizard">B60R22/00</span> to retrieve documents that mention safety belts or body
          harnesses. <span class="q style-scope keyword-wizard">CPC=B60R22</span> will match documents with exactly this CPC,
          <span class="q style-scope keyword-wizard">CPC=B60R22/low</span> matches documents with this CPC or a child
          classification of this CPC.
        </p>
          <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="filter-chips style-scope keyword-wizard">
        <span class="chip style-scope keyword-wizard" id="title" selected="">Title</span>
        <span class="chip style-scope keyword-wizard" id="abstract" selected="">Abstract</span>
        <span class="chip style-scope keyword-wizard" id="claims" selected="">Claims</span>
        <span class="chip style-scope keyword-wizard" id="fullDoc" selected="">Full Document</span>
      </div>
      
      <div class="cpc-field style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputCPC" class="style-scope keyword-wizard">or CPC</label></span>
        <div class="cpc-inputs style-scope keyword-wizard">
          <input class="keyword-input style-scope keyword-wizard" id="inputCPC" placeholder="Or search with CPC">
          <input type="checkbox" id="childCPC" checked="" class="style-scope keyword-wizard">
          <label class="checkbox-label style-scope keyword-wizard" for="childCPC">
            Include child classifications
          </label>
        </div>
      </div>
    </div>
    
    <div class="find-patents style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Find patents
        <iron-icon class="help-header style-scope keyword-wizard x-scope iron-icon-0" icon="icons:help-outline" id="searchBoolean"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="searchBooleanHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Keywords and boolean syntax (USPTO or EPO format)</b>:
          <span class="q style-scope keyword-wizard">seat belt</span> searches these two words, or their plurals and close
          synonyms. <span class="q style-scope keyword-wizard">"seat belt"</span> searches this exact phrase, in order.
          <span class="q style-scope keyword-wizard">-seat -belt</span> searches for documents not containing either word.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">For searches using boolean logic</b>, the default operator is
          <span class="q style-scope keyword-wizard">AND</span> with left associativity. <i class="style-scope keyword-wizard">Note:</i> this means
          <span class="q style-scope keyword-wizard">safety OR seat belt</span> is searched as <span class="q style-scope keyword-wizard">(safety OR seat)
          AND belt</span>. Each word automatically includes plurals and close synonyms. Adjacent
          words that are implicitly ANDed together, such as <span class="q style-scope keyword-wizard">(safety belt)</span>,
          are treated as a phrase when generating synonyms.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputAnd" class="style-scope keyword-wizard">with ALL of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputAnd" placeholder="with ALL of the words">
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputExact" class="style-scope keyword-wizard">with the EXACT PHRASE</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputExact" placeholder="with the EXACT PHRASE"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputOr" class="style-scope keyword-wizard">with AT LEAST ONE of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputOr" placeholder="with AT LEAST ONE of the words"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputMinus" class="style-scope keyword-wizard">WITHOUT the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputMinus" placeholder="WITHOUT the words"></div>
    </div>
    <div class="search-by style-scope keyword-wizard">
      <div class="wizard-header style-scope keyword-wizard">
          Search by
          <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="chem"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </div>
      
      <div class="help style-scope keyword-wizard" id="chemHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Chemistry searches</b> match terms (trade names, IUPAC names, etc.
          extracted from the entire document, and processed from .MOL files.)
        </p>
        <p class="style-scope keyword-wizard">Substructure (use <span class="q style-scope keyword-wizard">SSS=</span>) and similarity (use
          <span class="q style-scope keyword-wizard">~</span>) searches are limited to one per search at the top-level
          <span class="q style-scope keyword-wizard">AND</span> condition. Exact searches can be used multiple times throughout
          the search query.
        </p>
        <p class="style-scope keyword-wizard">Searching by SMILES or InChi key requires no special syntax. To search by SMARTS, use
          <span class="q style-scope keyword-wizard">SMARTS=</span>.
        </p>
        <p class="style-scope keyword-wizard">To search for multiple molecules, select "Batch" in the "Type" menu. Enter multiple
          molecules separated by whitespace or by comma.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      
      <div class="chemistry-field style-scope keyword-wizard">
          <span class="input-label style-scope keyword-wizard"><label for="inputChem" class="style-scope keyword-wizard">Chemistry</label></span>
          <span class="chem-type-label style-scope keyword-wizard"><label for="chemType" hidden="" class="style-scope keyword-wizard">Type</label></span>
          <select id="chemType" class="style-scope keyword-wizard">
            <option value="identical" class="style-scope keyword-wizard">Identical</option>
            <option value="substructure" class="style-scope keyword-wizard">Substructure</option>
            <option value="smarts" class="style-scope keyword-wizard">SMARTS</option>
            <option value="similarity" class="style-scope keyword-wizard">Similarity</option>
            <option value="batch" class="style-scope keyword-wizard">Batch</option>
          </select>
          <textarea class="keyword-input style-scope keyword-wizard" id="inputChem" placeholder="Trade name, SMILES, InChiKey"></textarea>
      </div>
      <div class="import style-scope keyword-wizard">
        <div class="wizard-header style-scope keyword-wizard">
          Patent numbers
        </div>
        <span class="import-button style-scope keyword-wizard">
          <a href="https://patents.google.com/import" class="style-scope keyword-wizard"><button class="style-scope keyword-wizard">Import</button></a>
        </span>
        <p class="import-text style-scope keyword-wizard">
          Search specific patents by importing a CSV or list of patent publication or application numbers.
        </p>
      </div>
    </div>
    
    <div class="wizard-buttons style-scope keyword-wizard">
      <button type="reset" class="style-scope keyword-wizard">Close</button>
      <button type="button" autofocus="" class="style-scope keyword-wizard">Add</button>
    </div>
  
  </paper-material>
</div>
</keyword-wizard>
          <overlay-tooltip positioning-target="#wizardIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Display advanced search options
    </div>
  </overlay-tooltip>
        </div>
      </div>
      <paper-material id="suggestMenu" class="style-scope search-box x-scope paper-material-0" elevation="1" hidden="">
    
    

    
        <template is="dom-repeat" class="style-scope search-box"></template>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Sorry, we couldn't find this patent number.
        </div>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> 
        </div>
      
  </paper-material>
      <button id="searchButton" class="style-scope search-box"><iron-icon class="style-scope search-box x-scope iron-icon-0" icon="search"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.5 14h-.79l-.28-.27C15.41 12.59 16 11.11 16 9.5 16 5.91 13.09 3 9.5 3S3 5.91 3 9.5 5.91 16 9.5 16c1.61 0 3.09-.59 4.23-1.57l.27.28v.79l5 4.99L20.49 19l-4.99-5zm-6 0C7.01 14 5 11.99 5 9.5S7.01 5 9.5 5 14 7.01 14 9.5 11.99 14 9.5 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></button>
    </div>
  </search-box>
          <template is="dom-if" class="style-scope search-header"></template>
          <div class="flex style-scope search-header"></div>
          
            <div id="header-container" class="style-scope search-header">
              <result-nav class="style-scope search-header">
    
    <div class="style-scope result-nav" hidden="">
      <state-modifier id="current" act="{&quot;type&quot;: &quot;BACK_TO_RESULTS&quot;}" inherit="" class="style-scope result-nav"><a id="link" href="#" class="style-scope state-modifier" inherit=""><span class="style-scope result-nav"></span> of
      <template is="dom-if" class="style-scope result-nav"></template>
      0<template is="dom-if" class="style-scope result-nav"></template></a></state-modifier>
      <state-modifier id="prevResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-left" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.41 7.41L14 6l-6 6 6 6 1.41-1.41L10.83 12z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier><state-modifier id="nextResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-right" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M10 6L8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier>
      <overlay-tooltip positioning-target="#prevResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Previous result
    </div>
  </overlay-tooltip>
      <overlay-tooltip positioning-target="#nextResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Next result
    </div>
  </overlay-tooltip>
    </div>
  </result-nav>
            </div>
          <template is="dom-if" class="style-scope search-header"></template>
        </div>
      </header>
    </div>
  </search-header>

      <div class="layout horizontal style-scope search-ui">
        <template is="dom-if" class="style-scope search-ui"></template>

        <div id="main" class="style-scope search-ui">
          <search-term-wizard class="style-scope search-ui"><pat-dialog open="" class="style-scope search-term-wizard">
  <span class="header style-scope search-term-wizard">
    <span class="title style-scope search-term-wizard">Search tools</span>
    <span id="language" class="style-scope search-term-wizard">
      <text-button id="textButton" selected="" class="style-scope search-term-wizard">Text
</text-button>
      <text-button id="classificationButton" class="style-scope search-term-wizard">Classification
</text-button>
      <text-button id="chemistryButton" class="style-scope search-term-wizard">Chemistry
</text-button>
      <text-button id="measureButton" class="style-scope search-term-wizard">Measure
</text-button>
      <text-button id="numbersButton" class="style-scope search-term-wizard">Numbers
</text-button>
    </span>
  </span>
  <span id="panels" class="style-scope search-term-wizard">
    <text-search-term-wizard id="textPanel" class="style-scope search-term-wizard" selected=""><span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Type a concept you want to search for here" class="style-scope text-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Type a concept you want to search for here">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="title" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Title</filter-chip>
  <filter-chip id="abstract" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Abstract</filter-chip>
  <filter-chip id="claims" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="all" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
All</filter-chip>
  <filter-chip id="any" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Any</filter-chip>
  <filter-chip id="exact" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="not" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Not</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope text-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope text-search-term-wizard">Add AND condition</span></mat-button></span></text-search-term-wizard>
    <classification-wizard id="classificationPanel" class="style-scope search-term-wizard"><span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope classification-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Enter a CPC here" uppercase="" class="style-scope classification-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Enter a CPC here">
  
</span>
</outlined-text-field>
</span>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope classification-wizard"></path>
  </svg>
  <filter-chip id="notExact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These CPCs and their children
  </filter-chip>
  <filter-chip selected="" id="exact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These exact CPCs
  </filter-chip>
</span>
<span class="style-scope classification-wizard">
  <mat-button id="button" filled="" class="style-scope classification-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope classification-wizard">Add AND condition</span></mat-button>
</span></classification-wizard>
    <chemistry-search-term-wizard id="chemistryPanel" class="style-scope search-term-wizard"><span class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Trade name, SMILES, InChI Key" class="style-scope chemistry-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Trade name, SMILES, InChI Key">
  
</span>
</outlined-text-field>
  <outlined-textarea id="textArea" placeholder="Enter multiple SMILES or InChI Keys, one per line" rows="4" class="style-scope chemistry-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple SMILES or InChI Keys, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
  <a href="https://support.google.com/faqs/answer/7049475#zippy=%2Csearching-by-chemistry" target="_blank" class="style-scope chemistry-search-term-wizard">
    <svg class="help style-scope chemistry-search-term-wizard" xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49">
      <path d="M11.95 18q.525 0 .888-.363.362-.362.362-.887t-.362-.887q-.363-.363-.888-.363t-.888.363q-.362.362-.362.887t.362.887q.363.363.888.363Zm-.9-3.85h1.85q0-.825.188-1.3.187-.475 1.062-1.3.65-.65 1.025-1.238.375-.587.375-1.412 0-1.4-1.025-2.15T12.1 6q-1.425 0-2.312.75-.888.75-1.238 1.8l1.65.65q.125-.45.563-.975Q11.2 7.7 12.1 7.7q.8 0 1.2.437.4.438.4.963 0 .5-.3.937-.3.438-.75.813-1.1.975-1.35 1.475-.25.5-.25 1.825ZM12 22q-2.075 0-3.9-.788-1.825-.787-3.175-2.137-1.35-1.35-2.137-3.175Q2 14.075 2 12t.788-3.9q.787-1.825 2.137-3.175 1.35-1.35 3.175-2.138Q9.925 2 12 2t3.9.787q1.825.788 3.175 2.138 1.35 1.35 2.137 3.175Q22 9.925 22 12t-.788 3.9q-.787 1.825-2.137 3.175-1.35 1.35-3.175 2.137Q14.075 22 12 22Zm0-2q3.35 0 5.675-2.325Q20 15.35 20 12q0-3.35-2.325-5.675Q15.35 4 12 4 8.65 4 6.325 6.325 4 8.65 4 12q0 3.35 2.325 5.675Q8.65 20 12 20Zm0-8Z" class="style-scope chemistry-search-term-wizard"></path>
    </svg>
  </a>
</span>
<span id="chemQuantifiers" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M5 21.2q-1.4 0-2-1.25-.6-1.25.3-2.325l5.5-6.7V5.15h-.825q-.475 0-.8-.338Q6.85 4.475 6.85 4q0-.475.325-.813.325-.337.8-.337h8.05q.475 0 .8.337.325.338.325.813 0 .475-.325.812-.325.338-.8.338H15.2v5.775l5.5 6.7q.9 1.075.3 2.325-.6 1.25-2 1.25Zm2.15-3.275h9.7l-3.275-3.85h-3.15Zm-2 1h13.7l-5.925-7.2V5.15h-1.85v6.575Zm6.85-6.9Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="exact" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="exactBatch" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact Batch</filter-chip>
  <filter-chip id="similar" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Similar</filter-chip>
  <filter-chip id="substructure" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure</filter-chip>
  <filter-chip id="smarts" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure (SMARTS)</filter-chip>
</span>
<span id="location" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="claims" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims only</filter-chip>
</span>
<span class="style-scope chemistry-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope chemistry-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope chemistry-search-term-wizard">Add AND condition</span></mat-button>
</span>
</chemistry-search-term-wizard>
    <measure-search-term-wizard id="measurePanel" class="style-scope search-term-wizard"><span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M4.1 18.15q-.95 0-1.612-.663-.663-.662-.663-1.612v-7.75q0-.95.663-1.613Q3.15 5.85 4.1 5.85h15.8q.95 0 1.613.662.662.663.662 1.613v7.75q0 .95-.662 1.612-.663.663-1.613.663Zm0-2.275h15.8v-7.75H17V12h-2V8.125h-2V12h-2V8.125H9V12H7V8.125H4.1v7.75ZM7 12h2Zm4 0h2Zm4 0h2Zm-3 0Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="measureExpression" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M3.875 20.15V8.85h4.25v11.3Zm6 0V3.85h4.25v16.3Zm6 0v-7.3h4.25v7.3Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="context" placeholder="activity, wavelength, embossing depth, absorption" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="activity, wavelength, embossing depth, absorption">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope measure-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope measure-search-term-wizard">Add AND condition</span></mat-button>
</span>
</measure-search-term-wizard>
    <numerical-search-term-wizard id="numericalPanel" class="style-scope search-term-wizard"><span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-textarea id="batch" placeholder="Enter multiple Patent Application and Publication Numbers, one per line" rows="4" class="style-scope numerical-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple Patent Application and Publication Numbers, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
</span>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="m10.825 23.45-1.6-1.625L10.9 20.15H8q-.35.9-1.162 1.488-.813.587-1.838.587-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.025.588-1.837Q2.95 16.35 3.85 16V8q-.9-.35-1.487-1.163Q1.775 6.025 1.775 5q0-1.35.938-2.288Q3.65 1.775 5 1.775q1.025 0 1.838.587Q7.65 2.95 8 3.85h2.9L9.225 2.175l1.6-1.625L15.275 5l-4.45 4.45-1.6-1.625L10.9 6.15H8q-.25.65-.725 1.125T6.15 8v8q.65.25 1.125.725T8 17.85h2.9l-1.675-1.675 1.6-1.625 4.45 4.45ZM19 22.225q-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.05.588-1.863.587-.812 1.487-1.137V8q-.9-.325-1.487-1.137-.588-.813-.588-1.863 0-1.35.938-2.288.937-.937 2.287-.937 1.35 0 2.288.937.937.938.937 2.288 0 1.05-.587 1.863Q21.05 7.675 20.15 8v8q.9.35 1.488 1.163.587.812.587 1.837 0 1.35-.937 2.288-.938.937-2.288.937ZM5 19.95q.4 0 .675-.275T5.95 19q0-.4-.275-.675T5 18.05q-.4 0-.675.275T4.05 19q0 .4.275.675T5 19.95Zm14 0q.4 0 .675-.275T19.95 19q0-.4-.275-.675T19 18.05q-.4 0-.675.275T18.05 19q0 .4.275.675t.675.275Zm-14-14q.4 0 .675-.275T5.95 5q0-.4-.275-.675T5 4.05q-.4 0-.675.275T4.05 5q0 .4.275.675T5 5.95Zm14 0q.4 0 .675-.275T19.95 5q0-.4-.275-.675T19 4.05q-.4 0-.675.275T18.05 5q0 .4.275.675T19 5.95ZM5 19Zm14 0ZM5 5Zm14 0Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <filter-chip id="applicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Application Numbers</filter-chip>
  <filter-chip id="publicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Publication Numbers</filter-chip>
  <filter-chip id="either" selected="" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Either</filter-chip>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M12 22.2q-2.1 0-3.962-.8-1.863-.8-3.25-2.175Q3.4 17.85 2.6 15.988 1.8 14.125 1.8 12t.8-3.988q.8-1.862 2.188-3.237Q6.175 3.4 8.038 2.6 9.9 1.8 12 1.8q2.125 0 3.988.8 1.862.8 3.237 2.175Q20.6 6.15 21.4 8.012q.8 1.863.8 3.988t-.8 3.988q-.8 1.862-2.175 3.237Q17.85 20.6 15.988 21.4q-1.863.8-3.988.8Zm-1-2.325v-1.95q-.8 0-1.387-.575-.588-.575-.588-1.4v-.975L4.275 10.2q-.075.45-.137.9-.063.45-.063.9 0 3 1.975 5.25T11 19.875Zm6.85-2.525q.5-.55.888-1.175.387-.625.65-1.313.262-.687.4-1.412.137-.725.137-1.45 0-2.425-1.338-4.438-1.337-2.012-3.612-2.887v.375q0 .825-.587 1.4-.588.575-1.388.575h-2v2q0 .4-.287.687-.288.288-.688.288h-2v2h5.95q.425 0 .713.287.287.288.287.688v2.975h1q.65 0 1.163.387.512.388.712 1.013Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryFilter" placeholder="Restrict search to these countries" class="style-scope numerical-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Restrict search to these countries">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M2.85 18.225V15.95h6.3v2.275Zm0-5.075v-2.3h12.3v2.3Zm0-5.1V5.775h18.3V8.05Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryOrder" placeholder="Prefer results from these countries in this order" class="style-scope numerical-search-term-wizard" value="US, EP, WO, JP, CN"><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Prefer results from these countries in this order">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope numerical-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope numerical-search-term-wizard">Add AND condition</span></mat-button>
</span>
</numerical-search-term-wizard>
  </span>

</pat-dialog>
</search-term-wizard>
          
      <div content="" class="style-scope search-result">
        <div id="mainContainer" class="vertical layout style-scope search-result">
          <template is="dom-if" class="style-scope search-result"></template>
          <result-container class="style-scope search-result">
    

    <paper-spinner class="style-scope result-container x-scope paper-spinner-0" aria-hidden="true" hidden=""><div id="spinnerContainer" class="  style-scope paper-spinner"><div class="spinner-layer layer-1 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-2 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-3 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-4 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div></div></paper-spinner>
    
      <patent-result class="style-scope result-container">
    
    
    <div class="layout horizontal style-scope patent-result">
      <div style="width: 1200px; height: auto; overflow: auto;" class="style-scope patent-result">
        <div id="wrapper" tabindex="0" class="style-scope patent-result">
          <result-tags class="style-scope patent-result"></result-tags>
          <h1 id="title" class="scroll-target style-scope patent-result">
            
  ANTIBODIES THAT INHIBIT THE DIMERIZATION OF c-MET AND USES OF THE SAME, MURINO HYBRIDOMA, ANTIBODY, ISOLATED NUCLEIC ACID, VECTOR, METHOD FOR THE PRODUCTION OF ANTIBODY, COMPOSITION, USE AND METHOD OF DIAGNOSIS INTO DETERMINATION OF DEPRESSION AND DETERMINATION DE c-MET
 
     </h1>
          <div class="horizontal layout style-scope patent-result">
            
            <div class="flex-3 style-scope patent-result" style="margin-top:-20px;overflow:hidden;" marginright="">
              <section id="abstract" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Abstract</div>
                  <div class="righthead style-scope patent-result">translated from Portuguese</div>
                </h3>
                <patent-text name="abstract" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><abstract mxw-id="PA368664829" lang="EN" source="national office" load-source="google" class="style-scope patent-text">
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">anticorpos que inibem a dimerização de c-met e usos dos mesmos, hibridoma de murino, anticorpo, ácido nucleico isolado, vetor, método para produção de anticorpo, composição, uso e método de diagnóstico in vitro de enfermidades induzidas por uma superexpressão ou subexpressão do receptor de c-met a presente invenção refere-se a um processo para a seleção de anticorpos anti-c-met capazes de inibir a ativação dependente de ligante e independente de ligante de c-met. mais particularmente, o referido processo é baseado na inibição da dimerização de c-met. em outro aspecto, a presente invenção refere-se a tais anticorpos e composições compreendendo tais anticorpos para o preparo de um medicamento para tratar câncer. processo de diagnóstico e kits também são parte da invenção.</span>antibodies that inhibit c-met dimerization and uses thereof, murine hybridoma, antibody, isolated nucleic acid, vector, method for antibody production, composition, use and in vitro diagnostic method of diseases induced by overexpression or underexpression of c-met receptor the present invention relates to a process for the selection of anti-c-met antibodies capable of inhibiting ligand-dependent and ligand-independent activation of c-met. more particularly, said process is based on the inhibition of c-met dimerization. in another aspect, the present invention relates to such antibodies and compositions comprising such antibodies for the preparation of a medicament for treating cancer. diagnostic process and kits are also part of the invention.</span>
  </p>
</abstract>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <section id="classifications" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Classifications</div>
                  <div id="machineClassifiedWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">machine-classified</div>
                  <div id="machineClassifiedCPCWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">cpc-machine-classified</div>
                  <div id="machineClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-machine-classified</div>
                  <div class="style-scope patent-result" hidden="">&nbsp;</div>
                  <div id="familyClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-family-classified</div>
                </h3>
                <overlay-tooltip positioning-target="#machineClassifiedWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedCPCWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The CPC classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#familyClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned based on a patent family member containing these classification codes.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <classification-viewer class="style-scope patent-result">
    
    <div class="table style-scope classification-viewer">
      
        <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/00"><a id="link" href="#" class="style-scope state-modifier">C07K16/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/18"><a id="link" href="#" class="style-scope state-modifier">C07K16/18</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/28"><a id="link" href="#" class="style-scope state-modifier">C07K16/28</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" first="true" data-cpc="C07K16/2863"><a id="link" href="#" class="style-scope state-modifier">C07K16/2863</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
      <template is="dom-repeat" class="style-scope classification-viewer"></template>
      
      <div class="style-scope classification-viewer">
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K39/00"><a id="link" href="#" class="style-scope state-modifier">A61K39/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing antigens or antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K39/395"><a id="link" href="#" class="style-scope state-modifier">A61K39/395</a></state-modifier>
                  <span class="description style-scope classification-tree">Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K39/39533"><a id="link" href="#" class="style-scope state-modifier">A61K39/39533</a></state-modifier>
                  <span class="description style-scope classification-tree">Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K39/39541"><a id="link" href="#" class="style-scope state-modifier">A61K39/39541</a></state-modifier>
                  <span class="description style-scope classification-tree">Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P1/00"><a id="link" href="#" class="style-scope state-modifier">A61P1/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the alimentary tract or the digestive system</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P1/04"><a id="link" href="#" class="style-scope state-modifier">A61P1/04</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P11/00"><a id="link" href="#" class="style-scope state-modifier">A61P11/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the respiratory system</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P13/00"><a id="link" href="#" class="style-scope state-modifier">A61P13/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the urinary system</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P13/08"><a id="link" href="#" class="style-scope state-modifier">A61P13/08</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the urinary system of the prostate</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P15/00"><a id="link" href="#" class="style-scope state-modifier">A61P15/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for genital or sexual disorders; Contraceptives</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P19/00"><a id="link" href="#" class="style-scope state-modifier">A61P19/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for skeletal disorders</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P35/00"><a id="link" href="#" class="style-scope state-modifier">A61P35/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Antineoplastic agents</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P43/00"><a id="link" href="#" class="style-scope state-modifier">A61P43/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/00"><a id="link" href="#" class="style-scope state-modifier">C07K16/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/18"><a id="link" href="#" class="style-scope state-modifier">C07K16/18</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/28"><a id="link" href="#" class="style-scope state-modifier">C07K16/28</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/30"><a id="link" href="#" class="style-scope state-modifier">C07K16/30</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/00"><a id="link" href="#" class="style-scope state-modifier">C07K16/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/18"><a id="link" href="#" class="style-scope state-modifier">C07K16/18</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/32"><a id="link" href="#" class="style-scope state-modifier">C07K16/32</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/00"><a id="link" href="#" class="style-scope state-modifier">C07K16/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/40"><a id="link" href="#" class="style-scope state-modifier">C07K16/40</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G"><a id="link" href="#" class="style-scope state-modifier">G</a></state-modifier>
                  <span class="description style-scope classification-tree">PHYSICS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01"><a id="link" href="#" class="style-scope state-modifier">G01</a></state-modifier>
                  <span class="description style-scope classification-tree">MEASURING; TESTING</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N"><a id="link" href="#" class="style-scope state-modifier">G01N</a></state-modifier>
                  <span class="description style-scope classification-tree">INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/00"><a id="link" href="#" class="style-scope state-modifier">G01N33/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/48"><a id="link" href="#" class="style-scope state-modifier">G01N33/48</a></state-modifier>
                  <span class="description style-scope classification-tree">Biological material, e.g. blood, urine; Haemocytometers</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/50"><a id="link" href="#" class="style-scope state-modifier">G01N33/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/53"><a id="link" href="#" class="style-scope state-modifier">G01N33/53</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoassay; Biospecific binding assay; Materials therefor</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/574"><a id="link" href="#" class="style-scope state-modifier">G01N33/574</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoassay; Biospecific binding assay; Materials therefor for cancer</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/57484"><a id="link" href="#" class="style-scope state-modifier">G01N33/57484</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/57492"><a id="link" href="#" class="style-scope state-modifier">G01N33/57492</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K39/00"><a id="link" href="#" class="style-scope state-modifier">A61K39/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing antigens or antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="A61K2039/505"><a id="link" href="#" class="style-scope state-modifier">A61K2039/505</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing antigens or antibodies comprising antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/00"><a id="link" href="#" class="style-scope state-modifier">C07K2317/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/20"><a id="link" href="#" class="style-scope state-modifier">C07K2317/20</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features characterized by taxonomic origin</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="C07K2317/24"><a id="link" href="#" class="style-scope state-modifier">C07K2317/24</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/00"><a id="link" href="#" class="style-scope state-modifier">C07K2317/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/70"><a id="link" href="#" class="style-scope state-modifier">C07K2317/70</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="C07K2317/73"><a id="link" href="#" class="style-scope state-modifier">C07K2317/73</a></state-modifier>
                  <span class="description style-scope classification-tree">Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/00"><a id="link" href="#" class="style-scope state-modifier">C07K2317/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/70"><a id="link" href="#" class="style-scope state-modifier">C07K2317/70</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="C07K2317/75"><a id="link" href="#" class="style-scope state-modifier">C07K2317/75</a></state-modifier>
                  <span class="description style-scope classification-tree">Agonist effect on antigen</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/00"><a id="link" href="#" class="style-scope state-modifier">C07K2317/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/70"><a id="link" href="#" class="style-scope state-modifier">C07K2317/70</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="C07K2317/76"><a id="link" href="#" class="style-scope state-modifier">C07K2317/76</a></state-modifier>
                  <span class="description style-scope classification-tree">Antagonist effect on antigen, e.g. neutralization or inhibition of binding</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/00"><a id="link" href="#" class="style-scope state-modifier">C07K2317/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/90"><a id="link" href="#" class="style-scope state-modifier">C07K2317/90</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="C07K2317/92"><a id="link" href="#" class="style-scope state-modifier">C07K2317/92</a></state-modifier>
                  <span class="description style-scope classification-tree">Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        <template is="dom-repeat" class="style-scope classification-viewer"></template>
        <div class="more style-scope classification-viewer" style="" hidden="">View 18 more classifications</div>
        <div class="more style-scope classification-viewer">Hide more classifications</div>
      </div>
      <template is="dom-if" class="style-scope classification-viewer"></template>
    </div>
  </classification-viewer>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              
                <section class="style-scope patent-result">
                  <h3 class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Landscapes</div>
                  </h3>
                  <div class="responsive-grid style-scope patent-result">
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Health &amp; Medical Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Health &amp; Medical Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Chemical &amp; Material Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Chemical &amp; Material Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    <template is="dom-repeat" class="style-scope patent-result"></template>
                  </div>
                  <s-more-inline class="style-scope patent-result"><hr aria-hidden="true" class="style-scope s-more-inline">

<div class="button style-scope s-more-inline">
  <span slot="expand_text" class="style-scope patent-result">Show more</span>
  <span class="expand more style-scope s-more-inline"></span>
</div>
<div class="button style-scope s-more-inline" hidden="">
  <span slot="collapse_text" class="style-scope patent-result">Show less</span>
  <span class="expand less style-scope s-more-inline"></span>
</div>
</s-more-inline>
                </section>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
            <div class="flex-2 style-scope patent-result">
              <section class="knowledge-card style-scope patent-result">
                <header class="style-scope patent-result">
                  <h2 id="pubnum" class="style-scope patent-result">BRPI0815564B1</h2>
                  <p class="tagline style-scope patent-result">Brazil</p>
                  <overlay-tooltip positioning-target="#pubnum" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                    <div style="max-width: 300px;" class="style-scope patent-result">Granted divisional patent</div>
                  
    </div>
  </overlay-tooltip>

                  <div class="knowledge-card-action-bar style-scope patent-result">
                    <a target="_blank" class="style-scope patent-result" href="https://patentimages.storage.googleapis.com/67/cb/aa/b116b52bad5922/BRPI0815564B1.pdf"><iron-icon icon="description" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download PDF</a>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_FIND_PRIOR_ART&quot;, &quot;keywords&quot;: $keywords, &quot;before&quot;: &quot;$before&quot;}" class="style-scope patent-result" data-keywords="[&quot;antibody&quot;,&quot;met&quot;,&quot;antibodies&quot;,&quot;cdr&quot;,&quot;murine&quot;]" data-before="20070712"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="find-in-page" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 19.59V8l-6-6H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c.45 0 .85-.15 1.19-.4l-4.43-4.43c-.8.52-1.74.83-2.76.83-2.76 0-5-2.24-5-5s2.24-5 5-5 5 2.24 5 5c0 1.02-.31 1.96-.83 2.75L20 19.59zM9 13c0 1.66 1.34 3 3 3s3-1.34 3-3-1.34-3-3-3-3 1.34-3 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Find Prior Art
                    </a></state-modifier>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_SIMILAR_DOCUMENTS&quot;, &quot;id&quot;: &quot;$id&quot;}" class="style-scope patent-result" data-id="patent/BRPI0815564B1"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="editor:functions" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M18 4H6v2l6.5 6L6 18v2h12v-3h-7l5-5-5-5h7z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Similar
                    </a></state-modifier>
                  </div>
                </header>

                <dl class="important-people style-scope patent-result">
                  
                    <dt class="style-scope patent-result">Other languages</dt>
                    <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/BRPI0815564B1/pt"><a id="link" href="#" class="style-scope state-modifier">Portuguese</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                  
                  <dt class="style-scope patent-result">Inventor</dt>
                  <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Goetsch Liliane"><a id="link" href="#" class="style-scope state-modifier">Goetsch Liliane</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>

                  <template is="dom-if" class="style-scope patent-result"></template>
                </dl>

                <hr class="style-scope patent-result">

                <application-timeline class="style-scope patent-result">
    
    
    <div class="wrap style-scope application-timeline">
      <div class="header style-scope application-timeline">Worldwide applications</div>
      <div class="event style-scope application-timeline">
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2007</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP2014681A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP07301231A</div>
                <div class="style-scope application-timeline">Filing date: 2007-07-12</div>
                <div class="style-scope application-timeline">Legal status: Withdrawn</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2008</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/MY158756A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">MY</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: MYPI2010000127A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CN103509112B/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">CN</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CN201310478511.XA</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/NZ613716A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">NZ</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: NZ613716A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP2535356B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP12183761.1A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/PL2188312T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">PL</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PL08786050T</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/SG183015A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">SG</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: SG2012050837A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/PA8789201A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">PA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PA20088789201A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CN103509113B/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">CN</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CN201310478556.7A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/ES2678495T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">ES</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: ES11162720.4T</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/DK2188312T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">DK</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: DK08786050.8T</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/HUE026026T2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">HU</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: HUE08786050A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP2535357B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP12183763.7A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP2415784B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP11162718.8A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/ES2693542T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">ES</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: ES12183763.7T</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CA2981821C/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">CA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CA2981821A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP2188312B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP08786050.8A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/MX353449B/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">MX</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: MX2014007693A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CA2694418C/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">CA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CA2694418A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CN103183739B/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">CN</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CN201310073997.9A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CA2888691C/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">CA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CA2888691A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/ES2542059T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">ES</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: ES08786050.8T</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/BRPI0815564B8/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline" this="">BR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: BRPI0815564A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: IP Right Grant</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/ME02341B/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">ME</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: MEP-2016-197A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/NZ583041A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">NZ</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: NZ583041A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/ES2686335T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">ES</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: ES11162718.8T</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/KR101701686B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">KR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: KR1020167002899A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: IP Right Grant</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/AU2008274171B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">AU</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: AU2008274171A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/KR101719084B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">KR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: KR1020157015922A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: IP Right Grant</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JP5562844B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">JP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: JP2010515513A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/KR101625234B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">KR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: KR1020107003216A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: IP Right Grant</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/RU2552161C2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">RU</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: RU2010104633/10A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP2415785B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP11162720.4A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/WO2009007427A2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">WO</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PCT/EP2008/059026</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: Application Filing</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CN101981054B/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">CN</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CN200880024368.4A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/RS54197B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">RS</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: RS20150560A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US8329173B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US12/440,571</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CA2982484C/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">CA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CA2982484A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/MX345391B/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">MX</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: MX2014008274A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/SI2188312T1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">SI</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: SI200831467T</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/PT2188312E/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">PT</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PT87860508T</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/ES2686693T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">ES</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: ES12183761.1T</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CL2008002015A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">CL</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CL2008002015A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/NZ599959A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">NZ</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: NZ599959A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/KR101701685B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">KR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: KR1020167002898A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: IP Right Grant</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/NZ599958A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">NZ</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: NZ599958A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-10</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/TWI592427B/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">TW</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: TW103121603A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-11</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/TWI549965B/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">TW</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: TW097126356A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-11</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/AR067517A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">AR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: ARP080102991A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-11</div>
                <div class="style-scope application-timeline">Legal status: IP Right Grant</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/TWI602829B/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">TW</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: TW104114444A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-11</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/TWI602830B/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">TW</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: TW104114445A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-11</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/SA08290423B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">SA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: SA08290423A</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-12</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2010</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/IL203114A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">IL</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: IL203114A</div>
                <div class="style-scope application-timeline">Filing date: 2010-01-03</div>
                <div class="style-scope application-timeline">Legal status: IP Right Grant</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/TN2010000016A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">TN</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: TNP2010000016A</div>
                <div class="style-scope application-timeline">Filing date: 2010-01-08</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/MX341012B/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">MX</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: MX2013010752A</div>
                <div class="style-scope application-timeline">Filing date: 2010-01-08</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/MA31977B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">MA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: MA32608A</div>
                <div class="style-scope application-timeline">Filing date: 2010-02-10</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/ZA201000966B/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">ZA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: ZA2010/00966A</div>
                <div class="style-scope application-timeline">Filing date: 2010-02-10</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CO6170364A2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">CO</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CO10016035A</div>
                <div class="style-scope application-timeline">Filing date: 2010-02-12</div>
                <div class="style-scope application-timeline">Legal status: IP Right Grant</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2011</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/HK1193620A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">HK</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: HK14106930.4A</div>
                <div class="style-scope application-timeline">Filing date: 2011-03-28</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/HK1193619A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">HK</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: HK14106929.7A</div>
                <div class="style-scope application-timeline">Filing date: 2011-03-28</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/HK1149024A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">HK</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: HK11103062.4A</div>
                <div class="style-scope application-timeline">Filing date: 2011-03-28</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2012</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US8871909B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US13/673,690</div>
                <div class="style-scope application-timeline">Filing date: 2012-11-09</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US8889832B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US13/673,726</div>
                <div class="style-scope application-timeline">Filing date: 2012-11-09</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US8871910B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US13/673,716</div>
                <div class="style-scope application-timeline">Filing date: 2012-11-09</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US9107907B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US13/673,752</div>
                <div class="style-scope application-timeline">Filing date: 2012-11-09</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/IL223106B/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">IL</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: IL223106A</div>
                <div class="style-scope application-timeline">Filing date: 2012-11-18</div>
                <div class="style-scope application-timeline">Legal status: IP Right Grant</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/IL223105B/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">IL</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: IL223105A</div>
                <div class="style-scope application-timeline">Filing date: 2012-11-18</div>
                <div class="style-scope application-timeline">Legal status: IP Right Grant</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/IL223108B/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">IL</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: IL223108A</div>
                <div class="style-scope application-timeline">Filing date: 2012-11-18</div>
                <div class="style-scope application-timeline">Legal status: IP Right Grant</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/IL223109B/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">IL</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: IL223109A</div>
                <div class="style-scope application-timeline">Filing date: 2012-11-18</div>
                <div class="style-scope application-timeline">Legal status: IP Right Grant</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2014</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JP5889925B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">JP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: JP2014000618A</div>
                <div class="style-scope application-timeline">Filing date: 2014-01-06</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JP5889924B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">JP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: JP2014000617A</div>
                <div class="style-scope application-timeline">Filing date: 2014-01-06</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JP5889923B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">JP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: JP2014000616A</div>
                <div class="style-scope application-timeline">Filing date: 2014-01-06</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2015</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US20150252114A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US14/660,046</div>
                <div class="style-scope application-timeline">Filing date: 2015-03-17</div>
                <div class="style-scope application-timeline">Legal status: Abandoned</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CY1116608T1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">CY</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CY20151100680T</div>
                <div class="style-scope application-timeline">Filing date: 2015-08-04</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/HRP20150887T1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">HR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: HRP20150887TT</div>
                <div class="style-scope application-timeline">Filing date: 2015-08-20</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2017</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/AR109659A2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">AR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: ARP170102558A</div>
                <div class="style-scope application-timeline">Filing date: 2017-09-15</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/AR109660A2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">AR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: ARP170102559A</div>
                <div class="style-scope application-timeline">Filing date: 2017-09-15</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/AR109535A2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">AR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: ARP170102560A</div>
                <div class="style-scope application-timeline">Filing date: 2017-09-15</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2018</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/PH12018502040A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">PH</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PH12018502040A</div>
                <div class="style-scope application-timeline">Filing date: 2018-09-24</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/PH12018502038A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">PH</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PH12018502038A</div>
                <div class="style-scope application-timeline">Filing date: 2018-09-24</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/PH12018502039A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">PH</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PH12018502039A</div>
                <div class="style-scope application-timeline">Filing date: 2018-09-24</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        <template is="dom-repeat" class="style-scope application-timeline"></template>
      </div>
      <hr class="style-scope application-timeline">
      <div class="header style-scope application-timeline">Application BRPI0815564A events <iron-icon id="legal" icon="icons:help-outline" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        <overlay-tooltip positioning-target="#legal" direction="right" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
          <div style="max-width: 300px;" class="style-scope application-timeline">
            A timeline of key events for this patent application, including priority claims, publications, legal status, reassignments, and litigation.<br class="style-scope application-timeline"><br class="style-scope application-timeline">
            Google has not performed a legal analysis and makes no representation as to the accuracy or completeness of the events listed.
          </div>
        
    </div>
  </overlay-tooltip>
      </div>
      <div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="litigation style-scope application-timeline"></div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><a target="_blank" class="style-scope application-timeline" href="https://patents.darts-ip.com/?family=38871713&amp;utm_source=google_patent&amp;utm_medium=platform_link&amp;utm_campaign=public_patent_search&amp;patent=BRPI0815564(B1)"><span class="title-text style-scope application-timeline">First worldwide family litigation filed</span></a><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><iron-icon id="icon" icon="icons:help-outline" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><overlay-tooltip positioning-target="#icon" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      <div class="description-item style-scope application-timeline">"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.</div><template is="dom-repeat" class="style-scope application-timeline"></template>
    </div>
  </overlay-tooltip><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="filed style-scope application-timeline">2008-07-10</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_ASSIGNEE&quot;, &quot;assignee&quot;: &quot;$assignee&quot;}" class="style-scope application-timeline" data-assignee="Pf Medicament"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Application filed by Pf Medicament</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2015-02-18</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/BRPI0815564A2/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of BRPI0815564A2</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2020-01-21</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/BRPI0815564B1/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of BRPI0815564B1</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2021-05-25</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/BRPI0815564B8/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of BRPI0815564B8</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><template is="dom-repeat" strip-whitespace="" class="style-scope application-timeline"></template>
      <template is="dom-if" class="style-scope application-timeline"></template>
    </div>
  </application-timeline>
                <hr class="style-scope patent-result">

                <dl class="links style-scope patent-result">
                  <dt class="style-scope patent-result">Info</dt>

                  
                  <dd class="style-scope patent-result"><a href="#patentCitations" class="style-scope patent-result">Patent citations (33)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#citedBy" class="style-scope patent-result">Cited by (97)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#legalEvents" class="style-scope patent-result">Legal events</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#similarDocuments" class="style-scope patent-result">Similar documents</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#relatedApplications" class="style-scope patent-result">Priority and Related Applications</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <dt class="style-scope patent-result">External links</dt>

                  <dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://worldwide.espacenet.com/publicationDetails/biblio?CC=BR&amp;NR=PI0815564B1&amp;KC=B1&amp;FT=D">Espacenet</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://globaldossier.uspto.gov/#/result/publication/BR/PI0815564/1">Global Dossier</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patents.stackexchange.com/questions/tagged/BRPI0815564B1">Discuss</a></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                </dl>
              </section>
            </div>
          </div>

          <div id="text" class="horizontal layout style-scope patent-result">
            <div class="flex flex-width style-scope patent-result" marginright="">
              <section id="description" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Description</div>
                  <div class="righthead style-scope patent-result">translated from Portuguese</div>
                </h3>
                <patent-text name="description" id="descriptionText" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><description mxw-id="PDES243927345" lang="EN" load-source="google" class="style-scope patent-text">
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Relatório Descritivo da Patente de Invenção para ANTICORPOS QUE INIBEM A DIMERIZAÇÃO DE c-MET E USOS DOS MESMOS, HIBRIDOMA DE MURINO, ANTICORPO, ÁCIDO NUCLEICO ISOLADO, VETOR, MÉTODO PARA PRODUÇÃO DE ANTICORPO, COMPOSIÇÃO, USO E MÉTODO DE DIAGNÓSTICO IN VITRO DE ENFERMIDADES INDUZIDAS POR UMA SUPEREXPRESSÃO OU SUBEXPRESSÃO DO RECEPTOR DE cMET.</span>Invention Patent Descriptive Report for ANTIBODIES THAT INHIBIT THE DIMERIZATION OF c-MET AND USES OF THE SAME, MURINO HYBRIDOMA, ANTIBODY, ISOLATED NUCLEIC ACID, VECTOR, METHOD FOR THE PRODUCTION OF ANTIBODY, COMPOSITION, USE AND METHOD OF THE INNOVATION OF DIAGNOSIS INDUCED BY OVEREXPRESSION OR UNDEREXPRESSION OF THE cMET RECEIVER.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CAMPO TÉCNICO [0001] A presente invenção refere-se a novos anticorpos capazes de se ligar especificamente ao receptor c-Met humano e/ou capaz de inibir especificamente a atividade de quinase de tirosina do referido receptor, especialmente anticorpos monoclonais originários de murino, quiméricos e humanizados, bem como as sequências de aminoácido e ácido nucleico que codificam esses anticorpos. Mais particularmente, anticorpos de acordo com a invenção são capazes de inibir a dimerização de c-Met. A invenção, da mesma forma, compreende o uso desses anticorpos como um medicamento para o tratamento profilático e/ou terapêutico de cânceres e qualquer patologia relacionada à superexpressão do referido receptor, bem como em processos ou kits para diagnóstico de enfermidades relacionadas à superexpressão de c-Met. A invenção, finalmente, compreende produtos e/ou composições compreendendo tais anticorpos em combinação com outros anticorpos e/ou compostos químicos direcionados contra outros fatores de crescimento envolvidos em progressão ou metástase de tumor e/ou compostos e/ou agentes anticâncer ou agentes conjugados com toxinas e seu uso para a prevenção e/ou tratamento de determinados cânceres.</span>TECHNICAL FIELD [0001] The present invention relates to new antibodies capable of specifically binding to the human c-Met receptor and / or capable of specifically inhibiting the tyrosine kinase activity of said receptor, especially chimeric murine monoclonal antibodies and humanized, as well as the amino acid and nucleic acid sequences that encode these antibodies. More particularly, antibodies according to the invention are able to inhibit dimerization of c-Met. The invention, likewise, comprises the use of these antibodies as a medicine for the prophylactic and / or therapeutic treatment of cancers and any pathology related to the overexpression of said receptor, as well as in processes or kits for diagnosing diseases related to overexpression of cancer. -Met. The invention, finally, comprises products and / or compositions comprising such antibodies in combination with other antibodies and / or chemical compounds directed against other growth factors involved in tumor progression or metastasis and / or anticancer compounds and / or agents or agents conjugated to toxins and their use for the prevention and / or treatment of certain cancers.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ANTECEDENTES DA INVENÇÃO [0002] Agentes direcionados à quinase de tirosina de receptor</span>BACKGROUND OF THE INVENTION [0002] Agents targeting receptor tyrosine kinase</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 15/146</span>Petition 870190095443, of 24/09/2019, p. 15/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2/131 (RTK), tais como os inibidores trastuzumab, cetuximab, bevacizumab, imatinib e gefitinib, têm ilustrado o interesse de direcionamento dessa classe de proteína para o tratamento de cânceres selecionados.</span>2/131 (RTK), such as the inhibitors trastuzumab, cetuximab, bevacizumab, imatinib and gefitinib, have illustrated the interest in targeting this class of protein for the treatment of selected cancers.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0003] c-Met é o membro protótipo de uma subfamília de RTKs a qual também inclui RON e SEA. A família de RTK c-Met é estruturalmente diferente das outras famílias de RTK e é o único receptor de alta afinidade conhecido para o fator de crescimento de hepatócito (HGF), também denominado fator de dispersão (SF) [D.P. Bottaro et al., Science 1991, 251: 802-804; L. Naldini et al., Eur. Mol. Biol. Org. J. 1991, 10: 2867-2878]. c-Met e HGF são amplamente expressas em uma variedade de tecidos e sua expressão está normalmente restrita à células de origem epitelial e mesenquimal, respectivamente [M.F. Di Renzo et al., Oncogene 1991, 6: 1997-2003; E. Sonnenberg et al., J. Cell. Biol. 1993, 123: 223-235]. Elas são requeridas para desenvolvimento normal de mamíferos e foi mostrado que são particularmente importantes em migração celular, diferenciação morfogênica e organização das estruturas tubulares tridimensionais, bem como crescimento e angiogênese [F. Baldt et al., Nature 1995, 376: 768-771; C. Schmidt et al., Nature. 1995: 373:699702; Tsarfaty et al., Science 1994, 263: 98-101]. Embora tenha sido mostrado que a regulação controlada de c-Met e HGF é importante no desenvolvimento, manutenção e reparo tecidual de mamíferos [Nagayama T, Nagayama M, Kohara S, Kamiguchi H, Shibuya M, Katoh Y, Itoh J, Shinohara Y., Brain Res. 2004, 5; 999(2): 155-66; Tahara Y, Ido A, Yamamoto S, Miyata Y, Uto H, Hori T, Hayashi K, Tsubouchi H., J Pharmacol Exp Ther. 2003, 307(1): 146-51], sua desregulação está envolvida na progressão de cânceres.</span>[0003] c-Met is the prototype member of a subfamily of RTKs which also includes RON and SEA. The c-Met RTK family is structurally different from other RTK families and is the only known high affinity receptor for hepatocyte growth factor (HGF), also called dispersion factor (SF) [D.P. Bottaro et al., Science 1991, 251: 802-804; L. Naldini et al., Eur. Mol. Biol. Org. J. 1991, 10: 2867-2878]. c-Met and HGF are widely expressed in a variety of tissues and their expression is normally restricted to cells of epithelial and mesenchymal origin, respectively [M.F. Di Renzo et al., Oncogene 1991, 6: 1997-2003; E. Sonnenberg et al., J. Cell. Biol. 1993, 123: 223-235]. They are required for normal mammalian development and have been shown to be particularly important in cell migration, morphogenic differentiation and organization of three-dimensional tubular structures, as well as growth and angiogenesis [F. Baldt et al., Nature 1995, 376: 768-771; C. Schmidt et al., Nature. 1995: 373: 699702; Tsarfaty et al., Science 1994, 263: 98-101]. Although controlled regulation of c-Met and HGF has been shown to be important in mammalian tissue development, maintenance and repair [Nagayama T, Nagayama M, Kohara S, Kamiguchi H, Shibuya M, Katoh Y, Itoh J, Shinohara Y. , Brain Res. 2004, 5; 999 (2): 155-66; Tahara Y, Ido A, Yamamoto S, Miyata Y, Uto H, Hori T, Hayashi K, Tsubouchi H., J Pharmacol Exp Ther. 2003, 307 (1): 146-51], its deregulation is involved in the progression of cancers.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0004] Sinalização anormal acionada por inativação inapropriada de c-Met é uma das alterações mais frequentes observadas em cânceres humanos e exerce um papel crucial em tumorigênese e</span>[0004] Abnormal signaling triggered by inappropriate c-Met inactivation is one of the most frequent changes seen in human cancers and plays a crucial role in tumorigenesis and</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 16/146</span>Petition 870190095443, of 24/09/2019, p. 16/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">3/131 metástase [Birchmeier et al., Nat. Rev. Mol. Cell Biol. 2003, 4: 915925; L. Trusolino e Comoglio P. M., Nat Rev. Cancer. 2002, 2(4): 289300].</span>3/131 metastasis [Birchmeier et al., Nat. Rev. Mol. Cell Biol. 2003, 4: 915925; L. Trusolino and Comoglio P. M., Nat Rev. Cancer. 2002, 2 (4): 289300].</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0005] Ativação inapropriada de c-Met pode surgir através de mecanismos dependente de ligantes e independentes de ligantes, os quais incluem superexpressão de c-Met e/ou ativação parácrina ou autócrina ou obtendo uma mutação de função [J.G. Christensen, Burrows J. e Salgia R., Cancer Latters. 2005, 226: 1-26]. Contudo, uma oligomerização do receptor de c-Met, na presença ou ausência do ligante, é requerida para regular a afinidade de ligação e cinética de ligação da quinase com relação ao ATP e substratos peptídicos contendo tirosina [Hays JL, Watowich SJ, Biochemistry, 17 de Agosto de 2004, 43: 10570-8]. A c-Met ativada recruta efetuadores de sinalização a seu sítio de multiancoragem localizado no domínio citoplásmico, resultando na ativação de diversas vias de sinalização chave, incluindo Ras-MAPK, PI3K, Src e Stat3 [Gao CF, Vande Woude GF, Cell Res. 2005, 15(1): 49-51; Furge KA, Zhang YW, Vande Woude GF, Oncogene. 2000, 19(49): 5582-9]. Essas vias são essenciais para proliferação, invasão e angiogênese de células tumorais e para evasão de apoptose [Furge KA, Zhang YW, Vande Woude GF, Oncogene,</span>[0005] Inappropriate activation of c-Met can arise through ligand-dependent and ligand-independent mechanisms, which include overexpression of c-Met and / or paracrine or autocrine activation or by obtaining a function mutation [J.G. Christensen, Burrows J. and Salgia R., Cancer Latters. 2005, 226: 1-26]. However, an oligomerization of the c-Met receptor, in the presence or absence of the ligand, is required to regulate the binding affinity and kinetics of kinase binding with respect to ATP and peptide substrates containing tyrosine [Hays JL, Watowich SJ, Biochemistry, August 17, 2004, 43: 10570-8]. The activated c-Met recruits signaling effectors to its multi-anchor site located in the cytoplasmic domain, resulting in the activation of several key signaling pathways, including Ras-MAPK, PI3K, Src and Stat3 [Gao CF, Vande Woude GF, Cell Res. 2005, 15 (1): 49-51; Furge KA, Zhang YW, Vande Woude GF, Oncogene. 2000, 19 (49): 5582-9]. These pathways are essential for tumor cell proliferation, invasion and angiogenesis and for evasion of apoptosis [Furge KA, Zhang YW, Vande Woude GF, Oncogene,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2000, 19(49): 5582-9; Gu H, Neel BG, Trends Cell Biol. Março de 2003, 13(3): 122-30; Fan S, Ma YX, Wang JA, Yuan RQ, Meng Q, Cao Y, Laterra JJ, Goldberg ID, Rosen EM, Oncogene. 27 de Abril de 2000, 19(18): 2212-23]. Além disso, uma faceta única da sinalização de cMet com relação à outras RTKs é sua interação reportada com complexos de adesão focal e parceiros de ligação de não-quinase, tais como integrinas α6β4 [Trusolino L, Bertotti A, Comoglio PM, Cell.</span>2000, 19 (49): 5582-9; Gu H, Neel BG, Trends Cell Biol. March 2003, 13 (3): 122-30; Fan S, Ma YX, Wang JA, Yuan RQ, Meng Q, Cao Y, Laterra JJ, Goldberg ID, Rosen EM, Oncogene. April 27, 2000, 19 (18): 2212-23]. In addition, a unique facet of cMet signaling compared to other RTKs is its reported interaction with focal adhesion complexes and non-kinase binding partners, such as α6β4 integrins [Trusolino L, Bertotti A, Comoglio PM, Cell.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2001, 107: 643-54], CD44v6 [Van der Voort R, Taher TE, Wielenga VJ, Spaargaren M, Prevo R, Smit L, David G, Hartmann G, Gherardi E, Pals ST, J Biol Chem. 1999, 274(10): 6499-506], Plexina B1 ou</span>2001, 107: 643-54], CD44v6 [Van der Voort R, Taher TE, Wielenga VJ, Spaargaren M, Prevo R, Smit L, David G, Hartmann G, Gherardi E, Pals ST, J Biol Chem. 1999, 274 (10): 6499-506], Plexin B1 or</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 17/146</span>Petition 870190095443, of 24/09/2019, p. 17/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">4/131 semaforinas [Giordano S, Corso S, Conrotto P, Artigiani S, Gilestro G, Barberis D, Tamagnone L, Comoglio PM, Nat Cell Biol. 2002, 4(9): 720-4; Conrotto P, Valdembri D, Corso S, Serini G, 5 Tamagnone L, Comoglio PM, Bussolino F, Giordano S, Blood. 2005, 105(11): 4321-9; Conrotto P, Corso S, Gamberini S, Comoglio PM, Giordano S, Oncogene. 2004, 23: 5131-7], as quais podem ainda se somar à complexidade de regulação de função celular por esse receptor. Finalmente, dados recentes demonstram que a c-Met poderia estar envolvida em resistência do tumor ao gefitinib ou erlotinib, sugerindo que combinações de compostos que objetivam o EGFR e c-Met poderiam ser de interesse significativo [Engelman JA et al., Science, 2007, 316: 1039-43].</span>4/131 semaphorins [Giordano S, Corso S, Conrotto P, Artigiani S, Gilestro G, Barberis D, Tamagnone L, Comoglio PM, Nat Cell Biol. 2002, 4 (9): 720-4; Conrotto P, Valdembri D, Corso S, Serini G, 5 Tamagnone L, Comoglio PM, Bussolino F, Giordano S, Blood. 2005, 105 (11): 4321-9; Conrotto P, Corso S, Gamberini S, Comoglio PM, Giordano S, Oncogene. 2004, 23: 5131-7], which can also add to the complexity of regulation of cellular function by this receptor. Finally, recent data demonstrate that c-Met could be involved in tumor resistance to gefitinib or erlotinib, suggesting that combinations of compounds that target EGFR and c-Met could be of significant interest [Engelman JA et al., Science, 2007 , 316: 1039-43].</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0006] Nos últimos anos, muitas estratégias diferentes foram desenvolvidas para atenuar a sinalização à c-Met em linhagens de células cancerígenas. Essas estratégias incluem i) neutralização de anticorpos contra c-Met ou HGF/SF [Cao B, Su Y, Oskarsson M, Zhao P, Kort EJ, Fisher RJ, Wang LM, Vande Woude GF, Proc Natl Acad Sci US. 2001, 98(13): 7443-8; Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, Westphal M, Lamszus K, Clin Cancer Res. 2006, 12(20): 6144-52] ou o uso do antagonista de HGF/SF, NK4, para prevenir ligação de ligante à c-Met [Kuba K, Matsumoto K, Date K, Shimura H, Tanaka M, Nakamura T, Cancer Res., 2000, 60: 6737-43], ii) pequenos inibidores do sítio de ligação de ATP à c-Met que bloqueiam a atividade de quinase [Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R, Lipson KE, Ramphal J, Do S, Cui JJ, Cherrington JM, Mendel DB, Cancer Res. 2003, 63: 7345-55], iii) polipeptídeo com domínio SH2 manipulado que interfere com o acesso ao sítio de multiancoragem e RNAi ou ribozima que reduz a expressão do receptor ou ligante. A maioria dessas abordagens mostra uma inibição</span>[0006] In recent years, many different strategies have been developed to mitigate c-Met signaling in cancer cell lines. These strategies include i) neutralization of antibodies against c-Met or HGF / SF [Cao B, Su Y, Oskarsson M, Zhao P, Kort EJ, Fisher RJ, Wang LM, Vande Woude GF, Proc Natl Acad Sci US. 2001, 98 (13): 7443-8; Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, Westphal M, Lamszus K, Clin Cancer Res. 2006, 12 (20): 6144-52] or the use of the HGF / SF antagonist, NK4 , to prevent ligand binding to c-Met [Kuba K, Matsumoto K, Date K, Shimura H, Tanaka M, Nakamura T, Cancer Res., 2000, 60: 6737-43], ii) small inhibitors of the binding site of ATP to c-Met that block kinase activity [Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R, Lipson KE, Ramphal J, Do S, Cui JJ, Cherrington JM, Mendel DB, Cancer Res. 2003, 63: 7345-55], iii) polypeptide with a manipulated SH2 domain that interferes with access to the multi-anchor site and RNAi or ribozyme that reduces receptor expression or binder. Most of these approaches show an inhibition</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 18/146</span>Petition 870190095443, of 24/09/2019, p. 18/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5/131 seletiva de c-Met, resultando em inibição de tumor e mostrando que cMet poderia ser de interesse para intervenção terapêutica em câncer.</span>5/131 selective c-Met, resulting in tumor inhibition and showing that cMet could be of interest for therapeutic intervention in cancer.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0007] Dentro das moléculas geradas para direcionamento de cMet, algumas são anticorpos gerados pela Genentech [W096/38557], os quais se comportam como um agonista potente quando adicionados isoladamente em vários modelos e como um antagonista quando usados como um fragmento Fab. Uma forma monovalente manipulada desse anticorpo descrita como 5D5 one armed (OA5D5) e produzida como uma proteína recombinante em E. coli é também o assunto de um pedido de patente [WO2006/015371] pela Genentech. Contudo, essa molécula, que não pode ser considerada como um anticorpo em virtude de sua base particular, mostra também mutações que poderiam ser imunogênicas em seres humanos. Em termos de atividade, essa molécula não glicosilada é desprovida de funções efetuadoras e, finalmente, não existe dados claros demonstrando que o OA5D5 inibe a dimerização de c-Met. Além disso, quando testado no modelo in vivo G55, uma linhagem de célula de glioblastoma que expressa c-Met, mas não mRNA e proteína de HGF e que cresce independentemente do ligante, o anti-c-Met one armed não teve efeito significativo sobre o crescimento do tumor G55, sugerindo que o OA5D5 atua primariamente através de bloqueio de ligação de HGF e não é capaz de direcionar tumores ativados independentemente de HGF [Martens T. et al., Clin. Cancer Res., 2006, 12(20): 6144-6152]. [0008] Outro anticorpo que direciona a c-Met é descrito pela Pfizer como um anticorpo que atua predominantemente como antagonista de c-Met e, em alguns casos, como um agonista de c-Met [WO 2005/016382]. Nenhum dado mostrando qualquer efeito dos anticorpos da Pfizer sobre a dimerização de c-Met é descrito nesse pedido.</span>[0007] Within the molecules generated for targeting cMet, some are antibodies generated by Genentech [W096 / 38557], which behave as a potent agonist when added alone in various models and as an antagonist when used as a Fab fragment. One monovalent manipulated form of that antibody described as 5D5 one armed (OA5D5) and produced as a recombinant protein in E. coli is also the subject of a patent application [WO2006 / 015371] by Genentech. However, this molecule, which cannot be considered as an antibody because of its particular base, also shows mutations that could be immunogenic in humans. In terms of activity, this non-glycosylated molecule is devoid of effector functions and, finally, there is no clear data demonstrating that OA5D5 inhibits c-Met dimerization. In addition, when tested on the G55 in vivo model, a glioblastoma cell line that expresses c-Met, but not mRNA and HGF protein and that grows independently of the ligand, anti-c-Met one armed had no significant effect on the growth of the G55 tumor, suggesting that OA5D5 acts primarily by blocking HGF binding and is unable to target activated tumors independently of HGF [Martens T. et al., Clin. Cancer Res., 2006, 12 (20): 6144-6152]. [0008] Another antibody that targets c-Met is described by Pfizer as an antibody that acts predominantly as a c-Met antagonist and, in some cases, as a c-Met agonist [WO 2005/016382]. No data showing any effect of Pfizer antibodies on c-Met dimerization is described in that application.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0009] Um dos aspectos inovadores da presente invenção é gerar</span>[0009] One of the innovative aspects of the present invention is to generate</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 19/146</span>Petition 870190095443, of 24/09/2019, p. 19/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">6/131 anticorpos monoclonais de camundongo sem atividade agonista intrínseca e inibição de dimerização de c-Met. Além de direcionamento de tumores dependente de ligantes, essa abordagem também confere ativações independente de ligantes de c-Met em virtude de sua superexpressão ou mutações dos domínios intracelulares os quais permaneceram dependentes de oligomerização para sinalização. Outro aspecto da atividade de tais anticorpos poderia ser um impedimento estérico para interação de c-Met com seus parceiros, que resultará em falha de funções de c-Met. Esses anticorpos serão, de preferência, humanizados e manipulados, mas não limitados a, como IgG1 humana para proporcionar funções efetuadoras, tais como ADCC e CDC, além de funções relacionadas ao bloqueio específico do receptor de c-Met.</span>6/131 mouse monoclonal antibodies without intrinsic agonist activity and inhibition of c-Met dimerization. In addition to ligand-dependent tumor targeting, this approach also confers independent activations of c-Met ligands due to their overexpression or mutations of the intracellular domains which remained dependent on oligomerization for signaling. Another aspect of the activity of such antibodies could be a steric impediment to interaction of c-Met with its partners, which will result in failure of c-Met functions. These antibodies will preferably be humanized and manipulated, but not limited to, as human IgG1 to provide effector functions, such as ADCC and CDC, in addition to functions related to specific c-Met receptor blockade.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DESCRIÇÃO DA INVENÇÃO [00010] Surpreendentemente, pela primeira vez, conseguiu-se gerar um anticorpo capaz de ligação à c-Met, mas também capaz de inibir a dimerização de c-Met. Se for verdade que, na técnica anterior, algumas vezes é sugerido que um anticorpo capaz de inibição da dimerização de c-Met com seus parceiros poderia ser interessante, nunca foi divulgado ou claramente sugerido um anticorpo capaz de fazer isso. Além disso, com relação à especificidade do anticorpo, não era evidente de maneira alguma como proceder a geração de tal anticorpo ativo.</span>DESCRIPTION OF THE INVENTION [00010] Surprisingly, for the first time, it was possible to generate an antibody capable of binding to c-Met, but also capable of inhibiting the dimerization of c-Met. If it is true that in the prior art it is sometimes suggested that an antibody capable of inhibiting c-Met dimerization with its partners could be interesting, an antibody capable of doing so has never been disclosed or clearly suggested. Furthermore, with respect to the specificity of the antibody, it was by no means clear how to proceed with the generation of such an active antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00011] Em um primeiro aspecto, um assunto da presente invenção é um processo para a geração e seleção de anticorpos de acordo com a invenção.</span>[00011] In a first aspect, a subject of the present invention is a process for the generation and selection of antibodies according to the invention.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00012] Mais particularmente, a invenção refere-se a um processo para a seleção de um anticorpo anti-c-Met ou um de seus fragmentos ou derivados funcionais, capaz de inibir a ativação dependente de ligante e independente de ligante de c-Met, o referido processo</span>[00012] More particularly, the invention relates to a process for the selection of an anti-c-Met antibody or one of its functional fragments or derivatives, capable of inhibiting ligand-dependent and ligand-independent activation of c-Met , that process</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 20/146</span>Petition 870190095443, of 24/09/2019, p. 20/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">7/131 compreendendo as seguintes etapas:</span>7/131 comprising the following steps:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">i) varredura dos anticorpos gerados e seleção de anticorpos capazes de se ligar especificamente à c-Met;</span>i) scanning the generated antibodies and selecting antibodies capable of specifically binding to c-Met;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ii) avaliação in vitro dos anticorpos selecionados da etapa i) e seleção de anticorpos capazes de inibir pelo menos 50%, de preferência pelo menos 60%, 70% ou 80% da proliferação de células tumorais para pelo menos um tipo de tumor; e, então, iii) testagem dos anticorpos selecionados da etapa ii) e seleção de anticorpos capazes de inibir a dimerização de c-Met.</span>ii) in vitro evaluation of the antibodies selected from step i) and selection of antibodies capable of inhibiting at least 50%, preferably at least 60%, 70% or 80% of tumor cell proliferation for at least one type of tumor; and then iii) testing the antibodies selected from step ii) and selecting antibodies capable of inhibiting c-Met dimerization.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00013] Conforme foi explicado acima, a inibição da dimerização de c-Met é um aspecto capital da invenção, uma vez que tais anticorpos representarão um interesse real por uma população maior de pacientes. Não apenas câncer c-Met-ativado dependente de ligante, conforme foi o caso para a presente invenção, mas também câncer cMet-ativado independente de ligante poderia ser tratado com anticorpos gerados através do processo da presente invenção.</span>[00013] As explained above, inhibition of c-Met dimerization is a major aspect of the invention, since such antibodies will represent a real interest in a larger patient population. Not only ligand-dependent c-Met-activated cancer, as was the case for the present invention, but also ligand-independent cMet-activated cancer could be treated with antibodies generated through the process of the present invention.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00014] A geração do anticorpo pode ser realizada através de qualquer método conhecido por aqueles versados na técnica tal como, por exemplo, fusão de uma célula de mieloma com células de baço de camundongos imunizados ou outras espécies compatíveis com as células de mieloma selecionadas [Kohler &amp; Milstein, 1975, Nature, 256: 495-497]. Os animais imunizados poderiam incluir camundongos transgênicos com loci de imunoglobulina humana os quais, então, produzem diretamente anticorpos humanos. Outra possível modalidade poderia consistir no uso de tecnologias de phage display para selecionar bibliotecas.</span>[00014] The generation of the antibody can be carried out by any method known to those skilled in the art such as, for example, fusion of a myeloma cell with spleen cells from immunized mice or other species compatible with the selected myeloma cells [ Kohler &amp; Milstein, 1975, Nature, 256: 495-497]. The immunized animals could include transgenic mice with human immunoglobulin loci which then directly produce human antibodies. Another possible modality could be the use of phage display technologies to select libraries.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00015] A etapa de seleção i) pode ser realizada através de qualquer método ou processo conhecido por aqueles versados na técnica. Como exemplos não limitativos, podem ser mencionados ELISA, BIAcore, imuno-histoquímica, análise por FACS e seleções</span>[00015] The selection step i) can be carried out using any method or process known to those skilled in the art. As non-limiting examples, ELISA, BIAcore, immunohistochemistry, FACS analysis and selections can be mentioned</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 21/146</span>Petition 870190095443, of 24/09/2019, p. 21/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">8/131 funcionais. Um processo preferido consiste em uma seleção através de ELISA sobre a proteína recombinante de c-Met e, então, através de análise por FACS sobre pelo menos uma linhagem de célula tumoral a fim de assegurar que os anticorpos produzidos serão capazes de reconhecer também o receptor nativo sobre células tumorais. Esse processo será descrito mais precisamente nos exemplos a seguir. [00016] Da mesma forma, a etapa ii) pode também ser realizada classicamente através de um método ou processo conhecido tal como, por exemplo, usando 3H-timidina ou qualquer outro agente de coloração de DNA, MTT, avaliação de ATP, etc. Um modelo de célula tumoral preferido na presente invenção pode consistir no modelo BcPC3.</span>Functional 8/131. A preferred process consists of selection via ELISA on the recombinant c-Met protein and then through FACS analysis on at least one tumor cell line to ensure that the antibodies produced will be able to recognize the receptor as well native on tumor cells. This process will be described more precisely in the following examples. [00016] Likewise, step ii) can also be performed classically through a known method or process such as, for example, using 3H-thymidine or any other DNA staining agent, MTT, ATP evaluation, etc. A preferred tumor cell model in the present invention can consist of the BcPC3 model.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00017] Por inibição da dimerização de c-Met, deve ser entendido, de preferência, a homodimerização de c-Met.</span>[00017] By inhibiting c-Met dimerization, c-Met homodimerization should preferably be understood.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00018] Em uma modalidade preferida da etapa iii) de seleção do processo da invenção, a referida etapa iii) consiste em avaliação de anticorpos através de análise BRET sobre células expressando c-MetRLuc/c-Met-YFP e seleção de anticorpos capazes de inibir pelo menos 30%, de preferência 35%, 40%, 45%, 50%, 55% e, mais preferivelmente, 60% da sinal de BRET.</span>[00018] In a preferred embodiment of step iii) for selecting the process of the invention, said step iii) consists of antibody evaluation through BRET analysis on cells expressing c-MetRLuc / c-Met-YFP and selection of antibodies capable of inhibit at least 30%, preferably 35%, 40%, 45%, 50%, 55% and, more preferably, 60% of the BRET signal.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00019] A tecnologia BRET é uma tecnologia conhecida como sendo representativa da dimerização de proteína [Angers et al., PNAS, 2000, 97: 3684-89].</span>[00019] BRET technology is a technology known to be representative of protein dimerization [Angers et al., PNAS, 2000, 97: 3684-89].</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00020] A tecnologia BRET, usada na etapa iii) do processo, é bemconhecida por aqueles versados na técnica e será detalhada nos exemplos a seguir. Mais particularmente, BRET (Transferência de Energia por Ressonância de Bioluminescência) é uma transferência de energia não radioativa que ocorre entre um doador bioluminescente (Luciferase Renilla (Rluc)) e um aceitador fluorescente, um mutante de GFP (Proteína Fluorescente Verde) ou YFP (Proteína Fluorescente</span>[00020] BRET technology, used in step iii) of the process, is well known to those skilled in the art and will be detailed in the following examples. More particularly, BRET (Bioluminescence Resonance Energy Transfer) is a non-radioactive energy transfer that occurs between a bioluminescent donor (Luciferase Renilla (Rluc)) and a fluorescent acceptor, a GFP (Green Fluorescent Protein) mutant or YFP ( Fluorescent Protein</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 22/146</span>Petition 870190095443, of 24/09/2019, p. 22/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">9/131</span>9/131</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Amarela). No presente caso, EYFP (Proteína Fluorescente Amarela Intensificada) foi usada. A eficácia de transferência depende da orientação e da distância entre o doador e o aceitador. Então, a transferência de energia pode ocorrer apenas se as duas moléculas estiverem em proximidade íntima (1-10 nm). Essa propriedade é usada para gerar ensaios de interação proteína-proteína. Na verdade, de forma a estudar a interação entre dois parceiros, o primeiro é geneticamente fundido à Luciferase Renilla e o segundo ao mutante amarelo da GFP. Proteínas de fusão são, em geral, mas não obrigatoriamente, expressas em células de mamífero. Na presença de seu substrato membrana-permeável (coelenterazina), Rluc emite luz azul. Se o mutante de GFP estiver mais próximo do que 10 nm da Rluc, uma transferência de energia pode ocorrer e um sinal amarelo adicional pode ser detectado. O sinal BRET é medido como a proporção entre a luz emitida pelo aceitador e a luz emitida pelo doador. Assim, o sinal BRET aumentará à medida que as duas proteínas de fusão são mantidas em proximidade ou se uma alteração conformacional mantiver Rluc e o mutante de GFP mais próximos. [00021] Se a análise BRET consiste em uma modalidade preferida, qualquer método conhecido por aqueles versados na técnica pode ser usado para medir a dimerização de c-Met. Sem limitação, as seguintes tecnologias podem ser mencionadas: FRET (Transferência de Energia por Ressonância de Fluorescência), HTRF (Fluorescência TempoDecomposta Homogênea), FLIM (Microscopia por Formação de Imagem por tempo de vida de Fluorescência) ou SW-FCCS (espectroscopia por relação cruzada de fluorescência com comprimento de onda único).</span>Yellow). In the present case, EYFP (Intensified Yellow Fluorescent Protein) was used. The effectiveness of transfer depends on the orientation and distance between the donor and the acceptor. Then, energy transfer can occur only if the two molecules are in close proximity (1-10 nm). This property is used to generate protein-protein interaction assays. In fact, in order to study the interaction between two partners, the first is genetically fused to Luciferase Renilla and the second to the yellow GFP mutant. Fusion proteins are generally, but not necessarily, expressed in mammalian cells. In the presence of its membrane-permeable substrate (coelenterazine), Rluc emits blue light. If the GFP mutant is closer than 10 nm to Rluc, an energy transfer can occur and an additional yellow signal can be detected. The BRET signal is measured as the ratio between the light emitted by the acceptor and the light emitted by the donor. Thus, the BRET signal will increase as the two fusion proteins are kept in close proximity or if a conformational change keeps Rluc and the GFP mutant closer. [00021] If the BRET analysis is a preferred modality, any method known to those skilled in the art can be used to measure the dimerization of c-Met. Without limitation, the following technologies can be mentioned: FRET (Fluorescence Resonance Energy Transfer), HTRF (Homogeneous Compound Time Fluorescence), FLIM (Fluorescence Lifetime Imaging Microscopy) or SW-FCCS (relationship spectroscopy) cross-fluorescence with single wavelength).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00022] Outras tecnologias clássicas também poderiam ser usadas, tais como coimunoprecipitação, Alpha Screen, ligação cruzada química, Duplo Híbrido, Cromatografia por Afinidade, ELISA ou</span>[00022] Other classic technologies could also be used, such as coimmunoprecipitation, Alpha Screen, chemical cross-linking, Double Hybrid, Affinity Chromatography, ELISA or</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 23/146</span>Petition 870190095443, of 24/09/2019, p. 23/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10/131</span>10/131</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Western blot.</span>Western blot.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00023] Em um segundo aspecto, um assunto da invenção é um anticorpo isolado ou um de seus fragmentos ou derivados funcionais, sendo obtidos através do referido processo. O referido anticorpo ou um de seus referidos fragmentos ou derivados é capaz de se ligar especificamente à c-Met humana e, se necessário, de preferência, além disso, capaz de inibir a fixação natural de seu ligante HGF e/ou capaz de inibir especificamente a atividade de quinase de tirosina da referida c-Met, o referido anticorpo sendo também capaz de inibir a dimerização de c-Met. Mais particularmente, os referidos anticorpos serão capazes de inibir a ativação dependente de ligante e independente de ligante de c-Met.</span>[00023] In a second aspect, a subject of the invention is an isolated antibody or one of its fragments or functional derivatives, being obtained through said process. Said antibody or one of its fragments or derivatives is capable of specifically binding to human c-Met and, if necessary, preferably furthermore, capable of inhibiting the natural fixation of its HGF ligand and / or capable of specifically inhibiting the tyrosine kinase activity of said c-Met, said antibody also being able to inhibit dimerization of c-Met. More particularly, said antibodies will be able to inhibit ligand-dependent and ligand-independent activation of c-Met.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00024] As expressões fragmentos e derivados funcionais serão definidas em detalhes depois na presente especificação.</span>[00024] The terms fragments and functional derivatives will be defined in detail later in the present specification.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00025] Deve ser entendido aqui que a invenção não refere-se aos anticorpos na forma natural, isto é, eles não estão em seu ambiente natural, mas eles foram capazes de ser isolados ou obtidos através de purificação a partir de fontes naturais ou mesmo obtidos através de recombinação genética ou através de síntese química e que eles podem, então, conter aminoácidos não-naturais, conforme será descrito aqui adiante.</span>[00025] It should be understood here that the invention does not refer to antibodies in the natural form, that is, they are not in their natural environment, but they were able to be isolated or obtained through purification from natural sources or even obtained through genetic recombination or through chemical synthesis and that they can then contain unnatural amino acids, as will be described hereinafter.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00026] Mais particularmente, de acordo com outro aspecto da invenção, é reivindicado um anticorpo ou um de seus fragmentos ou derivados funcionais, o referido anticorpo sendo caracterizado pelo fato de que ele compreende pelo menos uma região de determinação de complementaridade, CDR, escolhida de CDRs compreendendo a sequência de aminoácido SEQ ID Nos. 1 a 17 e 56 a 61.</span>[00026] More particularly, according to another aspect of the invention, an antibody or one of its functional fragments or derivatives is claimed, said antibody being characterized by the fact that it comprises at least one complementarity determining region, CDR, chosen of CDRs comprising the amino acid sequence SEQ ID Nos. 1 to 17 and 56 to 61.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00027] Qualquer anticorpo ou fragmentos ou derivados tendo pelo menos uma CDR cuja sequência tem pelo menos 80% de identidade, de preferência 85%, 90%, 95% e 98% de identidade, após</span>[00027] Any antibody or fragments or derivatives having at least one CDR whose sequence has at least 80% identity, preferably 85%, 90%, 95% and 98% identity, after</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 24/146</span>Petition 870190095443, of 24/09/2019, p. 24/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">11/131 alinhamento ótimo com as sequências SEQ ID NOs: 1 a 17 e 56 a 61 devem ser entendidos como um equivalente e, como uma consequência, como sendo parte da invenção.</span>11/131 optimal alignment with the sequences SEQ ID NOs: 1 to 17 and 56 to 61 should be understood as an equivalent and, as a consequence, as being part of the invention.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00028] Por regiões de CDR ou CDR(s), se pretende indicar as regiões hipervariáveis das cadeias pesada e leve das imunoglobulinas, conforme definido pela IMGT.</span>[00028] By regions of CDR or CDR (s), it is intended to indicate the hypervariable regions of the heavy and light chains of immunoglobulins, as defined by the IMGT.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00029] A numeração única IMGT foi definida para comparar os domínios variáveis, seja qual for o receptor antigênico, o tipo de cadeia ou a espécie [Lefranc M.-P., Immunology Today 18, 509 (1997) /Lefranc M.-P., The Immunologist, 7, 132-136 (1999) /Lefranc, M.-P., Pommié, C, Ruiz, M., Giudicelli, V., Foulquier, E., Truong, L., Thouvenin-Contet, V. e Lefranc, Dev. Comp. Immunol, 27, 55-77 (2003)]. Na numeração única IMGT, os aminoácidos conservados sempre têm a mesma posição, por exemplo, cisteína 23 (1<sup class="style-scope patent-text">a</sup>-CYS), triptofano 41 (CONSERVADO-TRP), o aminoácido hidrofóbico 89, cisteína 104 (2a-CYS), fenilalanina ou triptofano 118 (J-PHE ou JTRP). A numeração única IMGT proporciona uma delimitação padronizada das regiões de estrutura principal (posições 1 a 26, FR2IMGT: 39 a 55, FR3-IMGT: 66 a 104 e FR4-IMGT: 118 a 128) e das regiões de determinação de complementaridade: CDR1-IMGT: 27 a 38, CDR2-IMGT: 56 a 65 e CDR3-IMGT: 105 a 117. As lacunas representam posições desocupadas, os comprimentos das CDR-IMGT (mostradas entre colchetes e separadas por pontos, por exemplo, [8.8.13]) se tornam informação crucial. A numeração única IMGT é usada em representações gráficas 2D, designadas como IMGT Colliers de Perles [Ruiz, M. e Lefranc, M.-P., Immunogenetics, 53, 857883 (2002) /Kaas, Q. e Lefranc, M.-P., Current Bioinformatics, 2, 21-30 (2007)] e em estruturas 3D em IMGT/3Dstructure-DB [Kaas, Q., Ruiz, M. e Lefranc, M.-P., T cell receptor e MHC structural data. Nucl. Acids. Res., 32, D208-D210 (2004)].</span>[00029] The unique IMGT numbering was defined to compare the variable domains, whatever the antigenic receptor, the type of chain or the species [Lefranc M.-P., Immunology Today 18, 509 (1997) / Lefranc M.- P., The Immunologist, 7, 132-136 (1999) / Lefranc, M.-P., Pommié, C, Ruiz, M., Giudicelli, V., Foulquier, E., Truong, L., Thouvenin-Contet , V. and Lefranc, Dev. Comp. Immunol, 27, 55-77 (2003)]. In the single IMGT number, conserved amino acids always have the same position, for example, cysteine 23 (1 <sup class="style-scope patent-text">to</sup> -CYS), tryptophan 41 (CONSERVED-TRP), hydrophobic amino acid 89, cysteine 104 (2a-CYS), phenylalanine or tryptophan 118 (J-PHE or JTRP). The unique IMGT numbering provides a standardized delineation of the main structure regions (positions 1 to 26, FR2IMGT: 39 to 55, FR3-IMGT: 66 to 104 and FR4-IMGT: 118 to 128) and the complementarity determining regions: CDR1 -IMGT: 27 to 38, CDR2-IMGT: 56 to 65 and CDR3-IMGT: 105 to 117. Gaps represent unoccupied positions, the lengths of CDR-IMGT (shown in brackets and separated by periods, for example, [8.8. 13]) become crucial information. The unique IMGT numbering is used in 2D graphic representations, designated as Perles IMGT Colliers [Ruiz, M. and Lefranc, M.-P., Immunogenetics, 53, 857883 (2002) / Kaas, Q. and Lefranc, M.- P., Current Bioinformatics, 2, 21-30 (2007)] and in 3D structures in IMGT / 3Dstructure-DB [Kaas, Q., Ruiz, M. and Lefranc, M.-P., T cell receiver and MHC structural date. Nucl. Acids. Res., 32, D208-D210 (2004)].</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 25/146</span>Petition 870190095443, of 24/09/2019, p. 25/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">12/131 [00030] Existem três CDRs de cadeia pesada e 3 CDRs de cadeia leve. O termo CDR ou CDRs é usado aqui de forma a indicar, de acordo com o caso, uma dessas regiões ou várias ou mesmo o todo dessas regiões, as quais contêm a maioria dos resíduos de aminoácido responsáveis pela ligação por afinidade do anticorpo ao antígeno ou ao epítopo o qual elas reconhecem.</span>12/131 [00030] There are three heavy chain CDRs and three light chain CDRs. The term CDR or CDRs is used here to indicate, as the case may be, one of these regions or several or even all of these regions, which contain most of the amino acid residues responsible for the affinity binding of the antibody to the antigen or to the epitope they recognize.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00031] Por percentual de identidade entre duas sequências de ácido nucleico ou aminoácido no sentido da presente invenção, pretende-se indicar um percentual de nucleotídeos ou resíduos de aminoácido idênticos entre as duas sequências a serem comparadas, obtidas após o melhor alinhamento (alinhamento ótimo), esse percentual sendo puramente estatístico e as diferenças entre duas sequências sendo distribuídas aleatoriamente e sobre todo o seu comprimento. As comparações de sequências entre duas sequências de ácido nucleico ou aminoácido são, tradicionalmente, realizadas comparando essas sequências após ter alinhado as mesmas de uma maneira ótima, a referida comparação sendo capaz de ser realizada por segmentos ou através de uma janela de comparação. O alinhamento ótimo das sequências para a comparação pode ser realizado, além de manualmente, por meio do algoritmo de homologia local de Smith e Waterman (1981) [Ad. App. Math. 2: 482], por meio do algoritmo de homologia local de Neddleman e Wunsch (1970) [J. Mol. Biol. 48: 443], por meio do método de busca por similaridade de Pearson e Lipman (1988) [Proc. Natl. Acad. Sci. USA 85: 2444), por meio de um software de computador usando esses algoritmos (LACUNA, BESTFIT, FASTA e TFASTA no Pacote de Software Wisconsin Genetics, Genetics Computer Group, 575 Science Dr., Madison, WI ou mesmo através dos softwares de comparação BLAST N ou BLAST P).</span>[00031] By percentage of identity between two nucleic acid or amino acid sequences in the sense of the present invention, it is intended to indicate a percentage of identical nucleotides or amino acid residues between the two sequences to be compared, obtained after the best alignment (optimal alignment ), this percentage being purely statistical and the differences between two sequences being randomly distributed over its entire length. Sequence comparisons between two nucleic acid or amino acid sequences are traditionally performed by comparing these sequences after having optimally aligned them, said comparison being able to be performed by segments or through a comparison window. The optimal alignment of the sequences for comparison can be performed, in addition to manually, using the local homology algorithm of Smith and Waterman (1981) [Ad. Math app. 2: 482], using the local homology algorithm of Neddleman and Wunsch (1970) [J. Mol. Biol. 48: 443], using Pearson and Lipman's similarity search method (1988) [Proc. Natl. Acad. Sci. USA 85: 2444), using computer software using these algorithms (LACUNA, BESTFIT, FASTA and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI or even through the software of comparison BLAST N or BLAST P).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00032] O percentual de identidade entre duas sequências de ácido</span>[00032] The percentage of identity between two acid sequences</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 26/146</span>Petition 870190095443, of 24/09/2019, p. 26/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">13/131 nucleico ou aminoácido é determinado comparando essas duas sequências alinhadas de uma maneira ótima e na qual a sequência de ácido nucleico ou aminoácido a ser comparada pode compreender adições ou deleções com relação à sequência de referência para alinhamento ótimo entre essas duas sequências. O percentual de identidade é calculado determinando o número de posições idênticas entre as duas sequências, dividindo-se esse número de posições idênticas pelo número total de posições na janela de comparação e multiplicando-se o resultado obtido por 100 de forma a obter o percentual de identidade entre essas duas sequências.</span>13/131 nucleic or amino acid is determined by comparing these two sequences aligned in an optimal manner and in which the nucleic acid or amino acid sequence to be compared can comprise additions or deletions with respect to the reference sequence for optimal alignment between these two sequences. The percentage of identity is calculated by determining the number of identical positions between the two strings, dividing that number of identical positions by the total number of positions in the comparison window and multiplying the result obtained by 100 in order to obtain the percentage of identity between these two strings.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00033] Por exemplo, é possível usar o programa BLAST, BLAST 2 sequences (Tatusova et al., Blast 2 sequences - a new tool for comparing protein e nucleotide sequences, FEMS Microbiol Lett. 174: 247-250) disponível no site http://www.ncbi.nlm.nih.gov/gorf/bl2.html, os parâmetros usados sendo aqueles fornecidos pelo padrão (em particular para os parâmetros penalidade por abertura de lacuna: 5 e penalidade por extensão de lacuna: 2, a matriz escolhida sendo, por exemplo, a matriz BLOSUM 62 proposta pelo programa), o percentual de identidade entre as duas sequências a serem comparadas sendo calculado diretamente pelo programa.</span>[00033] For example, it is possible to use the BLAST program, BLAST 2 sequences (Tatusova et al., Blast 2 sequences - a new tool for comparing protein and nucleotide sequences, FEMS Microbiol Lett. 174: 247-250) available at http : //www.ncbi.nlm.nih.gov/gorf/bl2.html, the parameters used being those provided by the standard (in particular for the gap gap penalty parameters: 5 and gap gap penalty: 2, a chosen matrix being, for example, the BLOSUM 62 matrix proposed by the program), the percentage of identity between the two sequences to be compared being calculated directly by the program.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00034] Por sequência de aminoácido tendo pelo menos 80%, de preferência 85%, 90%, 95% e 98% de identidade com uma sequência de aminoácido de referência, aquelas tendo, com relação à sequência de referência, determinadas modificações, em particular uma deleção, adição ou substituição de pelo menos um aminoácido, um truncamento ou um alongamento, são preferidas. No caso de uma substituição de um ou mais aminoácidos consecutivos ou não consecutivos, são preferidas substituições nas quais os aminoácidos substituídos são substituídos por aminoácidos equivalentes. A expressão aminoácidos equivalentes se destina aqui a indicar</span>[00034] Per amino acid sequence having at least 80%, preferably 85%, 90%, 95% and 98% identity with a reference amino acid sequence, those having, with respect to the reference sequence, certain modifications, in in particular a deletion, addition or substitution of at least one amino acid, a truncation or an elongation are preferred. In the case of a substitution of one or more consecutive or non-consecutive amino acids, substitutions are preferred in which the substituted amino acids are replaced by equivalent amino acids. The term equivalent amino acids is intended here to indicate</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 27/146</span>Petition 870190095443, of 24/09/2019, p. 27/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">14/131 qualquer aminoácido capaz de ser substituído por um dos aminoácidos da estrutura básica sem, contudo, modificar essencialmente as atividades biológicas dos anticorpos correspondentes e tal como será definido depois, especialmente nos exemplos. Esses aminoácidos equivalentes podem ser determinados contando com sua homologia estrutural com os aminoácidos os quais eles substituem ou resultados de exames comparativos de atividade biológica entre os diferentes anticorpos capazes de serem realizados.</span>14/131 any amino acid capable of being substituted by one of the amino acids of the basic structure without, however, essentially modifying the biological activities of the corresponding antibodies and as will be defined later, especially in the examples. These equivalent amino acids can be determined using their structural homology with the amino acids they replace or the results of comparative tests of biological activity between the different antibodies capable of being performed.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00035] À guisa de exemplo, menção é feita às possibilidades de substituição capaz de ser realizada sem resultar em uma modificação profunda da atividade biológica do anticorpo modificado correspondente.</span>[00035] As an example, mention is made of the possibilities of substitution capable of being carried out without resulting in a profound modification of the biological activity of the corresponding modified antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00036] Como um exemplo não limitativo, a tabela 1 a seguir proporciona possibilidades de substituição concebíveis com uma conservação da atividade biológica do anticorpo modificado. As substituições inversas, naturalmente, também são possíveis, nas mesmas condições.</span>[00036] As a non-limiting example, Table 1 below provides conceivable substitution possibilities with a conservation of the biological activity of the modified antibody. Reverse substitutions, of course, are also possible, under the same conditions.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabela 1</span>Table 1</span>
  </p>
  <p class="style-scope patent-text">
    <tables class="style-scope patent-text">
      <patent-tables class="style-scope patent-text">
        <tgroup cols="2" class="style-scope patent-text">
          
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Resíduo original</span>
Original waste</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Substituição(ões)</span>
Replacement (s)</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Ala (A)</span>
Wing (A)</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Val, Gly, Pro</span>
Val, Gly, Pro</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Arg (R)</span>
Arg (R)</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Lys, His</span>
Lys, His</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Asn (N)</span>
Asn (N)</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Gln</span>
Gln</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Asp (D)</span>
Asp (D)</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Glu</span>
Glu</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Cys (C)</span>
Cys (C)</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Ser</span>
To be</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Gln (Q)</span>
Gln (Q)</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Asn</span>
Asn</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Glu (G)</span>
Glu (G)</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Asp</span>
Asp</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Gly (G)</span>
Gly (G)</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Ala</span>
Allah</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
His (H)</span>
His (H)</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Arg</span>
Arg</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Ile (I)</span>
Ile (I)</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Leu</span>
Read</span>
              </entry>
            </row>
          
        </tgroup>
      </patent-tables>
    </tables>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 28/146</span>Petition 870190095443, of 24/09/2019, p. 28/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15/131</span>15/131</span>
  </p>
  <p class="style-scope patent-text">
    <tables class="style-scope patent-text">
      <patent-tables class="style-scope patent-text">
        <tgroup cols="2" class="style-scope patent-text">
          
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Leu (L)</span>
Leu (L)</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Ile, Val, Met</span>
Ile, Val, Met</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Lys (K)</span>
Lys (K)</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Arg</span>
Arg</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Met (M)</span>
Met (M)</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Leu</span>
Read</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Phe (F)</span>
Phe (F)</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Tyr</span>
Tyr</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Pro (P)</span>
Pro (P)</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Ala</span>
Allah</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Ser (S)</span>
Being (S)</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Thr, Cys</span>
Thr, Cys</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Thr (T)</span>
Thr (T)</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Ser</span>
To be</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Trp (W)</span>
Trp (W)</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Tyr</span>
Tyr</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Tyr (Y)</span>
Tyr (Y)</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Phe, Trp</span>
Phe, Trp</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Val (V)</span>
Val (V)</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Leu, Ala</span>
Leu, Ala</span>
              </entry>
            </row>
          
        </tgroup>
      </patent-tables>
    </tables>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">00037] Deve ser entendido aqui que a invenção não refere-se a anticorpos na forma natural, isto é, eles não estão em seu ambiente natural, mas que eles foram capazes de serem isolados ou obtidos através de purificação a partir de fontes naturais ou mesmo obtidos através de recombinação genética ou através de síntese química e que eles podem, então, conter aminoácidos não-naturais, conforme será descrito aqui depois.</span>00037] It should be understood here that the invention does not refer to antibodies in the natural form, that is, they are not in their natural environment, but that they were able to be isolated or obtained through purification from natural sources or even obtained through genetic recombination or through chemical synthesis and that they can then contain unnatural amino acids, as will be described here later.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00038] De acordo com uma primeira abordagem, o anticorpo será definido por sua sequência de cadeia pesada. Mais particularmente, o anticorpo da invenção ou um de seus fragmentos ou derivados funcionais é caracterizado pelo fato de que ele compreende uma cadeia pesada compreendendo pelo menos uma CDR escolhida de CDRs compreendendo as sequências de aminoácido SEQ ID Nos. 1 a 9 e 56 a 58.</span>[00038] According to a first approach, the antibody will be defined by its heavy chain sequence. More particularly, the antibody of the invention or one of its functional fragments or derivatives is characterized by the fact that it comprises a heavy chain comprising at least one CDR chosen from CDRs comprising the amino acid sequences SEQ ID Nos. 1 to 9 and 56 to 58.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As sequências mencionadas são as seguintes:</span>The strings mentioned are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <tables class="style-scope patent-text">
      <patent-tables class="style-scope patent-text">
        <tgroup cols="2" class="style-scope patent-text">
          
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
SEQ ID No. 1:</span>
SEQ ID No. 1:</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
GYIFTAYT</span>
GYIFTAYT</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
SEQ ID No. 2:</span>
SEQ ID No. 2:</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
IKPNNGLA</span>
IKPNNGLA</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
SEQ ID No. 3:</span>
SEQ ID No. 3:</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
ARSEITTEFDY</span>
ARSEITTEFDY</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
SEQ ID No. 4:</span>
SEQ ID No. 4:</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
GYSFTDYT</span>
GYSFTDYT</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
SEQ ID No. 5:</span>
SEQ ID No. 5:</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
INPYNGGT</span>
INPYNGGT</span>
              </entry>
            </row>
          
        </tgroup>
      </patent-tables>
    </tables>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 29/146</span>Petition 870190095443, of 24/09/2019, p. 29/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">16/131</span>16/131</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID No. 6:</span>SEQ ID No. 6:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AREEITKDFDF</span>AREEITKDFDF</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 7:</span>SEQ ID NO: 7:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 8:</span>SEQ ID NO: 8:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">GYTFTDYN</span>GYTFTDYN</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">INPNNGGT</span>INPNNGGT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 9:</span>SEQ ID NO: 9:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ARGRYVGYYYAMDY</span>ARGRYVGYYYAMDY</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 56:</span>SEQ ID NO: 56:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">GYTFTSYW</span>GYTFTSYW</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 57:</span>SEQ ID NO: 57:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">INPTTGST</span>INPTTGST</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 58:</span>SEQ ID NO: 58:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AIGGYGSWFAY [00039] As CDRs da cadeia pesada poderiam ser escolhidas aleatoriamente nas sequências anteriores, isto é, SEQ ID NOs: 1 a 9 e 56 e 58.</span>AIGGYGSWFAY [00039] The heavy chain CDRs could be chosen randomly in the previous sequences, that is, SEQ ID NOs: 1 to 9 and 56 and 58.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00040] De acordo com um aspecto preferido, o anticorpo da invenção ou um de seus fragmentos ou derivados funcionais compreende uma cadeia pesada compreendendo pelo menos uma CDR escolhida de CDR-H1, CDR-H2 e CDR-H3, em que:</span>[00040] According to a preferred aspect, the antibody of the invention or one of its functional fragments or derivatives comprises a heavy chain comprising at least one CDR chosen from CDR-H1, CDR-H2 and CDR-H3, wherein:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- CDR-H1 compreende a sequência de aminoácido SEQ ID No. 1,4, 7 ou 56,</span>- CDR-H1 comprises the amino acid sequence SEQ ID No. 1,4, 7 or 56,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- CDR-H2 compreende a sequência de aminoácido SEQ ID No. 2, 5, 8 ou 57 e</span>- CDR-H2 comprises the amino acid sequence SEQ ID No. 2, 5, 8 or 57 and</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- CDR-H3 compreende a sequência de aminoácido SEQ ID No. 3, 6, 9 ou 58.</span>- CDR-H3 comprises the amino acid sequence SEQ ID No. 3, 6, 9 or 58.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00041] De acordo com uma primeira modalidade do referido aspecto, o anticorpo da invenção ou um de seus fragmentos ou derivados funcionais compreende uma cadeia pesada compreendendo CDR-H1, CDR-H2 e CDR-H3, em que CDR-H1 compreende a sequência de aminoácido SEQ ID NO: 1, CDR-H2 compreende a sequência de aminoácido SEQ ID NO: 2 e CDR-H3 compreende a sequência de aminoácido SEQ ID NO: 3.</span>[00041] According to a first embodiment of said aspect, the antibody of the invention or one of its functional fragments or derivatives comprises a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3, wherein CDR-H1 comprises the sequence amino acid SEQ ID NO: 1, CDR-H2 comprises the amino acid sequence SEQ ID NO: 2 and CDR-H3 comprises the amino acid sequence SEQ ID NO: 3.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00042] Mais particularmente, o referido anticorpo ou um de seus fragmentos ou derivados funcionais, de acordo com essa primeira modalidade compreende uma cadeia pesada de sequência</span>[00042] More particularly, said antibody or one of its functional fragments or derivatives, according to that first embodiment comprises a heavy chain of sequence</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 30/146</span>Petition 870190095443, of 24/09/2019, p. 30/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">17/131 compreendendo a sequência de aminoácido SEQ ID NO: 18.</span>17/131 comprising the amino acid sequence SEQ ID NO: 18.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00043] SEQ ID No. 18:EVQLQQSGPELVKPGASVKISCKTSGYIFT AYTMHWVRQSLGESLDWIGGIKPNNGLANYNQKFKGKATLTVDKSS STAYMDLRSLTSEDSAVYY CARSEITTEFDYWGQGTALTVSS [00044] De acordo com uma segunda modalidade do referido aspecto, o anticorpo da invenção ou um de seus fragmentos ou derivados funcionais, compreende uma cadeia pesada compreendendo CDR-H1, CDR-H2 e CDR-H3, em que CDR-H1 compreende a sequência de aminoácido e SEQ ID No. 4, CDR-H2 compreende a sequência de aminoácido SEQ ID No. 5 e CDR-H3 compreende a sequência de aminoácido e SEQ ID No. 6.</span>[00043] SEQ ID No. 18: EVQLQQSGPELVKPGASVKISCKTSGYIFT AYTMHWVRQSLGESLDWIGGIKPNNGLANYNQKFKGKATLTVDKSS STAYMDLRSLTSEDSAVYY CARSEITTEFDYWGGQGTALTVSS [000] H2 and CDR-H3, wherein CDR-H1 comprises the amino acid sequence and SEQ ID No. 4, CDR-H2 comprises the amino acid sequence SEQ ID No. 5 and CDR-H3 comprises the amino acid sequence and SEQ ID No. 6.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00045] O anticorpo ou um de seus fragmentos ou derivados funcionais, de acordo com a referida segunda modalidade compreenderá, de preferência, uma cadeia pesada da sequência compreendendo a sequência de aminoácido SEQ ID No. 19.</span>[00045] The antibody or one of its functional fragments or derivatives according to said second embodiment will preferably comprise a heavy chain of the sequence comprising the amino acid sequence SEQ ID No. 19.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00046] SEQ ID No. 19: EVQLQQSGPELVKPGASMKISCKASGYS FTDYTLNWVKQSHGKTLEWIGLINPYNGGTTYNQKFKGKATLTVDKS SSTAYMELLSLTSEDSAVYYCAREEITKDFDFWGQGTTLTVSS [00047] De acordo com uma terceira modalidade do referido aspecto, o anticorpo da invenção ou um de seus fragmentos ou derivados funcionais, compreende uma cadeia pesada compreendendo CDR-H1, CDR-H2 e CDR-H3, em que CDR-H1 compreende a sequência de aminoácido SEQ ID No. 7, CDR-H2 compreende a sequência de aminoácido SEQ ID No. 8 e CDR-H3 compreende a sequência de aminoácido SEQ ID No. 9.</span>[00046] SEQ ID No. 19: EVQLQQSGPELVKPGASMKISCKASGYS FTDYTLNWVKQSHGKTLEWIGLINPYNGGTTYNQKFKGKATLTVDKS SSTAYMELLSLTSEDSAVYYCAREEITKDFDFWGQGTTT and CDR-H3, wherein CDR-H1 comprises the amino acid sequence SEQ ID No. 7, CDR-H2 comprises the amino acid sequence SEQ ID No. 8 and CDR-H3 comprises the amino acid sequence SEQ ID No. 9.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00048] O anticorpo ou um de seus fragmentos ou derivados funcionais, de acordo com a referida terceira modalidade compreenderá, de preferência, uma cadeia pesada da sequência compreendendo a sequência aminoácido SEQ ID No. 20.</span>[00048] The antibody or one of its functional fragments or derivatives according to said third embodiment will preferably comprise a heavy chain of the sequence comprising the amino acid sequence SEQ ID No. 20.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00049] SEQ ID No. 20: EVLLQQSGPELVKPGASVKIPCKASGYTF</span>[00049] SEQ ID No. 20: EVLLQQSGPELVKPGASVKIPCKASGYTF</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 31/146</span>Petition 870190095443, of 24/09/2019, p. 31/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">18/131</span>18/131</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">TDYNMDWVKQSHGMSLEWIGDINPNNGGTIFNQKFKGKATLTVDKS</span>TDYNMDWVKQSHGMSLEWIGDINPNNGGTIFNQKFKGKATLTVDKS</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SSTAYMELRSLTSEDTAVYYCARGRYVGYYYAMDYWGQGTSVTVS</span>SSTAYMELRSLTSEDTAVYYCARGRYVGYYYAMDYWGQGTSVTVS</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">S [00050] De acordo com a quarta modalidade do referido aspecto, o anticorpo da invenção ou um de seus fragmentos ou derivados funcionais, compreende uma cadeia pesada compreendendo CDR-H1, CDR-H2 e CDR-H3, em que CDR-H1 compreende a sequência de aminoácido SEQ ID No. 56, CDR-H2 compreende a sequência de aminoácido SEQ ID No. 57 e CDR-H3 compreende a sequência de aminoácido SEQ ID No. 58.</span>S [00050] According to the fourth embodiment of said aspect, the antibody of the invention or one of its functional fragments or derivatives, comprises a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3, wherein CDR-H1 comprises the amino acid sequence SEQ ID No. 56, CDR-H2 comprises the amino acid sequence SEQ ID No. 57 and CDR-H3 comprises the amino acid sequence SEQ ID No. 58.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00051] O anticorpo ou um de seus fragmentos ou derivados funcionais, de acordo com a referida quarta modalidade compreenderá, de preferência, uma cadeia pesada da sequência compreendendo a sequência de aminoácido SEQ ID No. 62.</span>[00051] The antibody or one of its functional fragments or derivatives according to said fourth embodiment will preferably comprise a heavy chain of the sequence comprising the amino acid sequence SEQ ID No. 62.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00052] SEQ ID No. 62: QVQLQQSGAELAKPGASVKMSCKASGYTFT SYWMNWVKQRPGQGLEWIGYINPTTGSTDYNQKLKDKATLTADKSS NTAYMQLSSLTSEDSAVYYCAIGGYGSWFAYWGQGTLVTVSA [00053] Em uma segunda abordagem, o anticorpo será agora definido por sua sequência de cadeia leve. Mais particularmente, de acordo com um segundo aspecto particular da invenção, o anticorpo ou um de seus derivados ou fragmentos funcionais é caracterizado pelo fato de que ele compreende uma cadeia leve compreendendo pelo menos uma CDR escolhida de CDRs compreendendo a sequência de aminoácido SEQ ID Nos. 10 a 17 e 59 a 61.</span>[00052] SEQ ID No. 62: QVQLQQSGAELAKPGASVKMSCKASGYTFT SYWMNWVKQRPGQGLEWIGYINPTTGSTDYNQKLKDKATLTADKSS NTAYMQLSSLTSEDSAVYYCAIGGYGSWFAYWGQGTLVTV will now be defined [0002]. More particularly, according to a second particular aspect of the invention, the antibody or one of its derivatives or functional fragments is characterized by the fact that it comprises a light chain comprising at least one CDR chosen from CDRs comprising the amino acid sequence SEQ ID Nos. . 10 to 17 and 59 to 61.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As sequências mencionadas são as seguintes:</span>The strings mentioned are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <tables class="style-scope patent-text">
      <patent-tables class="style-scope patent-text">
        <tgroup cols="3" class="style-scope patent-text">
          
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
SEQ ID No. 10</span>
SEQ ID No. 10</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
ESVDSYANS
F</span>
ESVDSYANS
F</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
SEQ ID No.</span>
SEQ ID No.</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
11</span>
11</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
RAS</span>
RAS</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
SEQ ID No.</span>
SEQ ID No.</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
12</span>
12</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
QQSKEDPLT</span>
QQSKEDPLT</span>
              </entry>
            </row>
          
        </tgroup>
      </patent-tables>
    </tables>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 32/146</span>Petition 870190095443, of 24/09/2019, p. 32/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">19/131</span>19/131</span>
  </p>
  <p class="style-scope patent-text">
    <tables class="style-scope patent-text">
      <patent-tables class="style-scope patent-text">
        <tgroup cols="3" class="style-scope patent-text">
          
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
SEQ ID No.</span>
SEQ ID No.</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
13</span>
13</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
ESIDTYGNSF</span>
ESIDTYGNSF</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
SEQ ID No.</span>
SEQ ID No.</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
14</span>
14</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
QQSNEDPFT</span>
QQSNEDPFT</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
SEQ ID No.</span>
SEQ ID No.</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
15</span>
15</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
ENIYSN</span>
ENIYSN</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
SEQ ID No.</span>
SEQ ID No.</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
16</span>
16</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
AAT</span>
AAT</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
SEQ ID No.</span>
SEQ ID No.</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
17</span>
17</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
QHFWGPPYT</span>
QHFWGPPYT</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
SEQ ID No.</span>
SEQ ID No.</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
59</span>
59</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
SSVSSTY</span>
SSVSSTY</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
SEQ ID No.</span>
SEQ ID No.</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
60</span>
60</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
TTS</span>
TTS</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
SEQ ID No.</span>
SEQ ID No.</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
61</span>
61</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
HQWSSYPFT</span>
HQWSSYPFT</span>
              </entry>
            </row>
          
        </tgroup>
      </patent-tables>
    </tables>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00054] As CDRs da cadeia leve poderia ser escolhidas aleatoriamente nas sequências anteriores, isto é, SEQ ID Nos. 10 a 17 e 59 a 61.</span>[00054] The light chain CDRs could be chosen at random in the previous sequences, i.e. SEQ ID Nos. 10 to 17 and 59 to 61.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00055] De acordo com outro aspecto preferido, o anticorpo da invenção ou um de seus fragmentos ou derivados funcionais, compreende uma cadeia leve compreendendo pelo menos uma CDR escolhida de CDR-L1, CDR-L2 e CDR-L3, em que:</span>[00055] According to another preferred aspect, the antibody of the invention or one of its functional fragments or derivatives, comprises a light chain comprising at least one CDR chosen from CDR-L1, CDR-L2 and CDR-L3, wherein:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- CDR-L1 compreende a sequência de aminoácido SEQ ID No. 10, 13, 15 ou 59,</span>- CDR-L1 comprises the amino acid sequence SEQ ID No. 10, 13, 15 or 59,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- CDR-L2 compreende a sequência de aminoácido SEQ ID No. 11, 16 ou 60 e</span>- CDR-L2 comprises the amino acid sequence SEQ ID No. 11, 16 or 60 and</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- CDR-L3 compreende a sequência de aminoácido SEQ ID No. 12, 14, 17 ou 61.</span>- CDR-L3 comprises the amino acid sequence SEQ ID No. 12, 14, 17 or 61.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00056] De acordo com uma primeira modalidade do referido outro aspecto, o anticorpo da invenção ou um de seus fragmentos ou derivados funcionais, compreende uma cadeia leve compreendendo CDR-L1, CDR-L2 e CDR-L3, em que CDR-L1 compreende a sequência de aminoácido SEQ ID No. 10, CDR-L2 compreende a sequência de aminoácido SEQ ID No. 11 e CDR-L3 compreende a sequência de aminoácido SEQ ID No. 12.</span>[00056] According to a first embodiment of said other aspect, the antibody of the invention or one of its functional fragments or derivatives, comprises a light chain comprising CDR-L1, CDR-L2 and CDR-L3, wherein CDR-L1 comprises the amino acid sequence SEQ ID No. 10, CDR-L2 comprises the amino acid sequence SEQ ID No. 11 and CDR-L3 comprises the amino acid sequence SEQ ID No. 12.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00057] Mais particularmente, o referido anticorpo ou um de seus fragmentos ou derivados funcionais, de acordo com essa primeira</span>[00057] More particularly, said antibody or one of its functional fragments or derivatives, according to that first</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 33/146</span>Petition 870190095443, of 24/09/2019, p. 33/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20/131 modalidade compreende uma cadeia leve da sequência compreendendo a sequência de aminoácido SEQ ID No. 21.</span>The 20/131 embodiment comprises a light chain of the sequence comprising the amino acid sequence SEQ ID No. 21.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00058] SEQ ID No. 21: DIVLTQSPASLAVSLGQRATISCR</span>[00058] SEQ ID No. 21: DIVLTQSPASLAVSLGQRATISCR</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ASESVDS</span>ASESVDS</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">YANSFMHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSRTDFTLT INPVEADDVATYYCQQSKEDPLTFGSGTKLEMK [00059] De acordo com uma segunda modalidade do referido outro aspecto, o anticorpo da invenção ou um de seus fragmentos ou derivados funcionais, compreende uma cadeia leve compreendendo CDR-L1, CDR-L2 e CDR-L3, em que CDR-L1 compreende a sequência de aminoácido SEQ ID No. 13, CDR-L2 compreende a sequência de aminoácido SEQ ID No. 11 e CDR-L3 compreende a sequência de aminoácido SEQ ID No. 14.</span>YANSFMHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSRTDFTLT INPVEADDVATYYCQQSKEDPLTFGSGTKLEMK [00059] According to a second modality of the said other aspect, the antibody of the invention or one of its fragments or L-derivatives, comprises a L1 comprises the amino acid sequence SEQ ID No. 13, CDR-L2 comprises the amino acid sequence SEQ ID No. 11 and CDR-L3 comprises the amino acid sequence SEQ ID No. 14.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00060] O anticorpo ou um de seus fragmentos ou derivados funcionais, de acordo com a referida modalidade compreenderá, de preferência, uma cadeia leve da sequência compreendendo a sequência de aminoácido SEQ ID No. 22.</span>[00060] The antibody or one of its functional fragments or derivatives according to said embodiment will preferably comprise a light chain of the sequence comprising the amino acid sequence SEQ ID No. 22.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00061] SEQ ID No. 22:</span>[00061] SEQ ID No. 22:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">GIVLTQSPASLAVSLGQRATISCRVSESIDTY</span>GIVLTQSPASLAVSLGQRATISCRVSESIDTY</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">GNSFIHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSRTDFTLTIN PVEADDSATYYCQQSNEDPF TFGSGTKLEMK [00062] De acordo com uma terceira modalidade do referido outro aspecto, o anticorpo da invenção ou um de seus fragmentos ou derivados funcionais, compreende uma cadeia leve compreendendo CDR-L1, CDR-L2 e CDR-L3, em que CDR-L1 compreende a sequência de aminoácido SEQ ID No. 15, CDR-L2 compreende a sequência de aminoácido SEQ ID No. 16 e CDR-L3 compreende a sequência de aminoácido SEQ ID No. 17.</span>GNSFIHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSRTDFTLTIN PVEADDSATYYCQQSNEDPF TFGSGTKLEMK [00062] According to a third modality of the referred other aspect, the CD of the invention or one of its fragments or functional derivatives, L-R-R, comprises a light chain -L1 comprises the amino acid sequence SEQ ID No. 15, CDR-L2 comprises the amino acid sequence SEQ ID No. 16 and CDR-L3 comprises the amino acid sequence SEQ ID No. 17.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00063] O anticorpo ou um de seus fragmentos ou derivados funcionais, de acordo com a referida terceira modalidade</span>[00063] The antibody or one of its fragments or functional derivatives, according to said third modality</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 34/146</span>Petition 870190095443, of 24/09/2019, p. 34/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">21/131 compreenderá, de preferência, uma cadeia leve da sequência compreendendo a sequência de aminoácido SEQ ID No. 23.</span>21/131 will preferably comprise a light chain of the sequence comprising the amino acid sequence SEQ ID No. 23.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00064] SEQ ID No. 23: DIQMTQSPASLSVSVGETVTITCRASENIY</span>[00064] SEQ ID No. 23: DIQMTQSPASLSVSVGETVTITCRASENIY</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SNLAWYQQKQGKSPQLLVYAATNLVDGVPSRFSGSGSGTQYSLKIN</span>SNLAWYQQKQGKSPQLLVYAATNLVDGVPSRFSGSGSGTQYSLKIN</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SLQSEDFGSYYCQHFWGPPYTFGGGTKLE [00065] De acordo com uma quarta modalidade do referido outro aspecto, o anticorpo da invenção ou um de seus fragmentos ou derivados funcionais, compreende uma cadeia leve compreendendo CDR-L1, CDR-L2 e CDR-L3, em que CDR-L1 compreende a sequência de aminoácido SEQ ID No. 59, CDR-L2 compreende a sequência de aminoácido SEQ ID No. 60 e CDR-L3 compreende a sequência de aminoácido SEQ ID No. 61.</span>SLQSEDFGSYYCQHFWGPPYTFGGGTKLE [00065] According to a fourth embodiment of said other aspect, the antibody of the invention or one of its functional fragments or derivatives, comprises a light chain comprising CDR-L1, CDR-L2 and CDR-L3, wherein CDR-L1 comprises the amino acid sequence SEQ ID No. 59, CDR-L2 comprises the amino acid sequence SEQ ID No. 60 and CDR-L3 comprises the amino acid sequence SEQ ID No. 61.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00066] O anticorpo ou um de seus fragmentos ou derivados funcionais, de acordo com a referida modalidade compreenderá, de preferência, uma cadeia leve da sequência compreendendo a sequência de aminoácido SEQ ID No. 63. SEQ ID No. 63: QIVLTQSPAIMSASPGEKVTLTCSASS SVSSTY</span>[00066] The antibody or one of its functional fragments or derivatives according to said embodiment will preferably comprise a light chain of the sequence comprising the amino acid sequence SEQ ID No. 63. SEQ ID No. 63: QIVLTQSPAIMSASPGEKVTLTCSASS SVSSTY</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">LYWYQQKPGSSPKLWIYTTSILASGVPARFSGSGSGTSYSLTISSMET EDAASYFCHQWSSYPFTFGSGTKLDIK [00067] De acordo com uma terceira abordagem, o anticorpo será agora definido por sua sequência de cadeia leve e sua sequência de cadeia pesada. O anticorpo da invenção ou um de seus derivados ou fragmentos funcionais, é caracterizado pelo fato de que ele compreende uma cadeia pesada compreendendo a sequência de aminoácido SEQ ID No. 18, 19, 20 ou 62 e uma cadeia leve compreendendo a sequência de aminoácido SEQ ID No. 21, 22, 23 ou 63.</span>LYWYQQKPGSSPKLWIYTTSILASGVPARFSGSGSGTSYSLTISSMET EDAASYFCHQWSSYPFTFGSGTKLDIK [00067] According to a third approach, the antibody will now be defined by its light chain sequence and its heavy chain sequence. The antibody of the invention, or one of its derivatives or functional fragments, is characterized by the fact that it comprises a heavy chain comprising the amino acid sequence SEQ ID No. 18, 19, 20 or 62 and a light chain comprising the amino acid sequence SEQ ID No. 21, 22, 23 or 63.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00068] Mais particularmente, um anticorpo preferido ou um de seus derivados ou fragmentos funcionais, de acordo com a invenção, denominado 224G11, compreende uma cadeia pesada</span>[00068] More particularly, a preferred antibody or one of its derivatives or functional fragments, according to the invention, called 224G11, comprises a heavy chain</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 35/146</span>Petition 870190095443, of 24/09/2019, p. 35/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">22/131 compreendendo CDR-H1, CDR-H2 e CDR-H3 compreendendo, respectivamente, a sequência de aminoácido SEQ ID Nos. 1, 2 e 3; e uma cadeia leve compreendendo CDR-L1, CDR-L2 e CDR-L3 compreendendo, respectivamente, a sequência de aminoácido SEQ ID</span>22/131 comprising CDR-H1, CDR-H2 and CDR-H3 comprising, respectively, the amino acid sequence SEQ ID Nos. 1, 2 and 3; and a light chain comprising CDR-L1, CDR-L2 and CDR-L3 comprising, respectively, the amino acid sequence SEQ ID</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Nos. 10, 11 e 12.</span>We. 10, 11 and 12.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00069] Em outro aspecto, o anticorpo 224G11 compreende uma cadeia pesada compreendendo a sequência de aminoácido SEQ ID No. 18 e uma cadeia leve compreendendo a sequência de aminoácido SEQ ID No. 21.</span>[00069] In another aspect, the 224G11 antibody comprises a heavy chain comprising the amino acid sequence SEQ ID No. 18 and a light chain comprising the amino acid sequence SEQ ID No. 21.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00070] Outro anticorpo preferido ou um de seus fragmentos ou derivados funcionais, de acordo com a invenção, denominado 227H1, compreende uma cadeia pesada compreendendo CDR-H1, CDR-H2 e CDR-H3 compreendendo, respectivamente, a sequência de aminoácido SEQ ID Nos. 4, 5 e 6; e uma cadeia leve compreendendo CDR-L1, CDR-L2 e CDR-L3 compreendendo, respectivamente, a sequência de aminoácido SEQ ID Nos. 13,11 e 14.</span>[00070] Another preferred antibody or one of its functional fragments or derivatives, according to the invention, called 227H1, comprises a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3 comprising, respectively, the amino acid sequence SEQ ID We. 4, 5 and 6; and a light chain comprising CDR-L1, CDR-L2 and CDR-L3 comprising, respectively, the amino acid sequence SEQ ID Nos. 13.11 and 14.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00071] Em outro aspecto, o anticorpo 227H1 compreende uma cadeia pesada compreendendo a sequência de aminoácido SEQ ID No. 19 e uma cadeia leve compreendendo a sequência de aminoácido SEQ ID No. 22.</span>[00071] In another aspect, the 227H1 antibody comprises a heavy chain comprising the amino acid sequence SEQ ID No. 19 and a light chain comprising the amino acid sequence SEQ ID No. 22.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00072] Ainda outro anticorpo preferido ou um de seus fragmentos ou derivados funcionais, denominado 223C4, compreende uma cadeia pesada compreendendo CDR-H1, CDR-H2 e CDR-H3 compreendendo, respectivamente, a sequência de aminoácido SEQ ID Nos. 7, 8 e 9; e uma cadeia leve compreendendo CDR-L1, CDR-L2 e CDR-L3 compreendendo respectivamente a sequência de aminoácido SEQ ID Nos. 15, 16 e 17.</span>[00072] Yet another preferred antibody or one of its functional fragments or derivatives, called 223C4, comprises a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3 comprising, respectively, the amino acid sequence SEQ ID Nos. 7, 8 and 9; and a light chain comprising CDR-L1, CDR-L2 and CDR-L3 comprising the amino acid sequence SEQ ID Nos. 15, 16 and 17.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00073] Em outro aspecto, o anticorpo 223 C4 compreende uma cadeia pesada compreendendo a sequência de aminoácido SEQ ID No. 20 e uma cadeia leve compreendendo a sequência de aminoácido</span>[00073] In another aspect, the 223 C4 antibody comprises a heavy chain comprising the amino acid sequence SEQ ID No. 20 and a light chain comprising the amino acid sequence</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 36/146</span>Petition 870190095443, of 24/09/2019, p. 36/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">23/131</span>23/131</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID No. 23.</span>SEQ ID No. 23.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00074] Ainda outro anticorpo preferido ou um de seus fragmentos ou derivados funcionais, denominado 11E1, compreende uma cadeia pesada compreendendo CDR-H1, CDR-H2 e CDR-H3 compreendendo, respectivamente, a sequência de aminoácido SEQ ID Nos. 56, 57 e 58; e uma cadeia leve compreendendo CDR-L1, CDR-L2 e CDR-L3 compreendendo respectivamente a sequência de aminoácido SEQ ID Nos. 59, 60 e 61.</span>[00074] Yet another preferred antibody or one of its functional fragments or derivatives, called 11E1, comprises a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3 comprising, respectively, the amino acid sequence SEQ ID Nos. 56, 57 and 58; and a light chain comprising CDR-L1, CDR-L2 and CDR-L3 comprising the amino acid sequence SEQ ID Nos. 59, 60 and 61.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00075] Em outro aspecto, o anticorpo 11E1 compreende uma cadeia pesada compreendendo a sequência de aminoácido SEQ ID No. 62 e uma cadeia leve compreendendo a sequência de aminoácido SEQ ID No. 63.</span>[00075] In another aspect, the 11E1 antibody comprises a heavy chain comprising the amino acid sequence SEQ ID No. 62 and a light chain comprising the amino acid sequence SEQ ID No. 63.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00076] De acordo com outro aspecto, a invenção refere-se a um hibridoma de murino capaz de secretar a anticorpos monoclonais de acordo com a presente invenção, especialmente um hibridoma originário de murino, tal como depositado no Collection Nationale de Cultures de Microorganismes (CNCM, National Collection of Microorganism Cultures) (Institut Pasteur, Paris, França).</span>[00076] According to another aspect, the invention relates to a murine hybridoma capable of secreting monoclonal antibodies according to the present invention, especially a hybridoma originating from murine, as deposited in the Collection Nationale de Cultures de Microorganismes ( CNCM, National Collection of Microorganism Cultures) (Institut Pasteur, Paris, France).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00077] Os anticorpos monoclonais de acordo com a invenção ou um de seus fragmentos ou derivados funcionais são caracterizados pelo fato de que os referidos anticorpos são secretados pelo hibridoma depositados no CNCM em 14/03/2007 sob os números CNCM 1-3724 (correspondendo a 11E1), 1-3731 (correspondendo a 224G11), 1-3732 (correspondendo a 227H1) e em 06/07/2007 sob o número 1-3786 (correspondendo a 223C4). Esses hibridomas consistem em um hibridoma de murino resultando na fusão celular de esplenócitos de camundongo imunizado com uma linhagens de célula de mieloma (Sp20 Agl4).</span>[00077] The monoclonal antibodies according to the invention or one of its fragments or functional derivatives are characterized by the fact that said antibodies are secreted by the hybridoma deposited at the CNCM on 14/03/2007 under the numbers CNCM 1-3724 (corresponding to 11E1), 1-3731 (corresponding to 224G11), 1-3732 (corresponding to 227H1) and on 06/07/2007 under the number 1-3786 (corresponding to 223C4). These hybridomas consist of a murine hybridoma resulting in the cell fusion of immunized mouse splenocytes with a myeloma cell line (Sp20 Agl4).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00078] A tabela 2 a seguir reagrupa elementos referentes aos anticorpos preferidos.</span>[00078] Table 2 below regroups elements regarding the preferred antibodies.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 37/146</span>Petition 870190095443, of 24/09/2019, p. 37/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">24/131</span>24/131</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabela 2</span>Table 2</span>
  </p>
  <p class="style-scope patent-text">
    <tables class="style-scope patent-text">
      <patent-tables class="style-scope patent-text">
        <tgroup cols="9" class="style-scope patent-text">
          
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text"> </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
224G11
1-3731</span>
224G11
1-3731</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
227H1
1-3732</span>
227H1
1-3732</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
223C4
1-3786</span>
223C4
1-3786</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
11E1
1-3724</span>
11E1
1-3724</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text"> </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
SEQ</span>
SEQ</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
SEQ</span>
SEQ</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
SEQ</span>
SEQ</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
SEQ</span>
SEQ</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
SEQ</span>
SEQ</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
SEQ</span>
SEQ</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
SEQ</span>
SEQ</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
SEQ</span>
SEQ</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text"> </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
ID</span>
ID</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
ID</span>
ID</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
ID</span>
ID</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
ID</span>
ID</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
ID</span>
ID</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
ID</span>
ID</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
ID</span>
ID</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
ID</span>
ID</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text"> </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Prot.</span>
Prot.</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Nucl.</span>
Nucl.</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Prot.</span>
Prot.</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Nucl.</span>
Nucl.</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Prot.</span>
Prot.</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Nucl.</span>
Nucl.</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Prot.</span>
Prot.</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Nucl.</span>
Nucl.</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
CDR-
H1</span>
CDR-
H1</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
1</span>
1</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
24</span>
24</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
4</span>
4</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
27</span>
27</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
7</span>
7</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
30</span>
30</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
56</span>
56</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
64</span>
64</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
CDR-
H2</span>
CDR-
H2</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
2</span>
2</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
25</span>
25</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
5</span>
5</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
28</span>
28</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
8</span>
8</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
31</span>
31</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
57</span>
57</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
65</span>
65</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
CDR-
H3</span>
CDR-
H3</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
3</span>
3</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
26</span>
26</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
6</span>
6</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
29</span>
29</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
9</span>
9</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
32</span>
32</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
58</span>
58</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
66</span>
66</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Cadeia
H.</span>
Jail
H.</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
18</span>
18</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
41</span>
41</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
19</span>
19</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
42</span>
42</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
20</span>
20</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
43</span>
43</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
62</span>
62</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
70</span>
70</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
CDR-L1</span>
CDR-L1</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
10</span>
10</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
33</span>
33</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
13</span>
13</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
36</span>
36</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
15</span>
15</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
38</span>
38</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
59</span>
59</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
67</span>
67</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
CDR-L2</span>
CDR-L2</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
11</span>
11</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
34</span>
34</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
11</span>
11</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
34</span>
34</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
16</span>
16</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
39</span>
39</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
60</span>
60</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
68</span>
68</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
CDR-L3</span>
CDR-L3</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
12</span>
12</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
35</span>
35</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
14</span>
14</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
37</span>
37</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
17</span>
17</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
40</span>
40</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
61</span>
61</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
69</span>
69</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Cadeia
L.</span>
Jail
L.</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
21</span>
21</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
44</span>
44</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
22</span>
22</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
45</span>
45</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
23</span>
23</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
46</span>
46</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
63</span>
63</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
71</span>
71</span>
              </entry>
            </row>
          
        </tgroup>
      </patent-tables>
    </tables>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00079] A partir da tabela 2, está claro que CDR-L2 dos anticorpos 227H1 e 224G11 são similares. Esse exemplo sustenta claramente as reivindicações do presente pedido que abrangem anticorpos compreendendo pelo menos uma CDR aleatoriamente escolhida das sequências de CDR descritas.</span>[00079] From table 2, it is clear that CDR-L2 of antibodies 227H1 and 224G11 are similar. This example clearly supports the claims of the present application that encompass antibodies comprising at least one CDR randomly chosen from the described CDR sequences.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00080] De acordo com uma modalidade preferida, a invenção refere-se a anticorpos monoclonais.</span>[00080] According to a preferred embodiment, the invention relates to monoclonal antibodies.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00081] O termo Anticorpo Monoclonal é usado de acordo com seu significado comum para denotar um anticorpo obtido de uma população de anticorpos substancialmente homogêneos, isto é, os anticorpos individuais compreendendo a população são idênticos,</span>[00081] The term Monoclonal Antibody is used according to its common meaning to denote an antibody obtained from a population of substantially homogeneous antibodies, that is, the individual antibodies comprising the population are identical,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 38/146</span>Petition 870190095443, of 24/09/2019, p. 38/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25/131 exceto quanto à possíveis mutações que ocorrem naturalmente que podem estar presentes em quantidades mínimas. Em outras palavras, um anticorpo monoclonal consiste em um anticorpo homogêneo resultante da proliferação de um único clone de células (por exemplo, células de hibridoma, células hospedeiras eucariotas transfectadas com DNA que codifica o anticorpo homogêneo, células hospedeiras procariotas transformadas com o DNA que codifica o anticorpo homogêneo, etc.) e o qual é geralmente caracterizado por cadeias pesadas de um única classe e subclasse e cadeias leves de um único tipo. Anticorpos monoclonais são altamente específicos, sendo direcionados contra um único antígeno. Além disso, em contraste a preparações de anticorpos policlonais que, tipicamente, incluem diferentes anticorpos direcionados contra diferentes determinantes ou epítopo, cada anticorpo monoclonal é direcionado contra um único determinante sobre o antígeno.</span>25/131 except for possible naturally occurring mutations that may be present in minimal amounts. In other words, a monoclonal antibody consists of a homogeneous antibody resulting from the proliferation of a single cell clone (for example, hybridoma cells, eukaryotic host cells transfected with DNA encoding the homogeneous antibody, prokaryotic host cells transformed with the DNA encoding the homogeneous antibody, etc.) and which is generally characterized by heavy chains of a single class and subclass and light chains of a single type. Monoclonal antibodies are highly specific, being directed against a single antigen. In addition, in contrast to polyclonal antibody preparations that typically include different antibodies directed against different determinants or epitopes, each monoclonal antibody is directed against a single determinant on the antigen.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00082] Na presente descrição, os termos polipeptídeos, sequências polipeptídicas, sequências de aminoácido, peptídeos e proteínas, com referência a compostos de anticorpo ou sua sequência, são permutáveis.</span>[00082] In the present description, the terms polypeptides, polypeptide sequences, amino acid sequences, peptides and proteins, with reference to antibody compounds or their sequence, are interchangeable.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00083] De acordo com um aspecto da mesma forma particular, a presente invenção refere-se a um anticorpo quimérico ou um de seus fragmentos funcionais, de acordo com a invenção, caracterizado pelo fato de que o referido anticorpo, além disso, compreende as regiões constantes de cadeia leve e cadeia pesada derivadas de um anticorpo de uma espécie heteróloga ao camundongo, especialmente o homem e, de uma maneira preferida, pelo fato de que as regiões constantes de cadeia leve e cadeia pesada derivadas de um anticorpo humano são, respectivamente, a região Kappa e Gama-1, Gama-2 ou Gama-4. [00084] No presente pedido, IgG1 é preferida para proporcionar funções efetuadoras e, mais preferivelmente, ADCC e CDC.</span>[00083] According to a similarly particular aspect, the present invention relates to a chimeric antibody or one of its functional fragments, according to the invention, characterized by the fact that said antibody, in addition, comprises the light chain and heavy chain constant regions derived from an antibody of a species heterologous to the mouse, especially man, and preferably, due to the fact that the light chain and heavy chain constant regions derived from a human antibody are, respectively , the Kappa and Gamma-1, Gamma-2 or Gamma-4 regions. [00084] In the present application, IgG1 is preferred to provide effector functions and, more preferably, ADCC and CDC.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 39/146</span>Petition 870190095443, of 24/09/2019, p. 39/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">26/131 [00085] Aqueles habilitados reconhecerão que funções efetuadoras incluem, por exemplo, ligação a C1q; citotoxicidade dependente de complemento (CDC); ligação ao receptor Fc; citoxicidade celular mediada depende de antropo (ADCC); fagocitose; e sub-regulação de receptores na superfície celular (por exemplo, receptor de células de B; BCR).</span>26/131 [00085] Those enabled will recognize that effecting functions include, for example, connection to C1q; complement-dependent cytotoxicity (CDC); connection to the Fc receptor; cell-mediated cytoxicity depends on anthrope (ADCC); phagocytosis; and sub-regulation of receptors on the cell surface (e.g., B cell receptor; BCR).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00086] Os anticorpos de acordo com a presente invenção são, de preferência, anticorpos monoclonais específicos, especialmente originários de murino, quiméricos humanizados, os quais podem ser obtidos de acordo com métodos-padrão bem-conhecidos por aqueles versados na técnica.</span>[00086] The antibodies according to the present invention are preferably specific monoclonal antibodies, especially of murine, humanized chimeric antibodies, which can be obtained according to standard methods well known to those skilled in the art.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00087] Em geral, para o preparo de anticorpos monoclonais ou seus fragmentos ou derivados funcionais, especialmente originários de murino, é possível se referir a técnicas as quais são descritas, em particular, no manual Antibodies (Harlow e Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor NY, páginas 726, 1988) ou à técnica de preparo de hibridomas descrita por Kohler e Milstein (Nature, 256: 495-497, 1975).</span>[00087] In general, for the preparation of monoclonal antibodies or their fragments or functional derivatives, especially those originating from murine, it is possible to refer to techniques which are described, in particular, in the Antibodies manual (Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor NY, pages 726, 1988) or the hybridoma preparation technique described by Kohler and Milstein (Nature, 256: 495-497, 1975).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00088] Os anticorpos monoclonais de acordo com a invenção podem ser obtidos, por exemplo, de uma célula animal imunizada contra c-Met ou um de seus fragmentos contendo o epítopo especificamente reconhecido pelos referidos anticorpos monoclonais de acordo com a invenção. A referida c-Met ou um de seus referidos fragmentos pode ser especialmente produzida de acordo com métodos de trabalho usuais, através de recombinação genética começando com uma sequência de aminoácido contida na sequência de cDNA que codifica a c-Met ou através de síntese de peptídeo começando a partir de uma sequência de aminoácido compreendida na sequência peptídica da c-Met.</span>[00088] The monoclonal antibodies according to the invention can be obtained, for example, from an animal cell immunized against c-Met or one of its fragments containing the epitope specifically recognized by said monoclonal antibodies according to the invention. Said c-Met or one of its fragments can be specially produced according to usual working methods, through genetic recombination starting with an amino acid sequence contained in the cDNA sequence encoding the c-Met or through peptide synthesis starting from an amino acid sequence comprised in the c-Met peptide sequence.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00089] Os anticorpos monoclonais de acordo com a invenção</span>[00089] Monoclonal antibodies according to the invention</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 40/146</span>Petition 870190095443, of 24/09/2019, p. 40/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">27/131 podem, por exemplo, ser purificados sobre uma coluna de afinidade sobre a qual a c-Met ou um de seus fragmentos contendo o epítopo especificamente reconhecido pelos referidos anticorpos monoclonais de acordo com a invenção foi previamente imobilizada. Mais particularmente, os referidos anticorpos monoclonais podem ser purificados através de cromatografia sobre proteína A e/ou G, seguido ou não por cromatografia de troca iônica direcionada à eliminação dos contaminantes de proteína residual, bem como o DNA e a LPS em si, seguido ou não por cromatografia de exclusão sobre um gel de Sepharose™ de forma a eliminar os agregados potenciais em virtude da presença de dímeros ou outros multímeros. De uma maneira ainda mais preferida, o todo dessas técnicas pode ser usado simultânea ou sucessivamente.</span>27/131 can, for example, be purified on an affinity column on which c-Met or one of its fragments containing the epitope specifically recognized by said monoclonal antibodies according to the invention has been previously immobilized. More particularly, said monoclonal antibodies can be purified by chromatography on protein A and / or G, followed or not by ion exchange chromatography aimed at the elimination of residual protein contaminants, as well as the DNA and LPS itself, followed or not by exclusion chromatography on a Sepharose ™ gel in order to eliminate potential aggregates due to the presence of dimers or other multimers. Even more preferably, the whole of these techniques can be used simultaneously or successively.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00090] Anticorpos quiméricos ou humanizados são, da mesma forma, incluídos nos anticorpos de acordo com a presente invenção.</span>[00090] Chimeric or humanized antibodies are likewise included in the antibodies according to the present invention.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00091] Por anticorpo quimérico, entende-se um anticorpo o qual contém uma região variável natural (cadeia leve e cadeia pesada) derivado de um anticorpo de uma determinada espécie em combinação com as regiões constantes de cadeia leve e cadeia pesada de um anticorpo de uma espécie heteróloga à referida determinada espécie (por exemplo, camundongo, cavalo, coelho, cão, vaca, galinha, etc.).</span>[00091] Chimeric antibody means an antibody which contains a natural variable region (light chain and heavy chain) derived from an antibody of a particular species in combination with the light chain and heavy chain constant regions of an antibody from a species heterologous to that particular species (for example, mouse, horse, rabbit, dog, cow, chicken, etc.).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00092] Os anticorpos ou seus fragmentos do tipo quimérico de acordo com a invenção podem ser preparados usando as técnicas de recombinação genética. Por exemplo, o anticorpo quimérico pode ser produzido através de clonagem de um DNA recombinante contendo um promotor e uma sequência que codifica a região variável de um anticorpo monoclonal não-humano, especialmente de murino, de acordo com a invenção e uma sequência que codifica a região constante de um anticorpo humano. Um anticorpo quimérico da</span>[00092] The antibodies or fragments of the chimeric type according to the invention can be prepared using the techniques of genetic recombination. For example, the chimeric antibody can be produced by cloning recombinant DNA containing a promoter and a sequence that encodes the variable region of a non-human monoclonal antibody, especially murine, according to the invention and a sequence that encodes the constant region of a human antibody. A chimeric antibody from</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 41/146</span>Petition 870190095443, of 24/09/2019, p. 41/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">28/131 invenção codificado por tal gene recombinante será, por exemplo, uma quimera de camundongo-homem, a especificidade desse anticorpo sendo determinada pela região variável do DNA de murino e seu isotipo determinado pela região constante derivada do DNA humano. Para os métodos de preparo de anticorpos quiméricos é possível, por exemplo, se referir aos documentos Verhoeyn et al. (BioEssays, 8: 74, 1988), Morrison et al. (Proc. Natl. Acad. Sci. USA 82: 6851-6855, 1984) ou le brevet US 4.816.567.</span>The invention encoded by such a recombinant gene will, for example, be a mouse-human chimera, the specificity of that antibody being determined by the variable region of murine DNA and its isotype determined by the constant region derived from human DNA. For methods of preparing chimeric antibodies, it is possible, for example, to refer to the documents Verhoeyn et al. (BioEssays, 8: 74, 1988), Morrison et al. (Proc. Natl. Acad. Sci. USA 82: 6851-6855, 1984) or le brevet US 4,816,567.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00093] Por anticorpo humanizado, entende-se um anticorpo o qual contém regiões de CDR derivadas de um anticorpo de origem nãohumana, as outras partes da molécula de anticorpo sendo derivadas de um (ou de vários) anticorpo humano. Além disso, alguns dos resíduos dos segmentos do esqueleto (denominado FR) podem ser modificados de forma a conservar a afinidade de ligação (Jones et al., Nature, 321: 522-525, 1986; Verhoeyen et al., Science, 239: 15341536, 1988; Riechmann et al., Nature, 332: 323-327, 1988).</span>[00093] By humanized antibody is meant an antibody which contains regions of CDR derived from an antibody of non-human origin, the other parts of the antibody molecule being derived from one (or more) human antibody. In addition, some of the residues of the skeleton segments (called FR) can be modified in order to preserve the binding affinity (Jones et al., Nature, 321: 522-525, 1986; Verhoeyen et al., Science, 239: 15341536, 1988; Riechmann et al., Nature, 332: 323-327, 1988).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00094] Os anticorpos humanizados de acordo com a invenção ou seus fragmentos podem ser preparados através de métodos conhecidos por aqueles versados na técnica (tais como, por exemplo, aqueles descritos nos documentos de Singer et al., J. Immun. 150: 2844-2857, 1992; Mountain et al., Biotechnol. Genet. Eng. Rev., 10: 1142, 1992; ou Bebbington et al., Bio/Technology, 10: 169-175, 1992).</span>[00094] The humanized antibodies according to the invention or fragments thereof can be prepared by methods known to those skilled in the art (such as, for example, those described in the documents by Singer et al., J. Immun. 150: 2844 -2857, 1992; Mountain et al., Biotechnol. Genet. Eng. Rev., 10: 1142, 1992; or Bebbington et al., Bio / Technology, 10: 169-175, 1992).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00095] Outros métodos de humanização são conhecidos por aqueles versados na técnica como, por exemplo, o método de Enxertagem de CDR descrito pela Protein Design Lab (PDL) nos pedidos de patente EP 0 451261, EP 0 682 040, EP 0 9127, EP 0 566 647 ou US 5.530.101, US 6.180.370, US 5.585.089 e US 5.693.761. Os seguintes pedidos de patente também podem ser mencionados: US 5.639.641; US 6.054.297; US 5.886.152 e US 5.877.293.</span>[00095] Other methods of humanization are known to those skilled in the art such as, for example, the CDR Grafting method described by Protein Design Lab (PDL) in patent applications EP 0 451261, EP 0 682 040, EP 0 9127, EP 0 566 647 or US 5,530,101, US 6,180,370, US 5,585,089 and US 5,693,761. The following patent applications can also be mentioned: US 5,639,641; US 6,054,297; US 5,886,152 and US 5,877,293.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00096] Por fragmento funcional de um anticorpo de acordo com a</span>[00096] Per functional fragment of an antibody according to</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 42/146</span>Petition 870190095443, of 24/09/2019, p. 42/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">29/131 invenção, entende-se, em particular, um fragmento de anticorpo, tais como fragmentos Fv, scFv (sc para um única cadeia), Fab, F(ab')2, Fab', scFv-Fc ou diacorpos ou qualquer fragmento cujo tempo de meia-vida foi aumentado através de modificação química, tal como a adição de (poli)alquileno glicol, tal como (poli)etileno glicol (PEGuilação) (fragmentos peguilados denominados Fv-PEG, scFvPEG, Fab-PEG, F(ab')2-PEG ou Fab'-PEG)(PEG para Poli(Etileno) Glicol) ou através de incorporação em um lipossoma, os referidos fragmentos tendo pelo menos uma das CDRs característica de sequência SEQ ID Nos. 1 a 17 e 56 a 61 de acordo com a invenção e, especialmente, pelo fato de que ele é capaz de exercer, de uma maneira geral, uma atividade mesmo parcial do anticorpo do qual ele é derivado tal como, em particular, a capacidade de reconhecer e se ligar à c-Met e, se necessário, inibir a atividade da c-Met.</span>In particular, an antibody fragment, such as Fv, scFv (sc for a single chain), Fab, F (ab ') 2, Fab', scFv-Fc or diabody bodies or any fragment whose half-life has been increased by chemical modification, such as the addition of (poly) alkylene glycol, such as (poly) ethylene glycol (PEGylation) (pegylated fragments called Fv-PEG, scFvPEG, Fab-PEG, F (ab ') 2-PEG or Fab'-PEG) (PEG for Poly (Ethylene) Glycol) or by incorporation into a liposome, said fragments having at least one of the CDRs characteristic of sequence SEQ ID Nos. 1 to 17 and 56 to 61 according to the invention and, in particular, due to the fact that it is able, in general, to exert an even partial activity of the antibody from which it is derived such as, in particular, the capacity to recognize and bind to c-Met and, if necessary, inhibit c-Met activity.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00097] De preferência, os referidos fragmentos funcionais serão constituídos ou compreenderão uma sequência parcial da cadeia variável pesada ou leve do anticorpo do qual eles são derivados, a referida sequência parcial sendo suficiente para reter a mesma especificidade de ligação que o anticorpo do qual ela é derivada e uma afinidade suficiente, de preferência, pelo menos = 1/100, de uma maneira mais preferida pelo menos 1/10 daquela do anticorpo do qual ela é derivada com relação à c-Met. Tal fragmento funcional conterá no mínimo 5 aminoácidos, de preferência 6, 7, 8, 9, 10, 12, 15, 25, 50 e 100 aminoácidos consecutivos da sequência do anticorpo do qual ela é derivada.</span>[00097] Preferably, said functional fragments will consist of or comprise a partial sequence of the heavy or light variable chain of the antibody from which they are derived, said partial sequence being sufficient to retain the same binding specificity as the antibody from which it is derived. it is derived and a sufficient affinity, preferably at least = 1/100, more preferably at least 1/10 that of the antibody from which it is derived with respect to c-Met. Such a functional fragment will contain at least 5 amino acids, preferably 6, 7, 8, 9, 10, 12, 15, 25, 50 and 100 consecutive amino acids of the antibody sequence from which it is derived.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00098] De preferência, esses fragmentos funcionais serão fragmentos do tipo Fv, scFv, Fab, F(ab')2, F(ab'), scFv-Fc ou diacorpos, os quais, em geral, têm a mesma especificidade de ligação que o anticorpo do qual eles são derivados. Em uma modalidade mais preferida da invenção, esses fragmentos são selecionados dentre</span>[00098] Preferably, these functional fragments will be fragments of the type Fv, scFv, Fab, F (ab ') 2, F (ab'), scFv-Fc or diabody, which, in general, have the same binding specificity than the antibody from which they are derived. In a more preferred embodiment of the invention, these fragments are selected from among</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 43/146</span>Petition 870190095443, of 24/09/2019, p. 43/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30/131 fragmentos divalentes, tais como fragmentos F(ab')2. De acordo com a presente invenção, os fragmentos de anticorpo da invenção podem ser obtidos começando a partir de anticorpos, tal como descrito acima, através de métodos tais como digestão por enzimas tais como pepsina ou papaína e/ou através de de clivagem das ligações em ponte de dissulfeto por meio de redução química. De outra maneira, os fragmentos de anticorpo compreendidos na presente invenção podem ser obtidos através de métodos de recombinação genética da mesma forma bem-conhecidos por aqueles versados na técnica ou mesmo através de síntese de peptídeo por meio, por exemplo, de sintetizadores automáticos de peptídeo, tais como aqueles fornecidos pela companhia Applied Biosystems, etc.</span>30/131 divalent fragments, such as F (ab ') 2 fragments. According to the present invention, the antibody fragments of the invention can be obtained starting from antibodies, as described above, by methods such as digestion by enzymes such as pepsin or papain and / or by cleaving the bonds in disulfide bridge by chemical reduction. Otherwise, the antibody fragments comprised in the present invention can be obtained by means of genetic recombination methods in the same way well known to those skilled in the art or even by peptide synthesis using, for example, automatic peptide synthesizers. , such as those provided by the company Applied Biosystems, etc.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[00099] Por fragmento divalente, entende-se quaisquer fragmentos de anticorpo compreendendo dois braços e, mais particularmente, fragmentos F(ab')2.</span>[00099] By divalent fragment, we mean any antibody fragments comprising two arms and, more particularly, F (ab ') 2 fragments.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000100] Mais particularmente, a invenção compreende os anticorpos ou seus fragmentos funcionais de acordo com a presente invenção, especialmente anticorpos quiméricos ou humanizados obtidos através de recombinação genética ou através de síntese química.</span>[000100] More particularly, the invention comprises the antibodies or their functional fragments according to the present invention, especially chimeric or humanized antibodies obtained through genetic recombination or through chemical synthesis.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000101] Por derivados de um anticorpo de acordo com a invenção, entende-se uma proteína de ligação compreendendo uma base de proteína e pelo menos uma das CDRs selecionadas do anticorpo original de forma a manter a capacidade de ligação. Tais compostos são bem-conhecidos por aqueles versados na técnica e serão descritos em maiores detalhes na especificação a seguir.</span>[000101] By derivatives of an antibody according to the invention, we mean a binding protein comprising a protein base and at least one of the CDRs selected from the original antibody in order to maintain the binding capacity. Such compounds are well known to those skilled in the art and will be described in more detail in the specification below.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000102] Mais particularmente, o anticorpo ou um de seus fragmentos ou derivados funcionais de acordo com a invenção é caracterizado pelo fato de que o derivado consiste em uma proteína de ligação compreendendo uma base sobre a qual pelo menos uma CDR</span>[000102] More particularly, the antibody or one of its functional fragments or derivatives according to the invention is characterized by the fact that the derivative consists of a binding protein comprising a base on which at least one CDR</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 44/146</span>Petition 870190095443, of 24/09/2019, p. 44/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">31/131 foi enxertada para a conservação das propriedades de reconhecimento paratópicas do anticorpo original.</span>31/131 was grafted to preserve the paratopic recognition properties of the original antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000103] Uma ou várias sequências das 6 sequências de CDR descritas na invenção podem estar presentes sobre uma base de proteína. Nesse caso, a base de proteína reproduz a parte principal de proteína com uma duplicação apropriada da(s) CDR(s) enxertada(s), assim, permitindo que as mesmas mantenham suas propriedades de reconhecimento paratópicas do antígeno.</span>[000103] One or more sequences of the 6 CDR sequences described in the invention can be present on a protein basis. In this case, the protein base reproduces the main part of the protein with an appropriate duplication of the grafted CDR (s), thus allowing them to maintain their paratopic recognition properties of the antigen.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000104] Aqueles versados na técnica saberão como selecionar a base de proteína sobre a qual pelo menos uma CDR selecionada do anticorpo original poderia ser enxertada. Mais particularmente, sabe-se que, para ser selecionada, tal base deverá mostrar várias características, como segue (Skerra A., J. Mol. Recogn., 13, 2000, 167-187):</span>[000104] Those skilled in the art will know how to select the protein base on which at least one CDR selected from the original antibody could be grafted. More particularly, it is known that, to be selected, such a base must show several characteristics, as follows (Skerra A., J. Mol. Recogn., 13, 2000, 167-187):</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- boa conservação filogenética,</span>- good phylogenetic conservation,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- arquitetura robusta com uma organização molecular tridimensional bem-conhecida (tal como, por exemplo, cristalografia ou RMN),</span>- robust architecture with a well-known three-dimensional molecular organization (such as, for example, crystallography or NMR),</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- pequeno tamanho</span>- small size</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- nenhum ou apenas um baixo grau de modificações póstraducionais,</span>- none or only a low degree of post-institutional changes,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- facilidade de produzir, expressar e purificar [000105] Tal base de proteína pode ser, mas sem limitação, uma estrutura selecionada do grupo consistindo em fibronectina e, de preferência o décimo domínio de fibronectina do tipo III (FNfn10), lipocalina, anticalina (Skerra A., J. Biotechnol, 2001, 74(4): 257-75), o derivado de proteína Z do domínio B de proteína A estafilocócica, tioredoxina A ou qualquer proteína com domínio repetido, tal como repetição de anquirina (Kohl et al., PNAS, 2003, vol. 100, No. 4, 1700-1705), repetição de armadilo, repetição rica em leucina ou</span>- ease of producing, expressing and purifying [000105] Such a protein base can be, but without limitation, a structure selected from the group consisting of fibronectin and, preferably, the tenth domain of type III fibronectin (FNfn10), lipocalin, anticalin ( Skerra A., J. Biotechnol, 2001, 74 (4): 257-75), the protein derivative of the B domain of staphylococcal protein A, thioredoxin A or any protein with repeated domain, such as ankyrin repeat (Kohl et al., PNAS, 2003, vol. 100, No. 4, 1700-1705), repetition of arthritis, repetition rich in leucine or</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 45/146</span>Petition 870190095443, of 24/09/2019, p. 45/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">32/131 repetição de tetratricopeptídeo.</span>32/131 tetratricopeptide repeat.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000106] Também poderia ser mencionado um derivado de base de toxinas (tal como, por exemplo, toxinas de escorpião, inseto, planta ou molusco) ou inibidores de proteína de sintase de óxido nítrico neuronal (PIN).</span>[000106] A toxin-based derivative (such as, for example, scorpion, insect, plant or mollusk toxins) or neuronal nitric oxide synthase protein (PIN) inhibitors could also be mentioned.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000107] Como um exemplo não limitativo de tais construções híbridas pode ser mencionada a inserção da CDR-H1 (cadeia pesada) de um anticorpo anti-CD4, isto é, o anticorpo 13B8.2, em um dos loops expostos da PIN. As propriedades de ligação da proteína de ligação obtida permanecem similares ao anticorpo original (Bes et al., BBRC 343, 2006, 334-344). Também pode ser mencionada a enxertagem da CDR-H3 (cadeia pesada) de um anticorpo antilisozima VHH sobre um loop da neocarzinostatina (Nicaise et al., 2004).</span>[000107] As a non-limiting example of such hybrid constructs, mention may be made of inserting the CDR-H1 (heavy chain) of an anti-CD4 antibody, i.e., the 13B8.2 antibody, into one of the exposed PIN loops. The binding properties of the obtained binding protein remain similar to the original antibody (Bes et al., BBRC 343, 2006, 334-344). It can also be mentioned the grafting of the CDR-H3 (heavy chain) of an antilisozyme VHH antibody onto a neocarzinostatin loop (Nicaise et al., 2004).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000108] No caso da presente invenção, uma CDR interessante a ser conservada poderia ser, sem limitação, CDR-L2, uma vez que ela é conservada em dois anticorpos idênticos da invenção, isto é, 227H1 e 224G11.</span>[000108] In the case of the present invention, an interesting CDR to be conserved could be, without limitation, CDR-L2, since it is conserved in two identical antibodies of the invention, that is, 227H1 and 224G11.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000109] Conforme mencionado acima, tal base de proteína pode compreender de 1 a 6 CDR(s) do anticorpo original. Em uma modalidade preferida, mas sem qualquer limitação, aqueles versados na técnica poderiam selecionar pelo menos uma CDR da cadeia pesada, a referida cadeia pesada sendo conhecida por estar particularmente envolvida na especificidade do anticorpo. A seleção da(s) CDR(s) será evidente para aqueles versados na técnica através de um método conhecido (BES et al., FEBS letters 508, 2001,67-74).</span>[000109] As mentioned above, such a protein base can comprise from 1 to 6 CDR (s) of the original antibody. In a preferred embodiment, but without any limitation, those skilled in the art could select at least one heavy chain CDR, said heavy chain being known to be particularly involved in the specificity of the antibody. The selection of the CDR (s) will be evident to those skilled in the art through a known method (BES et al., FEBS letters 508, 2001,67-74).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000110] Como uma evidência, esses exemplos não são limitativos e qualquer outra base conhecida ou descrita deve ser incluída na presente especificação.</span>[000110] As an evidence, these examples are not limiting and any other known or described basis should be included in the present specification.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000111] De acordo com um novo aspecto, a presente invenção refere-se um ácido nucleico isolado, caracterizado pelo fato de que ele</span>[000111] According to a new aspect, the present invention relates to an isolated nucleic acid, characterized by the fact that it</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 46/146</span>Petition 870190095443, of 24/09/2019, p. 46/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">33/131 é escolhida dos ácido nucleicos a seguir:</span>33/131 is chosen from the following nucleic acids:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">a) um ácido nucleico, DNA ou RNA, que codifica um anticorpo ou um de seus fragmentos ou derivados funcionais, de acordo com a invenção;</span>a) a nucleic acid, DNA or RNA, which encodes an antibody or one of its functional fragments or derivatives, according to the invention;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">b) um ácido nucleico compreendendo uma sequência de DNA selecionado do grupo de sequências de:</span>b) a nucleic acid comprising a DNA sequence selected from the group of sequences of:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- uma sequência de ácido nucleico compreendendo as sequências SEQ ID No. 24, SEQ ID No. 25, SEQ ID No. 26 e as sequências SEQ ID No. 33, SEQ ID No. 34 e SEQ ID No. 35;</span>- a nucleic acid sequence comprising the sequences SEQ ID No. 24, SEQ ID No. 25, SEQ ID No. 26 and the sequences SEQ ID No. 33, SEQ ID No. 34 and SEQ ID No. 35;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- uma sequência de ácido nucleico compreendendo as sequências SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 29 e as sequências SEQ ID No. 36, SEQ ID No. 34 e SEQ ID No. 37;</span>- a nucleic acid sequence comprising the sequences SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 29 and the sequences SEQ ID No. 36, SEQ ID No. 34 and SEQ ID No. 37;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- uma sequência de ácido nucleico compreendendo as sequências SEQ ID No. 30, SEQ ID No. 31, SEQ ID No. 32 e as sequências SEQ ID No. 38, SEQ ID No. 39 e SEQ ID No. 40; e</span>- a nucleic acid sequence comprising the sequences SEQ ID No. 30, SEQ ID No. 31, SEQ ID No. 32 and the sequences SEQ ID No. 38, SEQ ID No. 39 and SEQ ID No. 40; and</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- uma sequência de ácido nucleico compreendendo as sequências SEQ ID No. 64, SEQ ID No. 65, SEQ ID No. 66 e as sequências SEQ ID No. 67, SEQ ID No. 68 e SEQ ID No. 69;</span>- a nucleic acid sequence comprising the sequences SEQ ID No. 64, SEQ ID No. 65, SEQ ID No. 66 and the sequences SEQ ID No. 67, SEQ ID No. 68 and SEQ ID No. 69;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">c) um ácido nucleico compreendendo uma sequência de DNA selecionada do grupo de sequências consistindo em:</span>c) a nucleic acid comprising a DNA sequence selected from the group of sequences consisting of:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- uma sequência de ácido nucleico compreendendoas sequências SEQ ID No. 41 e SEQ ID No. 44;</span>- a nucleic acid sequence comprising the sequences SEQ ID No. 41 and SEQ ID No. 44;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- uma sequência de ácido nucleico compreendendoas sequências SEQ ID No. 42 e SEQ ID No. 45;</span>- a nucleic acid sequence comprising the sequences SEQ ID No. 42 and SEQ ID No. 45;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- uma sequência de ácido nucleico compreendendoas sequências SEQ ID No. 43 e SEQ ID No. 46, e</span>- a nucleic acid sequence comprising the sequences SEQ ID No. 43 and SEQ ID No. 46, and</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- uma sequência de ácido nucleico compreendendoas sequências SEQ ID No. 70 e SEQ ID No. 71;</span>- a nucleic acid sequence comprising the sequences SEQ ID No. 70 and SEQ ID No. 71;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">d) Os ácidos nucleicos de RNA correspondentes aos ácidos nucleicos conforme definido em b) ou c);</span>d) The RNA nucleic acids corresponding to the nucleic acids as defined in b) or c);</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 47/146</span>Petition 870190095443, of 24/09/2019, p. 47/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">34/131</span>34/131</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">e) os ácidos nucléicos complementares aos ácidos nucléicos conforme definido em a), b) e c); e</span>e) nucleic acids complementary to nucleic acids as defined in a), b) and c); and</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">f) um ácido nucleico de pelo menos 18 nucleotídeos, capaz de se hibridizar, sob condições de alta estringência, com pelo menos uma das CDRs de sequências SEQ ID Nos. 24 a 40 e 64 a 69. [000112] Por ácido nucleico, nucleico ou sequência de ácido nucleico, polinucleotídeo, oligonucleotídeo, sequência de polinucleotídeo, sequência de nucleotídeo, termos os quais serão empregados indiferentemente na presente invenção, entende-se uma ligação precisa de nucleotídeos, a qual pode ser modificada ou não modificada, que permite que um fragmento ou uma região de um ácido nucleico seja definida, contendo ou não contendo nucleotídeos nãonaturais e sendo capaz de corresponder a um DNA fita dupla, um DNA fita simples, bem como aos produtos de transcrição dos referidos DNAs.</span>f) a nucleic acid of at least 18 nucleotides, capable of hybridizing, under conditions of high stringency, with at least one of the CDRs of SEQ ID Nos. 24 to 40 and 64 to 69. [000112] By nucleic acid, nucleic or nucleic acid sequence, polynucleotide, oligonucleotide, polynucleotide sequence, nucleotide sequence, terms which will be used interchangeably in the present invention, a precise connection is understood nucleotide, which can be modified or unmodified, which allows a fragment or region of a nucleic acid to be defined, containing or not containing non-natural nucleotides and being able to correspond to a double-stranded DNA, a single-stranded DNA, as well as to the transcription products of said DNAs.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000113] Deve também ser entendido aqui que a presente invenção não refere-se à sequências de nucleotídeo em seu ambiente cromossômico natural, isto é, no estado natural. Ela refere-se à sequências as quais foram isoladas e/ou purificadas, isto é, elas foram selecionadas direta ou indiretamente, por exemplo, através de cópia, seu ambiente tendo sido pelo menos parcialmente modificado. Assim, da mesma forma, ela se destina a indicar aqui os ácidos nucleicos isolados obtidos através de recombinação genética, por exemplo, por meio de células hospedeiras ou obtidos através de síntese química.</span>[000113] It should also be understood here that the present invention does not refer to nucleotide sequences in their natural chromosomal environment, that is, in the natural state. It refers to the sequences which have been isolated and / or purified, that is, they have been selected directly or indirectly, for example, by copying, their environment having been at least partially modified. Thus, in the same way, it is intended to indicate here the isolated nucleic acids obtained through genetic recombination, for example, through host cells or obtained through chemical synthesis.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000114] Uma hibridização sob condições de alta estringência significa que as condições de temperatura e condições de resistência iônica são escolhidas de uma forma tal que elas permitem a manutenção da hibridização entre dois fragmentos de DNA complementar. À guisa de ilustração, condições de alta estringência da etapa de hibridização para fins de definição dos fragmentos de</span>[000114] A hybridization under conditions of high stringency means that the temperature conditions and ionic resistance conditions are chosen in such a way that they allow the maintenance of the hybridization between two fragments of complementary DNA. By way of illustration, high stringency conditions of the hybridization stage for the purpose of defining the fragments of</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 48/146</span>Petition 870190095443, of 24/09/2019, p. 48/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35/131 polinucleotídeo descritos acima são, vantajosamente, as seguintes. [000115] A hibridização de DNA-DNA ou DNA-RNA é realizada em duas etapas: (1) pré-hibridização a 42°C durante 3 horas em tampão de fosfato (a 20 mM, pH de 7,5) contendo 5 x SSC (1 x SSC corresponde a NaCl a 0,15 M + solução de citrato de sódio a 0,015 M), 50 % de formamida, 7 % de dodecil sulfato de sódio (SDS), 10 x Denhardt's, 5 % de sulfato de dextrano e 1 % de DNA de esperma de salmão; (2) hibridização real durante 20 horas em uma temperatura dependente do tamanho da sonda (isto é : 42°C, para um tamanho de sonda &gt; 100 nucleotídeos) seguido por 2 lavagens de 20 minutos a 20°C em 2 x SSC + 2% de SDS, 1 lavagem de 20 minutos a 20°C em 0,1 x SSC + 0,1 % de SDS. A última lavagem é realizada em 0,1 x SSC + 0,1 % de SDS durante 30 minutos a 60°C para um tamanho de sonda &gt; 100 nucleotídeos. As condições de hibridização de alta estringência descritas acima para um polinucleotídeo de tamanho definido podem ser adaptadas por aqueles versados na técnica para oligonucleotídeos de maior ou menor tamanho, de acordo com o ensinamento de Sambrook et al. (1989, Molecular cloning: a laboratory manual. 2<sup class="style-scope patent-text">a</sup> Ed. Cold Spring Harbor).</span>35/131 polynucleotides described above are advantageously the following. [000115] DNA-DNA or DNA-RNA hybridization is performed in two stages: (1) prehybridization at 42 ° C for 3 hours in phosphate buffer (at 20 mM, pH 7.5) containing 5 x SSC (1 x SSC corresponds to 0.15 M NaCl + 0.015 M sodium citrate solution), 50% formamide, 7% sodium dodecyl sulfate (SDS), 10 x Denhardt's, 5% dextran sulfate and 1% salmon sperm DNA; (2) real hybridization for 20 hours at a temperature dependent on the size of the probe (ie: 42 ° C, for a probe size&gt; 100 nucleotides) followed by 2 washes of 20 minutes at 20 ° C in 2 x SSC + 2 % SDS, 1 20 minute wash at 20 ° C in 0.1 x SSC + 0.1% SDS. The last wash is performed in 0.1 x SSC + 0.1% SDS for 30 minutes at 60 ° C for a probe size&gt; 100 nucleotides. The high stringency hybridization conditions described above for a polynucleotide of defined size can be adapted by those skilled in the art for larger or smaller oligonucleotides, according to the teaching of Sambrook et al. (1989, Molecular cloning: a laboratory manual. 2 <sup class="style-scope patent-text">to</sup> Ed. Cold Spring Harbor).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000116] A invenção, da mesma forma, refere-se a um vetor compreendendo um ácido nucleico de acordo com a presente invenção.</span>[000116] The invention, likewise, relates to a vector comprising a nucleic acid according to the present invention.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000117] A invenção direciona especificamente a vetores de clonagem e/ou vetores de expressão, os quais contêm uma sequência de nucleotídeo de acordo com a invenção.</span>[000117] The invention specifically targets cloning vectors and / or expression vectors, which contain a nucleotide sequence according to the invention.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000118] Os vetores de acordo com a invenção contêm, de preferência, elementos os quais permitem a expressão e/ou a secreção das sequências de nucleotídeo em uma determinada célula hospedeira. O vetor deve, portanto, conter um promotor, sinais de início e término de tradução, bem como regiões apropriadas de</span>[000118] The vectors according to the invention preferably contain elements which allow the expression and / or secretion of the nucleotide sequences in a given host cell. The vector must therefore contain a promoter, translation start and end signals, as well as appropriate regions of</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 49/146</span>Petition 870190095443, of 24/09/2019, p. 49/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">36/131 regulação de transcrição. Ele deve ser capaz de ser mantido de uma maneira estável na célula hospedeira e pode, opcionalmente, ter sinais particulares os quais especificam a secreção da proteína traduzida. Esses diferentes elementos são escolhidos e otimizados por aqueles versados na técnica como uma função da célula hospedeira usada. Para esse efeito, as sequências de nucleotídeo de acordo com a invenção podem ser inseridas em vetores de reprodução autônoma no hospedeiro escolhido ou ser vetores integrativos do hospedeiro escolhido.</span>36/131 regulation of transcription. It must be able to be maintained in a stable manner in the host cell and may, optionally, have particular signals which specify the secretion of the translated protein. These different elements are chosen and optimized by those skilled in the art as a function of the host cell used. For this purpose, the nucleotide sequences according to the invention can be inserted into autonomously reproducing vectors in the chosen host or be integrative vectors of the chosen host.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000119] Tais vetores são preparações através de métodos atualmente usados por aqueles versados na técnica e os clones resultantes podem ser introduzidos em um hospedeiro apropriado através de métodos-padrão, tais como lipofecção, eletroporação, choque térmico ou métodos químicos.</span>[000119] Such vectors are preparations using methods currently used by those skilled in the art and the resulting clones can be introduced into an appropriate host using standard methods, such as lipofection, electroporation, thermal shock or chemical methods.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000120] Os vetores de acordo com a invenção são, por exemplo, vetores de origem plasmídica ou viral. Eles são úteis para transformação de células hospedeiras de forma a clonar ou expressar as sequências de nucleotídeo de acordo com a invenção.</span>[000120] The vectors according to the invention are, for example, vectors of plasmid or viral origin. They are useful for transforming host cells in order to clone or express the nucleotide sequences according to the invention.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000121] A invenção, da mesma forma, compreende as células hospedeiras transformadas por ou compreendendo um vetor de acordo com a invenção.</span>[000121] The invention, likewise, comprises host cells transformed by or comprising a vector according to the invention.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000122] A célula hospedeira pode ser escolhida de sistemas procariotas ou eucariotas, por exemplo, células bacterianas mas, da mesma forma, células de levedo ou células animais, em particular células de mamífero. Da mesma forma, é possível usar células de inseto ou células de planta.</span>[000122] The host cell can be chosen from prokaryotic or eukaryotic systems, for example, bacterial cells but, likewise, yeast cells or animal cells, in particular mammalian cells. Likewise, it is possible to use insect cells or plant cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000123] A invenção, da mesma forma, refere-se a animais, exceto o homem, os quais compreendem pelo menos uma célula transformada de acordo com a invenção.</span>[000123] The invention, likewise, refers to animals, except man, which comprise at least one cell transformed according to the invention.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000124] De acordo com outro aspecto, um assunto da invenção é</span>[000124] According to another aspect, a subject of the invention is</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 50/146</span>Petition 870190095443, of 24/09/2019, p. 50/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">37/131 um processo para a produção de um anticorpo ou um de seus fragmentos funcionais de acordo com a invenção, caracterizado pelo fato de que ele compreende os seguintes estágios:</span>37/131 a process for the production of an antibody or one of its functional fragments according to the invention, characterized by the fact that it comprises the following stages:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">a) cultura em um meio e condições de cultura apropriadas de uma célula hospedeira de acordo com a invenção; e</span>a) culture in a medium and appropriate culture conditions of a host cell according to the invention; and</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">b) a recuperação dos referidos anticorpos ou um de seus fragmentos funcionais assim produzidos começando a partir do meio de cultura ou das referidas células cultivadas.</span>b) recovering said antibodies or one of their functional fragments so produced starting from the culture medium or from said cultured cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000125] As células transformadas de acordo com a invenção podem ser usadas em processos para preparo de polipeptídeos recombinantes de acordo com a invenção. Os processos para preparo de um polipeptídeo de acordo com a invenção na forma recombinante, caracterizado pelo fato de que eles empregam um vetor e/ou uma célula transformada por um vetor de acordo com a invenção são, em si, compreendidos na presente invenção. De preferência, uma célula transformada por um vetor de acordo com a invenção é cultivada sob condições as quais permitem a expressão do referido polipeptídeo e o referido peptídeo recombinante é recuperado.</span>[000125] Cells transformed according to the invention can be used in processes for preparing recombinant polypeptides according to the invention. The processes for preparing a polypeptide according to the invention in recombinant form, characterized by the fact that they employ a vector and / or a cell transformed by a vector according to the invention, are in themselves understood in the present invention. Preferably, a cell transformed by a vector according to the invention is cultured under conditions which allow expression of said polypeptide and said recombinant peptide is recovered.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000126] Conforme foi dito, a célula hospedeira pode ser escolhida de sistemas procariotas ou eucariotas. Em particular, é possível identificar sequências de nucleotídeo de acordo com a invenção que facilitam a secreção em tal sistema procariota ou eucariota. Um vetor de acordo com a invenção trazendo tal sequência pode, portanto, vantajosamente, ser usado para a produção de proteínas recombinantes destinadas a serem secretadas. Na realidade, a purificação dessas proteínas recombinantes de interesse será facilitada pelo fato de que elas estão presentes no sobrenadante da cultura de célula ao invés de no interior das células hospedeiras.</span>[000126] As stated, the host cell can be chosen from prokaryotic or eukaryotic systems. In particular, it is possible to identify nucleotide sequences according to the invention that facilitate secretion in such a prokaryotic or eukaryotic system. A vector according to the invention carrying such a sequence can therefore advantageously be used for the production of recombinant proteins intended to be secreted. In reality, the purification of these recombinant proteins of interest will be facilitated by the fact that they are present in the cell culture supernatant rather than inside the host cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000127] Da mesma forma, é possível preparar os polipeptídeos de acordo com a invenção através de síntese química. Tal processo de</span>[000127] Likewise, it is possible to prepare the polypeptides according to the invention through chemical synthesis. Such a process of</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 51/146</span>Petition 870190095443, of 24/09/2019, p. 51/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">38/131 preparo é, da mesma forma, um assunto da invenção. Aqueles versados na técnica conhecerão os processos de síntese química, por exemplo, as técnicas empregando fases sólidas [Steward et al., 1984, Solid phase peptide synthesis, Pierce Chem. Company, Rockford, 111, 2<sup class="style-scope patent-text">a</sup> ed., (1984)] ou técnicas usando fases sólidas parciais, através de condensação de fragmentos ou através de uma síntese clássica em solução. Os polipeptídeos obtidos através de síntese química e sendo capazes de conter aminoácidos não-naturais correspondentes são, da mesma forma, compreendidos na invenção.</span>38/131 preparation is likewise a subject of the invention. Those skilled in the art will know the processes of chemical synthesis, for example, techniques employing solid phases [Steward et al., 1984, Solid phase peptide synthesis, Pierce Chem. Company, Rockford, 111, 2nd ed., (1984)] or techniques using partial solid phases, by condensation of fragments or by a classical synthesis in solution. Polypeptides obtained through chemical synthesis and being able to contain corresponding unnatural amino acids are likewise included in the invention.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000128] Os anticorpos ou um de seus fragmentos ou derivados funcionais capazes de serem obtidos através de um processo de acordo com a invenção são, da mesma forma, compreendidos na presente invenção.</span>[000128] Antibodies or one of its fragments or functional derivatives capable of being obtained by a process according to the invention are likewise included in the present invention.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000129] A invenção também refere-se ao anticorpo da invenção como um medicamento.</span>[000129] The invention also refers to the antibody of the invention as a medicament.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000130] A invenção, da mesma forma, refere-se a uma composição farmacêutica compreendendo, como forma de princípio ativo, um composto consistindo em um anticorpo ou um de seus fragmentos funcionais de acordo com a invenção, de preferência, misturado com um excipiente e/ou um veículo farmaceuticamente aceitável.</span>[000130] The invention, likewise, relates to a pharmaceutical composition comprising, as a form of active ingredient, a compound consisting of an antibody or one of its functional fragments according to the invention, preferably mixed with an excipient and / or a pharmaceutically acceptable carrier.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000131] Outra modalidade complementar da invenção consiste em uma composição tal como descrito acima a qual compreende, além disso, como um produto combinado para uso simultâneo, separado ou sequencial, um anticorpo antitumoral.</span>[000131] Another complementary embodiment of the invention consists of a composition as described above which further comprises, as a combined product for simultaneous, separate or sequential use, an anti-tumor antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000132] Mais preferivelmente, o referido segundo anticorpo antitumoral poderia ser escolhido de anticorpos anti-IGF-IR, antiEGFR, anti-HER2/neu, anti-VEGFR, anti-VEGF, etc., ou quaisquer outros anticorpos antitumorais conhecidos por aqueles versados na técnica. É evidente que o uso, como segundo anticorpo, de fragmentos ou derivados funcionais dos anticorpos mencionados acima é parte da</span>[000132] More preferably, said second anti-tumor antibody could be chosen from anti-IGF-IR, antiEGFR, anti-HER2 / neu, anti-VEGFR, anti-VEGF, etc. antibodies, or any other anti-tumor antibodies known to those skilled in the art. in the technique. It is evident that the use, as a second antibody, of fragments or functional derivatives of the antibodies mentioned above is part of the</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 52/146</span>Petition 870190095443, of 24/09/2019, p. 52/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">39/131 invenção.</span>39/131 invention.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000133] Como um anticorpo mais preferido, anticorpos anti-EGFR são selecionados tal como, por exemplo, o anticorpo C225 (Erbitux).</span>[000133] As a more preferred antibody, anti-EGFR antibodies are selected such as, for example, the C225 antibody (Erbitux).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000134] Uso simultâneo deve ser entendido como significando a administração dos dois compostos da composição de acordo com a invenção em uma forma farmacêutica única e idêntica.</span>[000134] Simultaneous use should be understood as meaning the administration of the two compounds of the composition according to the invention in a single and identical pharmaceutical form.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000135] Uso separado deve ser entendido como significando a administração, ao mesmo tempo, dos dois compostos da composição de acordo com a invenção em formas farmacêuticas distintas.</span>[000135] Separate use should be understood as meaning the administration, at the same time, of the two compounds of the composition according to the invention in different pharmaceutical forms.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000136] Uso sequencial deve ser entendido como significando a administração sucessiva dos dois compostos da composição de acordo com a invenção, cada um em uma forma farmacêutica distinta.</span>[000136] Sequential use should be understood as meaning the successive administration of the two compounds of the composition according to the invention, each in a different pharmaceutical form.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000137] De um modo geral, a composição de acordo com a invenção aumenta consideravelmente a eficácia do tratamento de câncer. Em outras palavras, o efeito terapêutico dos anticorpos anti-cMet de acordo com a invenção é potencializado de uma maneira inesperada através da administração de um agente citotóxico. Outra principal subsequente vantagem produzida por uma composição de acordo com a invenção refere-se à possibilidade de uso de menores doses eficazes de princípio ativo, o que permite os riscos de aparecimento de efeitos secundários sejam evitados ou sejam reduzidos, em particular os efeitos do agente citotóxico.</span>[000137] In general, the composition according to the invention considerably increases the effectiveness of cancer treatment. In other words, the therapeutic effect of the anti-cMet antibodies according to the invention is enhanced in an unexpected way through the administration of a cytotoxic agent. Another main subsequent advantage produced by a composition according to the invention relates to the possibility of using lower effective doses of active principle, which allows the risks of the appearance of side effects to be avoided or reduced, in particular the effects of the agent. cytotoxic.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000138] Além disso, essa composição de acordo com a invenção permitirá que o efeito terapêutico esperado seja obtido mais rapidamente.</span>[000138] Furthermore, this composition according to the invention will allow the expected therapeutic effect to be obtained more quickly.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000139] A composição da invenção também pode ser caracterizada pelo fato de que ela compreende, além disso, como um produto combinado para uso simultâneo, separado ou sequencial, um agente citotóxico/citostático.</span>[000139] The composition of the invention can also be characterized by the fact that it further comprises, as a combined product for simultaneous, separate or sequential use, a cytotoxic / cytostatic agent.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000140] Por agentes terapêuticos anticâncer ou agentes</span>[000140] By anti-cancer therapeutic agents or agents</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 53/146</span>Petition 870190095443, of 24/09/2019, p. 53/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40/131 citotóxicos/citoestáticos entende-se uma substância a qual, quando administrada a um indivíduo, trata ou previne o desenvolvimento de câncer no corpo do indivíduo. Como um exemplo não limitativo de tais agentes, podem ser mencionados agentes de alquilação, antimetabólitos, antibióticos antitumor, inibidores mitóticos, inibidores de função de cromatina, agentes antiangiogênese, antiestrogênios, antiandrogênios ou imunomoduladores.</span>40/131 cytotoxic / cytostatic means a substance which, when administered to an individual, treats or prevents the development of cancer in the individual's body. As a non-limiting example of such agents, alkylating agents, antimetabolites, antitumor antibiotics, mitotic inhibitors, chromatin function inhibitors, antiangiogenesis agents, antiestrogens, antiandrogens or immunomodulators can be mentioned.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000141] Tais agentes são, por exemplo, citados na edição de 2001 de VIDAL, na página destinada aos compostos relacionados à coluna de cancerologia e hematologia Citotóxicos, esses compostos citotóxicos citados por referência a esse documento são citados aqui como agentes citotóxicos preferidos.</span>[000141] Such agents are, for example, cited in the 2001 edition of VIDAL, on the page for compounds related to the column of cancerology and cytotoxic hematology, those cytotoxic compounds cited by reference to this document are cited here as preferred cytotoxic agents.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000142] Mais particularmente, os seguintes agentes são preferidos de acordo com a invenção.</span>[000142] More particularly, the following agents are preferred according to the invention.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000143] Agente de alquilação refere-se a qualquer substância a qual pode se reticula ou alquilar qualquer molécula, de preferência. ácido nucleico (por exemplo, DNA), dentro de uma célula. Exemplos de agente de alquilação incluem mostarda de nitrogênio, tal como mecloretamina, clorambucol, melfaleno, cloridrato, pipobromeno, prednimustina, fosfato dissódico ou estramustina; oxazoforinas, tais como ciclofosfamida, altretamina, trofosfamida, sulfofosfamida ou ifosfamida; aziridinas ou imina-etilenos, tais como, tiotepa, trietilenamina ou altetramina; nitrosoureia, tal como carmustina, estreptozocina, fotemustina ou lomustina; sulfonatos de alquila, tais como, bussulfano, treossulfano ou improssulfano; triazenos, tal como dacarbazina; ou complexos de platina, tais como cis-platina, oxaliplatina e carboplatina.</span>[000143] Alkylating agent refers to any substance which can be cross-linked or alkylated any molecule, preferably. nucleic acid (for example, DNA), inside a cell. Examples of an alkylating agent include nitrogen mustard, such as meclorethamine, chlorambucol, melphalene, hydrochloride, pipobromene, prednimustine, disodium phosphate or estramustine; oxazophorines, such as cyclophosphamide, altretamine, trophosphamide, sulfophosphamide or ifosfamide; aziridines or imine-ethylenes, such as, thiotepa, triethylenamine or altetramine; nitrosourea, such as carmustine, streptozocin, photemustine or lomustine; alkyl sulfonates, such as busulfan, thosulfan or improsulfan; triazenes, such as dacarbazine; or platinum complexes, such as cis-platinum, oxaliplatin and carboplatin.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000144] Anti-metabólitos refere-se à substâncias que bloqueiam o crescimento celular e/ou metabolismo através de interferência com determinadas atividades, usualmente síntese de DNA. Exemplos de</span>[000144] Anti-metabolites refers to substances that block cell growth and / or metabolism through interference with certain activities, usually DNA synthesis. Examples of</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 54/146</span>Petition 870190095443, of 24/09/2019, p. 54/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">41/131 anti-metabólitos incluem metotrexato, 5-fluoruracila, floxuridina, 5fluorodeoxiuridina, capecitabina, citarabina, fludarabina, arabinosídeo de citosina, 6-mercaptopurina (6-MP), 6-tioguanina (6-TG), clorodeoxiadenosina, 5-azacitidina, gemcitabina, cladribina, deóxicoformicina e pentostatina.</span>41/131 anti-metabolites include methotrexate, 5-fluorouracil, floxuridine, 5fluorodeoxyuridine, capecitabine, cytarabine, fludarabine, cytosine arabinoside, 6-mercaptopurine (6-MP), 6-thioguanine (6-TG), chlorideoxide , gemcitabine, cladribine, deoxychoformicin and pentostatin.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000145] Antibióticos antitumor refere-se a compostos os quais podem prevenir ou inibir a síntese de DNA, RNA e/ou proteína. Exemplos de antibióticos antitumor incluem doxorubicina, daunorubicina, idarubicina, valrubicina, mitoxantrona, dactinomicina, mitramicina, plicamicina, mitomicina C, bleomicina e procarbazina.</span>[000145] Antitumor antibiotics refer to compounds which can prevent or inhibit the synthesis of DNA, RNA and / or protein. Examples of anti-tumor antibiotics include doxorubicin, daunorubicin, idarubicin, valrubicin, mitoxantrone, dactinomycin, mitramycin, plicamycin, mitomycin C, bleomycin and procarbazine.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000146] Inibidores mitóticos impedem a progreção normal do ciclo celular e mitose. Em geral, inibidores de microtúbulo ou taxoides, tais como paclitaxel e docetaxel são capazes de inibir a mitose. Vinca alcaloides, tais como vinblastina, vincristina, vindesina e vinorelbina, também são capazes de inibir a mitose.</span>[000146] Mitotic inhibitors prevent normal cell cycle progression and mitosis. In general, microtubule or taxoid inhibitors, such as paclitaxel and docetaxel are able to inhibit mitosis. Vinca alkaloids, such as vinblastine, vincristine, vindesine and vinorelbine, are also capable of inhibiting mitosis.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000147] Inibidores da função de cromatina ou inibidores de topoisomerase refere-se a substâncias as quais inibem a função normal de proteínas de modelamento de cromatina, tais como topoisomerase I ou topoisomerase II. Exemplos de inibidores de função de cromatina incluem, para topoisomerase I, camptotecina e seus derivados, tais como topotecano ou irinotecano e, para topoisomerase II, etoposídeo, fosfato de etoposídeo e teniposídeo.</span>[000147] Chromatin function inhibitors or topoisomerase inhibitors refers to substances which inhibit the normal function of chromatin modeling proteins, such as topoisomerase I or topoisomerase II. Examples of inhibitors of chromatin function include, for topoisomerase I, camptothecin and its derivatives, such as topotecan or irinotecan and, for topoisomerase II, etoposide, etoposide phosphate and teniposide.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000148] Agente antiangiogênese refere-se a qualquer fármaco, composto, substância ou agente o qual inibe o crescimento de vasos sanguíneos. Agentes antiangiogênese exemplificativos incluem, mas não estão limitados a, razoxina, marimastat, batimastat, prinomastat, tanomastat, ilomastat, CGS-27023A, halofuginon, COL-3, neovastat, BMS-275291, talidomida, CDC 501, DMXAA, L-651582, esqualamina, endostatina, SU5416, SU6668, interferon-alfa, EMD121974, interleucina-12, IM862, angiostatina e vitaxina.</span>[000148] Antiangiogenesis agent refers to any drug, compound, substance or agent which inhibits the growth of blood vessels. Exemplary antiangiogenesis agents include, but are not limited to, razoxin, marimastat, batimastat, prinomastat, tanomastat, ilomastat, CGS-27023A, halofuginon, COL-3, neovastat, BMS-275291, thalidomide, CDC 501, DMXAA, L-65, squalamine, endostatin, SU5416, SU6668, interferon-alpha, EMD121974, interleukin-12, IM862, angiostatin and vitaxin.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 55/146</span>Petition 870190095443, of 24/09/2019, p. 55/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">42/131 [000149] Antiestrogênio ou agente antiestrogênico refere-se a qualquer substância a qual reduz, antagozina ou inibe a ação do estrogênio. Exemplos de agentes antiestrogênio são tamoxifeno, toremifeno, raloxifeno, droloxifeno, iodoxifeno, anastrozola, letrozola e exemestano.</span>42/131 [000149] Antiestrogen or antiestrogenic agent refers to any substance which reduces, antagozine or inhibits the action of estrogen. Examples of anti-estrogen agents are tamoxifen, toremifene, raloxifene, droloxifene, iodoxifene, anastrozola, letrozole and exemestane.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000150] Antiandrogênios ou agente antiandrogênio refere-se a qualquer substância a qual reduz, antagoniza ou inibe a ação de um androgênio. Exemplos de antiandrogênio são flutamida, nilutamida, bicalutamida, esprironolactona, acetato de ciproterona, finasterida e cimitidina.</span>[000150] Antiandrogens or antiandrogen agent refers to any substance which reduces, antagonizes or inhibits the action of an androgen. Examples of anti-androgen are flutamide, nilutamide, bicalutamide, sprironolactone, cyproterone acetate, finasteride and cimitidine.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000151] Imunomoduladores são substâncias as quais estimulam o sistema imune. Exemplos de imunomoduladores incluem, interferon, interleucina, tal como aldesleucina, OCT-43, denileucina diflitox e interleucina-2, fatores de necrose tumoral, tal como tasonermina ou outros moduladores, tais como lentinano, sizofirano, roquinimex, pidotimod, pegademase, timopentina, poli I:C ou levamisola em conjunto com 5-fluorouracila.</span>[000151] Immunomodulators are substances which stimulate the immune system. Examples of immunomodulators include, interferon, interleukin, such as aldesleukin, OCT-43, denileukin diflitox and interleukin-2, tumor necrosis factors, such as tasonermin or other modulators, such as lentinan, sizofiran, roquinimex, pidotimod, pegademase, timadema, timade poly I: C or levamisole in conjunction with 5-fluorouracil.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000152] Para maiores detalhes, aqueles versados na técnica poderiam se referir ao manual editado pela the Association Française des Enseignants de Chimie Thérapeutique e intitulado Traité de chimie thérapeutique, vol. 6, Medicaments antitumoraux et perspectives dans le traitement des cancers, edição TEC &amp; DOC, 2003.</span>[000152] For more details, those versed in the technique could refer to the manual edited by the Association Française des Enseignants by Chimie Thérapeutique and entitled Traité de chimie thérapeutique, vol. 6, Anti-tumor drugs and perspectives on treatment of cancers, TEC &amp; DOC edition, 2003.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000153] Também podem ser mencionados como agentes químicos ou agentes citotóxicos todos os inibidores de quinase tais como, por exemplo, gefitinib ou erlotinib.</span>[000153] All kinase inhibitors such as, for example, gefitinib or erlotinib can also be mentioned as chemical agents or cytotoxic agents.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000154] Em uma modalidade particularmente preferida, a referida composição como um produto combinado de acordo com a invenção é caracterizada pelo fato de que o referido agente citotóxico é acoplado quimicamente ao referido anticorpo para uso simultâneo.</span>[000154] In a particularly preferred embodiment, said composition as a combined product according to the invention is characterized by the fact that said cytotoxic agent is chemically coupled to said antibody for simultaneous use.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 56/146</span>Petition 870190095443, of 24/09/2019, p. 56/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">43/131 [000155] De forma a facilitar o acoplamento entre o referido agente citotóxico e o referido anticorpo de acordo com a invenção, é especialmente possível introduzir moléculas espaçadoras entre os dois compostos a serem acoplados, tais como (poli)alquileno glicóis, tal como polietileno glicol ou mesmo aminoácidos ou, em outra modalidade, usar derivados ativos dos referidos agentes citotóxicos nos quais foram introduzidas funções capazes de reação com o referido anticorpo de acordo com a invenção. Esses métodos de acoplamento são bem-conhecidos por aqueles versados na técnica e não serão expandidos na presente descrição.</span>43/131 [000155] In order to facilitate the coupling between said cytotoxic agent and said antibody according to the invention, it is especially possible to introduce spacer molecules between the two compounds to be coupled, such as (poly) alkylene glycols, such as such as polyethylene glycol or even amino acids or, in another embodiment, to use active derivatives of said cytotoxic agents in which functions capable of reacting with said antibody according to the invention have been introduced. Such coupling methods are well known to those skilled in the art and will not be expanded on in the present description.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000156] A invenção refere-se, em outro aspecto, a uma composição caracterizada pelo fato de que pelo menos um dos referidos anticorpos ou um de seus fragmentos ou derivados funcionais é conjugado com uma toxina celular e/ou um radioelemento.</span>[000156] The invention relates, in another aspect, to a composition characterized by the fact that at least one of said antibodies or one of its functional fragments or derivatives is conjugated to a cellular toxin and / or a radio element.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000157] De preferência, a referida toxina ou o referido radioelemento é capaz de inibir pelo menos uma atividade celular de células expressando a c-Met, de uma maneira mais preferida capaz de prevenir o crescimento ou a proliferação da referida célula, especialmente de inativar totalmente a referida célula.</span>[000157] Preferably, said toxin or said radio element is capable of inhibiting at least one cell activity of cells expressing c-Met, in a more preferred way capable of preventing the growth or proliferation of said cell, especially of inactivating that cell.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000158] De preferência também, a referida toxina é uma toxina enterobacteriana, especialmente exotoxina A de Pseudomonas.</span>[000158] Preferably also, said toxin is an enterobacterial toxin, especially Pseudomonas exotoxin A.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000159] Os radioelementos (ou radioisótopos), de preferência conjugados aos anticorpos empregados para a terapia, são radioisótopos os quais emitem raios gama e, de preferência, iodo<sup class="style-scope patent-text">131</sup>, ítrio<sup class="style-scope patent-text">90</sup>, ouro<sup class="style-scope patent-text">199</sup>, paládio<sup class="style-scope patent-text">100</sup>, cobre<sup class="style-scope patent-text">67</sup>, bismuto<sup class="style-scope patent-text">217</sup> e antimônio<sup class="style-scope patent-text">211</sup>. Os radioisótopos os quais emitem raios beta e alfa podem, da mesma forma, ser usados para a terapia.</span>[000159] Radioelements (or radioisotopes), preferably conjugated to antibodies used for therapy, are radioisotopes which emit gamma rays and, preferably, iodine <sup class="style-scope patent-text">131</sup> , yttrium <sup class="style-scope patent-text">90</sup> , gold <sup class="style-scope patent-text">199</sup> , palladium <sup class="style-scope patent-text">100</sup> , copper <sup class="style-scope patent-text">67</sup> , bismuth <sup class="style-scope patent-text">217</sup> and antimony <sup class="style-scope patent-text">211</sup> . Radioisotopes which emit beta and alpha rays can likewise be used for therapy.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000160] Por toxina ou radioelemento conjugado a pelo menos um anticorpo ou um de seus fragmentos funcionais de acordo com a invenção, entende-se qualquer meio que permite que a referida toxina</span>[000160] By toxin or radio element conjugated to at least one antibody or one of its functional fragments according to the invention, we mean any means that allows said toxin</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 57/146</span>Petition 870190095443, of 24/09/2019, p. 57/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">44/131 ou o referido radioelemento se liguem ao referido pelo menos um anticorpo, especialmente através de acoplamento covalente entre os dois compostos, com ou sem a introdução de uma molécula de ligação.</span>44/131 or said radio element binds to said at least one antibody, especially through covalent coupling between the two compounds, with or without the introduction of a binding molecule.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000161] Dentre os agentes que permitem a ligação de uma maneira química (covalente), eletroestática ou não-covalente de todos ou parte dos componentes do conjugado, menção pode ser particularmente feita a benzoquinona, carbodiimida e mais particularmente EDC (cloridrato de 1-etil-3-[3-dimetil-aminopropil]-carbodiimida), dimaleimida, ácido ditiobis-nitrobenzoico (DTNB), tioacetato de Nsuccinimidil S-acetila (SATA), os agentes de ligação em ponte tendo um ou mais grupos fenilazida que reagem com raios ultravioleta (U.V.) e, de preferência, N-[-4-(azidosalicilamino)butil]-3'-(2-piridilditio)propionamida (APDP), 3-(2-piridilditio)propionato de N-succinimidila (SPDP), 6-hidrazino-nicotinamida (HYNIC).</span>[000161] Among the agents that allow chemical (covalent), electrostatic or non-covalent bonding of all or part of the components of the conjugate, mention may be made particularly of benzoquinone, carbodiimide and more particularly EDC (1- ethyl-3- [3-dimethyl-aminopropyl] -carbodiimide), dimaleimide, dithiobis-nitrobenzoic acid (DTNB), Nsuccinimidyl S-acetyl thioacetate (SATA), bridging agents having one or more phenylazide groups that react with ultraviolet (UV) and preferably N - [- 4- (azidosalicylamino) butyl] -3 '- (2-pyridyldithio) propionamide (APDP), N-succinimidyl 3- (2-pyridyldithio) propionate (SPDP) , 6-hydrazino-nicotinamide (HYNIC).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000162] Outra forma de acoplamento, especialmente para os radioelementos, pode consistir no uso de um quelante de íons bifuncional.</span>[000162] Another form of coupling, especially for radio elements, may consist of the use of a bifunctional ion chelator.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000163] Dentre esses quelatos, é possível mencionar os quelatos derivados de EDTA (ácido etilenodiaminatetra-acético) ou de DTPA (ácido dietilenetriaminapenta-acético), os quais foram desenvolvidos para ligação de metais, especialmente metais radioativos e imunoglobulinas. Assim, DPA e seus derivados podem ser substituídos por diferentes grupos sobre a cadeia de carbono de forma a aumentar a estabilidade e a rigidez do completo de ligante-metal (Krejcarek et al. (1977); Brechbiel et al. (1991); Gansow (1991); Patente US 4.831.175).</span>[000163] Among these chelates, it is possible to mention the chelates derived from EDTA (ethylenediaminetetraacetic acid) or DTPA (diethylenetriamineapenta-acetic acid), which have been developed to bind metals, especially radioactive metals and immunoglobulins. Thus, DPA and its derivatives can be substituted by different groups on the carbon chain in order to increase the stability and rigidity of the binder-metal complete (Krejcarek et al. (1977); Brechbiel et al. (1991); Gansow (1991); US Patent 4,831,175).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000164] Por exemplo, ácido dietilenotriaminapenta-acético (DTPA) e seus derivados, os quais têm sido usados amplamente em medicina e em biologia há muito tempo em sua forma livre ou na forma de um</span>[000164] For example, diethylenetriamineapentaacetic acid (DTPA) and its derivatives, which have been used extensively in medicine and biology for a long time in its free form or in the form of a</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 58/146</span>Petition 870190095443, of 24/09/2019, p. 58/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45/131 complexo com um íon metálico, tem a característica acentuada de formação de quelatos estáveis com íons metálicos e de ser acoplado com proteínas de interesse terapêutico ou diagnóstico, tais como anticorpos para o desenvolvimento de radioimunoconjugados em terapia de câncer (Meases et al., (1984); Gansow et al. (1990)).</span>45/131 complex with a metal ion, has the marked characteristic of forming stable chelates with metal ions and of being coupled with proteins of therapeutic or diagnostic interest, such as antibodies for the development of radioimmunoconjugates in cancer therapy (Meases et al. , (1984); Gansow et al. (1990)).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000165] Da mesma forma, de preferência, o referido pelo menos um anticorpo que forma o referido conjugado de acordo com a invenção é escolhido de seus fragmentos funcionais, especialmente dos fragmentos com deleção de seu componente Fc, tais como os fragmentos scFv.</span>[000165] Likewise, preferably, said at least one antibody that forms said conjugate according to the invention is chosen from its functional fragments, especially fragments with deletion of its Fc component, such as scFv fragments.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000166] Conforme já mencionado, em uma modalidade preferida da invenção, o referido agente citoestático/citotóxico e a referida toxina e/ou um radioelemento é acoplado quimicamente a pelo menos um dos elementos da referida composição para uso simultâneo.</span>[000166] As already mentioned, in a preferred embodiment of the invention, said cytostatic / cytotoxic agent and said toxin and / or a radio element is chemically coupled to at least one of the elements of said composition for simultaneous use.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000167] A presente invenção compreende a composição descrita como um medicamento.</span>[000167] The present invention comprises the composition described as a medicament.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000168] A presente invenção, além disso, compreende o uso da composição de acordo com a invenção para o preparo de um medicamento.</span>[000168] The present invention, furthermore, comprises the use of the composition according to the invention for the preparation of a medicament.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000169] Em outro aspecto, a invenção lida com o uso de um anticorpo ou um de seus fragmentos ou derivados funcionais e/ou de uma composição conforme descrito acima para o preparo de um medicamento destinado a inibir o crescimento e/ou a proliferação de células tumorais.</span>[000169] In another aspect, the invention deals with the use of an antibody or one of its functional fragments or derivatives and / or a composition as described above for the preparation of a medicament intended to inhibit the growth and / or proliferation of tumor cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000170] Outro aspecto da invenção consiste no uso de um anticorpo ou um de seus fragmentos ou derivados funcionais e/ou de uma composição conforme descrito acima ou do uso mencionado acima para o preparo de um medicamento destinado à prevenção ou ao tratamento de câncer.</span>[000170] Another aspect of the invention is the use of an antibody or one of its functional fragments or derivatives and / or a composition as described above or the use mentioned above for the preparation of a medicament intended for the prevention or treatment of cancer.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000171] Também é compreendido na presente invenção um método</span>[000171] Also included in the present invention is a method</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 59/146</span>Petition 870190095443, of 24/09/2019, p. 59/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">46/131 destinado a inibir o crescimento e/ou a proliferação de células tumorais em um paciente compreendendo a administração, a um paciente que precisa do mesmo, de um anticorpo ou um de seus fragmentos ou derivados funcionais de acordo com a invenção, de um anticorpo produzido através de um hibridoma de acordo com a invenção ou uma composição de acordo com a invenção.</span>46/131 intended to inhibit the growth and / or proliferation of tumor cells in a patient comprising administering, to a patient in need of it, an antibody or one of its functional fragments or derivatives according to the invention, of a antibody produced by a hybridoma according to the invention or a composition according to the invention.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000172] A presente invenção ainda compreende um método para a prevenção ou o tratamento de câncer em um paciente que precisa do mesmo compreendendo a administração, ao paciente, de um anticorpo ou um de seus fragmentos ou derivados funcionais de acordo com a invenção, de um anticorpo produzido por um hibridoma de acordo com a invenção ou uma composição de acordo com a invenção.</span>[000172] The present invention further comprises a method for the prevention or treatment of cancer in a patient who needs it comprising administration, to the patient, of an antibody or one of its functional fragments or derivatives according to the invention, of an antibody produced by a hybridoma according to the invention or a composition according to the invention.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000173] Em um aspecto preferido particular, o referido câncer é um câncer escolhido de câncer de próstata, osteosarcomas, câncer de pulmão, câncer de mama, câncer endometrial, glioblastoma ou câncer de cólon.</span>[000173] In a particular preferred aspect, said cancer is a cancer chosen from prostate cancer, osteosarcomas, lung cancer, breast cancer, endometrial cancer, glioblastoma or colon cancer.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000174] Conforme explicado antes, uma vantagem da invenção é permitir o tratamento de cânceres relacionados à ativação de Met dependentes e independentes de HGF.</span>[000174] As explained before, an advantage of the invention is to allow the treatment of cancers related to the activation of HGF-dependent and independent Met.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000175] A invenção, em ainda outro aspecto, abrange um método de diagnóstico in vitro de enfermidades induzidas por uma superexpressão ou uma subexpressão do receptor de c-Met começando a partir de uma amostra biológica na qual a presença anormal do receptor de c-Met é suspeita, o referido método sendo caracterizado pelo fato de que ele compreende uma etapa em que a referida amostra biológica é contatada com um anticorpo da invenção, sendo possível que o referido anticorpo seja, se necessário, rotulado.</span>[000175] The invention, in yet another aspect, encompasses a method of in vitro diagnosis of diseases induced by an overexpression or underexpression of the c-Met receptor starting from a biological sample in which the abnormal presence of the c-Met receptor Met is suspect, said method being characterized by the fact that it comprises a step in which said biological sample is contacted with an antibody of the invention, it being possible that said antibody is, if necessary, labeled.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000176] De preferência, a referida enfermidade relacionada à presença anormal do receptor de c-Met no referido método diagnóstico será câncer.</span>[000176] Preferably, said disease related to the abnormal presence of the c-Met receptor in said diagnostic method will be cancer.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 60/146</span>Petition 870190095443, of 24/09/2019, p. 60/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">47/131 [000177] O referido anticorpo ou um de seus fragmentos funcionais pode estar presente na forma de um imunoconjugado ou de um anticorpo rotulado, de modo a obter um sinal detectável e/ou quantificável.</span>47/131 [000177] Said antibody or one of its functional fragments can be present in the form of an immunoconjugate or a labeled antibody, in order to obtain a detectable and / or quantifiable signal.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000178] Os anticorpos rotulados de acordo com a invenção ou seus fragmentos funcionais incluem, por exemplo, anticorpos denominados imunoconjugados os quais podem ser conjugados, por exemplo, com enzimas tais como peroxidase, fosfatase alcalina, beta-Dgalactosidase, oxidase de glicose, amilase de glicose, anidrase carbônica, acetilcolinesterase, lisozima, de-hidrogenase de malato ou de-hidrogenase de 6-fosfato de glicose ou por uma molécula, tal como biotina, digoxigenina ou 5-bromodeoxiuridina. Rótulos fluorescentes podem, da mesma forma, ser conjugados aos anticorpos ou seus fragmentos funcionais de acordo com a invenção e incluem especialmente fluoresceína e seus derivados, fluorocromo, rodamina e seus derivados, GFP (GFP para Proteína Fluorescente Verde), dansila, unbeliferona, etc. Em tais conjugados, os anticorpos da invenção ou seus fragmentos funcionais podem ser preparados através de métodos conhecidos por aqueles versados na técnica. Eles podem ser acoplados a enzimas ou aos rótulos fluorescentes diretamente ou por intermédio de um grupo espaçador ou de um grupo de ligação, tal como um polialdeído, tal como glutaraldeído, ácido etilenodiaminatetra-acético (EDTA), ácido dietileno-triaminapentaacético (DPTA) ou na presença de agentes de acoplamento, tais como aqueles mencionados acima para os conjugados terapêuticos. Os conjugados contendo rótulos do tipo fluoresceína podem ser preparados através de reação com um isotilcianato.</span>[000178] The antibodies labeled according to the invention or their functional fragments include, for example, antibodies called immunoconjugates which can be conjugated, for example, with enzymes such as peroxidase, alkaline phosphatase, beta-Dgalactosidase, glucose oxidase, amylase glucose, carbonic anhydrase, acetylcholinesterase, lysozyme, malate dehydrogenase or glucose 6-phosphate dehydrogenase or by a molecule, such as biotin, digoxigenin or 5-bromodeoxyuridine. Fluorescent labels can likewise be conjugated to the antibodies or their functional fragments according to the invention and include especially fluorescein and its derivatives, fluorochrome, rhodamine and its derivatives, GFP (GFP for Green Fluorescent Protein), dansila, unbeliferone, etc. . In such conjugates, the antibodies of the invention or their functional fragments can be prepared by methods known to those skilled in the art. They can be coupled to enzymes or fluorescent labels directly or via a spacer group or a linking group, such as a polyaldehyde, such as glutaraldehyde, ethylene diaminetetraacetic acid (EDTA), diethylene triaminapentaacetic acid (DPTA) or in the presence of coupling agents, such as those mentioned above for therapeutic conjugates. Conjugates containing fluorescein-like labels can be prepared by reaction with an isothylcyanate.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000179] Outros conjugados podem, da mesma forma, incluir rótulos quimioluminescentes, tais como luminol e os dioxetanos, rótulos bioluminescentes, tais como luciferase e luciferina ou mesmo rótulos</span>[000179] Other conjugates may likewise include chemiluminescent labels, such as luminol and dioxetanes, bioluminescent labels, such as luciferase and luciferin or even labels</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 61/146</span>Petition 870190095443, of 24/09/2019, p. 61/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">48/131 radioativos, tais como iodo<sup class="style-scope patent-text">123</sup>, iodo<sup class="style-scope patent-text">125</sup>, iodo<sup class="style-scope patent-text">126</sup>, iodo<sup class="style-scope patent-text">133</sup>, bromo, tecnécio<sup class="style-scope patent-text">99m</sup>, índio<sup class="style-scope patent-text">111</sup>, índio<sup class="style-scope patent-text">113m</sup>, gálio<sup class="style-scope patent-text">67</sup>, gálio<sup class="style-scope patent-text">68</sup>, ruténio<sup class="style-scope patent-text">95</sup>, ruténio<sup class="style-scope patent-text">97</sup>, ruténio<sup class="style-scope patent-text">103</sup>, ruténio<sup class="style-scope patent-text">105</sup>, mercúrio<sup class="style-scope patent-text">107</sup>, mercúrio<sup class="style-scope patent-text">203</sup>, rênio<sup class="style-scope patent-text">99m</sup>, rênio<sup class="style-scope patent-text">101</sup>, rênio<sup class="style-scope patent-text">105</sup>, escândio<sup class="style-scope patent-text">47</sup>, telúrio<sup class="style-scope patent-text">121m</sup>, telúrio<sup class="style-scope patent-text">122m</sup>, telúrio<sup class="style-scope patent-text">125m</sup>, túlio<sup class="style-scope patent-text">165</sup>, túlio<sup class="style-scope patent-text">167</sup>, túlio<sup class="style-scope patent-text">168</sup>, flúor<sup class="style-scope patent-text">18</sup>, ítrio<sup class="style-scope patent-text">199</sup>, iodo<sup class="style-scope patent-text">131</sup>. Os métodos conhecidos por aqueles versados na técnica existentes para acoplamento dos radioisótopos terapêuticos aos anticorpos, seja diretamente ou através de um agente quelante tal como EDTA, DTPA mencionados acima podem ser usados para os radioelementos os quais podem ser usados em diagnóstico. Da mesma forma, é possível mencionar rotulação com Na[I<sup class="style-scope patent-text">125</sup>] através do método com cloramina T [Hunter W.M. e Greenwood F.C. (1962) Nature 194: 495] ou mesmo com tecnécio<sup class="style-scope patent-text">99m </sup>através da técnica de Crockford et al. (Patente US 4.424.200) ou ligação através de DTPA, conforme descrito por Hnatowich (Patente US 4.479.930).</span>Radioactive 48/131, such as iodine <sup class="style-scope patent-text">123</sup> , iodine <sup class="style-scope patent-text">125</sup> , iodine <sup class="style-scope patent-text">126</sup> , iodine <sup class="style-scope patent-text">133</sup> , bromine, technetium <sup class="style-scope patent-text">99m</sup> , indium <sup class="style-scope patent-text">111</sup> , indium <sup class="style-scope patent-text">113m</sup> , gallium <sup class="style-scope patent-text">67</sup> , gallium <sup class="style-scope patent-text">68</sup> , ruthenium <sup class="style-scope patent-text">95</sup> , ruthenium <sup class="style-scope patent-text">97</sup> , ruthenium <sup class="style-scope patent-text">103</sup> , ruthenium <sup class="style-scope patent-text">105</sup> , mercury <sup class="style-scope patent-text">107</sup> , mercury <sup class="style-scope patent-text">203</sup> , rhenium <sup class="style-scope patent-text">99m</sup> , rhenium <sup class="style-scope patent-text">101</sup> , rhenium <sup class="style-scope patent-text">105</sup> , scandium <sup class="style-scope patent-text">47</sup> , tellurium <sup class="style-scope patent-text">121m</sup> , tellurium <sup class="style-scope patent-text">122m</sup> , tellurium <sup class="style-scope patent-text">125m</sup> , túlio <sup class="style-scope patent-text">165</sup> , túlio <sup class="style-scope patent-text">167</sup> , túlio <sup class="style-scope patent-text">168</sup> , fluorine <sup class="style-scope patent-text">18</sup> , yttrium <sup class="style-scope patent-text">199</sup> , iodine <sup class="style-scope patent-text">131</sup> . The methods known to those skilled in the art for coupling therapeutic radioisotopes to antibodies, either directly or through a chelating agent such as EDTA, DTPA mentioned above, can be used for radioelements which can be used in diagnosis. Likewise, it is possible to mention labeling with Na [I <sup class="style-scope patent-text">125</sup> ] using the method with chloramine T [Hunter WM and Greenwood FC (1962) Nature 194: 495] or even with technetium <sup class="style-scope patent-text">99m</sup> using the technique of Crockford et al. (US patent 4,424,200) or connection via DTPA, as described by Hnatowich (US patent 4,479,930).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000180] Assim, os anticorpos ou seus fragmentos funcionais de acordo com a invenção podem ser empregados em um processo para a detecção e/ou a quantificação de uma superexpressão ou de uma subexpressão, de preferência uma superexpressão do receptor de cMet em uma amostra biológica, caracterizado pelo fato de que ele compreende as seguintes etapas:</span>[000180] Thus, the antibodies or their functional fragments according to the invention can be used in a process for the detection and / or quantification of an overexpression or an underexpression, preferably an overexpression of the cMet receptor in a biological sample , characterized by the fact that it comprises the following steps:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">a) o contato da amostra biológica com um anticorpo ou um de seus fragmentos funcionais de acordo com a invenção; e</span>a) contact of the biological sample with an antibody or one of its functional fragments according to the invention; and</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">b) a demonstração do completo de anticorpo/c-Met possivelmente formado.</span>b) the demonstration of the possibly formed antibody / c-Met complete.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000181] Em uma modalidade particular, os anticorpos ou seus fragmentos funcionais de acordo com a invenção podem ser empregados em um processo para a detecção e/ou a quantificação do receptor de c-Met em uma amostra biológica, para o monitoramento da eficácia de um tratamento terapêutico e/ou profilático de um câncer</span>[000181] In a particular embodiment, the antibodies or their functional fragments according to the invention can be used in a process for the detection and / or quantification of the c-Met receptor in a biological sample, for monitoring the effectiveness of a therapeutic and / or prophylactic treatment of cancer</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 62/146</span>Petition 870190095443, of 24/09/2019, p. 62/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">49/131 dependente de c-Met.</span>49/131 dependent on c-Met.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000182] Mais geralmente, os anticorpos ou seus fragmentos funcionais de acordo com a invenção podem ser vantajosamente empregados em qualquer situação onde a expressão do receptor de cMet deve ser observada de uma maneira qualitativa e/ou quantitativa. [000183] De preferência, a amostra biológica é formada por um fluído biológico, tal como soro, sangue íntegro, células, uma amostra tecidual ou biópsias de origem humana.</span>[000182] More generally, the antibodies or their functional fragments according to the invention can be advantageously employed in any situation where the expression of the cMet receptor must be observed in a qualitative and / or quantitative manner. [000183] Preferably, the biological sample is formed by a biological fluid, such as serum, whole blood, cells, a tissue sample or biopsies of human origin.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000184] Qualquer procedimento ou teste convencional pode ser empregado de forma a realizar tal detecção e/ou dosagem. O referido teste pode ser um teste de competição ou em sanduich ou qualquer teste conhecido por aqueles versados na técnica dependente da formação de um complexo imune do tipo anticorpo-antígeno. Seguindo as aplicações de acordo com a invenção, o anticorpo ou seus fragmentos funcionais podem ser imobilizados ou rotulados. Essa imobilização pode ser realizada sobre numerosos suportes conhecidos por aqueles versados na técnica. Esses suportes podem incluir especialmente vidro, poliestireno, polipropileno, polietileno, dextrano, náilon ou células naturais ou modificadas. Esses suportes podem ser solúveis ou insolúveis.</span>[000184] Any conventional procedure or test can be employed in order to perform such detection and / or dosage. Said test can be a competition or sandwich test or any test known to those skilled in the art dependent on the formation of an antibody-antigen-like immune complex. Following the applications according to the invention, the antibody or its functional fragments can be immobilized or labeled. Such immobilization can be carried out on numerous supports known to those skilled in the art. Such supports can especially include glass, polystyrene, polypropylene, polyethylene, dextran, nylon or natural or modified cells. Such supports can be soluble or insoluble.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000185] À guisa de exemplo, um método preferido leva a processos imunoenzimáticos de acordo com a técnica ELISA, através de imonofluorescência ou da técnica de radioimunoensaio (RIA) ou equivalente.</span>[000185] By way of example, a preferred method leads to immunoenzymatic processes according to the ELISA technique, through imonofluorescence or the radioimmunoassay technique (RIA) or equivalent.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000186] Assim, a presente invenção, da mesma forma, compreende os kits ou conjuntos necessários para a realização de um método de diagnóstico de enfermidades induzidas por uma superexpressão ou uma subexpressão do receptor de c-Met ou para realização de um processo para a detecção e/ou a quantificação de uma superexpressão ou uma subexpressão do receptor de c-Met. Em uma</span>[000186] Thus, the present invention, likewise, comprises the kits or sets necessary for carrying out a method of diagnosing illnesses induced by an overexpression or underexpression of the c-Met receptor or for carrying out a process for the detecting and / or quantifying an overexpression or underexpression of the c-Met receptor. In a</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 63/146</span>Petition 870190095443, of 24/09/2019, p. 63/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50/131 amostra biológica, de preferência, uma superexpressão do referido receptor caracterizado pelo fato de que o referido kit ou conjunto compreende os seguintes elementos:</span>50/131 biological sample, preferably an overexpression of said receptor characterized by the fact that said kit or set comprises the following elements:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">a) um anticorpo ou seus fragmentos funcionais de acordo com a invenção;</span>a) an antibody or its functional fragments according to the invention;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">b) opcionalmente, os reagentes para a formação do meio favorável à reação imunológica;</span>b) optionally, the reagents for the formation of the environment favorable to the immunological reaction;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">c) opcionalmente, os reagentes que permitem a demonstração de complexos de anticorpo/c-Met produzidos pela reação imunológica.</span>c) optionally, reagents that allow the demonstration of antibody / c-Met complexes produced by the immunological reaction.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000187] Um assunto da invenção é, da mesma forma, o uso de um anticorpo ou uma composição de acordo com a invenção para o preparo de um medicamento destinado ao direcionamento específico de um composto biologicamente ativo à células expressando ou superexpressando o receptor de c-Met.</span>[000187] A subject of the invention is, likewise, the use of an antibody or a composition according to the invention for the preparation of a drug intended for the specific targeting of a biologically active compound to cells expressing or overexpressing the c receptor -Met.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000188] Entende-se aqui por composto biologicamente ativo qualquer composto capaz de modular, especialmente de inibir a atividade celular, em particular, seu crescimento, sua proliferação, transcrição ou tradução gênica.</span>[000188] A biologically active compound is understood here as any compound capable of modulating, especially inhibiting cellular activity, in particular, its growth, proliferation, transcription or gene translation.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000189] Um assunto da invenção é também um reagente diagnóstico in vivo compreendendo um anticorpo de acordo com a invenção ou seus fragmentos funcionais, de preferência rotulado, especialmente radiorrotulado e seu uso em formação de imagem médica, em particular, para detecção de câncer relacionado à expressão ou superexpressão, por uma célula, do receptor de c-Met.</span>[000189] A subject of the invention is also an in vivo diagnostic reagent comprising an antibody according to the invention or its functional fragments, preferably labeled, especially radio-labeled and its use in medical imaging, in particular, for the detection of related cancer the expression or overexpression, by a cell, of the c-Met receptor.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000190] A invenção, da mesma forma, refere-se a uma composição como um produto combinado ou a um conjugado ou radioelementos de toxina/anti-c-Met de acordo com a invenção como um medicamento.</span>[000190] The invention, likewise, relates to a composition as a combined product or to a toxin / anti-c-Met conjugate or radio elements according to the invention as a medicament.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000191] De preferência, a referida composição como um produto</span>[000191] Preferably, said composition as a product</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 64/146</span>Petition 870190095443, of 24/09/2019, p. 64/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">51/131 combinado ou o referido conjugado de acordo com a invenção será misturado com um excipiente e/ou um veículo farmaceuticamente aceitável.</span>51/131 combined or said conjugate according to the invention will be mixed with an excipient and / or a pharmaceutically acceptable carrier.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000192] Na presente descrição, veículo farmaceuticamente aceitável se destina a indicar um composto ou uma combinação de compostos que entram em uma composição farmacêutica sem provocar reações secundárias e o qual permite, por exemplo, facilitação da administração do(s) composto(s) ativo(s), um aumento em sua expectativa de vida e/ou em sua eficácia no corpo, um aumento em sua solubilidade em solução ou mesmo um aprimoramento em sua conservação.</span>[000192] In the present description, pharmaceutically acceptable carrier is intended to indicate a compound or a combination of compounds that enter a pharmaceutical composition without causing side reactions and which allows, for example, facilitating the administration of the compound (s) active (s), an increase in its life expectancy and / or its effectiveness in the body, an increase in its solubility in solution or even an improvement in its conservation.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000193] Esses veículos farmaceuticamente aceitáveis são bemconhecidos e será adaptados por aqueles versados na técnica como uma função da natureza e/ou do modo de administração do(s) composto(s) ativo(s) escolhido(s).</span>[000193] These pharmaceutically acceptable vehicles are well known and will be adapted by those skilled in the art as a function of the nature and / or mode of administration of the chosen active compound (s).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000194] De preferência, esses compostos serão administrados através da via sistêmica, em particular através da via intravenosa, através da via intramuscular, intradérmica, intraperitoneal ou subcutânea ou através da via oral. De uma maneira mais preferida, a composição compreendendo os anticorpos de acordo com a invenção será administrada várias vezes, de uma maneira sequencial.</span>[000194] Preferably, these compounds will be administered via the systemic route, in particular via the intravenous route, via the intramuscular, intradermal, intraperitoneal or subcutaneous route or via the oral route. More preferably, the composition comprising the antibodies according to the invention will be administered several times, in a sequential manner.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000195] Seus modos de administração, dosagens e formas farmacêuticas ótimas podem ser determinados de acordo com critérios geralmente levados em conta no estabelecimento de um tratamento adaptado a um paciente tal como, por exemplo, a idade ou o peso corporal do paciente, a gravidade de sua condição geral, a tolerância ao tratamento e os efeitos secundários notados.</span>[000195] Their modes of administration, dosages and optimal pharmaceutical forms can be determined according to criteria generally taken into account when establishing a treatment adapted to a patient such as, for example, the patient's age or body weight, severity their general condition, tolerance to treatment and the side effects noted.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000196] Outras características e vantagens da invenção aparecerão na continuação da descrição com os exemplos e as figuras, em que: [000197] Figura 1: exemplos de perfis por FACS dos anticorpos anti</span>[000196] Other features and advantages of the invention will appear in the continuation of the description with the examples and figures, where: [000197] Figure 1: examples of FACS profiles of anti antibodies</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 65/146</span>Petition 870190095443, of 24/09/2019, p. 65/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">52/131 c-Met selecionados;</span>52/131 selected c-Met;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000198] Figuras 2 A e 2B: inibição in vitro de proliferação de BXPC3 por anticorpos que objetivam c-Met;</span>[000198] Figures 2 A and 2B: in vitro inhibition of BXPC3 proliferation by antibodies that target c-Met;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000199] Figura 3: inibição de dimerização de c-Met;</span>[000199] Figure 3: inhibition of c-Met dimerization;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000200] Figura 4: reconhecimento de proteína por anticorpos anti-cMet;</span>[000200] Figure 4: protein recognition by anti-cMet antibodies;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000201] Figuras 5A e 5B: Mapeamento de epítopo de 11E1 e 5D5 através de análise BIAcore;</span>[000201] Figures 5A and 5B: Epitope mapping of 11E1 and 5D5 through BIAcore analysis;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000202] Figuras 6A e 6B: efeito de MAbs sobre a fosforilação de cMet;</span>[000202] Figures 6A and 6B: effect of MAbs on phosphorylation of cMet;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000203] Figuras 7A e 7B: deslocamento de HGF rádio-rotulada por anticorpos anti-c-Met;</span>[000203] Figures 7A and 7B: displacement of radio-labeled HGF by anti-c-Met antibodies;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000204] Figura 8: inibição de invasão por anticorpos anti-c-Met [nessa Figura, SVF significa Soro Fetal de Bezerro (FCS)];</span>[000204] Figure 8: invasion inhibition by anti-c-Met antibodies [in this Figure, SVF means Fetal Calf Serum (FCS)];</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000205] Figura 9: efeito de anticorpos anti-c-Met sobre a cicatrização de ferimentos;</span>[000205] Figure 9: effect of anti-c-Met antibodies on wound healing;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000206] Figuras 10A e 10B: ensaio de dispersão;</span>[000206] Figures 10A and 10B: dispersion test;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000207] Figura 11: ensaio de tubulogênese tridimensional;</span>[000207] Figure 11: three-dimensional tubulogenesis assay;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000208] Figuras 12A e 12B: efeito de anticorpos sobre a formação de esferoide;</span>[000208] Figures 12A and 12B: effect of antibodies on spheroid formation;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000209] Figura 13: atividade in vivo de Mabs anti-c-Met no modelo de xenoenxerto U87MG;</span>[000209] Figure 13: in vivo activity of anti-c-Met Mabs in the U87MG xenograft model;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000210] Figura 14: expressão de HGF por um conjunto de linhagens de células tumorais;</span>[000210] Figure 14: HGF expression by a set of tumor cell lines;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000211] Figuras 15A e 15B: caracterização da linhagem de célula NCI-H441; com a Figura 15A correspondendo à análise de RT-PCR quantitativa e a Figura 15B correspondendo à análise por FACS ;</span>[000211] Figures 15A and 15B: characterization of the cell line NCI-H441; with Figure 15A corresponding to the quantitative RT-PCR analysis and Figure 15B corresponding to the FACS analysis;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000212] Figura 16: atividade in vivo de anticorpos anti-c-Met sobre o modelo de xenoenxerto NCI-H441;</span>[000212] Figure 16: in vivo activity of anti-c-Met antibodies on the NCI-H441 xenograft model;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000213] Figura 17A: alinhamento de VL de 224G11 ao gene de</span>[000213] Figure 17A: VL alignment of 224G11 to the gene of</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 66/146</span>Petition 870190095443, of 24/09/2019, p. 66/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">53/131 linhagem germinativa de murino IGKV3-5*01;</span>53/131 murine germline IGKV3-5 * 01;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000214] Figura 17B: alinhamento de VL de 224G11 ao gene de linhagem germinativa de murino IGKJ4*01;</span>[000214] Figure 17B: VL alignment of 224G11 to the murine germline gene IGKJ4 * 01;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000215] Figura 18A: alinhamento de VL de 224G11 aos genes de linhagem germinativa humana IGKV3-11*01 e IGKV4-1*01;</span>[000215] Figure 18A: VL alignment of 224G11 to human germline genes IGKV3-11 * 01 and IGKV4-1 * 01;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000216] Figura 18B: alinhamento de VL de 224G11 ao gene de linhagem germinativa humana IGKJ4*02;</span>[000216] Figure 18B: VL alignment of 224G11 to the human germline gene IGKJ4 * 02;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000217] Figura 19A: versão humanizada baseada em IGKV3-11*01 de VL de 224G11 com mutações mencionadas;</span>[000217] Figure 19A: humanized version based on IGKV3-11 * 01 of 224G11 VL with mentioned mutations;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000218] Figura 19B: versão humanizada baseada em IGKV4-1*01 de VL de 224G11 com mutações mencionadas;</span>[000218] Figure 19B: humanized version based on IGKV4-1 * 01 of 224G11 VL with mentioned mutations;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000219] Figura 20A: alinhamento de VH de 224G11 ao gene de linhagem germinativa de murino IGHV1-18*01;</span>[000219] Figure 20A: 224G11 VH alignment to the murine germline gene IGHV1-18 * 01;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000220] Figura 20B: alinhamento de VH de 224G11 ao gene de linhagem germinativa de murino IGHD2-4*01;</span>[000220] Figure 20B: VH alignment of 224G11 to the murine germline gene IGHD2-4 * 01;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000221] Figura 20C: alinhamento de VH de 224G11 ao genede linhagem germinativa de murino IGHJ2*01;</span>[000221] Figure 20C: 224G11 VH alignment to the genus of murine germline IGHJ2 * 01;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000222] Figura 21A: alinhamento de VH de 224G11 ao genede linhagem germinativa humana IGHVl-2*02;</span>[000222] Figure 21A: VH alignment of 224G11 to the human germline strain IGHV1-2 * 02;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000223] Figura 2IB: alinhamento de VH de 224G11 ao genede linhagem germinativa humana IGHJ4*01;</span>[000223] Figure 2IB: VH alignment of 224G11 to the human germline strain IGHJ4 * 01;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000224] Figura 22: VH de 224G11 humanizada com mutações mencionadas;</span>[000224] Figure 22: Humanized 224G11 VH with mentioned mutations;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000225] Figura 23A: alinhamento de VL de 227H1 ao genede linhagem germinativa de murino IGKV3-5*01;</span>[000225] Figure 23A: 227H1 VL alignment to the genus of murine germline IGKV3-5 * 01;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000226] Figura 23B: alinhamento de VL de 227H1 ao genede linhagem germinativa de murino IGKJ4*01;</span>[000226] Figure 23B: 227H1 VL alignment to the genus of murine germline IGKJ4 * 01;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000227] Figura 24A: alinhamento de VL de 227H1 ao genede linhagem germinativa humana IGKV3-11*01 e IGKV4-1*01;</span>[000227] Figure 24A: 227H1 VL alignment with the human germline strain IGKV3-11 * 01 and IGKV4-1 * 01;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000228] Figura 24B: alinhamento de VL de 227H1 ao genede</span>[000228] Figure 24B: 227H1 VL alignment to the genede</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 67/146</span>Petition 870190095443, of 24/09/2019, p. 67/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">54/131 linhagem germinativa humana IGKJ4*02;</span>54/131 human germline IGKJ4 * 02;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000229] Figura 25A: versão humanizada baseada IGKV3-11*01 da</span>[000229] Figure 25A: humanized version based on IGKV3-11 * 01 of</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">VL de 227H1 com mutações mencionadas;</span>227H1 VL with mentioned mutations;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000230] Figura 25B: versão humanizada baseada IGKV4-1*01 da</span>[000230] Figure 25B: humanized version based on IGKV4-1 * 01 of</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">VL de 227H1 com mutações mencionadas;</span>227H1 VL with mentioned mutations;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000231] Figura 26A: alinhamento de VH de 227H1 ao genede linhagem germinativa de murino IGHV1-18*01;</span>[000231] Figure 26A: 227H1 VH alignment to the genus of murine germline IGHV1-18 * 01;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000232] Figura 26B: alinhamento de VH de 227H1 ao genede linhagem germinativa de murino IGHD1-1*02;</span>[000232] Figure 26B: 227H1 VH alignment to the genus of murine germline IGHD1-1 * 02;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000233] Figura 26C: alinhamento de VH de 227H1 ao genede linhagem germinativa de murino IGHJ2*01;</span>[000233] Figure 26C: 227H1 VH alignment to the genus of murine germline IGHJ2 * 01;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000234] Figura 27A: alinhamento de VH de 227H1 ao gene de linhagem germinativa humana IGHV1-2*02;</span>[000234] Figure 27A: 227H1 VH alignment to the human germline gene IGHV1-2 * 02;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000235] Figura 27B: alinhamento de VH de 227H1 ao gene de linhagem germinativa humana IGHJ4*01;</span>[000235] Figure 27B: VH alignment of 227H1 to the human germline gene IGHJ4 * 01;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000236] Figura 28: VH de 227H1 humanizada com mutações mencionadas;</span>[000236] Figure 28: Humanized 227H1 VH with mentioned mutations;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000237] Figura 29A: alinhamento de VL de 223C4 ao gene de linhagem germinativa de murino IGKV12-46*01;</span>[000237] Figure 29A: 223C4 VL alignment to the murine germline gene IGKV12-46 * 01;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000238] Figura 29B: alinhamento de VL de 223C4 ao genede linhagem germinativa de murino IGKJ2*01;</span>[000238] Figure 29B: 223C4 VL alignment to the genus of murine germline IGKJ2 * 01;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000239] Figura 30A: alinhamento de VL de 223C4 ao genede linhagem germinativa humana IGKV1-NL1 *01;</span>[000239] Figure 30A: 223C4 VL alignment with the human germline genotype IGKV1-NL1 * 01;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000240] Figura 30B: Alinhamento de VL de 223C4 ao genede linhagem germinativa humana IGKJ2*01;</span>[000240] Figure 30B: Alignment of 223C4 VL to the human germline strain IGKJ2 * 01;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000241] Figura 31: VL de 223C4 humanizada com mutações mencionadas;</span>[000241] Figure 31: VL of 223C4 humanized with the mentioned mutations;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000242] Figura 32A: alinhamento de 223C4 VH ao genede linhagem germinativa de murino IGHV1-18*01;</span>[000242] Figure 32A: 223C4 VH alignment to the genus of murine germline IGHV1-18 * 01;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000243] Figura 32B: alinhamento de 223C4 VH ao genede</span>[000243] Figure 32B: 223C4 VH alignment to the genede</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 68/146</span>Petition 870190095443, of 24/09/2019, p. 68/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55/131 linhagem germinativa de murino IGHD6-3*01;</span>55/131 murine germline IGHD6-3 * 01;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000244] Figura 32C: alinhamento de 223C4 VH ao gene de linhagem germinativa de murino IGHJ4*01;</span>[000244] Figure 32C: alignment of 223C4 VH to the murine germline gene IGHJ4 * 01;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000245] Figura 33A: alinhamento de 223C4 VH ao gene de linhagem germinativa humana IGHV1-2*02;</span>[000245] Figure 33A: 223C4 VH alignment with the human germline gene IGHV1-2 * 02;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000246] Figura 33B: alinhamento de 223C4 VH ao gene de linhagem germinativa humana IGHD1-26*01;</span>[000246] Figure 33B: 223C4 VH alignment to the human germline gene IGHD1-26 * 01;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000247] Figura 33C: alinhamento de 223C4 VH ao gene de linhagem germinativa humana IGHJ6*01; e [000248] Figura 34: VH de 223C4 humanizada com mutações mencionadas;</span>[000247] Figure 33C: alignment of 223C4 VH to the human germline gene IGHJ6 * 01; and [000248] Figure 34: Humanized 223C4 VH with mentioned mutations;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000249] Figura 35: atividade antitumor do Mab 224G11 de murino isoladamente ou combinado com Navelbine® sobre o modelo de tumor de xenoenxerto NCI-H441 estabelecido;</span>[000249] Figure 35: antitumor activity of murine Mab 224G11 alone or combined with Navelbine® on the established NCI-H441 xenograft tumor model;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000250] Figura 36: avaliação de Mabs anti-c-Met sobre a proliferação de HUVEC;</span>[000250] Figure 36: evaluation of anti-c-Met Mabs on the proliferation of HUVEC;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000251] Figura 37: avaliação de Mabs anti-c-Met sobre a formação de tubo em HUVEC;</span>[000251] Figure 37: evaluation of anti-c-Met Mabs on tube formation in HUVEC;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000252] Figura 38A: alinhamento de VL de 11E1 ao gene de linhagem germinativa de murino IGKV4-79*01;</span>[000252] Figure 38A: alignment of 11E1 VL to murine germline gene IGKV4-79 * 01;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000253] Figura 38B: alinhamento de VL de 11E1 ao gene de linhagem germinativa de murino IGKJ4*01;</span>[000253] Figure 38B: alignment of 11E1 VL to murine germline gene IGKJ4 * 01;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000254] Figura 39A: alinhamento de VL de 11E1 ao gene de linhagem germinativa humana IGKV3D-7*01;</span>[000254] Figure 39A: alignment of 11E1 VL to the human germline gene IGKV3D-7 * 01;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000255] Figura 39B: alinhamento de VL de 11E1 ao gene de linhagem germinativa humana IGKJ4*02;</span>[000255] Figure 39B: alignment of 11E1 VL to the human germline gene IGKJ4 * 02;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000256] Figura 40: versão Humanizada de VL de 11E1 com mutações mencionadas;</span>[000256] Figure 40: Humanized version of 11E1 VL with mentioned mutations;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000257] Figura 41A: alinhamento de VH de 11E1 ao gene de linhagem germinativa de murino IGHV1-7*01;</span>[000257] Figure 41A: alignment of 11E1 VH to murine germline gene IGHV1-7 * 01;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 69/146</span>Petition 870190095443, of 24/09/2019, p. 69/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">56/131 [000258] Figura 4IB: alinhamento de VH de 11E1 ao gene de linhagem germinativa de murino IGHD4-1*01;</span>56/131 [000258] Figure 4IB: alignment of 11E1 VH to murine germline gene IGHD4-1 * 01;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000259] Figura 41C: alinhamento de VH de 11E1 ao gene de linhagem germinativa de murino IGHJ3*01;</span>[000259] Figure 41C: alignment of 11E1 VH to murine germline gene IGHJ3 * 01;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000260] Figura 42A: alinhamento de VH de 11E1 aos genes de linhagem germinativa humana IGHV1-2*02 e IGHV1-46*01;</span>[000260] Figure 42A: alignment of 11E1 VH to human germline genes IGHV1-2 * 02 and IGHV1-46 * 01;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000261] Figura 42B: alinhamento de VH de 11E1 ao gene de linhagem germinativa humana IGHJ4*03;</span>[000261] Figure 42B: alignment of 11E1 VH to the human germline gene IGHJ4 * 03;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000262] Figura 43: VH de 11E1 humanizada com mutações mencionadas;</span>[000262] Figure 43: Humanized 11E1 VH with mentioned mutations;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000263] Figuras 44A e 44B: ensaio de fosforilação de c-Met sobre células A549. Avaliação de Mabs purificados 11E1 e 224G11, na ausência ou presença de HGF, a 30 pg/ml (Figura 44A) ou dentro de uma faixa de dose de 0,0015 a 30 pg/ml de forma a determinar os valores de EC50 (Figura 44B);</span>[000263] Figures 44A and 44B: c-Met phosphorylation assay on A549 cells. Evaluation of purified Mabs 11E1 and 224G11, in the absence or presence of HGF, at 30 pg / ml (Figure 44A) or within a dose range of 0.0015 to 30 pg / ml in order to determine the EC50 values (Figure 44B);</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000264] Figura 45: combinação in vivo de Mab 224G11com</span>[000264] Figure 45: Mab 224G11com in vivo combination</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Navelbine® no modelo de xenoenxerto NCI-H441 em NSCLC;</span>Navelbine® in the NSC-H441 xenograft model in NSCLC;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000265] Figura 46: combinação in vivo de Mab 224G11com</span>[000265] Figure 46: Mab 224G11com in vivo combination</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Doxorubicina no modelo de xenoenxerto NCI-H441 em NSCLC;</span>Doxorubicin in the NCI-H441 xenograft model in NSCLC;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000266] Figura 47: combinação in vivo de Mab 224G11com</span>[000266] Figure 47: Mab 224G11com in vivo combination</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Docetaxel no modelo de xenoenxerto NCI-H441 em NSCLC;</span>Docetaxel in the NSC-H441 xenograft model in NSCLC;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000267] Figura 48: combinação in vivo de Mab 224G11com</span>[000267] Figure 48: Mab 224G11com in vivo combination</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Temozolomida no modelo de xenoenxerto NCI-H441 em NSCLC;</span>Temozolomide in the NCI-H441 xenograft model in NSCLC;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000268] Figuras 49A, 49B, 49C e 49D: efeito de Mabs anti-c-Met sobre o efeito de crescimento de esferoide U87-MG;</span>[000268] Figures 49A, 49B, 49C and 49D: effect of anti-c-Met Mabs on the growth effect of U87-MG spheroid;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000269] Figuras 50A e 5OB: atividade in vitro de formas quiméricas e humanizadas de 224G11 no ensaio de fosfo-cMet;</span>[000269] Figures 50A and 5OB: in vitro activity of chimeric and humanized forms of 224G11 in the phospho-cMet assay;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000270] Figura 51: configurações de análise Biacores;</span>[000270] Figure 51: Biacores analysis settings;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000271] Figura 52: atividade in vivo de 224G11 sobre células MDAMB-231 coimplantadas com células MRC5 como uma fonte de HGF</span>[000271] Figure 52: 224G11 in vivo activity on MDAMB-231 cells co-implanted with MRC5 cells as a source of HGF</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 70/146</span>Petition 870190095443, of 24/09/2019, p. 70/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">57/131 humana sobre camundongos nus atímicos;</span>57/131 human over athymic nude mice;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000272] Figura 53: ensaio de ligação baseado em ELISA ao FccMet. A atividade de ligação anti-Fc-c-Met foi medida em um ensaio baseado em ELISA onde conjugados anti-Fc de murino foram usados para detectar os anticorpos monoclonais de murino purificados 11E1, 224G11 e 227H1. As atividades de ligação dependentes de dose sobre Fc-c-Met recombinante revestido sobre plástico foram medidas a 450 nm;</span>[000272] Figure 53: ELISA-based binding assay to FccMet. The anti-Fc-c-Met binding activity was measured in an ELISA-based assay where anti-murine Fc conjugates were used to detect the purified murine monoclonal antibodies 11E1, 224G11 and 227H1. Dose-dependent binding activities on plastic-coated recombinant Fc-c-Met were measured at 450 nm;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000273] Figura 54: ensaio de competição de HGF-cMet. Nesse ensaio baseado em ELISA, a ligação residual de Fc-c-Met recombinante ao HGF revestido sobre plástico na presença de anticorpos monoclonais de murino purificados 11E1, 224G11 e 227H1 foi detectada com um conjugado anti-Fc de murino e medida a 450 nm;</span>[000273] Figure 54: HGF-cMet competition test. In that ELISA-based assay, residual binding of recombinant Fc-c-Met to plastic-coated HGF in the presence of purified murine monoclonal antibodies 11E1, 224G11 and 227H1 was detected with a murine anti-Fc conjugate and measured at 450 nm;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000274] Figura 55: alinhamento de sequências de aminoácido dos domínios VH recombinantes 227H1-derivados. A sequência de aminoácido de VH de 227H1 é alinhada com a sequência de estrutura principal receptora humana selecionada, com apenas os aminoácidos mencionados que se verificou serem diferentes da sequência VH de 227H1 de murino. As sequências de VH de 227H1 HZ1, HZ2 e HZ3 correspondem às versões humanizadas implementadas do domínio VH de 227H1 de murino, com os resíduos de murino restantes em negrito. Em HZ3, 10 resíduos (*) foram automaticamente trocados por suas contrapartes humanas. Em HZ2, os sete resíduos do terceiro grupo (3) foram estudados. Em HZ1VH, os nove resíduos do segundo grupo (2) sofreram mutação para suas contrapartes humanas, apenas os seis resíduos do primeiro grupo (1) permanecem de murino;</span>[000274] Figure 55: alignment of amino acid sequences of recombinant 227H1-derived VH domains. The 227H1 VH amino acid sequence is aligned with the selected human receptor backbone sequence, with only the mentioned amino acids found to be different from the murine 227H1 VH sequence. The 227H1 VH sequences HZ1, HZ2 and HZ3 correspond to the implemented humanized versions of the murine 227H1 VH domain, with the remaining murine residues in bold. In HZ3, 10 residues (*) were automatically exchanged for their human counterparts. In HZ2, the seven residues from the third group (3) were studied. In HZ1VH, the nine residues of the second group (2) have mutated to their human counterparts, only the six residues of the first group (1) remain murine;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000275] Figura 56: ensaio de ligação a Fc-c-Met baseado em ELISA de anticorpos 227H1 recombinantes. A atividade de ligação anti-FccMet foi medida em um ensaio baseado em ELISA onde conjugados</span>[000275] Figure 56: Fc-c-Met binding assay based on ELISA of recombinant 227H1 antibodies. The anti-FccMet binding activity was measured in an ELISA-based assay where conjugates</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 71/146</span>Petition 870190095443, of 24/09/2019, p. 71/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">58/131 de Fc humana foram usados para detectar anticorpos recombinantes quiméricos e humanizados 227H1-derivados. As atividades de ligação dependentes de dose sobre Fc-c-Met recombinante revestido sobre plástico de anticorpos 227H1 derivados de domínios VH humanizados foram medidas a 450 nm e, então, comparadas com aquelas do anticorpo quimérico de origem/de referência;</span>58/131 of human Fc were used to detect 227H1-derived chimeric and humanized recombinant antibodies. Dose-dependent binding activities on recombinant Fc-c-Met coated on plastic of 227H1 antibodies derived from humanized VH domains were measured at 450 nm and then compared with those of the source / reference chimeric antibody;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000276] Figura 57: ensaio de ligação a Fc-c-Met baseado em ELISA de anticorpos 227H1 recombinantes. A atividade de ligação anti-FccMet foi medida em um ensaio baseado em ELISA onde conjugados de Fc humana foram usados para detectar anticorpos recombinantes quiméricos e humanizados 227H1-derivados. As atividades de ligação dependentes de dose sobre Fc-c-Met recombinante revestido sobre plástico do anticorpo 227H1 humanizado HZ4VH-derivado foram medidas a 450 nm e, então, comparadas àquelas do anticorpo quimérico de origem/de referência;</span>[000276] Figure 57: Fc-c-Met binding assay based on ELISA of recombinant 227H1 antibodies. The anti-FccMet binding activity was measured in an ELISA-based assay where human Fc conjugates were used to detect 227H1-derived chimeric and humanized recombinant antibodies. Dose-dependent binding activities on recombinant plastic-coated recombinant Fc-c-Met of the humanized HZ4VH-derived 227H1 antibody were measured at 450 nm and then compared to those of the source / reference chimeric antibody;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000277] Figura 58: ensaio de competição de HGF-cMet de anticorpos recombinantes e 227H1 de murino. Nesse ensaio baseado em ELISA, a ligação residual de Fc-cMet recombinante a HGF revestido sobre plástico na presença das diferentes formas do anticorpo 227H1 foi detectada com um anticorpo anti-c-Met biotinilado não relacionado. O anticorpo monoclonal 227H1 purificado de murino, anticorpos quiméricos e 227-H1-derivados humanizados HZ4VHderivados foram testados e comparados com relação à suas capacidades de competir com a ligação HGF-cMet quando medido a 450 nm;</span>[000277] Figure 58: HGF-cMet competition assay for recombinant antibodies and murine 227H1. In that ELISA-based assay, residual binding of recombinant Fc-cMet to HGF coated on plastic in the presence of different forms of the 227H1 antibody was detected with an unrelated biotinylated anti-c-Met antibody. The murine purified 227H1 monoclonal antibody, chimeric antibodies and humanized HZ4VH-derived 227-H1-derivatives were tested and compared for their ability to compete with the HGF-cMet bond when measured at 450 nm;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000278] Figura 59: sequência do domínio variável humanizado de VH de 227H1-HZ. * corresponde aos aminoácidos alterados para suas contrapartes humanas; ! corresponde aos aminoácidos humanizados durante a implementação HZ3 para HZ1; § corresponde aos aminoácidos humanizados no final da sequência VH de 227H1-HZ;</span>[000278] Figure 59: sequence of the humanized VH variable domain of 227H1-HZ. * corresponds to the modified amino acids for their human counterparts; ! corresponds to the humanized amino acids during the HZ3 to HZ1 implementation; § corresponds to the humanized amino acids at the end of the 227H1-HZ VH sequence;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 72/146</span>Petition 870190095443, of 24/09/2019, p. 72/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">59/131 [000279] Figura 60: alinhamento de sequências de aminoácido de domínios VH recombinantes 11E1-derivados. A VH da sequência de aminoácido de 11E1 é alinhada com a sequência de estrutura principal receptora humana selecionada, com mencionados apenas os aminoácidos que se descobriu serem diferentes da sequência VH de 11E1 de murino. As sequências HZ VH1, VH2 e VH3 de 11E1 correspondem às versões humanizadas implementadas do domínio VH de 11E1 de murino, com os resíduos de murino restantes em negrito. Em HZ VH3, sete resíduos (*) foram automaticamente trocados por suas contrapartes humanas. Em HZ VH2, os sete resíduos do terceiro grupo (3) foram estudados. Em HZ VH1, os cinco resíduos do segundo grupo (2) sofreram mutação para suas contrapartes humanas, apenas os cinco resíduos do primeiro grupo (1) permanecem de murino;</span>59/131 [000279] Figure 60: alignment of amino acid sequences of recombinant 11E1-derived VH domains. The VH of the 11E1 amino acid sequence is aligned with the selected human receptor backbone sequence, with only the amino acids found to be different from the murine 11E1 VH sequence mentioned. The 11E1 HZ VH1, VH2 and VH3 sequences correspond to the implemented humanized versions of the murine 11E1 VH domain, with the remaining murine residues in bold. In HZ VH3, seven residues (*) were automatically exchanged for their human counterparts. In HZ VH2, the seven residues of the third group (3) were studied. In HZ VH1, the five residues of the second group (2) have mutated to their human counterparts, only the five residues of the first group (1) remain murine;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000280] Figura 61: ensaio de ligação baseado em ELISA de FccMet a anticorpos recombinantes 11E1. A atividade de ligação anti-FccMet foi medida em um ensaio baseado em ELISA onde conjugados anti-Fc humana foram usados para detectar anticorpos recombinantes quiméricos e humanizados 11E1-derivados. As atividades de ligação dependentes de dose sobre Fc-c-Met revestido sobre plástico de anticorpos 11E1 derivados de domínios VH humanizados foram medidas a 450 nm e, então, comparadas com aquelas do anticorpo quimérico de origem/de referência;</span>[000280] Figure 61: FccMet ELISA-based binding assay to 11E1 recombinant antibodies. The anti-FccMet binding activity was measured in an ELISA-based assay where anti-human Fc conjugates were used to detect 11E1-derived chimeric and humanized recombinant antibodies. Dose-dependent binding activities on plastic coated Fc-c-Met of 11E1 antibodies derived from humanized VH domains were measured at 450 nm and then compared with those of the chimeric antibody of origin / reference;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000281] Figura 62: alinhamento de sequência de aminoácido de domínios VL recombinantes 11E1-derivados. A VL da sequência de aminoácido de 11E1 é alinhada à sequência de estrutura principal receptora humana selecionada, mencionados apenas o aminoácidos que se verificou serem diferentes da VL de murino da sequência de 11E1. As sequências HZ VL1, VL2 e VL3 de 11E1 correspondem às versões humanizadas implementadas do domínio VL de murino de</span>[000281] Figure 62: amino acid sequence alignment of 11E1-derived recombinant VL domains. The VL of the 11E1 amino acid sequence is aligned with the selected human receptor backbone sequence, mentioning only the amino acids that were found to be different from the murine VL of the 11E1 sequence. The sequences HZ VL1, VL2 and VL3 of 11E1 correspond to the humanized versions implemented of the murine VL domain of</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 73/146</span>Petition 870190095443, of 24/09/2019, p. 73/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60/131</span>60/131</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">11E1, com os resíduos de murino restantes em negrito. Em HZ VL3, dez resíduos (*) foram automaticamente trocados por suas contrapartes humanas. Em HZ VL2, os oito resíduos do terceiro grupo (3) foram estudados. Em HZ VL1, os oito resíduos do segundo grupo (2) sofreram mutação para suas contrapartes humanas, apenas os quatro resíduos do primeiro grupo (1) permanecem de murino;</span>11E1, with the remaining murine residues in bold. In HZ VL3, ten residues (*) were automatically exchanged for their human counterparts. In HZ VL2, the eight residues from the third group (3) were studied. In HZ VL1, the eight residues of the second group (2) have mutated to their human counterparts, only the four residues of the first group (1) remain murine;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000282] Figura 63: ensaio de ligação a Fc-c-Met baseado em ELISA de anticorpos 11E1 recombinantes. A atividade de ligação anti-FccMet foi medida em um ensaio baseado em ELISA onde conjugados anti-Fc humana foram usados para detectar anticorpos recombinantes quiméricos e humanizados 11E1-derivados. As atividades de ligação dependentes de dose sobre Fc-c-Met recombinante revestido sobre plástico de anticorpos 11E1 derivados de domínios VL humanizados foram medida a 450 nm e, então, comparadas àquelas do anticorpo quimérico de origem/de referência;</span>[000282] Figure 63: Fc-c-Met binding assay based on ELISA of recombinant 11E1 antibodies. The anti-FccMet binding activity was measured in an ELISA-based assay where anti-human Fc conjugates were used to detect 11E1-derived chimeric and humanized recombinant antibodies. Dose-dependent binding activities on recombinant Fc-c-Met coated on plastic of 11E1 antibodies derived from humanized VL domains were measured at 450 nm and then compared to those of the source / reference chimeric antibody;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000283] Figura 64: ensaio de ligação a Fc-c-Met baseado em ELISA de anticorpos 11E1 recombinantes. A atividade de ligação anti-FccMet foi medida em um ensaio baseado em ELISA onde conjugados anti-Fc humana foram usados para detectar anticorpos recombinantes quiméricos e humanizados 11E1-derivados. As atividades de ligação dependentes de dose a Fc-c-Met recombinante revestido sobre plástico de anticorpos 11E1 derivados de domínios humanizados únicos ou duplos foram medidas a 450 nm e, então, comparadas com aquelas do anticorpo quimérico de origem/de referência;</span>[000283] Figure 64: Fc-c-Met binding assay based on ELISA of recombinant 11E1 antibodies. The anti-FccMet binding activity was measured in an ELISA-based assay where anti-human Fc conjugates were used to detect 11E1-derived chimeric and humanized recombinant antibodies. Dose-dependent binding activities to recombinant Fc-c-Met coated on plastic from 11E1 antibodies derived from single or double humanized domains were measured at 450 nm and then compared with those of the source / reference chimeric antibody;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000284] Figura 65: alinhamento de sequências de aminoácido de VH da sequência de domínio de 224G11. A sequência de aminoácido de VH de 224G11 é alinhada com à sequência VH de 227H1 (são sublinhados resíduos não-homólogos) e à sequência de estrutura principal receptora humana selecionada, mencionados apenas os aminoácidos que se verificou serem diferentes da sequência VH de</span>[000284] Figure 65: VH amino acid sequence alignment of the 224G11 domain sequence. The 224G11 VH amino acid sequence is aligned with the 227H1 VH sequence (non-homologous residues are underlined) and the selected human receptor main structure sequence, mentioning only the amino acids found to be different from the VH sequence of</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 74/146</span>Petition 870190095443, of 24/09/2019, p. 74/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">61/131</span>61/131</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">224G11 de murino. A sequência VH0 de 224G11 HZ corresponde à versão humanizada 227H1-baseada/total-IMGT do domínio VH de</span>Murine 224G11. The VH0 sequence of 224G11 HZ corresponds to the humanized version 227H1-based / total-IMGT of the VH domain of</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">224G11 de murino. Nessa sequência, nenhum resíduo fora das CDRsIMGT permanece de murino;</span>Murine 224G11. In this sequence, no residue outside the CDRsIMGT remains from a murine;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000285] Figura 66: ensaio de ligação a Fc-c-Met baseado em ELISA de anticorpos 224G11 recombinantes. A atividade de ligação anti-FccMet foi medida em um ensaio baseado em ELISA onde conjugados anti-Fc humana foram usados para detectar anticorpos recombinantes derivados de 224G11 humanizados e derivados de HZVH0 quiméricos. As atividades de ligação dependentes de dose a Fc-c-Met recombinante revestido sobre plástico do anticorpo 224G11 derivado de domínio VH humanizado HZVH0 total-IMGT foram medidas a 450 nm e, então, comparadas àquelas do anticorpo quimérico de origem/de referência;</span>[000285] Figure 66: Fc-c-Met binding assay based on ELISA of recombinant 224G11 antibodies. The anti-FccMet binding activity was measured in an ELISA-based assay where anti-human Fc conjugates were used to detect recombinant antibodies derived from humanized 224G11 and chimeric HZVH0 derivatives. Dose-dependent binding activities to recombinant plastic-coated recombinant Fc-c-Met of 224G11 antibody derived from humanized HZVH0 total-IMGT domain were measured at 450 nm and then compared to those of the source / reference chimeric antibody;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000286] Figura 67: ensaio de competição de HGF-cMet de anticorpos recombinantes e 224G11 de murino. Nesse ensaio baseado em ELISA, a ligação residual de Fc-cMet recombinante ao HGF revestido sobre plástico na presença das diferentes formas do anticorpo 224G11 foi detectada com um anticorpo anti-cMet biotinilado não relacionado. O anticorpo monoclonal 224G11 purificado de murino, anticorpos quiméricos e recombinantes derivados de 224G11 humanizados HZVH0-derivados foram testados e suas capacidades de competir pela ligação com HGF-cMet quando medida a 450 nm;</span>[000286] Figure 67: HGF-cMet competition assay for recombinant and murine 224G11 antibodies. In that ELISA-based assay, residual binding of recombinant Fc-cMet to plastic-coated HGF in the presence of different forms of the 224G11 antibody was detected with an unrelated biotinylated anti-cMet antibody. The murine purified 224G11 monoclonal antibody, chimeric and recombinant antibodies derived from humanized HZVH0-derived 224G11 were tested and their ability to compete for binding with HGF-cMet when measured at 450 nm;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000287] Figura 68: alinhamento de sequências de aminoácido de sequências de domínio VL de 224G11. A sequência de aminoácido de VL de 224G11 é alinhada às duas sequências de estrutura principal humanas receptoras selecionadas, mencionados apenas os aminoácidos que se verificou serem diferentes da sequência VL de 224G11 de murino. A sequência Hz VL3 de 224G11 corresponde à versão humanizada com CDR1 mais curta do domínio VH de 224G11</span>[000287] Figure 68: amino acid sequence alignment of 224G11 VL domain sequences. The 224G11 VL amino acid sequence is aligned with the two selected human main structure sequences, mentioned only the amino acids found to be different from the murine 224G11 VL sequence. The 224G11 Hz VL3 sequence corresponds to the shorter CDR1 humanized version of the 224G11 VH domain</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 75/146</span>Petition 870190095443, of 24/09/2019, p. 75/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">62/131 de murino, enquanto que HZ VL6 corresponde à versão com CDR1 mais longa, com os resíduos de murino restantes em negrito. Para ambas as versões humanizadas básicas, os resíduos de murino restantes são classificação para um processo de humanização adicional, onde * corresponde aos aminoácidos humanizados nas versões básicas e 3, 2 e 1 correspondem aos grupos de resíduos para o design das versões humanizadas implementadas;</span>62/131 of murine, while HZ VL6 corresponds to the version with the longest CDR1, with the remaining murine residues in bold. For both basic humanized versions, the remaining murine residues are classified for an additional humanization process, where * corresponds to the humanized amino acids in the basic versions and 3, 2 and 1 correspond to the residue groups for the design of the implemented humanized versions;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000288] Figura 69: ensaio de ligação a Fc-c-Met baseado em ELISA de anticorpos 224G11 recombinantes. A atividade de ligação anti-FccMet foi medida em um ensaio baseado em ELISA onde conjugados anti-Fc humana foram usados para detectar anticorpos recombinantes 22G11-derivados quiméricos e humanizados. As atividades de ligação dependentes de dose a Fc-c-Met recombinante revestido sobre plástico de anticorpos 224G11 derivados de domínios VL3 e VL6 humanizados foram medidas a 450 nm e, então, comparadas com aquelas do anticorpo quimérico de origem/de referência;</span>[000288] Figure 69: Fc-c-Met binding assay based on ELISA of recombinant 224G11 antibodies. The anti-FccMet binding activity was measured in an ELISA-based assay where anti-human Fc conjugates were used to detect chimeric and humanized 22G11-derived recombinant antibodies. Dose-dependent binding activities to recombinant Fc-c-Met coated on 224G11 plastic antibodies derived from humanized VL3 and VL6 domains were measured at 450 nm and then compared with those of the source / reference chimeric antibody;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000289] Figura 70: ensaio de ligação a Fc-c-Met baseado em ELISA de anticorpos 224G11 recombinantes. A atividade de ligação anti-FccMet foi medida em um ensaio baseado em ELISA onde conjugados anti-Fc humana foram usados para detectar anticorpos recombinantes 224G11-derivados quiméricos e humanizados. As atividades de ligação dependentes de dose a Fc-c-Met recombinante revestido sobre plástico de anticorpos 224G11 derivados de domínios VL humanizados foram medidas a 450 nm e, então, comparadas com aquelas do anticorpo quimérico de origem/de referência;</span>[000289] Figure 70: Fc-c-Met binding assay based on ELISA of recombinant 224G11 antibodies. The anti-FccMet binding activity was measured in an ELISA-based assay where anti-human Fc conjugates were used to detect chimeric and humanized 224G11-derived recombinant antibodies. Dose-dependent binding activities to recombinant Fc-c-Met coated on plastic with 224G11 antibodies derived from humanized VL domains were measured at 450 nm and then compared with those of the source / reference chimeric antibody;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000290] Figura 71: ensaio de competição de HGF-cMet de anticorpos recombinantes e 224G11 de murino. Nesse ensaio baseado em ELISA, a ligação residual de Fc-cMet recombinante ao HGF revestido sobre plástico na presença das diferentes formas do anticorpo 224G11 foi detectada com um anticorpo anti-cMet biotinilado</span>[000290] Figure 71: HGF-cMet competition assay for recombinant and murine 224G11 antibodies. In this ELISA-based assay, residual binding of recombinant Fc-cMet to HGF coated on plastic in the presence of different forms of the 224G11 antibody was detected with a biotinylated anti-cMet antibody</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 76/146</span>Petition 870190095443, of 24/09/2019, p. 76/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">63/131 não relacionado. Anticorpo monoclonal 224G11 purificado de murino, anticorpos quiméricos e recombinante 224G11-derivado de HZ VL4 foram testados e suas capacidades de competir pela ligação com</span>63/131 not listed. Purified murine 224G11 monoclonal antibody, chimeric antibodies and HZ VL4-derived 224G11-recombinant antibodies have been tested and their ability to compete for binding with</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">HGF-cMet quando medida a 450 nm;</span>HGF-cMet when measured at 450 nm;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000291] Figura 72: sequência de aminoácido da sequência de domínio VL VL4 do 224G11 humanizado. * corresponde aos aminoácidos trocados por suas contrapartes humanas na versão HZ VL6 básica; ! corresponde aos aminoácidos humanizados durante a implementação HZ VL6 para HZ VL4; § corresponde aos aminoácidos que permaneceram de murino na sequência VL4 do 224G11-HZ;</span>[000291] Figure 72: amino acid sequence of the humanized 224G11 VL4 VL domain domain sequence. * corresponds to the amino acids exchanged by their human counterparts in the basic HZ VL6 version; ! corresponds to the humanized amino acids during the implementation HZ VL6 to HZ VL4; § corresponds to the amino acids that remained murine in the VL4 sequence of 224G11-HZ;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000292] Figura 73: ensaio baseado em ELISA de ligação a Fc-cMet de anticorpos 224G11 recombinantes. A atividade de ligação anti-FccMet foi medida em um ensaio baseado em ELISA onde conjugados anti-Fc humana foram usados para detectar anticorpos recombinantes quiméricos e humanizados 22G11-derivados. As atividades de ligação dependentes de dose sobre Fc-c-Met recombinante revestido sobre plástico de anticorpos 224G11 derivados de domínios humanizados únicos ou duplos foram medidas a 450 nm e, então, comparada com aquelas do anticorpo de origem/de referência;</span>[000292] Figure 73: Fc-cMet-based ELISA assay for recombinant 224G11 antibodies. The anti-FccMet binding activity was measured in an ELISA-based assay where anti-human Fc conjugates were used to detect 22G11-derived chimeric and humanized recombinant antibodies. Dose-dependent binding activities on recombinant Fc-c-Met coated on plastic from 224G11 antibodies derived from humanized single or double domains were measured at 450 nm and then compared with those of the source / reference antibody;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000293] Figura 74: ensaio de competição de HGF-cMet de anticorpos recombinantes e 224G11 de murino. Nesse ensaio baseado em ELISA, a ligação residual de Fc-c-Met recombinante ao HGF revestido sobre plástico na presença de diferentes formas do anticorpo 224G11 foi detectada com um anticorpo anti-c-Met biotinilado não relacionado. O anticorpo monoclonal 224G11 de murino purificado, anticorpos quiméricos e recombinantes 224G11-derivados totalmente humanizados foram testados e comparados com relação às suas capacidades de competir com a ligação ao HGF-cMet quando medido a 450 nm;</span>[000293] Figure 74: HGF-cMet competition assay for recombinant and murine 224G11 antibodies. In that ELISA-based assay, residual binding of recombinant Fc-c-Met to plastic-coated HGF in the presence of different forms of the 224G11 antibody was detected with an unrelated biotinylated anti-c-Met antibody. Purified murine 224G11 monoclonal antibody, fully humanized 224G11-derived chimeric and recombinant antibodies were tested and compared for their ability to compete with binding to HGF-cMet when measured at 450 nm;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000294] Figura 75: ensaio de ligação a Fc-cMet baseado em ELISA</span>[000294] Figure 75: ELISA-based Fc-cMet binding assay</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 77/146</span>Petition 870190095443, of 24/09/2019, p. 77/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">64/131 de anticorpos recombinantes 224G11. A atividade de ligação anti-FccMet foi medida em um ensaio baseado em ELISA onde conjugados anti-Fc humana foram usados para detectar anticorpos recombinantes quiméricos e humanizados 22G11-5 derivados. As atividades de ligação dependentes de dose sobre Fc-c-Met recombinante revestido sobre plástico de mutantes únicos dos anticorpos 224G11 VL4derivados totalmente humanizados foram medidas a 450 nm e, então, comparadas com aquelas do anticorpo quimérico de origem/de referência;</span>64/131 of 224G11 recombinant antibodies. The anti-FccMet binding activity was measured in an ELISA-based assay where anti-human Fc conjugates were used to detect 22G11-5 chimeric and humanized recombinant antibodies. Dose-dependent binding activities on recombinant Fc-c-Met coated on plastic of single mutants of fully humanized derived 224G11 VL4 antibodies were measured at 450 nm and then compared with those of the source / reference chimeric antibody;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000295] Figura 76: ensaio de ligação a Fc-cMet baseado em ELISA de anticorpos recombinantes 224G11. A atividade de ligação anti-FccMet foi medida em um ensaio baseado em ELISA onde conjugados anti-Fc humana foram usados para detectar anticorpos recombinantes quiméricos e humanizados 22G11-derivados. As atividades de ligação dependentes de dose sobre Fc-c-Met recombinante revestido sobre plástico de mutantes únicos e múltiplos dos anticorpos 224G11 VL4derivado totalmente humanizados foi medida a 450 nm e, então, comparada com aquelas do anticorpo quimérico de origem/de referência; e [000296] Figura 77: ensaio de competição de HGF-cMet de anticorpos recombinantes e 224G11 de murino. Nesse ensaio baseado em ELISA, a ligação residual de Fc-c-Met recombinante ao HGF revestido sobre plástico na presença de diferentes formas do anticorpo 224G11 foi detectada com um anticorpo anti-c-Met biotinilado não relacionado. Anticorpo monoclonal 224G11 de murino purificado, mutantes quiméricos e únicos ou múltiplos dos anticorpos recombinantes 224G11 VL4-derivatizados totalmente humanizados foram testados e comparados com relação à suas capacidades de competir com a ligação de HGF-cMet quando medida a 450 nm.</span>[000295] Figure 76: Fc-cMet binding assay based on 224G11 recombinant antibody ELISA. The anti-FccMet binding activity was measured in an ELISA-based assay where anti-human Fc conjugates were used to detect 22G11-derived chimeric and humanized recombinant antibodies. Dose-dependent binding activities on recombinant Fc-c-Met coated on plastic of single and multiple mutants of fully humanized 224G11 VL4-derived antibodies were measured at 450 nm and then compared with those of the source / reference chimeric antibody; and [000296] Figure 77: HGF-cMet competition assay for recombinant and murine 224G11 antibodies. In that ELISA-based assay, residual binding of recombinant Fc-c-Met to plastic-coated HGF in the presence of different forms of the 224G11 antibody was detected with an unrelated biotinylated anti-c-Met antibody. Purified murine 224G11 monoclonal antibody, chimeric and single or multiple mutants of the fully humanized VL4-derivatized 224G11 recombinant antibodies were tested and compared for their ability to compete with HGF-cMet binding when measured at 450 nm.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 1: geração de anticorpos contra c-Met</span>Example 1: generation of antibodies against c-Met</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 78/146</span>Petition 870190095443, of 24/09/2019, p. 78/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65/131 [000297] Para gerar anticorpos anti-c-Met, camundongos BALB/c de 8 semanas de idade foram imunizados 3 a 5 vezes subcutaneamente com uma linhagem de célula CHO transfectada que expressa c-Met sobre sua membrana plasmática (20 x 10<sup class="style-scope patent-text">6</sup> células/dose/camundongo) ou 2 a 3 vezes com uma proteína de fusão do domínio extracelular de c-Met (10-15 pg/dose/camundongo) (R&amp;D Systems, Catálogo n° 358MT) ou fragmentos dessa proteína recombinante misturados com adjuvante completo de Freund para a primeira imunização e adjuvante incompleto de Freund para as seguintes. Protocolos mistos, nos quais camundongos receberam células CHO-cMet e proteínas recombinantes também foram realizados. Três dias antes de fusão celular, os camundongos receberam um reforço i.p. ou i.v. com a proteína recombinante ou fragmentos. Então, os baços dos camundongos foram coletados e fundidos à células de mieloma SP2/0Ag14 (ATCC) e submetidos à seleção com HAT. Quatro fusões foram realizadas. Em geral, para o preparo de anticorpos monoclonais ou seus fragmentos funcionais de acordo com a invenção, especialmente originários de murino, é possível se referir a técnicas as quais são descritas, em particular, no manual Antibodies (Harlow e Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor NY, página 726, 1988) ou à técnica de preparo de hibridomas descrita por Kohler e Milstein (Nature, 256: 495-497, 1975). [000298] Os hibridomas obtidos foram inicialmente selecionados através de ELISA sobre a proteína recombinante c-Met e, então, através de análise por FACS sobre linhagens de célula A549 NSCLC, pancreática BxPC3 e glioblastoma U87-MG (perfis representativos foram apresentados na Figura 1) a fim de assegurar que os anticorpos produzidos eram capazes de reconhecer também o receptor nativo sobre células tumorais. Reagentes positivos nesses 2 testes foram amplificados, clonados e um conjunto de hibridomas foi recuperado,</span>65/131 [000297] To generate anti-c-Met antibodies, 8-week-old BALB / c mice were immunized 3 to 5 times subcutaneously with a transfected CHO cell line that expresses c-Met on their plasma membrane (20 x 10 <sup class="style-scope patent-text">6</sup> cells / dose / mouse) or 2 to 3 times with a fusion protein from the extracellular domain of c-Met (10-15 pg / dose / mouse) (R&amp;D Systems, Catalog No. 358MT) or fragments of that recombinant protein mixed with complete Freund's adjuvant for the first immunization and incomplete Freund's adjuvant for the following. Mixed protocols, in which mice were given CHO-cMet cells and recombinant proteins were also performed. Three days before cell fusion, the mice received an ip or iv boost with the recombinant protein or fragments. Then, the spleens of the mice were collected and fused to myeloma cells SP2 / 0Ag14 (ATCC) and subjected to selection with HAT. Four mergers were carried out. In general, for the preparation of monoclonal antibodies or their functional fragments according to the invention, especially those originating from murine, it is possible to refer to techniques which are described, in particular, in the Antibodies manual (Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor NY, page 726, 1988) or the hybridoma preparation technique described by Kohler and Milstein (Nature, 256: 495-497, 1975). [000298] The hybridomas obtained were initially selected by ELISA on the recombinant protein c-Met and then by FACS analysis on cell lines A549 NSCLC, pancreatic BxPC3 and glioblastoma U87-MG (representative profiles were shown in Figure 1 ) to ensure that the antibodies produced were able to recognize the native receptor on tumor cells as well. Positive reagents in these 2 tests were amplified, cloned and a set of hybridomas was recovered,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 79/146</span>Petition 870190095443, of 24/09/2019, p. 79/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">66/131 purificado e selecionado com relação à sua capacidade de inibir a proliferação celular in vitro no modelo BxPC3.</span>66/131 purified and selected with respect to its ability to inhibit cell proliferation in vitro in the BxPC3 model.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000299] Para essa finalidade, 50 000 células BxPC3 foram colocadas em lâminas com 96 poços em meio RPMI, L-glutamina a 2 mM, sem SVF. 24 horas após colocação, os anticorpos a serem testados foram adicionados em uma concentração final oscilando de 0,0097 a 40 gg/ml, 60 min antes da adição de 100 ng/ml de hHGF. Após 3 dias, as células receberam um pulso de 0,5 gCi de [<sup class="style-scope patent-text">3</sup>H]timidina durante 16 horas. A magnitude de [<sup class="style-scope patent-text">3</sup>H]timidina incorporada em DNA insolúvel em ácido tricloroacético foi quantificada através de contagem de cintilação de líquido. Os resultados foram expressos como dados brutos para avaliar prontamente o efeito agonístico intrínseco de cada Mab (Figuras 2A e 2B).</span>[000299] For that purpose, 50,000 BxPC3 cells were placed on 96 well slides in RPMI medium, 2 mM L-glutamine, without SVF. 24 hours after placement, the antibodies to be tested were added in a final concentration ranging from 0.0097 to 40 gg / ml, 60 min before the addition of 100 ng / ml of hHGF. After 3 days, the cells received a 0.5 gCi pulse of [ <sup class="style-scope patent-text">3</sup> H] thymidine for 16 hours. The magnitude of [ <sup class="style-scope patent-text">3</sup> H] thymidine incorporated in DNA insoluble in trichloroacetic acid was quantified by liquid scintillation counting. The results were expressed as raw data to readily assess the intrinsic agonistic effect of each Mab (Figures 2A and 2B).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000300] Então, anticorpos que inibem pelo menos 50% da proliferação celular foram avaliados como sobrenadantes através de análise BRET sobre células transfectadas com c-Met. Para essa finalidade, linhagens de células CHO estáveis expressando C-MetRluc ou C-Met-Rluc e C-Met-K1100A-YFP foram geradas. As células foram distribuídas em microlâminas brancas com 96 poços em meio de cultura DMEM-F12/FBS a 5% um ou dois dias antes dos experimentos BRET. As células foram primeiro cultivadas a 37°C com 5% de CO2 de forma a permitir fixação das células à lâmina. Às células foram, então, fornecidos 200 gl de DMEM/poço durante a noite. Imediatamente antes do experimento, o DMEM foi removido e as células rapidamente lavadas com PBS. As células foram incubadas em PBS na presença ou ausência de anticorpos a serem testados ou compostos de referência, 10 min a 37°C antes da adição de coelenterazina, com ou sem HGF, em um volume final de 50 gl. Após incubação durante mais 10 minutos a 37°C, a aquisição de emissão de luz a 485 nm e 530 nm foi iniciada usando o luminômetro Mithras</span>[000300] Then, antibodies that inhibit at least 50% of cell proliferation were evaluated as supernatants by BRET analysis on cells transfected with c-Met. For this purpose, stable CHO cell lines expressing C-MetRluc or C-Met-Rluc and C-Met-K1100A-YFP were generated. The cells were distributed in white microlayers with 96 wells in DMEM-F12 / 5% FBS culture medium one or two days before the BRET experiments. The cells were first cultured at 37 ° C with 5% CO2 in order to allow attachment of the cells to the slide. The cells were then supplied with 200 µl DMEM / well overnight. Immediately before the experiment, the DMEM was removed and the cells were quickly washed with PBS. The cells were incubated in PBS in the presence or absence of antibodies to be tested or reference compounds, 10 min at 37 ° C before the addition of coelenterazine, with or without HGF, in a final volume of 50 gl. After incubating for another 10 minutes at 37 ° C, the acquisition of light emission at 485 nm and 530 nm was initiated using the Mithras luminometer</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 80/146</span>Petition 870190095443, of 24/09/2019, p. 80/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">67/131 (Berthold) (1 s/comprimento de onda/poço, repetido 15 vezes).</span>67/131 (Berthold) (1 s / wavelength / well, repeated 15 times).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000301] A proporção BRET foi definida conforme previamente [Angers et al., Proc. Natl. Acad. Sci. USA, 2000, 97: 3684-3689] como: [(emissão a 530 nm)-(emissão a 485 nm) X Cf]/(emissão a 485 nm), onde Cf corresponde a (emissão a 530 nm) /(emissão a 485 nm) para células expressando a proteína de fusão Rluc apenas nas mesmas condições experimentais. Simplificação dessa equação mostra que a proporção BRET corresponde à proporção de 530/485 nm obtida quando os dois parceiros estavam presentes, corrigida pela proporção de 530/485 nm obtida sob as mesmas condições experimentais, quando apenas o parceiro fundido à luciferase de R. reniformis estava presente. Para fins de facilidade de leitura, os resultados são expressos em unidades de miliBRET (mBU); mBU corresponde à proporção BRET multiplicada por 1000.</span>[000301] The BRET ratio was defined as previously [Angers et al., Proc. Natl. Acad. Sci. USA, 2000, 97: 3684-3689] as: [(emission at 530 nm) - (emission at 485 nm) X Cf] / (emission at 485 nm), where Cf corresponds to (emission at 530 nm) / (emission at 485 nm) for cells expressing the Rluc fusion protein only under the same experimental conditions. Simplification of this equation shows that the BRET ratio corresponds to the proportion of 530/485 nm obtained when the two partners were present, corrected by the proportion of 530/485 nm obtained under the same experimental conditions, when only the partner fused to the luciferase of R. reniformis I was present. For ease of reading, the results are expressed in units of milliBRET (mBU); mBU corresponds to the BRET ratio multiplied by 1000.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000302] Após esse segundo teste in vitro, 4 anticorpos i) sem atividade intrínseca como uma molécula inteira no teste funcional de proliferação, ii) que inibem significativamente a proliferação de BxPC3 (Figuras 2A e 2B) e iii) que inibem a dimerização de c-Met (Figura 3) foram selecionados. Esses 3 anticorpos do isotipo IgG1 kappa foram descritos como 11E1, 224G11, 223C4 e 227H1. Nos experimentos, o Mab 5D5, gerado pela Genentech e disponível na ATCC, foi adicionado como um controle para a atividade agonística intrínseca.</span>[000302] After that second in vitro test, 4 antibodies i) without intrinsic activity as a whole molecule in the functional proliferation test, ii) which significantly inhibit the proliferation of BxPC3 (Figures 2A and 2B) and iii) which inhibit the dimerization of c-Met (Figure 3) were selected. These 3 antibodies of the IgG1 kappa isotype have been described as 11E1, 224G11, 223C4 and 227H1. In the experiments, Mab 5D5, generated by Genentech and available at ATCC, was added as a control for intrinsic agonistic activity.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000303] As Figuras 2A e 2B demonstram que 11E1, 224G11, 223C4 e 227H1 não tinham qualquer atividade agonista em contraste ao 5D5, o qual induziu a uma estimulação dose-dependente de proliferação celular na ausência de ligante. Uma inibição significativa de proliferação celular foi observada com os 4 anticorpos selecionados. 5D5 não teve efeito sobre a proliferação celular induzida por HGF nesse teste.</span>[000303] Figures 2A and 2B demonstrate that 11E1, 224G11, 223C4 and 227H1 had no agonist activity in contrast to 5D5, which induced a dose-dependent stimulation of cell proliferation in the absence of ligand. A significant inhibition of cell proliferation was observed with the 4 antibodies selected. 5D5 had no effect on HGF-induced cell proliferation in that test.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000304] Quando avaliados com relação ao bloqueio de dimerização,</span>[000304] When evaluated with respect to dimerization block,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 81/146</span>Petition 870190095443, of 24/09/2019, p. 81/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">68/131 efeitos significativos atingindo uma inibição de 32, 55, 69 e 52% de dimerização para 224G11, 223C4, 11E1 e 227H1, respectivamente, foram observados. Comparado com os sinais basais nos respectivos experimentos, o anticorpo 5D5 não tem efeito nesse modelo de dimerização.</span>68/131 significant effects reaching an inhibition of 32, 55, 69 and 52% of dimerization for 224G11, 223C4, 11E1 and 227H1, respectively, were observed. Compared with the baseline signals in the respective experiments, the 5D5 antibody has no effect on this dimerization model.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 2: reconhecimento de proteína por anticorpos anti-c-Met [000305] Para caracterizar o padrão de reconhecimento dos 3 anticorpos selecionados, 3 ELISAs foram configurados com a proteína c-Met recombinante, seu fragmento monomérico (obtido através de clivagem da proteína c-Met-Fc recombinante e o domínio SEMA recombinante).</span>Example 2: protein recognition by anti-c-Met antibodies [000305] To characterize the pattern of recognition of the 3 selected antibodies, 3 ELISAs were configured with the recombinant c-Met protein, its monomeric fragment (obtained through cleavage of protein c Recombinant Met-Fc and the recombinant SEMA domain).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000306] Os resultados apresentados na Figura 4 demonstraram que os 4 anticorpos reconheciam proteínas diméricas e monoméricas. Para realizar esses ELISAs, a proteína c-Met dimérica humana (R&amp;D Sytems, catn° 358MT) é revestida na concentração de 0,7 pg/ml em PBS durante a noite a 4°C. Após saturação das lâminas (Costar n°3690) com uma solução de gelatina a 0,5% durante 2 horas a 37°C, sobrenadantes de hibridoma são incubados 1 hora a 37°C. Uma vez enxaguadas com PBS, o anticorpo anti-HRP de camundongo (Jackson ImmunoResearch, catálogo n°115-035-164) é adicionado a cada poço em uma diluição de 1/5000 em tampão para ELISA (gelatina a 0,1%/Tween 20 a 0,05% em PBS) e as lâminas incubadas durante 1 hora a 37°C. Após 3 lavagens em PBS, a atividade da peroxidase é revelada através da adição de 50 pl de substrato TMB (Uptima). A reação é deixada ocorrer durante 5 min em temperatura ambiente. A reação é cessada através da adição de 50 pl/poço de uma solução a 1 M de H2SO4 e lida sobre um leitor para lâminas a 450 nm. O mesmo tipo de protocolo foi realizado sobre c-Met monomérica e o domínio SEMA mas, nesses casos, as proteínas foram revestidas a 5 e 3 pg/ml, respectivamente.</span>[000306] The results shown in Figure 4 demonstrated that the 4 antibodies recognized dimeric and monomeric proteins. To perform these ELISAs, the human dimeric c-Met protein (R&amp;D Sytems, catn ° 358MT) is coated at a concentration of 0.7 pg / ml in PBS overnight at 4 ° C. After saturation of the slides (Costar n ° 3690) with a 0.5% gelatin solution for 2 hours at 37 ° C, hybridoma supernatants are incubated 1 hour at 37 ° C. Once rinsed with PBS, the mouse anti-HRP antibody (Jackson ImmunoResearch, catalog No. 115-035-164) is added to each well in a 1/5000 dilution in ELISA buffer (0.1% gelatin / 0.05% Tween 20 in PBS) and the slides incubated for 1 hour at 37 ° C. After 3 washes in PBS, the peroxidase activity is revealed by adding 50 pl of TMB substrate (Uptima). The reaction is allowed to proceed for 5 min at room temperature. The reaction is stopped by adding 50 µl / well of a 1 M solution of H2SO4 and read on a slide reader at 450 nm. The same type of protocol was performed on monomeric c-Met and the SEMA domain, but in these cases, the proteins were coated at 5 and 3 pg / ml, respectively.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 82/146</span>Petition 870190095443, of 24/09/2019, p. 82/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">69/131 [000307] O Mab 5D5 introduzido como um controle positivo reconheceu, conforme esperado, a proteína SEMA. 224G11, 227H1 e</span>69/131 [000307] Mab 5D5 introduced as a positive control recognized, as expected, the SEMA protein. 224G11, 227H1 and</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">223C4 não se ligam ao domínio SEMA. 11E1 é capaz de se ligar ao</span>223C4 do not bind to the SEMA domain. 11E1 is able to connect to</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEMA.</span>SEMA.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000308] Para determinar se 11E1 e 5D5, ambos reconhecendo o domínio SEMA, competem por epítopos em sobreposição, análise BIAcore foi realizada. O sistema BIAcore, baseado no fenômeno de Ressonância de Plasmônio em Superfície, distribui dados através de monitoramento de eventos em tempo real. Ele é, então, útil para agrupar anticorpos nos assim denominados experimentos de mapeamento de epítopo. Um par de anticorpos incapaz de se ligar ao mesmo tempo sobre a molécula antigênica é classificado no mesmo grupo (sítios de ligação idênticos ou próximos). Em oposição, quando seus respectivos sítios de ligação estão suficientemente distintas para permitir uma ligação simultânea de ambos os anticorpos, esses últimos são classificados em dois grupos diferentes. Em tais experimentos, o antígeno é comumente usado como o ligante (imobilizado sobre a lasca sensora) e os anticorpos são usados sem qualquer rotulação como analitos (fase em solução).</span>[000308] To determine whether 11E1 and 5D5, both recognizing the SEMA domain, compete for overlapping epitopes, BIAcore analysis was performed. The BIAcore system, based on the Plasmonium Resonance on Surface phenomenon, distributes data by monitoring events in real time. It is then useful for grouping antibodies in so-called epitope mapping experiments. A pair of antibodies unable to bind on the antigenic molecule at the same time is classified in the same group (identical or close binding sites). In contrast, when their respective binding sites are sufficiently distinct to allow simultaneous binding of both antibodies, the latter are classified into two different groups. In such experiments, the antigen is commonly used as the ligand (immobilized on the sensor chip) and the antibodies are used without any labeling as analytes (solution phase).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000309] Todos os experimentos descritos acima foram feitos sobre um instrumento BIAcore X (GE Healthcare Europe GmbH). Uma lasca sensora CM5 (BIAcore) ativada por um Mab anti-Tag-6His de camundongo (R&amp;D System ref. MAB050) foi preparada seguindo as instruções do fabricante usando o kit de acoplamento de amina (BIAcore). O tampão de operação (HBS-EP) e tampão de regeneração (Glicina, HCl) são da BIAcore. Uma versão solúvel recombinante do receptor de HGF humano produzido como uma molécula quimérica cMet-Fc-Tag His era da R&amp;D Systems (ref. 358-MT-CF). Os experimentos foram feitos a 25°C, em uma taxa de fluxo de 30 pl/min. Uma solução a 10 pg/ml de c-Met em tampão de operação foi injetada</span>[000309] All experiments described above were done on a BIAcore X instrument (GE Healthcare Europe GmbH). A CM5 sensor chip (BIAcore) activated by a mouse anti-Tag-6His Mab (R&amp;D System ref. MAB050) was prepared following the manufacturer's instructions using the amine coupling kit (BIAcore). The operation buffer (HBS-EP) and regeneration buffer (Glycine, HCl) are from BIAcore. A soluble recombinant version of the human HGF receptor produced as a cMet-Fc-Tag His chimeric molecule was from R&amp;D Systems (ref. 358-MT-CF). The experiments were carried out at 25 ° C, at a flow rate of 30 pl / min. A 10 pg / ml solution of c-Met in operating buffer was injected</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 83/146</span>Petition 870190095443, of 24/09/2019, p. 83/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">70/131 durante um minuto na célula de fluxo 2 (fc2), tipicamente, 270 RU da forma solúvel de c-Met foram capturados. A célula de fluxo 1 (fc1) foi usada como uma referência para verificar qualquer ligação nãoespecífica dos anticorpos à matriz da lasca sensora.</span>70/131 for one minute in flow cell 2 (fc2), typically 270 RU of the soluble form of c-Met was captured. Flow cell 1 (fc1) was used as a reference to check for any non-specific binding of antibodies to the sensor chip matrix.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000310] Injeções sequenciais de anticorpos a serem testadas foram realizadas. Um anticorpo foi injetado sobre ambas as células de fluxo durante 2 minutos. Um segundo anticorpo (ou o mesmo) foi, então, injetado nas mesmas condições. Se nenhuma ligação significativa foi observada, uma terceira injeção foi feita com outro anticorpo. A lasca sensora foi, então, regenerada através de uma única injeção de 30 s do tampão de regeneração. Anticorpos e c-Met-Fc foram descartados nesse estágio.</span>[000310] Sequential injections of antibodies to be tested were performed. An antibody was injected over both flow cells for 2 minutes. A second antibody (or the same) was then injected under the same conditions. If no significant binding was observed, a third injection was made with another antibody. The sensor chip was then regenerated through a single 30 s injection of the regeneration buffer. Antibodies and c-Met-Fc were discarded at this stage.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Análise dos resultados:</span>Analysis of the results:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000311] A capacidade de um anticorpo A de bloquear a ligação de um anticorpo B é calculada pela proporção BIA/C=(R2A/B/R1B)x100: onde R2A/B é a resposta correspondendo à ligação do MAb B quando ele é injetado após o Mab A e R1B é a resposta correspondendo à ligação do MAb B quando ele é injetado primeiro. Uma A BIA/C abaixo de 20% significa que A é capaz de bloquear a ligação de B, de modo que A e B têm sítios de ligação próximos.</span>[000311] The ability of an antibody A to block the binding of an antibody B is calculated by the ratio BIA / C = (R2A / B / R1B) x100: where R2A / B is the response corresponding to the binding of MAb B when it is injected after Mab A and R1B is the response corresponding to the binding of MAb B when it is injected first. A A BIA / C below 20% means that A is able to block the binding of B, so that A and B have close binding sites.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000312] O mapeamento de epítopo foi realizado com 2 Mabs, 11E1 e 5D5.</span>[000312] Epitope mapping was performed with 2 Mabs, 11E1 and 5D5.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabela 3</span>Table 3</span>
  </p>
  <p class="style-scope patent-text">
    <tables class="style-scope patent-text">
      <patent-tables class="style-scope patent-text">
        <tgroup cols="3" class="style-scope patent-text">
          
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
2° Ab (B)
1° Ab (A)</span>
2nd Ab (B)
1st Ab (A)</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
11E1</span>
11E1</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
5D5</span>
5D5</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
11E1</span>
11E1</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
6,5%</span>
6.5%</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
84,2%</span>
84.2%</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
5D5</span>
5D5</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
98,4%</span>
98.4%</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
11,0%</span>
11.0%</span>
              </entry>
            </row>
          
        </tgroup>
      </patent-tables>
    </tables>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000313] Visualização da ligação em torno de 270RU de c-Met-Fc capturada pela injeções sequenciais de 2 minutos dos Mabs 5D5 (primeiro), 5D5 (segundo) e 11E1 (terceiro) em uma concentração de</span>[000313] Visualization of the connection around 270RU of c-Met-Fc captured by the 2-minute sequential injections of Mabs 5D5 (first), 5D5 (second) and 11E1 (third) in a concentration of</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 84/146</span>Petition 870190095443, of 24/09/2019, p. 84/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">71/131 pg/ml cada demonstrou que 5D5 e 11E1 se ligam claramente a dois sítios distantes (Figura 5A). Essa observação foi confirmada pela sequência recíproca do anticorpo (Figura 5B).</span>71/131 pg / ml each demonstrated that 5D5 and 11E1 clearly bind to two distant sites (Figure 5A). This observation was confirmed by the reciprocal antibody sequence (Figure 5B).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000314] A Tabela 3 resume a proporção de cálculo obtida com as diferentes sequências desses 2 anticorpos. Valores em preto (mais de 75%) significam que o Mab A não bloqueia a ligação do Mab B. Valores em negrito/itálico (abaixo de 20%) significam que os sítios de ligação de ambos os anticorpos (A e B) são idênticos ou suficientemente próximos para impossibilitar uma ligação simultânea. Exemplo 3: efeito de Mabs sobre a fosforilação de c-Met [000315] Para determinar a atividade de anticorpos anti-c-Met sobre a fosforilação de c-Met, um ensaio ELISA de fosfo c-Met foi configurado. Resumidamente, 500 000 células A549 foram cultivadas em cada poço de lâminas com 6 poços em meio F12K + FCS a 10%. 16 horas antes de adição de HGF (100 ng/ml), as células foram privadas e cada anticorpo a ser testado foi adicionado em uma concentração final de 30 pg/ml 15 minutos antes de estimulação com ligante. 15 minutos após a adição de HGF, tampão de lise gelado foi adicionado, as células foram raspadas e lisatos de célula coletados e centrifugados a 13 000 rpm durante 10 min a 4°C. Os sobrenadantes foram quantificados com um kit BCA (Pierce) e armazenadas a -20°C. Para o ensaio ELISA, um anticorpo anti-c-Met de cabra (R&amp;D ref. AF276) foi usado como um anticorpo de captura (revestimento durante a noite a 4°C) e, após uma etapa de saturação (1 h em RT) com um tampão de TBS-BSA a 5%, 25 pg de proteína dos diferentes lisatos celulares foram adicionados a cada poço da lâmina com 96 poços. Após um tempo de incubação de 90 minutos em RT, as lâminas foram lavadas quatro vezes e um anticorpo anti-fosfo-c-Met (anti-pY12301234-1235 c-Met de coelho) foi adicionado. Após um tempo de incubação adicional de 1 hora e 4 lavagens, um anti-HRP de coelho</span>[000314] Table 3 summarizes the proportion of calculation obtained with the different sequences of these 2 antibodies. Black values (more than 75%) mean that Mab A does not block the binding of Mab B. Values in bold / italics (below 20%) mean that the binding sites of both antibodies (A and B) are identical or close enough to make a simultaneous connection impossible. Example 3: Effect of Mabs on C-Met Phosphorylation [000315] To determine the activity of anti-c-Met antibodies on c-Met phosphorylation, a c-Met phospho ELISA assay was set up. Briefly, 500,000 A549 cells were cultured in each slide well with 6 wells in 10% F12K + FCS medium. 16 hours before adding HGF (100 ng / ml), cells were deprived and each antibody to be tested was added in a final concentration of 30 pg / ml 15 minutes before stimulation with ligand. 15 minutes after adding HGF, cold lysis buffer was added, cells were scraped and cell lysates collected and centrifuged at 13,000 rpm for 10 min at 4 ° C. Supernatants were quantified with a BCA kit (Pierce) and stored at -20 ° C. For the ELISA assay, a goat anti-c-Met antibody (R&amp;D ref. AF276) was used as a capture antibody (overnight coating at 4 ° C) and, after a saturation step (1 hr in RT) with a 5% TBS-BSA buffer, 25 pg of protein from the different cell lysates was added to each well of the 96-well slide. After an incubation time of 90 minutes in RT, the slides were washed four times and an anti-phospho-c-Met antibody (rabbit anti-pY12301234-1235 c-Met) was added. After an additional 1 hour incubation time and 4 washes, a rabbit anti-HRP</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 85/146</span>Petition 870190095443, of 24/09/2019, p. 85/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">72/131 (Biosource) foi adicionado durante 1 hora em RT e, então, substrato</span>72/131 (Biosource) was added for 1 hour in RT and then substrate</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Luminol foi adicionado antes de avaliação da luminescência com um dispositivo Mithras. Os resultados apresentados na Figura 6B demonstraram que 11E1, 224G11, 223C4 e 227H1 inibem a fosforilação de c-Met em 68, 54, 80 e 65%, respectivamente, comparado com o Mab 5D5, o qual mostrou uma inibição mais fraca de fosforilação de c-Met (42%). Nesse teste, um fraco efeito basal (menos de 20%) foi observado com os 4 anticorpos candidatos (Figura 6A). Conforme descrito nos vários exemplos apresentados nessa patente, esse fraco efeito basal não tem consequências sobre a atividade dos anticorpos em outros testes in vitro e in vivo. O 5D5 usado como um controle mostrou, nesse teste, um efeito basal significativo.</span>Luminol was added prior to luminescence assessment with a Mithras device. The results shown in Figure 6B demonstrated that 11E1, 224G11, 223C4 and 227H1 inhibit c-Met phosphorylation by 68, 54, 80 and 65%, respectively, compared to Mab 5D5, which showed a weaker inhibition of phosphorylation of c-Met (42%). In this test, a weak baseline effect (less than 20%) was observed with the 4 candidate antibodies (Figure 6A). As described in the various examples presented in that patent, this weak basal effect has no consequences on the activity of antibodies in other tests in vitro and in vivo. The 5D5 used as a control showed, in this test, a significant baseline effect.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 4: deslocamento de HGF rádio-rotulado por anticorpos anti-cMet [000316] Para determinar se os anticorpos anti-c-Met eram capazes de deslocar o HGF, experimentos de ligação foram configurados. Resumidamente, microlâminas com 96 poços FlashPlate de proteína A (Perkin Elmer) foram saturadas com gelatina a 0,5% em PBS (200 gl/poço, 2 h em temperatura ambiente) antes da adição de c-Met-Fc recombinante (R&amp;D Systems) como uma proteína de revestimento. Dois mil gl de uma solução de c-Met-Fc a 1 gg/ml em PBS foram adicionados a cada poço. As lâminas foram, então, incubadas durante a noite a 4°C. Os sítios de proteína A residual livres foram ainda saturados com uma hIgG não relevante (0,5 gg/poço em PBS) durante 2 h em temperatura ambiente. As lâminas foram lavadas com PBS após cada etapa.</span>Example 4: displacement of radio-labeled HGF by anti-cMet antibodies [000316] To determine whether anti-c-Met antibodies were able to displace HGF, binding experiments were set up. Briefly, 96 micro-slides FlashPlate protein A (Perkin Elmer) were saturated with 0.5% gelatin in PBS (200 g / well, 2 h at room temperature) before adding recombinant c-Met-Fc (R&amp;D Systems ) as a coating protein. Two thousand g of a 1 gg / ml solution of c-Met-Fc in PBS was added to each well. The slides were then incubated overnight at 4 ° C. The free residual protein A sites were further saturated with a non-relevant hIgG (0.5 gg / well in PBS) for 2 h at room temperature. The slides were washed with PBS after each step.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000317] Para ensaios de competição, a ligação de [<sup class="style-scope patent-text">125</sup>I]-HGF (atividade específica ~ 2.000 Ci/mmol) a 200 gM à c-Met imobilizada foi medida na presença de concentrações variadas dos anticorpos</span>[000317] For competition assays, the binding of [ <sup class="style-scope patent-text">125</sup> I] -HGF (specific activity ~ 2,000 Ci / mmol) at 200 gM to immobilized c-Met was measured in the presence of varying concentrations of antibodies</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 86/146</span>Petition 870190095443, of 24/09/2019, p. 86/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">73/131 monoclonais anti-c-Met 11E1, 224G11, 223C4, 227H1 ou HGF (R&amp;D Systems), oscilando de 0,1 pM a 1 pM em PBS, pH de 7,4. As lâminas foram incubadas em temperatura ambiente durante 6 h, então, contadas sobre um Contador de Cintilação Packard Top Count Microplate. A ligação não-específica foi determinada na presença de HGF a 1 pM. O anticorpo monoclonal 9G4, o qual não é direcionado à c-Met, mas reconhece especificamente uma proteína de E. coli, foi usado como um controle de isotipo de IgG1 de camundongo.</span>73/131 monoclonal anti-c-Met 11E1, 224G11, 223C4, 227H1 or HGF (R&amp;D Systems), ranging from 0.1 pM to 1 pM in PBS, pH 7.4. The slides were incubated at room temperature for 6 h, then counted on a Packard Top Count Microplate Scintillation Counter. Non-specific binding was determined in the presence of 1 pM HGF. The monoclonal antibody 9G4, which is not directed to c-Met, but specifically recognizes an E. coli protein, was used as a mouse IgG1 isotype control.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000318] O percentual de ligação [<sup class="style-scope patent-text">125</sup>I]-HGF específica total foi plotado como uma função da concentração de ligante sobre gráficos semilog. As concentrações de vários inibidores requeridos para inibir a ligação de rádio ligante em 50% (IC50) foram determinadas graficamente a partir das curvas de competição sigmoidais obtidas (Figuras 7A e 7B).</span>[000318] The percentage of total specific [ <sup class="style-scope patent-text">125</sup> I] -HGF binding was plotted as a function of the concentration of ligand on semilog plots. The concentrations of various inhibitors required to inhibit the radio ligand binding by 50% (IC50) were determined graphically from the sigmoidal competition curves obtained (Figures 7A and 7B).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000319] Conforme esperado, HGF não-rádiorrotulado foi capaz de deslocar totalmente a ligação de [<sup class="style-scope patent-text">125</sup>I]-HGF à c-Met imobilizada, enquanto que o anticorpo de controle 9G4 não mostra qualquer atividade de bloqueio de HGF (Figuras 7A e 7B). Os anticorpos monoclonais anti-c-Met 11E1, 224G11, 223C4 e 227H1 foram capazes de inibir a ligação de [<sup class="style-scope patent-text">125</sup>I]-HGF à c-Met imobilizada, com valores de IC50 de 20 nM, a 3 nM, a 2,7 nM e a 5,8 nM, respectivamente. Os valores de IC50 determinados para os anticorpos 224G11, 223C4 e 227H1 eram comparáveis ao valor de IC50 determinado para o HGF não-rádiorrotulado, o qual estava compreendido entre 3 e 5 nM, enquanto que o anticorpo 11E1 exibiu um maior valor de IC50.</span>[000319] As expected, non-radio-labeled HGF was able to fully displace the binding of [ <sup class="style-scope patent-text">125</sup> I] -HGF to the immobilized c-Met, whereas the control antibody 9G4 does not show any HGF blocking activity (Figures 7A and 7B ). Monoclonal anti-c-Met antibodies 11E1, 224G11, 223C4 and 227H1 were able to inhibit the binding of [ <sup class="style-scope patent-text">125</sup> I] -HGF to immobilized c-Met, with IC 50 values of 20 nM, at 3 nM, at 2.7 nM and 5.8 nM, respectively. The IC50 values determined for the 224G11, 223C4 and 227H1 antibodies were comparable to the IC50 value determined for the non-radio-labeled HGF, which was between 3 and 5 nM, while the 11E1 antibody exhibited a higher IC50 value.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 5: inibição de invasão por anticorpos anti-c-Met [000320] Para avaliar o efeito de inibição dos anticorpos anti-c-Met sobre o processo de invasão, células A549 foram colocadas na câmara superior de câmaras de invasão BD BioCoat™ Matrigel™ (poços com 6,5 mm de diâmetro com membranas de policarbonato</span>Example 5: invasion inhibition by anti-c-Met antibodies [000320] To assess the inhibition effect of anti-c-Met antibodies on the invasion process, A549 cells were placed in the upper chamber of BD BioCoat ™ Matrigel invasion chambers ™ (6.5 mm diameter wells with polycarbonate membranes</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 87/146</span>Petition 870190095443, of 24/09/2019, p. 87/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">74/131 com um tamanho de 8 gm). As células A459 foram privadas de soro 24 horas antes de realização do ensaio de invasão. Então, 500 000 células A549 foram colocadas em um tampão de quimiotaxia (meio DMEM, BSA a 0,1%, Hepes a 12 mM) na poço superior de cada câmara, sobre o revestimento de Matrigel, com ou sem o anticorpo a ser testado (concentração final de Mab de 10 gg/ml). Após 1 hora de incubação das lâminas a 37°C com 5% de CO2, as câmaras inferiores foram enchidas com meio de crescimento contendo 400 ng/ml de rhHGF ou com meio de crescimento apenas. As câmaras foram incubadas durante mais 48 horas a 37°C com 5% de CO2. Ao final desse tempo de incubação, as células que permaneceram sobre a superfície superior do filtro foram gentilmente removidas com um cotonete, as células que migraram para a superfície inferior do filtro foram submetidas à lise, coradas com tampão corante CyQuant GR (Invitrogen) e contadas usando um leitor de fluorescência Berthold Mithras LB940. Todas as condições foram testadas como triplicatas.</span>74/131 with a size of 8 gm). A459 cells were deprived of serum 24 hours before the invasion assay was performed. Then, 500,000 A549 cells were placed in a chemotaxis buffer (DMEM medium, 0.1% BSA, 12 mM Hepes) in the upper well of each chamber, on the Matrigel coating, with or without the antibody to be tested (final concentration of Mab of 10 gg / ml). After 1 hour of incubation of the slides at 37 ° C with 5% CO2, the lower chambers were filled with growth medium containing 400 ng / ml rhHGF or with growth medium only. The chambers were incubated for an additional 48 hours at 37 ° C with 5% CO2. At the end of this incubation time, the cells that remained on the upper surface of the filter were gently removed with a cotton swab, the cells that migrated to the lower surface of the filter were subjected to lysis, stained with CyQuant GR (Invitrogen) dye buffer and counted using a Berthold Mithras LB940 fluorescence reader. All conditions were tested as triplicates.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000321] Conforme esperado, o HGF induziu a uma invasão significativa de células tumorais comparado com aquela observada com FCS a 10% introduzido como um controle positivo (Figura 8). A IgG1 de murino 9G4 introduzida como um controle de isotipo não tem efeito significativo sobre a invasão basal ou induzida por HGF quando comparado a células colocadas na lâmina sem IgG. Nenhum efeito agonista foi percebido com h 11E1, 224G11, 223C4 e 227H1 quando adicionados isoladamente e inibição significativa e comparável da invasão HGF-induzida foi observada com os 3 Mabs.</span>[000321] As expected, HGF induced a significant invasion of tumor cells compared to that observed with 10% FCS introduced as a positive control (Figure 8). Murine IgG1 9G4 introduced as an isotype control has no significant effect on basal or HGF-induced invasion when compared to cells placed on the slide without IgG. No agonist effects were seen with h 11E1, 224G11, 223C4 and 227H1 when added alone and significant and comparable inhibition of HGF-induced invasion was observed with the 3 Mabs.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 6: inibição de cicatrização de ferimento pelos anticorpos antic-Met [000322] HGF estimula a motilidade. Para determinar se os anticorpos anti-HGF eram capazes de inibir a migração, células NCIH441 foram crescidas em alta densidade e um vão foi introduzido com</span>Example 6: inhibition of wound healing by anti-Met [000322] HGF antibodies stimulates motility. To determine whether anti-HGF antibodies were able to inhibit migration, NCIH441 cells were grown in high density and a gap was introduced with</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 88/146</span>Petition 870190095443, of 24/09/2019, p. 88/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">75/131 a ponta de uma pipeta P200. As células foram, então, estimuladas a migrar através do vão com HGF (100 ng/ml) na presença ou na ausência de 11E1. Poços com 11E1 apenas também foram avaliados. Cada condição testada foi avaliada como seis réplicas e 3 experimentos independentes foram realizados. Após uma incubação durante a noite, as células foram visualizadas com uma Câmera Axio Vision (direciona x4).</span>75/131 the tip of a P200 pipette. The cells were then stimulated to migrate through the gap with HGF (100 ng / ml) in the presence or absence of 11E1. Wells with 11E1 only were also evaluated. Each condition tested was evaluated as six replicates and 3 independent experiments were performed. After an overnight incubation, the cells were visualized with an Axio Vision Camera (directs x4).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000323] HGF induziu a uma migração significativa, resultando em um fechamento completo do vão dentro de uma noite (Figura 9). A IgG1 irrelevante 9G4 usada como um controle de isotipo é sem qualquer efeito sobre a migração celular. Conforme esperado, um efeito agonista foi observado com o 5D5 quando adicionado isoladamente, mas uma inibição significativa de migração celular é observada com esse anticorpo na presença de HGF na porção do vão que permaneceu aberta. O fragmento Fab de 5D5 não teve qualquer efeito agonista quando adicionado isoladamente. Contudo, nenhuma atividade desse fragmento foi observada na presença de HGF. Conforme observado com o controle de isotipo 9G4, o MAb 11E1 não teve efeito agonista quando adicionado e se comportou como um antagonista total na presença de HGF.</span>[000323] HGF induced a significant migration, resulting in a complete closure of the gap within one night (Figure 9). The irrelevant 9G4 IgG1 used as an isotype control is without any effect on cell migration. As expected, an agonist effect was observed with 5D5 when added alone, but a significant inhibition of cell migration is observed with this antibody in the presence of HGF in the portion of the gap that remained open. The 5D5 Fab fragment had no agonist effect when added alone. However, no activity of this fragment was observed in the presence of HGF. As observed with the 9G4 isotype control, MAb 11E1 had no agonist effect when added and behaved as a total antagonist in the presence of HGF.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 7: ensaio de dispersão [000324] Células SK-HEP-1 foram cultivadas em baixa densidade (1 x 10<sup class="style-scope patent-text">4</sup> células/poço) em uma lâmina com 24 poços em DMEM com FCS a 10% e crescidas durante 24 horas antes da adição, ao mesmo tempo, de HGF (100 ng/ml) e anticorpos a serem testados (10 pg/ml). Após 72 horas de incubação, as colônias foram fixadas e coradas com violeta cristal a 0,2% em metanol e avaliadas com relação à dispersão visualmente. Cada condição foi testada como uma triplicata e 3 experimentos independentes foram realizados.</span>Example 7: dispersion assay [000324] SK-HEP-1 cells were cultured at low density (1 x 10 <sup class="style-scope patent-text">4</sup> cells / well) on a 24-well slide in DMEM with 10% FCS and grown for 24 hours before addition , at the same time, of HGF (100 ng / ml) and antibodies to be tested (10 pg / ml). After 72 hours of incubation, the colonies were fixed and stained with 0.2% crystal violet in methanol and visually evaluated for dispersion. Each condition was tested as a triplicate and 3 independent experiments were performed.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000325] A adição de HGF às células SK-HEP-1 induziu a uma</span>[000325] The addition of HGF to SK-HEP-1 cells induced a</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 89/146</span>Petition 870190095443, of 24/09/2019, p. 89/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">76/131 dispersão celular significativa (Figuras 10A e 10B). O anticorpo 9G4 introduzido como um controle de isotipo não teve qualquer efeito isoladamente ou na presença de HGF. Conforme esperado,o anticorpo 5D5 mostrou um efeito agonista significativo isoladamente e nenhum efeito inibitório foi observado quando 5D5 foi adicionado com HGF (Figura 10A). Nenhum efeito agonístico foi observado com 11E1 (Figura 10A) nem com 224G11 (Figura 10B) adicionados isoladamente. Um efeito inibitório muito significativo desses anticorpos foi demonstrado na presença de HGF (Figuras 10A e 10B).</span>76/131 significant cell dispersion (Figures 10A and 10B). The 9G4 antibody introduced as an isotype control had no effect alone or in the presence of HGF. As expected, the 5D5 antibody showed a significant agonist effect alone and no inhibitory effects were seen when 5D5 was added with HGF (Figure 10A). No agonistic effects were observed with 11E1 (Figure 10A) or 224G11 (Figure 10B) added alone. A very significant inhibitory effect of these antibodies has been demonstrated in the presence of HGF (Figures 10A and 10B).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 8: ensaio de tubulogênese tridimensional [000326] Células SK-HEP-1 foram cultivadas a 1 x 10<sup class="style-scope patent-text">4</sup> células/poço em uma lâmina com 24 poços em DMEM com FCS a 10%/Matrigel (50/50) e incubadas durante 30 min antes da adição, ao mesmo tempo, de HGF (100 ng/ml) e anticorpos a serem testados (10 pg/ml). Após 7 dias de incubação, as células foram avaliadas com relação à formação de tubo visualmente. Cada condição foi testada como uma triplicata e 3 experimentos independentes foram realizados.</span>Example 8: three-dimensional tubulogenesis assay [000326] SK-HEP-1 cells were cultured at 1 x 10 <sup class="style-scope patent-text">4</sup> cells / well in a 24-well slide in DMEM with 10% FCS / Matrigel (50/50) and incubated for 30 min before adding, at the same time, HGF (100 ng / ml) and antibodies to be tested (10 pg / ml). After 7 days of incubation, the cells were evaluated visually for tube formation. Each condition was tested as a triplicate and 3 independent experiments were performed.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000327] A adição de HGF induziu a uma formação significativa de tubo em SK-HEP-1 (Figura 11). O anticorpo 9G4 introduzido como um controle de isotipo não teve qualquer efeito isoladamente ou na presença de HGF. Conforme esperado, o anticorpo 5D5 mostrou um efeito agonista significativo isoladamente e nenhum efeito inibitório foi observado quando 5D5 foi adicionado com HGF. Nenhum efeito agonístico foi observado com 11E1, 223 C4 e 224G11 adicionados isoladamente e um efeito inibitório total foi demonstrado com 11E1 e 223C4 na presença de HGF. Uma inibição parcial, mas significativa, foi observada com o Mab 224G11.</span>[000327] The addition of HGF induced significant tube formation in SK-HEP-1 (Figure 11). The 9G4 antibody introduced as an isotype control had no effect alone or in the presence of HGF. As expected, the 5D5 antibody showed a significant agonist effect alone and no inhibitory effects were seen when 5D5 was added with HGF. No agonistic effect was observed with 11E1, 223 C4 and 224G11 added alone and a total inhibitory effect was demonstrated with 11E1 and 223C4 in the presence of HGF. A partial but significant inhibition was seen with Mab 224G11.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 9: formação de esferoide [000328] Para avaliar a capacidade de anticorpos anti-c-Met de inibir o crescimento de tumor in vitro, em um modelo mais próximo de uma</span>Example 9: spheroid formation [000328] To assess the ability of anti-c-Met antibodies to inhibit tumor growth in vitro, in a model closer to a</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 90/146</span>Petition 870190095443, of 24/09/2019, p. 90/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">77/131 situação in vivo, esferoides de células de glioblastoma humano U87MG (ATCC n°10 HTB-14) foram gerados. As células crescidas como uma monocamada foram soltas com tripsina-EDTA e resuspensas em meio de cultura de células completo (DMEM) suplementado com FBS a 10%. Os esferoides foram iniciados através de inoculação de 625 células em poços únicas de lâminas de fundo redondo com 96 poços em DMEM-FCS a 10%. Para impedir a adesão celular a um substrato, as lâminas foram pré-revestidas com poliHEMA em etanol a 95% e secas ao ar em temperatura ambiente. As lâminas foram incubadas sob condições padrões de cultura de célula a 37°C, 5% de CO2 em incubadoras umidificadas. Anticorpos monoclonais purificados (10 pg/ml) foram adicionados após 3 e 7 dias de cultura de esferoide. HGF (400 ng/ml) foi adicionado uma vez após 4 dias de cultura. Os esferoides foram mantidos em cultura durante pelo menos 10 dias. Então, o crescimento de esferoide foi monitorado através de medição da área de esferoides usando um módulo de medição automática do software Axio Vision. A área foi expressa em pm<sup class="style-scope patent-text">2</sup>. 8-16 esferoides foram avaliados para cada condição.</span>77/131 in vivo situation, human glioblastoma cell spheroids U87MG (ATCC No. 10 HTB-14) were generated. The cells grown as a monolayer were released with trypsin-EDTA and resuspended in complete cell culture medium (DMEM) supplemented with 10% FBS. Spheroids were initiated by inoculating 625 cells in single wells of 96-well round-bottom slides in 10% DMEM-FCS. To prevent cell adhesion to a substrate, the slides were pre-coated with polyHEMA in 95% ethanol and air-dried at room temperature. The slides were incubated under standard cell culture conditions at 37 ° C, 5% CO2 in humidified incubators. Purified monoclonal antibodies (10 pg / ml) were added after 3 and 7 days of spheroid culture. HGF (400 ng / ml) was added once after 4 days of culture. The spheroids were kept in culture for at least 10 days. Then, spheroid growth was monitored by measuring the spheroid area using an automatic measurement module from the Axio Vision software. The area was expressed in pm <sup class="style-scope patent-text">2</sup> . 8-16 spheroids were assessed for each condition.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000329] As Figuras 12A e 12B mostraram que, na presença de FCS a 10%, nenhuma estimulação foi observada quando HGF foi adicionado ao meio completo. Conforme esperado, o controle de isotipo 9G4 não teve efeito sobre o crescimento de esferoide. 11E1 e 223C4 reduziram significativamente o crescimento de esferoide na presença e ausência de HGF. Nenhum efeito foi observado com o fragmento Fab de 5D5.</span>[000329] Figures 12A and 12B showed that, in the presence of 10% FCS, no stimulation was observed when HGF was added to the complete medium. As expected, the 9G4 isotype control had no effect on spheroid growth. 11E1 and 223C4 significantly reduced spheroid growth in the presence and absence of HGF. No effect was seen with the 5D5 Fab fragment.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 10: atividade in vivo de Mabs anti-c-Met no modelo de xenoenxerto U87MG [000330] Camundongos atímicos de seis a oito semanas de idade foram alojados em gaiolas com filtro por cima esterilizadas, mantidos em condições estéreis e manipulados de acordo com as diretrizes</span>Example 10: in vivo activity of anti-c-Met Mabs in the U87MG xenograft model [000330] Six to eight week old athymic mice were housed in sterile filter cages, kept in sterile conditions and handled according to guidelines</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 91/146</span>Petition 870190095443, of 24/09/2019, p. 91/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">78/131</span>78/131</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Francesas e Européias. U87,MG, uma linhagem de células de glioblastoma, expressando c-Met e autócrina para o ligante HGF, foi selecionada para avaliações in vivo. Os camundongos foram injetados subcutaneamente com 5 x 106 células. Então, seis dias após implante das células, os tumores eram mensuráveis (aproximadamente 100 mm<sup class="style-scope patent-text">3</sup>), os animais foram divididos em grupos de 6 camundongos com tamanho de tumor comparável e tratados duas vezes por semana com 1 mg/dose de cada anticorpo a ser testado. Os camundongos foram acompanhados para a observação da taxa de crescimento do xenoenxerto e alterações do peso corporal. O volume do tumor foi calculado através da fórmula: π (Pi)/6 X comprimento X largura X altura.</span>French and European. U87, MG, a glioblastoma cell line, expressing c-Met and autocrine for the HGF ligand, was selected for in vivo evaluations. The mice were injected subcutaneously with 5 x 10 6 cells. Then, six days after cell implantation, the tumors were measurable (approximately 100 mm <sup class="style-scope patent-text">3</sup> ), the animals were divided into groups of 6 mice of comparable tumor size and treated twice a week with 1 mg / dose of each antibody to be tested. The mice were monitored for the observation of the xenograft growth rate and changes in body weight. The tumor volume was calculated using the formula: π (Pi) / 6 X length X width X height.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000331] Os resultados obtidos são resumidos na Figura 13 e demonstraram que todos os anticorpos testados inibem significativamente o crescimento in vivo de células U87-MG. O uso de um anticorpo de neutralização anti-IGF-IR (IgG1) no painel A demonstra que a inibição observada in vivo é especificamente relacionada à modulação do eixo HGF-cMet.</span>[000331] The results obtained are summarized in Figure 13 and demonstrated that all antibodies tested significantly inhibited the in vivo growth of U87-MG cells. The use of an anti-IGF-IR neutralizing antibody (IgG1) in panel A demonstrates that the inhibition observed in vivo is specifically related to the modulation of the HGF-cMet axis.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 11: atividade in vivo de Mabs anti-c-Met no modelo de xenoenxerto NCI-H441 [000332] NCI-H441 é derivado de adenocarcinoma papilar de pulmão, expressa altos níveis de c-Met e demonstra fosforilação constitutiva de RTK c-Met.</span>Example 11: In vivo activity of anti-c-Met Mabs in the NCI-H441 xenograft model [000332] NCI-H441 is derived from papillary lung adenocarcinoma, expresses high levels of c-Met and demonstrates constitutive phosphorylation of RTK c-Met .</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000333] Para determinar se essa linhagem de célula expressa altos níveis de c-Met e é capaz de produzir HGF, RT-PCR quantitativa e FACS ou ELISA (Quantikine HGF; R&amp;D Systems) foram realizados. Para RT-PCR quantitativa, os níveis de HGF total ou transcrito de cMet em linhagens de célula foram avaliados através de PCR quantitativa usando a técnica-padrão TaqMan™. Os níveis de HGF ou transcrito de c-Met foram normalizados para a proteína Ribossômica</span>[000333] To determine whether this cell line expresses high levels of c-Met and is capable of producing quantitative HGF, RT-PCR and FACS or ELISA (Quantikine HGF; R&amp;D Systems) were performed. For quantitative RT-PCR, levels of total HGF or cMet transcript in cell lines were assessed using quantitative PCR using the standard TaqMan ™ technique. Levels of HGF or c-Met transcript have been normalized for Ribosomal protein</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 92/146</span>Petition 870190095443, of 24/09/2019, p. 92/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">79/131 do gene de controle housekeeping, grande, P0 (RPL0) e os resultados foram expressos como valores de expressão normalizados (método 2-ddCT).</span>79/131 of the housekeeping control gene, large, P0 (RPL0) and the results were expressed as normalized expression values (method 2-ddCT).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000334] Os conjuntos de primer/sonda para RPL0 eram dianteiro, 5'gaaactctgcattctcgcttcctg-3' (SEQ ID No. 47); reverso, 5'aggactcgtttgtacccgttga-3' (SEQ ID No. 48); e sonda 5'-(FAM)tgcagattggctacccaactgttgca-(TAMRA)-3' (SEQ ID No. 49). Os conjuntos de primer/sonda para HGF foram dianteiro, 5'aacaatgcctctggttcc-3' (SEQ ID No. 50); reverso, 5'-cttgtagctgcgtcctttac3' (SEQ ID No. 51); e sonda, 5'-(FAM)-ccttcaatagcatgtcaagtggagtga(TAMRA)-3' (SEQ ID No. 52). Os conjuntos de primer/sonda para cMet foram dianteiro, 5'-cattaaaggagacctcaccatagctaat-3' (SEQ ID No. 53); reverso, 5'-cctgatcgagaaaccacaacct-3' (SEQ ID No. 54); e sonda, 5'-(FAM)-catgaagcgaccctctgatgtccca-(TAMRA)-3' (SEQ ID No. 55). O protocolo de termo-ciclização consistia em fusão a 50°C durante 2 minutos e 95°C durante 10 minutos, seguido por 40 ciclos a 95°C durante 15 segundos e 62°C durante 1 minuto.</span>[000334] The primer / probe sets for RPL0 were front, 5'gaaactctgcattctcgcttcctg-3 '(SEQ ID No. 47); reverse, 5'aggactcgtttgtacccgttga-3 '(SEQ ID No. 48); and probe 5 '- (FAM) tgcagattggctacccaactgttgca- (TAMRA) -3' (SEQ ID No. 49). The primer / probe sets for HGF were front, 5'aacaatgcctctggttcc-3 '(SEQ ID No. 50); reverse, 5'-cttgtagctgcgtcctttac3 '(SEQ ID No. 51); and probe, 5 '- (FAM) -ccttcaatagcatgtcaagtggagtga (TAMRA) -3' (SEQ ID No. 52). The primer / probe sets for cMet were front, 5'-cattaaaggagacctcaccatagctaat-3 '(SEQ ID No. 53); reverse, 5'-cctgatcgagaaaccacaacct-3 '(SEQ ID No. 54); and probe, 5 '- (FAM) -catgaagcgaccctctgatgtccca- (TAMRA) -3' (SEQ ID No. 55). The thermocycling protocol consisted of fusion at 50 ° C for 2 minutes and 95 ° C for 10 minutes, followed by 40 cycles at 95 ° C for 15 seconds and 62 ° C for 1 minute.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000335] Nenhum mRNA para HGF foi encontrado em NCI-H441 (Figura 14) e HGF não é detectável, através de ELISA, em sobrenadantes de NCI-H441. Nesses experimentos, U87-MG, uma linhagem de célula de glioblastoma conhecida como uma linhagem de célula autócrina para HGF, foi introduzida como um controle positivo. A análise por RT-PCR mostrou um nível significativo de mRNA de HGF em U87-MG e 1,9 ng de HGF/milhão de células foram detectados no sobrenadante de células U87-MG. RT-PCR quantitativa e análise por FACS, Figuras 15A e 15B, demonstraram que, conforme esperado, as células NCI-H441 superexpressam significativamente c-Met e que essa expressão era dramaticamente maior do que aquela observada para células U87-MG. Nesse experimento, a linhagem de células MCF-7 foi introduzida como um controle negativo. Tomados juntos,</span>[000335] No mRNA for HGF was found in NCI-H441 (Figure 14) and HGF is not detectable, via ELISA, in NCI-H441 supernatants. In these experiments, U87-MG, a glioblastoma cell line known as an autocrine cell line for HGF, was introduced as a positive control. RT-PCR analysis showed a significant level of HGF mRNA in U87-MG and 1.9 ng HGF / million cells were detected in the U87-MG cell supernatant. Quantitative RT-PCR and FACS analysis, Figures 15A and 15B, demonstrated that, as expected, NCI-H441 cells significantly overexpress c-Met and that this expression was dramatically greater than that seen for U87-MG cells. In this experiment, the MCF-7 cell line was introduced as a negative control. Taken together,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 93/146</span>Petition 870190095443, of 24/09/2019, p. 93/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">80/131</span>80/131</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">NCI-H441 aparece como uma linhagem de célula não-autócrina constitutivamente ativada capaz de crescer independentemente do ligante HGF, na qual uma dimerização independente de ligante de cMet ocorreu como uma consequência da superexpressão do receptor. [000336] A avaliação de anticorpos anti-c-met sobre a atividade in vivo dessa linhagem de célula não-autócrina pôde fornecer alguns insights sobre sua potência ao conferir a dimerização de c-Met. [000337] A Figura 16 demonstra que 224G11, 11E1 e 227H1 inibiram significativamente o crescimento in vivo de NCI-H441, sugerindo que, além de inibição dependente de ligante, esses anticorpos capazes de inibir a dimerização também são capazes de direcionar uma inibição independente de ligante de c-met. Conforme mencionado acima na especificação, com essa última propriedade, é mostrado que 224G11, 11E1 e 227H1 são diferentes do anticorpo anti-c-Met 5D5 com um braço (OA-5D5).</span>NCI-H441 appears as a constitutively activated non-autocrine cell line capable of growing independently of the HGF ligand, in which a cMet ligand-independent dimerization occurred as a consequence of receptor overexpression. [000336] The evaluation of anti-c-met antibodies on the in vivo activity of this non-autocrine cell line could provide some insights into its potency by checking the dimerization of c-Met. [000337] Figure 16 demonstrates that 224G11, 11E1 and 227H1 significantly inhibited the in vivo growth of NCI-H441, suggesting that, in addition to ligand-dependent inhibition, these antibodies capable of inhibiting dimerization are also capable of targeting an inhibition independent of c-met ligand. As mentioned above in the specification, with this last property, it is shown that 224G11, 11E1 and 227H1 are different from the anti-c-Met 5D5 antibody with one arm (OA-5D5).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 12: processo de humanização através de enxertagem de CDR do anticorpo 224G11</span>Example 12: humanization process through 224G11 antibody CDR grafting</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I - Humanização do domínio variável com cadeia leve Comparação da sequência de nucleotídeo da VL de 224G11 aos genes de linhagem germinativa de murino [000338] Como uma etapa preliminar, a sequência nucleotídica da VL de 224G11 foi comparada a sequências de genes de linhagem germinativa de murino, parte do banco de dados IMGT (http://imgt. cines. fr).</span>I - Humanization of the light chain variable domain Comparison of the nucleotide sequence of the 224G11 VL to the murine germline genes [000338] As a preliminary step, the nucleotide sequence of the 224G11 VL was compared to sequences of germline genes from murine, part of the IMGT database (http: // imgt. cines. fr).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000339] Genes de linhagem germinativa IGKV3-5*01 e IGKJ4*01 de murino com uma identidade de sequência de 99,31% pela região V e 94,28% para a região J, respectivamente, foram identificados. Com relação à identidade obtida, foi decidido usar diretamente as sequências de VL de 224G11 para buscar homologias humanas. [000340] Esses alinhamentos são representados nas Figuras 17A</span>[000339] Murine IGKV3-5 * 01 and IGKJ4 * 01 germline genes with a sequence identity of 99.31% by region V and 94.28% for region J, respectively, were identified. Regarding the obtained identity, it was decided to directly use the 224G11 VL sequences to search for human homologies. [000340] These alignments are represented in Figures 17A</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 94/146</span>Petition 870190095443, of 24/09/2019, p. 94/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">81/131 para o gene V e 17B para o gene J.</span>81/131 for the V gene and 17B for the J gene.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Comparação da sequência de nucleotídeo da VL de</span>Comparison of the nucleotide sequence of the VL of</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">224G11 com genes de linhagem germinativa humana [000341] De forma a identificar o melhor candidato humano para a enxertagem de CDR, o gene de linhagem germinativa humana mostrando a melhor identidade com a VL de 224G11 foi buscado. Para essa finalidade, a sequência nucleotídica da VL de 224G11 foi alinhada às sequências de genes de linhagem germinativa humana, parte do banco de dados IMGT. Para otimização da seleção, alinhamentos entre as sequências protéicas foram feitos para buscar as melhores homologias.</span>224G11 with human germline genes [000341] In order to identify the best human candidate for CDR grafting, the human germline gene showing the best identity with the 224G11 VL was sought. For this purpose, the nucleotide sequence of the 224G11 VL was aligned with the human germline gene sequences, part of the IMGT database. To optimize the selection, alignments between the protein sequences were made to seek the best homologies.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000342] Esses dois métodos complementares levaram à identificação de duas possíveis sequências V humanas receptoras para a VL de murino de CDRs de 224G11. Alinhamento nucleotídico proporciona um gene de linhagem germinativa humana IGKV3-11*01 com uma identidade de sequência de 75,99%, enquanto que alinhamento protéico proporciona o gene de linhagem germinativa humana IGKV4-1*01 com uma identidade de sequência de 67,30%. É notável que, em ambos os casos, os dois genes de linhagem germinativa mais próximos e as sequências analisadas mostrem diferentes comprimentos de aminoácido da CDR1 (10 aminoácidos na VL de 224G11; 6 aminoácidos em IGKV3-11*01; 12 aminoácidos em IGKV4-1*01). Para a região J, o melhor escore de homologia foi primeiro obtido com o IGKJ3*01 humano, mostrando uma identidade de sequência de 80%. Mas um número maior de nucleotídeos idênticos consecutivos e uma melhor adaptação de aminoácido foram encontrados no alinhamento com o gene de linhagem germinativa humana IGKJ4*02 (identidade de sequência de 77,14%). Assim, o gene de linhagem germinativa IGKJ4*02 foi selecionado como uma região J humana receptora para a VL de murino de CDRs de 11E1.</span>[000342] These two complementary methods led to the identification of two possible human V sequences that are receptors for the murine VL of 224G11 CDRs. Nucleotide alignment provides a human germline gene IGKV3-11 * 01 with a sequence identity of 75.99%, while protein alignment provides the human germline gene IGKV4-1 * 01 with a sequence identity of 67.30 %. It is notable that, in both cases, the two closest germline genes and the sequences analyzed show different lengths of CDR1 amino acid (10 amino acids in VL of 224G11; 6 amino acids in IGKV3-11 * 01; 12 amino acids in IGKV4- 1 * 01). For region J, the best homology score was first obtained with human IGKJ3 * 01, showing a sequence identity of 80%. But a greater number of consecutive identical nucleotides and better amino acid adaptation were found in alignment with the human germline gene IGKJ4 * 02 (sequence identity 77.14%). Thus, the germline gene IGKJ4 * 02 was selected as a recipient human J region for murine VL of 11E1 CDRs.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 95/146</span>Petition 870190095443, of 24/09/2019, p. 95/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">82/131 [000343] Os alinhamentos são representados nas Figuras 18A para a região V e 18B para a região J.</span>82/131 [000343] The alignments are shown in Figures 18A for region V and 18B for region J.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Versão humanizada da VL de 224G11 [000344] Dada a possibilidade de duas regiões V humanas receptoras para a VL de murino de CDRs de 224G11, duas versões humanizadas do domínio de VL de 224G11 serão descritas. A primeira corresponde a um experimento inicial para uma estrutura principal humana com um comprimento de CDR1 mais curto (IGKV3-11*01), a segunda com um comprimento de CDR1 mais longo (IGKV4-1*01).</span>Humanized version of the 224G11 VL [000344] Given the possibility of two human V regions for the murine VL of 224G11 CDRs, two humanized versions of the 224G11 VL domain will be described. The first corresponds to an initial experiment for a human main structure with a shorter CDR1 length (IGKV3-11 * 01), the second with a longer CDR1 length (IGKV4-1 * 01).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">a) Versão humanizada baseada em IGKV3-11*01 da VL de 224G11 [000345] As etapas a seguir no processo de humanização consistem em ligação das sequências de genes de linhagem germinativa selecionados IGKV3-11*01 e IGKJ4*02 e também das CDRs da VL de murino de 224G11 às frameworks dessas sequências de genes de linhagem germinativa.</span>a) Humanized version based on IGKV3-11 * 01 of the 224G11 VL [000345] The steps to follow in the humanization process consist of linking the selected germline gene sequences IGKV3-11 * 01 and IGKJ4 * 02 and also the CDRs from the murine VL of 224G11 to the frameworks of these germline gene sequences.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000346] Conforme representado na Figura 19A, os resíduos em negrito na sequência VL de 224G11 correspondem aos vinte e cinco aminoácidos que se verificou serem diferentes entre o domínio VL de 224G11 e as frameworks humanas selecionadas (FR humana, isto é, IGKV3-11*01 e IGKJ4*02).</span>[000346] As shown in Figure 19A, the residues in bold in the 224G11 VL sequence correspond to the twenty-five amino acids that were found to be different between the 224G11 VL domain and the selected human frameworks (human FR, ie IGKV3-11 * 01 and IGKJ4 * 02).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000347] Com relação ao vários critérios, tais como sua participação na interface VH/VL, na ligação a antígeno ou na estrutura da CDR, a classe de aminoácido muda entre resíduos de murino e humano, a localização do resíduo na estrutura 3D do domínio variável, três dos vinte e cinco resíduos diferentes foram identificados como tendo sofrido eventual mutação. Esses três resíduos definidos mais importantes e mutações em suas contrapartes humanas sendo M39 de murino para L humana, H40 para A e R84 para G. Esses resíduos classificados como um são mostrados na Figura 19A como resíduos</span>[000347] Regarding several criteria, such as their participation in the VH / VL interface, in the antigen binding or in the CDR structure, the class of amino acid changes between murine and human residues, the location of the residue in the 3D structure of the domain variable, three of the twenty-five different residues were identified as having mutated. These three most important defined residues and mutations in their human counterparts being M39 from murine to human L, H40 to A and R84 to G. These residues classified as one are shown in Figure 19A as residues</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 96/146</span>Petition 870190095443, of 24/09/2019, p. 96/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">83/131 em negrito na sequência HZ1VL de 224G11, onde eles permaneceram de murino.</span>83/131 in bold in the 224G11 HZ1VL sequence, where they remained murine.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000348] Naturalmente, os resíduos mencionados acima a serem testados não são limitados, mas devem ser considerados como mutações preferenciais.</span>[000348] Naturally, the residues mentioned above to be tested are not limited, but must be considered as preferential mutations.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000349] Como o auxílio de um modelo molecular, outras mutações poderiam ser identificadas. Podem ser mencionados os resíduos classificados como dois a seguir, isto é, resíduos 15 (L/P), 49 (P/A), 67 (L/R), 68 (E/A), 93 (P/S) e 99 (V/F) sobre os quais mutações poderiam também ser consideradas em outra modalidade preferida.</span>[000349] As the aid of a molecular model, other mutations could be identified. Waste classified as two can be mentioned below, that is, waste 15 (L / P), 49 (P / A), 67 (L / R), 68 (E / A), 93 (P / S) and 99 (V / F) on which mutations could also be considered in another preferred modality.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000350] Naturalmente, os resíduos mencionados acima a serem eventualmente testados não estão limitados, mas devem ser considerados como mutações preferenciais. Em outra modalidade preferida, todos os dezesseis outros resíduos classificados como três dentre os vinte e cinco aminoácidos diferentes poderiam ser reconsiderados.</span>[000350] Of course, the residues mentioned above to be tested are not limited, but should be considered as preferential mutations. In another preferred embodiment, all sixteen other residues classified as three out of twenty-five different amino acids could be reconsidered.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000351] Todas as mutações acima serão testadas individualmente ou de acordo com várias combinações.</span>[000351] All of the above mutations will be tested individually or according to various combinations.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000352] A Figura 19A representa a VL de 224G11 humanizada baseada em IGKV3-11*01 implementada com as mutações mencionadas acima claramente identificadas. O número sob cada mutação proposta corresponde à classificação na qual a referida mutação foi feita.</span>[000352] Figure 19A represents the humanized 224G11 VL based on IGKV3-11 * 01 implemented with the mutations mentioned above clearly identified. The number under each proposed mutation corresponds to the classification in which the mutation was made.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">b) Versão humanizada baseada em IGKV4-1*01 da VL de 224G11 [000353] As seguintes etapas no processo de humanização consistem em ligação de sequências de genes de linhagem germinativa selecionados IGKV4-1*01 e IGKJ4*02 e também das CDRs da VL de murino de 224G11 às frameworks dessas sequências de genes de linhagem germinativa.</span>b) Humanized version based on IGKV4-1 * 01 of the 224G11 VL [000353] The following steps in the humanization process consist of linking sequences of selected germline genes IGKV4-1 * 01 and IGKJ4 * 02 and also of the CDRs of the Murine VL of 224G11 to the frameworks of these germline gene sequences.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 97/146</span>Petition 870190095443, of 24/09/2019, p. 97/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">84/131 [000354] Conforme representado na Figura 19B, os resíduos em negrito na sequência VL de 224G11 correspondem aos vinte e dois aminoácidos que se verificou serem diferentes entre o domínio VL de</span>84/131 [000354] As shown in Figure 19B, the residues in bold in the 224G11 VL sequence correspond to the twenty-two amino acids that were found to be different between the VL domain of</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">224G11 e as frameworks humanas selecionadas (FR humana, isto é,</span>224G11 and the selected human frameworks (human FR, that is,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">IGKV4-1*01 e IGKJ4*02).</span>IGKV4-1 * 01 and IGKJ4 * 02).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000355] Com relação a vários critérios, tais como sua participação na interface VH/VL, na ligação ao antígeno ou na estrutura de CDR, as alterações de classe de aminoácido entre resíduos de murino e humanos, localização do resíduo na estrutura 3D do domínio variável, quatro dos vinte e dois diferentes resíduos foram identificados como tendo sofrido eventual mutação. Esses quatro resíduos definidos mais importantes e mutações em suas contrapartes humanas sendo L4 de murino para M humana, M39 para L, H40 para A e R84 para G. Esses resíduos classificados como um são mostrados na Figura 19B como resíduos em negrito na sequência HZ2VL de 224G11, onde eles permaneceram de murino.</span>[000355] With respect to several criteria, such as their participation in the VH / VL interface, in the binding to the antigen or in the CDR structure, changes in the amino acid class between murine and human residues, location of the residue in the 3D structure of the domain variable, four of the twenty-two different residues were identified as having undergone an eventual mutation. These four most important defined residues and mutations in their human counterparts being murine L4 for human M, M39 for L, H40 for A and R84 for G. These residues classified as one are shown in Figure 19B as residues in bold in the HZ2VL sequence of 224G11, where they remained a murine.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000356] Naturalmente, os resíduos mencionados acima a serem testados não são limitados, mas devem ser considerados como mutações preferenciais.</span>[000356] Naturally, the residues mentioned above to be tested are not limited, but must be considered as preferential mutations.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000357] Com o auxílio de um modelo molecular, outras mutações poderiam ser identificadas. Podem ser mencionados os seguintes resíduos classificados como dois, isto é, resíduos 25 (A/S), 66 (N/T), 67 (L/R), e 93 (P/S) sobre os quais mutações também poderiam ser consideradas em outra modalidade preferida.</span>[000357] With the aid of a molecular model, other mutations could be identified. The following residues classified as two can be mentioned, that is, residues 25 (A / S), 66 (N / T), 67 (L / R), and 93 (P / S) on which mutations could also be considered in another preferred embodiment.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000358] Naturalmente, os resíduos mencionados acima a serem eventualmente testados não são limitados, mas devem ser considerados como mutações preferenciais. Em outra modalidade preferida, todos os catorze outros resíduos classificados como três dentre os vinte e dois diferentes aminoácidos poderiam ser reconsiderados.</span>[000358] Naturally, the residues mentioned above to be tested are not limited, but should be considered as preferential mutations. In another preferred embodiment, all fourteen other residues classified as three out of twenty-two different amino acids could be reconsidered.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 98/146</span>Petition 870190095443, of 24/09/2019, p. 98/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">85/131 [000359] Todas as mutações mencionadas acima serão testadas individualmente ou de acordo com várias combinações.</span>85/131 [000359] All the mutations mentioned above will be tested individually or according to various combinations.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000360] A Figura 19B representa a VL de HGF humanizada baseada em IGKV4-1*01 implementada com as mutações mencionadas acima claramente identificadas. O número sob cada mutação proposta corresponde à classificação na qual a referida mutação será feita.</span>[000360] Figure 19B represents the humanized HGF VL based on IGKV4-1 * 01 implemented with the aforementioned mutations clearly identified. The number under each proposed mutation corresponds to the classification in which that mutation will be made.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">II - Humanização do domínio variável de cadeia pesada</span>II - Humanization of the heavy chain variable domain</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Comparação da sequência nucleotídica da VH de 224G11 aos genes de linhagem germinativa de murino [000361] Como uma etapa preliminar, a sequência nucleotídica da VH de 224G11 foi comparada às sequências dos genes de linhagem germinativa de murino, parte do banco de dados IMGT (http://imgt.cines.fr).</span>Comparison of the 224G11 VH nucleotide sequence to the murine germline genes [000361] As a preliminary step, the 224G11 VH nucleotide sequence was compared to the sequences of the murine germline genes, part of the IMGT database (http : //imgt.cines.fr).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000362] Genes de linhagem germinativa IGHV1-18*01, IGHD2-4*01 e IGHJ2*01 de murino com uma identidade de sequência de 92,70% para a região V, 75,00% para a região D e 89,36% para a região J, respectivamente, foram identificados. Com relação à identidade obtida, foi decidido usar diretamente as sequências de VH de 224G11 para buscar homologias humanas.</span>[000362] Murine IGHV1-18 * 01, IGHD2-4 * 01 and IGHJ2 * 01 germline genes with a sequence identity of 92.70% for region V, 75.00% for region D and 89, 36% for region J, respectively, were identified. Regarding the obtained identity, it was decided to directly use the 224G11 VH sequences to search for human homologies.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000363] Esses alinhamentos são representados nas Figura 20A para o gene V, 20B para o gene D e 20C para o gene J.</span>[000363] These alignments are represented in Figure 20A for gene V, 20B for gene D and 20C for gene J.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Comparação da sequência nucleotídica da VH de 224G11 aos genes de linhagem germinativa humana [000364] De forma a identificar o melhor candidato humano para a enxertagem de CDR, o gene de linhagem germinativa humana mostrando a melhor identidade com a VH de 224G11 foi buscado. Para essa finalidade, a sequência nucleotídica da VH de 224G11 foi alinhada às sequências do gene de linhagem germinativa humana, parte do banco de dados IMGT. Para otimização da seleção,</span>Comparison of the 224G11 VH nucleotide sequence with the human germline genes [000364] In order to identify the best human candidate for CDR grafting, the human germline gene showing the best identity with the 224G11 VH was sought. For this purpose, the 224G11 VH nucleotide sequence was aligned with the human germline gene sequences, part of the IMGT database. For optimization of the selection,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 99/146</span>Petition 870190095443, of 24/09/2019, p. 99/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">86/131 alinhamentos entre as sequências proteicas foram feitos para buscar melhores homologias.</span>86/131 alignments between protein sequences were made to seek better homologies.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000365] Esses dois métodos complementares levam à identificação da mesma sequência V IGHV1-2*02 receptora humana para a VH de murino de CDRs de 224G11 com uma identidade de sequência de 75,00% a nível nucleotídico e 64,30% a nível proteico.</span>[000365] These two complementary methods lead to the identification of the same human IGHV1-2 * 02 receptor sequence for murine VH of 224G11 CDRs with a sequence identity of 75.00% at the nucleotide level and 64.30% at the level protein.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000366] É notável que a região D pertence estritamente à região CDR3 no domínio VH. O processo de humanização é baseado em uma abordagem de enxertagem de CDR. Análise dos D-genes humanos mais próximos não é útil nessa estratégia.</span>[000366] It is notable that region D belongs strictly to the CDR3 region in the VH domain. The humanization process is based on a CDR grafting approach. Analysis of the closest human D-genes is not useful in this strategy.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000367] Buscas por homologias para a região J levam à identificação do gene de linhagem germinativa humana IGHJ4*04 com uma identidade de sequência de 78,72%.</span>[000367] Searches for homologies for the J region lead to the identification of the human germline gene IGHJ4 * 04 with a sequence identity of 78.72%.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000368] O gene de linhagem germinativa V humana IGHV1-2*02 e o gene de linhagem germinativa J humana IGHJ4*01 foram, assim, selecionados como sequências humanas receptoras para a VH de murino de CDRs de 224G11.</span>[000368] The human V germline gene IGHV1-2 * 02 and the human J germline gene IGHJ4 * 01 were thus selected as human human sequences for 224G11 CDR murine VH.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000369] Os alinhamentos são representados na Figura 21A para a região V e 21B para a região J.</span>[000369] The alignments are represented in Figure 21A for region V and 21B for region J.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Versão humanizada de VH de 224G11 [000370] As etapas seguintes no processo de humanização consistem em ligação das sequências de genes de linhagem germinativa selecionados IGHV1-2*02 e IGHJ4*01 e também das CDRs da VH de murino de 224G11 às frameworks dessas sequências de genes de linhagem germinativa.</span>Humanized version of 224G11 VH [000370] The next steps in the humanization process consist of linking the selected germline gene sequences IGHV1-2 * 02 and IGHJ4 * 01 and also the CDRs of the 224G11 murine VH to the frameworks of these sequences of germline genes.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000371] Conforme representado na Figura 22, os resíduos em negrito na sequência VH de 224G11 correspondem aos trinta aminoácidos que se verificou serem diferentes entre o domínio V de 224G11 e as frameworks humanas selecionadas (FR humana, isto é, IGHV1-2*02 e IGHJ4*01).</span>[000371] As shown in Figure 22, the residues in bold in the VH sequence of 224G11 correspond to the thirty amino acids that were found to be different between the V domain of 224G11 and the selected human frameworks (human FR, ie, IGHV1-2 * 02 and IGHJ4 * 01).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 100/146</span>Petition 870190095443, of 24/09/2019, p. 100/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">87/131 [000372] Com relação a vários critérios, tais como sua participação conhecida na interface VH/VL, na ligação a antígeno ou na estrutura da CDR, as alterações de classe de aminoácido entre resíduos de murino e humanos, localização do resíduo na estrutura 3D do domínio variável, quatro dos trinta diferentes resíduos foram identificados como tendo sofrido eventual mutação. Esses quatro resíduos definidos mais importantes e mutações em suas contrapartes humanas sendo D51 de murino para E humana, G55 para W, V80 para R e K82 para T. Esses resíduos classificados como um são mostrados na Figura 22 como resíduos em negrito na sequência HZVH de 224G11, onde eles permaneceram de murino. Naturalmente, os resíduos mencionados acima a serem testados não são limitados, mas devem ser considerados como mutações preferenciais.</span>87/131 [000372] Regarding several criteria, such as their known participation in the VH / VL interface, in the antigen binding or in the CDR structure, changes in the amino acid class between murine and human residues, location of the residue in the 3D structure of the variable domain, four of the thirty different residues were identified as having undergone eventual mutation. These four most important defined residues and mutations in their human counterparts being murine D51 for human E, G55 for W, V80 for R and K82 for T. These residues classified as one are shown in Figure 22 as residues in bold in the HZVH sequence of 224G11, where they remained a murine. Naturally, the residues mentioned above to be tested are not limited, but must be considered as preferential mutations.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000373] Com o auxílio de um modelo molecular, outras mutações poderiam ser identificadas. Podem ser mencionados os seguintes resíduos classificados como dois, isto é, resíduos 25 (T/A), 48 (E/Q), 49 (S/G), 53 (I/M), 76 (AV), 78 (L/M) e 90 (D/E) sobre os quais mutações também poderiam ser consideradas em outra modalidade preferida.</span>[000373] With the aid of a molecular model, other mutations could be identified. The following residues classified as two can be mentioned, that is, residues 25 (T / A), 48 (E / Q), 49 (S / G), 53 (I / M), 76 (AV), 78 (L / M) and 90 (D / E) on which mutations could also be considered in another preferred modality.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000374] Naturalmente, os resíduos mencionados acima a serem eventualmente testados não são limitados, mas devem ser considerados como mutações preferenciais. Em outra modalidade preferida, todos os dezenove outros resíduos classificados como três entre os trinta diferentes aminoácidos poderiam ser reconsiderados.</span>[000374] Of course, the residues mentioned above to be tested are not limited, but should be considered as preferential mutations. In another preferred embodiment, all nineteen other residues classified as three out of thirty different amino acids could be reconsidered.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000375] Todas as mutações mencionadas acima serão testadas individualmente ou de acordo com várias combinações.</span>[000375] All the mutations mentioned above will be tested individually or according to various combinations.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000376] A Figura 22 representa a VH humanizada de 224G11 com as mutações mencionadas acima claramente identificadas. O número sob cada mutação proposta corresponde à classificação na qual a referida mutação será feita.</span>[000376] Figure 22 represents the humanized HV of 224G11 with the mutations mentioned above clearly identified. The number under each proposed mutation corresponds to the classification in which that mutation will be made.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 101/146</span>Petition 870190095443, of 24/09/2019, p. 101/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">88/131</span>88/131</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 13: processo de humanização através de enxertagem de CDR do anticorpo 227H1</span>Example 13: humanization process through 227H1 antibody CDR grafting</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I - Humanização do domínio variável de cadeia leve Comparação da sequência nucleotídica da VL de 227H1 aos genes de linhagem germinativa de murino [000377] Como uma etapa preliminar, a sequência nucleotídica da VL de 227H1 foi comparada às sequências dos genes de linhagem germinativa de murino, parte do banco de dados IMGT (http://im.gt. cines.fr).</span>I - Humanization of the light chain variable domain Comparison of the nucleotide sequence of the 227H1 VL to the murine germline genes [000377] As a preliminary step, the nucleotide sequence of the 227H1 VL was compared to the sequences of the murine germline genes , part of the IMGT database (http://im.gt. cines.fr).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000378] Genes de linhagem germinativa de murino IGKV3-5*01 e IGKJ4*01 com uma identidade de sequência de 96,90% para a região V e 97,29% para a região J, respectivamente, foram identificados. Com relação à identidade obtida, foi decidido usar diretamente as sequências de VL de 227H1 para buscar homologias humanas.</span>[000378] Murine germline genes IGKV3-5 * 01 and IGKJ4 * 01 with a sequence identity of 96.90% for region V and 97.29% for region J, respectively, were identified. Regarding the obtained identity, it was decided to use the 227H1 VL sequences directly to search for human homologies.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000379] Esses alinhamentos são representados nas Figuras 23A para o gene V e 23B para o gene J.</span>[000379] These alignments are represented in Figures 23A for gene V and 23B for gene J.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Comparação da sequência nucleotídica da VL de 227H1 aos genes de linhagem germinativa humana [000380] De forma a identificar o melhor candidato humano para a enxertagem de CDR, o gene de linhagem germinativa humana mostrando a melhor identidade com a VL de 227H1 foi buscado. Para essa finalidade, a sequência nucleotídica da VL de 227H1 foi alinhada com as sequências do gene de linhagem germinativa humana, parte do banco de dados IMGT. Para otimização da seleção, alinhamentos entre as sequências proteicas foram feitos para buscar melhores homologias.</span>Comparison of the nucleotide sequence of the 227H1 VL to the human germline genes [000380] In order to identify the best human candidate for CDR grafting, the human germline gene showing the best identity with the 227H1 VL was sought. For this purpose, the nucleotide sequence of the 227H1 VL was aligned with the sequences of the human germline gene, part of the IMGT database. To optimize the selection, alignments between protein sequences were made to seek better homologies.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000381] Esses dois métodos complementares levam à identificação duas possíveis sequências V humanas receptoras para a VL de murino de CDRs de 227H1. Alinhamento nucleotídico proporciona o gene de linhagem germinativa humana IGKV3-11*01 com uma</span>[000381] These two complementary methods lead to the identification of two possible human V sequences that are receptors for the murine VL of 227H1 CDRs. Nucleotide alignment provides the human germline gene IGKV3-11 * 01 with a</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 102/146</span>Petition 870190095443, of 24/09/2019, p. 102/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">89/131 identidade de sequência de 74,91%, enquanto que alinhamento proteico proporciona o gene de linhagem germinativa humana IGKV41*01, com uma identidade de sequência de 64,00%. É notável que, em ambos os casos, os dois genes de linhagem germinativa mais próximos e as sequências analisadas mostrem diferentes comprimentos de aminoácido da CDR1 (10 aminoácidos na VL de 227H1; 6 aminoácidos em IGKV3-11*01; 12 aminoácidos em IGKV41*01).</span>89/131 sequence identity of 74.91%, while protein alignment provides the human germline gene IGKV41 * 01, with a sequence identity of 64.00%. It is notable that, in both cases, the two closest germline genes and the sequences analyzed show different lengths of CDR1 amino acid (10 amino acids in VL of 227H1; 6 amino acids in IGKV3-11 * 01; 12 amino acids in IGKV41 * 01).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000382] Para a região J, o melhor escore de homologia foi primeiro obtido com o IGKJ3*01 humano mostrando uma identidade de sequência de 78,38%. Mas um maior número de nucleotídeos consecutivos idênticos e uma melhor adaptação de aminoácido foram encontrados no alinhamento com o gene de linhagem germinativa humana IGKJ4*02 (identidade de sequência de 75,68%). Assim, o gene de linhagem germinativa IGKJ4*02 foi selecionado como região J humana receptora para a VL de murino de CDRs de 227H1.</span>[000382] For region J, the best homology score was first obtained with the human IGKJ3 * 01 showing a sequence identity of 78.38%. But a greater number of consecutive identical nucleotides and a better adaptation of the amino acid were found in alignment with the human germline gene IGKJ4 * 02 (sequence identity 75.68%). Thus, the germline gene IGKJ4 * 02 was selected as the recipient human J region for the murine VL of 227H1 CDRs.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000383] Os alinhamentos são representados na Figuras 24A para a região V e 24B para a região J.</span>[000383] The alignments are represented in Figures 24A for region V and 24B for region J.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Versão humanizada de VL de 224G11 [000384] Dada a possibilidade de duas regiões V humanas receptoras para a VL de murino de CDRs de 227H1, duas versões humanizadas do domínio VL de 227H1 serão descritas. A primeira corresponde a um experimento inicial para uma estrutura principal humana com um comprimento de CDR1 mais curto (IGKV3-11*01), a segunda com um comprimento de CDR1 mais longo (IGKV4-1*01).</span>Humanized version of 224G11 VL [000384] Given the possibility of two human V regions that are receptors for the murine VL of 227H1 CDRs, two humanized versions of the 227H1 VL domain will be described. The first corresponds to an initial experiment for a human main structure with a shorter CDR1 length (IGKV3-11 * 01), the second with a longer CDR1 length (IGKV4-1 * 01).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">a) Versão humanizada de VL de 227H1 baseada em IGKV3-11 *01 [000385] As etapas seguintes no processo de humanização consistem em ligação das sequências de genes de linhagem germinativa selecionados IGKV3-11*01 e IGKJ4*02 e também das</span>a) Humanized version of 227H1 VL based on IGKV3-11 * 01 [000385] The following steps in the humanization process consist of linking the selected germline gene sequences IGKV3-11 * 01 and IGKJ4 * 02 and also the</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 103/146</span>Petition 870190095443, of 24/09/2019, p. 103/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">90/131</span>90/131</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CDRs da VL de murino de 227H1 às frameworks dessas sequências de genes de linhagem germinativa.</span>CDRs of the 227H1 murine VL to the frameworks of these germline gene sequences.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000386] Conforme representado na Figura 25A, os resíduos em negrito na sequência VL de 227H1 correspondem aos vinte e seis aminoácidos que se verificou serem diferentes entre o domínio VL de 227H1 e as frameworks humanas selecionadas (FR humana, isto é, IGKV3-11*01 e IGKJ4*02).</span>[000386] As shown in Figure 25A, the residues in bold in the 227H1 VL sequence correspond to the twenty-six amino acids that were found to be different between the 227H1 VL domain and the selected human frameworks (human FR, ie IGKV3-11 * 01 and IGKJ4 * 02).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000387] Com relação a vários critérios, tais como sua participação conhecida na interface VH/VL, na ligação a antígeno ou na estrutura da CDR, as alterações de classe de aminoácido entre resíduos de murino e humanos, localização do resíduo na estrutura 3D do domínio variável, três dos vinte e seis diferentes resíduos foram identificados como tendo sofrido eventual mutação. Esses três resíduos definidos mais importantes e mutações em suas contrapartes humanas sendo I39 de murino para L humana, H40 para A e R84 para G. Esses resíduos classificados como um são mostrados na Figura 25A como resíduos em negrito na sequência HZ1VL de 227H1, onde eles permaneceram de murino.</span>[000387] With respect to several criteria, such as their known participation in the VH / VL interface, in the antigen binding or in the CDR structure, the changes in the amino acid class between murine and human residues, location of the residue in the 3D structure of the variable domain, three of the twenty-six different residues were identified as having undergone an eventual mutation. These three most important defined residues and mutations in their human counterparts being I39 from murine to human L, H40 to A and R84 to G. These residues classified as one are shown in Figure 25A as residues in bold in the HZ1VL sequence of 227H1, where they remained murine.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000388] Naturalmente, os resíduos mencionados acima a serem testados não são limitados, mas devem ser considerados como mutações preferenciais.</span>[000388] Of course, the residues mentioned above to be tested are not limited, but should be considered as preferential mutations.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000389] Com o auxílio de um modelo molecular, outras mutações poderiam ser identificadas. Podem ser mencionados os seguintes resíduos classificados como dois, isto é, resíduos 15 (L/P), 25 (V/A), 49 (P/A), 67 (L/R), 68 (E/A), 93 (P/S) e 99 (S/F) sobre os quais mutações também poderiam ser consideradas em outra modalidade preferida.</span>[000389] With the aid of a molecular model, other mutations could be identified. The following waste classified as two can be mentioned, that is, waste 15 (L / P), 25 (V / A), 49 (P / A), 67 (L / R), 68 (E / A), 93 (P / S) and 99 (S / F) on which mutations could also be considered in another preferred modality.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000390] Naturalmente, os resíduos mencionados acima a serem eventualmente testados não são limitados, mas devem ser considerados como mutações preferenciais. Em outra modalidade</span>[000390] Naturally, the residues mentioned above to be tested are not limited, but must be considered as preferential mutations. In another modality</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 104/146</span>Petition 870190095443, of 24/09/2019, p. 104/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">91/131 preferida, todos os dezesseis outros resíduos classificados como três dentre os vinte e cinco diferentes aminoácidos poderiam ser reconsiderados.</span>91/131 preferred, all sixteen other residues classified as three out of twenty-five different amino acids could be reconsidered.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000391] Todas as mutações mencionadas acima serão testadas individualmente ou de acordo com várias combinações.</span>[000391] All the mutations mentioned above will be tested individually or according to various combinations.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000392] Figura 25A representa a VL humanizada de 227H1 baseada em IGKV3-11*01 implementada com as mutações mencionadas acima claramente identificadas. O número sob cada mutação proposta corresponde à classificação na qual a referida mutação será feita.</span>[000392] Figure 25A represents the humanized VL of 227H1 based on IGKV3-11 * 01 implemented with the mutations mentioned above clearly identified. The number under each proposed mutation corresponds to the classification in which that mutation will be made.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">b) Versão humanizada de VL de 227H1 baseada em IGKV4-1 *01 [000393] As etapas seguintes no processo de humanização consistem em ligação das sequências de genes de linhagem germinativa selecionados IGKV4-1*01 e IGKJ4*02 e também das CDRs da VL de murino de 227H1 às frameworks dessas sequências de genes de linhagem germinativa.</span>b) Humanized version of 227H1 VL based on IGKV4-1 * 01 [000393] The next steps in the humanization process consist of linking the selected germline gene sequences IGKV4-1 * 01 and IGKJ4 * 02 and also the CDRs of the Murine VL of 227H1 to the frameworks of these germline gene sequences.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000394] Conforme representado na Figura 25B, os resíduos em negrito na sequência VL de 227H1 correspondem aos vinte e quatro aminoácidos que se verificou serem diferentes entre o domínio VL de 227H1 e as frameworks humanas selecionadas (FR humana, isto é, IGKV4-1*01 e IGKJ4*02).</span>[000394] As shown in Figure 25B, the residues in bold in the 227H1 VL sequence correspond to the twenty-four amino acids that were found to be different between the 227H1 VL domain and the selected human frameworks (human FR, ie IGKV4-1 * 01 and IGKJ4 * 02).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000395] Com relação a vários critérios, tais como sua participação conhecida in VH/VL 2 0 interface, na ligação a antígeno ou na estrutura da CDR, as alterações de classe de aminoácido entre resíduos de murino e humanos, localização do resíduo na estrutura 3D do domínio variável, quatro dos vinte e quatro diferentes resíduos foram identificados como tendo sofrido eventual mutação. Esses quatro resíduos definidos mais importantes e mutações em suas contrapartes humanas sendo L4 de murino para M humana, 139 para</span>[000395] With respect to several criteria, such as their known participation in VH / VL 2 0 interface, in the antigen binding or in the CDR structure, the changes in amino acid class between murine and human residues, location of the residue in the structure 3D of the variable domain, four of the twenty-four different residues were identified as having undergone an eventual mutation. Those four most important defined residues and mutations in their human counterparts being L4 from murine to human M, 139 to</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 105/146</span>Petition 870190095443, of 24/09/2019, p. 105/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">92/131</span>92/131</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">L, H40 para A e R84 para G. Esses resíduos classificados como um são mostrados na Figura 25B como resíduos em negrito na sequência</span>L, H40 for A and R84 for G. These residues classified as one are shown in Figure 25B as residues in bold in the sequence</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">HZ2VL de 227H1, onde eles permaneceram de murino.</span>227H1 HZ2VL, where they remained murine.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000396] Naturalmente, os resíduos mencionados acima a serem testados não são limitados, mas devem ser considerados como mutações preferenciais.</span>[000396] Naturally, the residues mentioned above to be tested are not limited, but must be considered as preferential mutations.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000397] Com o auxílio de um modelo molecular, outras mutações poderiam ser identificadas. Podem ser mencionados os seguintes resíduos classificados como dois, isto é, resíduos 25 (V/S), 66 (N/T), 67 (L/R), e 93 (P/S) sobre os quais mutações também poderiam ser consideradas em outra modalidade preferida.</span>[000397] With the aid of a molecular model, other mutations could be identified. The following residues classified as two can be mentioned, that is, residues 25 (V / S), 66 (N / T), 67 (L / R), and 93 (P / S) on which mutations could also be considered in another preferred embodiment.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000398] Naturalmente, os resíduos mencionados acima a serem eventualmente testados não são limitados, mas devem ser considerados como mutações preferenciais. Em outra modalidade preferida, todos os dezesseis outros resíduos classificados como três dentre os vinte e dois diferentes aminoácidos poderiam ser reconsiderados.</span>[000398] Of course, the residues mentioned above to be tested are not limited, but should be considered as preferential mutations. In another preferred embodiment, all sixteen other residues classified as three out of twenty-two different amino acids could be reconsidered.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000399] Todas as mutações mencionadas acima serão testadas individualmente ou de acordo com várias combinações.</span>[000399] All the mutations mentioned above will be tested individually or according to various combinations.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000400] Figura 25B representa a VL humanizada de 227H1 baseada em IGKV4-1*01 implementada com as mutações mencionadas acima claramente identificadas. O número sob cada mutação proposta corresponde à classificação na qual a referida mutação será feita.</span>[000400] Figure 25B represents the humanized VL of 227H1 based on IGKV4-1 * 01 implemented with the mutations mentioned above clearly identified. The number under each proposed mutation corresponds to the classification in which that mutation will be made.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">II - Humanização do domínio variável de cadeia pesada Comparação da sequência nucleotídica da VH de 227H1 aos genes de linhagem germinativa de murino [000401] Como uma etapa preliminar, a sequência nucleotídica da VH de 227H1 foi comparada às sequências dos genes de linhagem germinativa de murino, parte do banco de dados IMGT</span>II - Humanization of the heavy chain variable domain Comparison of the 227H1 VH nucleotide sequence to the murine germline genes [000401] As a preliminary step, the 227H1 VH nucleotide sequence was compared to the sequences of the murine germline genes , part of the IMGT database</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 106/146</span>Petition 870190095443, of 24/09/2019, p. 106/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">93/131 (http://imgt.cines.fr).</span>93/131 (http://imgt.cines.fr).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000402] Genes de linhagem germinativa de murino IGHV1-18*01, IGHD1-1*02 e IGHJ2*01 com uma identidade de sequência de 92,70% para a região V, 63,63% para a região D e 91,48% para a região J, respectivamente, foram identificados. Com relação à identidade obtida, foi decidido usar diretamente as sequências VH de 227H1 para buscar homologias humanas.</span>[000402] Murine germline genes IGHV1-18 * 01, IGHD1-1 * 02 and IGHJ2 * 01 with a sequence identity of 92.70% for region V, 63.63% for region D and 91, 48% for region J, respectively, were identified. Regarding the obtained identity, it was decided to directly use the 227H1 VH sequences to search for human homologies.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000403] Esses alinhamentos são representados nas Figuras 26A para o gene V, 26B para o gene D e 26C para o gene J.</span>[000403] These alignments are represented in Figures 26A for gene V, 26B for gene D and 26C for gene J.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Comparação da sequência nucleotídica da VH de 227H1 aos genes de linhagem germinativa humana [000404] De forma a identificar o melhor candidato humano para a enxertagem de CDR, o gene de linhagem germinativa humana mostrando a melhor identidade com a VH de 224G11 foi buscado. Para essa finalidade, a sequência nucleotídica da VH de 227H1 foi alinhada às sequências do gene de linhagem germinativa humana, parte do banco de dados IMGT. A sequência V receptora humana IGHV1-2*02 para uma VH de murino de CDRs de 224G11 com uma identidade de sequência de 72,92% foi, assim, identificada.</span>Comparison of the 227H1 VH nucleotide sequence to the human germline genes [000404] In order to identify the best human candidate for CDR grafting, the human germline gene showing the best identity with the 224G11 VH was sought. For this purpose, the 227H1 VH nucleotide sequence was aligned with the human germline gene sequences, part of the IMGT database. The human receptor V sequence IGHV1-2 * 02 for a murine VH of 224G11 CDRs with a sequence identity of 72.92% was thus identified.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000405] É notável que a região D pertence estritamente à região CDR3 no domínio VH. O processo de humanização é baseado em uma abordagem de enxertagem de CDR. Análise dos D-genes humanos mais próximos não é útil nessa estratégia.</span>[000405] It is notable that the D region belongs strictly to the CDR3 region in the VH domain. The humanization process is based on a CDR grafting approach. Analysis of the closest human D-genes is not useful in this strategy.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000406] Buscas por homologias para a região J levam à identificação do gene de linhagem germinativa humana IGHJ4*01 com uma identidade de sequência de 78,72%.</span>[000406] Searches for homologies for the J region lead to the identification of the human germline gene IGHJ4 * 01 with a sequence identity of 78.72%.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000407] O gene de linhagem germinativa V humana IGHV1-2*02 e o gene de linhagem germinativa J humana IGHJ4*01 foram, assim, selecionados como sequências humanas receptoras para a VH de murino de CDRs de 227H1.</span>[000407] The human V germline gene IGHV1-2 * 02 and the human J germline gene IGHJ4 * 01 were thus selected as human receptor sequences for the murine VH of 227H1 CDRs.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 107/146</span>Petition 870190095443, of 24/09/2019, p. 107/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">94/131 [000408] Os alinhamentos são representados na Figuras 27A para a região V e 27B para a região J.</span>94/131 [000408] The alignments are shown in Figures 27A for region V and 27B for region J.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000409] Para otimização da seleção, aqueles versados na técnica também poderiam fazer alinhamentos entre as sequências proteicas de forma a auxiliá-los na escolha.</span>[000409] To optimize the selection, those versed in the technique could also make alignments between the protein sequences in order to assist them in choosing.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Versão humanizada de VH de 227H1 [000410] As etapas seguintes no processo de humanização consistem em ligação das sequências de genes de linhagem germinativa selecionados IGHV1-2*02 e IGHJ4*01 e também das CDRs da VH de murino de 227H1 às frameworks dessas sequências de genes de linhagem germinativa.</span>Humanized version of 227H1 VH [000410] The next steps in the humanization process consist of linking the selected germline gene sequences IGHV1-2 * 02 and IGHJ4 * 01 and also the 227H1 murine VH CDRs to the frameworks of these sequences of germline genes.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000411] Conforme representado na Figura 28, os resíduos em negrito na sequência VH de 227H1 correspondem aos trinta e dois aminoácidos que se verificou serem diferentes entre o domínio VH de 227H1 e as frameworks humanas selecionadas (FR humana, isto é, IGHV1-2*02 e IGHJ4*01).</span>[000411] As shown in Figure 28, the residues in bold in the 227H1 VH sequence correspond to the thirty-two amino acids that were found to be different between the 227H1 VH domain and the selected human frameworks (human FR, ie, IGHV1-2 * 02 and IGHJ4 * 01).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000412] Com relação a vários critérios, tais como sua participação conhecida na interface VH/VL, na ligação a antígeno ou na estrutura da CDR, as alterações de classe de aminoácido entre resíduos de murino e humanos, localização do resíduo na estrutura 3D do domínio variável, seis dos trinta e dois diferentes resíduos foram identificados como tendo sofrido eventual mutação. Esses seis resíduos definidos mais importantes e mutações em suas contrapartes humanas sendo L39 de murino para M humana, N40 para H, L55 para W, T66 para N, V80 para R e K82 para T. Esses resíduos classificados como um são mostrados na Figura 28 como resíduos em negrito na sequência HZVH de 227H1, onde eles permaneceram de murino.</span>[000412] Regarding several criteria, such as their known participation in the VH / VL interface, in the antigen binding or in the CDR structure, changes in the amino acid class between murine and human residues, location of the residue in the 3D structure of the variable domain, six of the thirty-two different residues were identified as having undergone an eventual mutation. These six most important defined residues and mutations in their human counterparts being L39 from murine to human M, N40 to H, L55 to W, T66 to N, V80 to R and K82 to T. These residues classified as one are shown in Figure 28 as residues in bold in the 227H1 HZVH sequence, where they remained murine.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000413] Naturalmente, os resíduos mencionados acima a serem testados não são limitados, mas devem ser considerados como mutações preferenciais.</span>[000413] Naturally, the residues mentioned above to be tested are not limited, but must be considered as preferential mutations.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 108/146</span>Petition 870190095443, of 24/09/2019, p. 108/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">95/131 [000414] Com o auxílio de um modelo molecular, outras mutações poderiam ser identificadas. Podem ser mencionados os seguintes resíduos classificados como dois, isto é, resíduos 48 (K/Q), 49 (T/G), (I/M), 76 (A/V) e 78 (L/M) sobre os quais mutações também poderiam ser consideradas em outra modalidade preferida.</span>95/131 [000414] With the aid of a molecular model, other mutations could be identified. The following wastes classified as two can be mentioned, that is, wastes 48 (K / Q), 49 (T / G), (I / M), 76 (A / V) and 78 (L / M) on which mutations could also be considered in another preferred modality.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000415] Naturalmente, os resíduos mencionados acima a serem eventualmente testados não são limitados, mas devem ser considerados como mutações preferenciais. Em outra modalidade preferida, todos os vinte e um outros resíduos classificados como três entre os trinta diferentes aminoácidos poderiam ser reconsiderados.</span>[000415] Of course, the residues mentioned above to be tested are not limited, but should be considered as preferential mutations. In another preferred embodiment, all twenty-one other residues classified as three out of thirty different amino acids could be reconsidered.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000416] Todas as mutações mencionadas acima serão testadas individualmente ou de acordo com várias combinações.</span>[000416] All of the mutations mentioned above will be tested individually or according to various combinations.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000417] Figura 28 representa a VH humanizada de 227H1 com as mutações mencionadas acima claramente identificadas. O número sob cada mutação proposta corresponde à classificação na qual a referida mutação será feita.</span>[000417] Figure 28 represents the humanized VH of 227H1 with the mutations mentioned above clearly identified. The number under each proposed mutation corresponds to the classification in which that mutation will be made.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 14: processo de humanização através de enxertagem de CDR do anticorpo 223C4</span>Example 14: humanization process through 223C4 antibody CDR grafting</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I - Humanização do domínio variável de cadeia leve</span>I - Humanization of the light chain variable domain</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Comparação da sequência nucleotídica da VL de 223C4 aos genes de linhagem germinativa de murino [000418] Como uma etapa preliminar, a sequência nucleotídica da VL de 223C4 foi comparada às sequências de genes de linhagem germinativa de murino, parte do banco de dados IMGT (http://imgt.cines.fr).</span>Comparison of the 223C4 VL nucleotide sequence to murine germline genes [000418] As a preliminary step, the 223C4 VL nucleotide sequence was compared to the murine germline gene sequences, part of the IMGT database (http : //imgt.cines.fr).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000419] Genes de linhagem germinativa de murino IGKV12-46*01 e IGKJ2*01 com uma identidade de sequência de 99,64% para a região V e 94,59% para a região J, respectivamente, foram identificados. Com relação à identidade obtida, foi decidido usar diretamente as sequências VL de 223C4 para buscar homologias humanas.</span>[000419] Murine germline genes IGKV12-46 * 01 and IGKJ2 * 01 with a sequence identity of 99.64% for region V and 94.59% for region J, respectively, were identified. Regarding the obtained identity, it was decided to directly use the 223C4 VL sequences to search for human homologies.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 109/146</span>Petition 870190095443, of 24/09/2019, p. 109/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">96/131 [000420] Esses alinhamentos são representados nas Figuras 29A para o gene V e 29B para o gene J.</span>96/131 [000420] These alignments are represented in Figures 29A for gene V and 29B for gene J.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Comparação da sequência nucleotídica da VL de 223C4 aos genes de linhagem germinativa humana [000421] De forma a identificar o melhor candidato humano para a enxertagem de CDR, o gene de linhagem germinativa humana mostrando a melhor identidade com a VL de 223C4 foi buscado. Para essa finalidade, a sequência nucleotídica da VL de 223C4 foi alinhada às sequências do gene de linhagem germinativa humana, parte do banco de dados IMGT.</span>Comparison of the nucleotide sequence of the 223C4 VL to the human germline genes [000421] In order to identify the best human candidate for CDR grafting, the human germline gene showing the best identity with the 223C4 VL was sought. For this purpose, the nucleotide sequence of the 223C4 VL was aligned with the sequences of the human germline gene, part of the IMGT database.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000422] Genes de linhagem germinativa humana IGKV1-NL1*01 e IGKJ2*01 com uma identidade de sequência de 78,49% para a região V e 81,08% para a região J, respectivamente, foram identificados. Os genes de linhagem germinativa IGKV1-NL1*01 para a região V e IGKJ2*01 para a região J foram, assim, selecionados como sequências humanas receptoras para a VL de murino de CDRs de 223C4.</span>[000422] Human germline genes IGKV1-NL1 * 01 and IGKJ2 * 01 with a sequence identity of 78.49% for region V and 81.08% for region J, respectively, have been identified. The germline genes IGKV1-NL1 * 01 for region V and IGKJ2 * 01 for region J were thus selected as human sequences for the murine VL of 223C4 CDRs.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000423] Os alinhamentos são representados na Figuras 30A para a região V e 3OB para a região J.</span>[000423] The alignments are represented in Figures 30A for region V and 3OB for region J.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000424] Para otimização da seleção, aqueles versados na técnica também poderiam fazer alinhamentos entre as sequências proteicas de forma a auxiliá-los na escolha.</span>[000424] To optimize the selection, those versed in the technique could also make alignments between the protein sequences in order to assist them in choosing.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Versão humanizada de VL de 223C4 [000425] As etapas seguintes no processo de humanização consistem em ligação das sequências de genes de linhagem germinativa selecionados IGKV1-NL1*01 e IGKJ2*01 e também das CDRs da VL de murino de 223C4 às frameworks dessas sequências de genes de linhagem germinativa.</span>Humanized version of 223C4 VL [000425] The next steps in the humanization process consist of linking the selected germline gene sequences IGKV1-NL1 * 01 and IGKJ2 * 01 and also the CDRs of the 223C4 murine VL to the frameworks of these sequences of germline genes.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000426] Nesse estágio do processo, um modelo molecular dos domínios Fv de 223C4 de murino poderia ser desenvolvido e é útil na</span>[000426] At this stage of the process, a molecular model of the murine 223C4 Fv domains could be developed and is useful in</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 110/146</span>Petition 870190095443, of 24/09/2019, p. 110/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">97/131 escolha dos resíduos de murino a serem conservados em virtude de seus papéis na manutenção da estrutura tridimensional da molécula ou no sítio de ligação a antígeno e função. Mais particularmente, 9 resíduos que sofreram eventual mutação foram identificados.</span>97/131 choice of murine residues to be conserved due to their role in maintaining the molecule's three-dimensional structure or at the antigen-binding site and function. More particularly, 9 residues that have been mutated have been identified.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000427] Em uma primeira etapa, resíduos envolvidos nas âncoras ou estrutura de CDR serão testados. Tais resíduos são os resíduos 66 (R/N) e resíduo 68 (E/V).</span>[000427] In a first step, residues involved in the anchors or CDR structure will be tested. Such residues are residues 66 (R / N) and residue 68 (E / V).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000428] Em uma segunda etapa, resíduos expostos a solvente e, como tal, que também podem estar envolvidos em imunogenicidade, também serão testados. Esses são os resíduos 49 (A/S), 51 (K/Q), 69 (S/D), 86 (D/Q) e 92 (S/N).</span>[000428] In a second stage, residues exposed to solvent and, as such, which may also be involved in immunogenicity, will also be tested. These are residues 49 (A / S), 51 (K / Q), 69 (Y / D), 86 (D / Q) and 92 (Y / N).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000429] Então, em uma terceira etapa, resíduos envolvidos na estrutura/duplicação do domínio variável também poderiam sofrer mutação. Esses resíduos são os resíduos 46 (P/Q) e o resíduo 96 (P/S).</span>[000429] Then, in a third stage, residues involved in the structure / duplication of the variable domain could also undergo mutation. These residues are residues 46 (P / Q) and residue 96 (P / S).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000430] Naturalmente, os resíduos mencionados acima a serem testados não são limitados, mas devem ser considerados como mutações preferenciais.</span>[000430] Naturally, the residues mentioned above to be tested are not limited, but must be considered as preferential mutations.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000431] Com o auxílio de um modelo molecular, outras mutações poderiam ser identificadas. Podem ser mencionados os seguintes resíduos, isto é, resíduos 9 (S/A), 13 (A/V), 17 (D/E), 18 (R/T), 54 (L/V), 88 (T/S), 90 (T/K), 100 (A/G) e 101 (T/S), sobre os quais mutações também poderiam ser consideradas em outra modalidade preferida.</span>[000431] With the aid of a molecular model, other mutations could be identified. The following residues can be mentioned, that is, residues 9 (S / A), 13 (A / V), 17 (D / E), 18 (R / T), 54 (L / V), 88 (T / S), 90 (T / K), 100 (A / G) and 101 (T / S), on which mutations could also be considered in another preferred modality.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000432] Todas as mutações mencionadas acima serão testadas individualmente ou de acordo com várias combinações.</span>[000432] All the mutations mentioned above will be tested individually or according to various combinations.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000433] Figura 31 representa a VL humanizada de 223C4 com as mutações mencionadas acima claramente identificadas. O número sob cada mutação proposta corresponde à classificação na qual a referida mutação será feita.</span>[000433] Figure 31 represents the humanized VL of 223C4 with the mutations mentioned above clearly identified. The number under each proposed mutation corresponds to the classification in which that mutation will be made.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 111/146</span>Petition 870190095443, of 24/09/2019, p. 111/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">98/131</span>98/131</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">II - Humanização do domínio variável de cadeia pesada Comparação da sequência nucleotídica da VH de 223C4 aos genes de linhagem germinativa de murino [000434] Como uma etapa preliminar, a sequência nucleotídica da VH de 223C4 foi comparada às sequências dos genes de linhagem germinativa de murino, parte do banco de dados IMGT (http://imgt.cines.fr).</span>II - Humanization of the heavy chain variable domain Comparison of the 223C4 VH nucleotide sequence to the murine germline genes [000434] As a preliminary step, the 223C4 VH nucleotide sequence was compared to the sequences of the murine germline genes , part of the IMGT database (http://imgt.cines.fr).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000435] Os genes de linhagem germinativa de murino IGHV1 -18*01, IGHD6-3*01 e IGHJ4*01 com uma identidade de sequência de 98,95% para a região V, 72,72% para a região D e 98,11% para a região J, respectivamente, foram identificados. Com relação à identidade obtida, foi decidido usar diretamente as sequências de VH de 223C4 para buscar homologias humanas.</span>[000435] The murine germline genes IGHV1 -18 * 01, IGHD6-3 * 01 and IGHJ4 * 01 with a sequence identity of 98.95% for region V, 72.72% for region D and 98 , 11% for region J, respectively, were identified. Regarding the obtained identity, it was decided to directly use the 223C4 VH sequences to search for human homologies.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000436] Esses alinhamentos são representados nas Figuras 32A para o gene V, 32B para o gene D e 32C para o gene J.</span>[000436] These alignments are represented in Figures 32A for gene V, 32B for gene D and 32C for gene J.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Comparação da sequência nucleotídica da VH de 223C4 aos genes de linhagem germinativa humana [000437] De forma a identificar o melhor candidato humano para a enxertagem de CDR, o gene de linhagem germinativa humana mostrando a melhor identidade com a VH de 223C4 foi buscado. Para essa finalidade, a sequência nucleotídica da VH de 223C4 foi alinhada às sequências do gene de linhagem germinativa humana, parte do banco de dados IMGT. Os genes de linhagem germinativa humana IGHV1-2*02, IGHD1-26*01 e IGHJ6*01 com uma identidade de sequência de 76,38% para a região V, 75,00% para a região D e 77,41% para a região J, respectivamente, foram identificados. Os genes de linhagem germinativa IGHV1-2*02 para a região V e IGHJ6*01 para a região J foram, assim, selecionados como sequências humanas receptoras para as CDRs de VH de murino de 223C4.</span>Comparison of the 223C4 VH nucleotide sequence to the human germline genes [000437] In order to identify the best human candidate for CDR grafting, the human germline gene showing the best identity with the 223C4 VH was sought. For this purpose, the 223C4 VH nucleotide sequence was aligned to the human germline gene sequences, part of the IMGT database. The human germline genes IGHV1-2 * 02, IGHD1-26 * 01 and IGHJ6 * 01 with a sequence identity of 76.38% for region V, 75.00% for region D and 77.41% for region J, respectively, were identified. The germline genes IGHV1-2 * 02 for region V and IGHJ6 * 01 for region J were thus selected as human receptor sequences for 223C4 murine VH CDRs.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 112/146</span>Petition 870190095443, of 24/09/2019, p. 112/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">99/131 [000438] Os alinhamentos são representados na Figuras 33A para a região V, 33B para a região D e 33C para a região J.</span>99/131 [000438] The alignments are represented in Figures 33A for region V, 33B for region D and 33C for region J.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000439] Para otimização da seleção, aqueles versados na técnica também poderiam fazer alinhamentos entre as sequências proteicas de forma a auxiliá-los na escolha.</span>[000439] To optimize the selection, those versed in the technique could also make alignments between the protein sequences in order to assist them in choosing.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Versão humanizada de VH de 223C4 [000440] As etapas seguintes no processo de humanização consistem em ligação das sequências de genes de linhagem germinativa selecionados IGHV1-2*02 e IGHJ6*01 e também das CDRs da VH de 223C4 de murino às frameworks dessas sequências de genes de linhagem germinativa.</span>Humanized version of 223C4 VH [000440] The following steps in the humanization process consist of linking the selected germline gene sequences IGHV1-2 * 02 and IGHJ6 * 01 and also the murine 223C4 VH CDRs to the frameworks of these sequences of germline genes.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000441] Nesse estágio do processo, um modelo molecular dos domínios Fv de 223C4 de murino poderia ser desenvolvido e é útil na escolha dos resíduos de murino a serem conservados em virtude de seus papéis na manutenção da estrutura tridimensional da molécula ou no sítio de ligação a antígeno e função. Mais particularmente, 14 resíduos como tendo sofrido eventual mutação foram identificados.</span>[000441] At this stage of the process, a molecular model of the murine 223C4 Fv domains could be developed and is useful in choosing the murine residues to be conserved due to their role in maintaining the three-dimensional structure of the molecule or at the binding site the antigen and function. More particularly, 14 residues that have been mutated have been identified.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000442] Em uma primeira etapa, resíduos envolvidos nas âncoras ou estrutura de CDR serão testados. Tais resíduos são os resíduos 40 (H/D), 45 (A/S), 55 (W/D), 66 (N/I) e 67 (Y/F).</span>[000442] In a first step, residues involved in the anchors or CDR structure will be tested. Such residues are residues 40 (H / D), 45 (A / S), 55 (W / D), 66 (N / I) and 67 (Y / F).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000443] Em uma segunda etapa, resíduos expostos a solvente e, como tal, que também podem estar envolvidos em imunogenicidade, também serão testados. Esses são os resíduos 1 (Q/E), 3 (Q/L), 5 (V/Q), 48 (Q/M) e 80 (R/V).</span>[000443] In a second stage, residues exposed to solvent and, as such, which may also be involved in immunogenicity, will also be tested. These are residues 1 (Q / E), 3 (Q / L), 5 (V / Q), 48 (Q / M) and 80 (R / V).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000444] Então, em uma terceira etapa, resíduos envolvidos na estrutura/duplicação do domínio variável também poderiam sofrer mutação. Esses são os resíduos 9 (A/P), 13 (K/V), 22 (S/P) e 46 (P/H). [000445] Naturalmente, os resíduos mencionados acima a serem testados não são limitados, mas devem ser considerados como mutações preferenciais.</span>[000444] Then, in a third stage, residues involved in the structure / duplication of the variable domain could also undergo mutation. These are residues 9 (A / P), 13 (K / V), 22 (S / P) and 46 (P / H). [000445] Naturally, the residues mentioned above to be tested are not limited, but must be considered as preferential mutations.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 113/146</span>Petition 870190095443, of 24/09/2019, p. 113/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">100/131 [000446] Com o auxílio de um modelo molecular, outras mutações poderiam ser identificadas. Podem ser mencionados os seguintes resíduos, isto é, resíduos 12 (V/L), 21 (V/I), 43 (R/K), 49 (G/S), 53 (M/I), 68 (A/N), 72 (Q/K), 75 (R/K), 76 (V/A), 78 (M/L), 82 (T/K), 84 (I/S), 92 (S/R), 93 (R/S), 95 (R/T) e 97 (D/E), sobre os quais mutações também poderiam ser consideradas em outra modalidade preferida.</span>100/131 [000446] With the aid of a molecular model, other mutations could be identified. The following residues can be mentioned, that is, residues 12 (V / L), 21 (V / I), 43 (R / K), 49 (G / S), 53 (M / I), 68 (A / N), 72 (Q / K), 75 (R / K), 76 (V / A), 78 (M / L), 82 (T / K), 84 (I / S), 92 (S / R) ), 93 (R / S), 95 (R / T) and 97 (D / E), on which mutations could also be considered in another preferred modality.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000447] Todas as mutações mencionadas acima serão testadas individualmente ou de acordo com várias combinações.</span>[000447] All of the mutations mentioned above will be tested individually or according to various combinations.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000448] A Figura 34 representa a VH humanizada de 223C4 com as mutações mencionadas acima claramente identificadas. O número sob cada mutação proposta corresponde à classificação na qual a referida mutação será feita.</span>[000448] Figure 34 represents the humanized 223C4 VH with the mutations mentioned above clearly identified. The number under each proposed mutation corresponds to the classification in which that mutation will be made.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 15: atividade antitumor do Mab 224G11 de murino isoladamente ou combinado com o agente quimioterapêutico Navelbine® sobre o modelo de tumor de xenoenxerto NCI-H441 estabelecido [000449] Abordagens quimioterapêuticas de sucesso dependem, em parte, da resposta celular a indutores apoptóticos e do equilíbrio entre vias pró- e antiapoptóticas dentro da célula. O efeito proliferativo da cMet ativada sobre a sobrevivência celular foi documentado. Ele resulta principalmente de uma expressão aumentada das proteínas antiapoptóticas Bcl-x1 e Bcl-2 como uma consequência de sinalização PI3-K-mediada a qual, por sua vez, inibe a apoptose dependente de mitocôndria (caspase 9). Na verdade, é concebível que o sistema HGF/c-Met, com seu efeito regulatório acentuado sobre o processo apoptótico, também possa influenciar a sensibilidade de células cancerígenas a químio. Essa hipótese foi testada com o Navelbine®, um agente quimioterapêutico comercializado usado para o tratamento de câncer de pulmão (Aapro et al., Crit. Rev. Oncol. Hematol. 2001, 40: 251-263; Curran et al., Drugs Aging. 2002, 19: 695-697). O modelo</span>Example 15: Anti-tumor activity of murine Mab 224G11 alone or combined with the chemotherapeutic agent Navelbine® on the established NCI-H441 xenograft tumor model [000449] Successful chemotherapeutic approaches depend, in part, on the cellular response to apoptotic inducers and the balance between pro- and anti-apoptotic pathways within the cell. The proliferative effect of activated cMet on cell survival has been documented. It results mainly from an increased expression of the anti-apoptotic proteins Bcl-x1 and Bcl-2 as a consequence of PI3-K-mediated signaling which, in turn, inhibits mitochondria-dependent apoptosis (caspase 9). In fact, it is conceivable that the HGF / c-Met system, with its marked regulatory effect on the apoptotic process, could also influence the sensitivity of cancer cells to chemotherapy. This hypothesis was tested with Navelbine®, a marketed chemotherapeutic agent used to treat lung cancer (Aapro et al., Crit. Rev. Oncol. Hematol. 2001, 40: 251-263; Curran et al., Drugs Aging 2002, 19: 695-697). The model</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 114/146</span>Petition 870190095443, of 24/09/2019, p. 114/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">101/131 de xenoenxerto NSCLC NCI-H441 foi usado, uma vez que foi previamente descrito que essa linhagem de célula é sensível ao</span>101/131 NSCLC NCI-H441 xenograft was used, since it was previously described that this cell line is sensitive to</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Navelbine® (Kraus-Berthier et al., Clin. Cancer Res., 2000; 6: 297-304) e terapia objetivando a c-Met (Zou H. T. et al., Cancer Res. 2007, 67:</span>Navelbine® (Kraus-Berthier et al., Clin. Cancer Res., 2000; 6: 297-304) and therapy targeting c-Met (Zou H. T. et al., Cancer Res. 2007, 67:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">4408-4417).</span>4408-4417).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000450] Resumidamente, células NCI-H441 da ATCC foram rotineiramente cultivadas em meio RPMI 1640, FCS a 10% e LGlutamina a 1%. As células foram divididas dois dias antes de enxertagem, de modo que elas estavam na fase exponencial de crescimento. Dez milhões de células NCI-H441 foram enxertadas em PBS a camundongos nus Swiss de 7 semanas de idade. Três dias após implante, os tumores foram medidos e os animais foram divididos em 4 grupos de 6 camundongos com tamanho de tumor comparável. Os camundongos foram tratados i.p. com uma dose de carregamento de 2 mg de 224G11/camundongo e, então, duas vezes por semana durante 43 dias, com 1 mg de anticorpo/camundongo. O MAb 9G4 foi usado como um controle de isotipo.</span>[000450] Briefly, ATCC NCI-H441 cells were routinely cultured in RPMI 1640 medium, 10% FCS and 1% LGlutamine. The cells were divided two days before grafting, so that they were in the exponential growth phase. Ten million NCI-H441 cells were grafted into PBS to 7 week old Swiss nude mice. Three days after implantation, the tumors were measured and the animals were divided into 4 groups of 6 mice with comparable tumor size. The mice were treated i.p. with a loading dose of 2 mg of 224G11 / mouse and then twice a week for 43 days with 1 mg of antibody / mouse. MAb 9G4 was used as an isotype control.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000451] Navelbine® foi fornecido através de injeções i.p. em uma dose de 8 mg/kg nos dias 5, 12, 19 pós-injeção de células. Para terapia combinada com 224G11 e Navelbine®, os dois compostos foram administrados separadamente. nessa experiência, os 2 compostos foram usados em sua dosagem ótima. O volume do tumor foi medido duas vezes por semana e calculado através da fórmula: p/6 X comprimento X largura X altura.</span>[000451] Navelbine® was supplied through i.p. at a dose of 8 mg / kg on days 5, 12, 19 after cell injection. For combination therapy with 224G11 and Navelbine®, the two compounds were administered separately. in this experiment, the 2 compounds were used in their optimal dosage. The tumor volume was measured twice a week and calculated using the formula: p / 6 X length X width X height.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000452] A Figura 35 demonstra que 224G11 é tão eficiente quanto o Navelbine® quando usado isoladamente como uma terapia com um único agente. Um benefício significativo de combinação de ambas as terapias foi observado, com regressões completas do tumor observadas para 3 dos 6 camundongos no dia 63.</span>[000452] Figure 35 demonstrates that 224G11 is as efficient as Navelbine® when used alone as a therapy with a single agent. A significant benefit from combining both therapies was observed, with complete tumor regressions seen for 3 of the 6 mice on day 63.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 16: inibidores de c-Met e angiogênese</span>Example 16: c-Met inhibitors and angiogenesis</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 115/146</span>Petition 870190095443, of 24/09/2019, p. 115/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">102/131 [000453] Além de seu papel direto na regulação de uma variedade de funções de células tumorais, a ativação de c-Met também foi implicada em angiogênese tumoral. Células endoteliais expressam cMet e o HGF estimula o crescimento, invasão e motilidade de células endoteliais (Nakamura Y. et al., Biochem. Biophys. Res., Commun. 1995, 215: 483-488; Bussolino F. et al., J. Cell Biol. 1992, 119: 629641). A regulação coordenada de crescimento, invasão e motilidade em células endoteliais vasculares pelo HGF/c-Met foi demonstrada como resultando na formação de tubos endoteliais capilares 3D in vitro (Rosen E.M. et al., Supplementum to Experientia 1991,59: 76-88).</span>102/131 [000453] In addition to its direct role in regulating a variety of tumor cell functions, c-Met activation has also been implicated in tumor angiogenesis. Endothelial cells express cMet and HGF stimulates the growth, invasion and motility of endothelial cells (Nakamura Y. et al., Biochem. Biophys. Res., Commun. 1995, 215: 483-488; Bussolino F. et al., J Cell Biol 1992, 119: 629641). The coordinated regulation of growth, invasion and motility in vascular endothelial cells by HGF / c-Met has been shown to result in the formation of 3D capillary endothelial tubes in vitro (Rosen EM et al., Supplementum to Experientia 1991,59: 76-88) .</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000454] Para determinar uma interferência potencial de MAbs antic-Met com angiogênese HGF-induzida, dois conjuntos de experimentos foram realizados, incluindo i) a avaliação de MAbs sobre a proliferação de HUVECs e ii) o teste de MAbs sobre a formação de tubo em HUVECs.</span>[000454] To determine a potential interference of anti-Met MAbs with HGF-induced angiogenesis, two sets of experiments were performed, including i) the evaluation of MAbs on the proliferation of HUVECs and ii) the MAbs test on tube formation in HUVECs.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000455] Para experimentos de proliferação, 7500 HUVECs foram colocadas em cada poço de uma lâmina com 96 poços previamente revestida com laminina. As células foram crescidas 24 horas no meio de ensaio EMB-2 suplementado com FBS a 0,5% e heparina. Então, MAbs a serem testados (0,15 a 40 pg/ml) foram adicionados durante 1 h antes da adição de 20 ng/ml de HGF. Após mais 24 horas, as células foram submetidas a um pulso de 0,5 pCi de [<sup class="style-scope patent-text">3</sup>H] Timidina. A magnitude de [<sup class="style-scope patent-text">3</sup>H] Timidina incorporada foi quantificada através de contagem de cintilação de líquido. Nesse experimento, o MAb 9G4 é um anticorpo irrelevante usado como um controle de isotipo de IgG1.</span>[000455] For proliferation experiments, 7500 HUVECs were placed in each well of a 96-well slide previously coated with laminin. The cells were grown 24 hours in the EMB-2 assay medium supplemented with 0.5% FBS and heparin. Then, MAbs to be tested (0.15 to 40 pg / ml) were added for 1 h before the addition of 20 ng / ml of HGF. After an additional 24 hours, the cells were subjected to a 0.5 pCi pulse of [ <sup class="style-scope patent-text">3</sup> H] Thymidine. The magnitude of [ <sup class="style-scope patent-text">3</sup> H] incorporated thymidine was quantified by liquid scintillation counting. In this experiment, MAb 9G4 is an irrelevant antibody used as an IgG1 isotype control.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000456] Os resultados, expressos como dados brutos na Figura 36, demonstram que, conforme esperado, o HGF é um indutor potente de crescimento de células HUVEC. Anticorpos avaliados na ausência de HGF não mostram qualquer atividade proliferativa agonista sobre as HUVECs, qualquer que seja a dose testada. Na presença de HGF,</span>[000456] The results, expressed as raw data in Figure 36, demonstrate that, as expected, HGF is a potent inducer of HUVEC cell growth. Antibodies evaluated in the absence of HGF do not show any proliferative agonist activity on HUVECs, regardless of the tested dose. In the presence of HGF,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 116/146</span>Petition 870190095443, of 24/09/2019, p. 116/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">103/131 uma inibição dose-dependente dramática foi observada para ambos os</span>103/131 a dramatic dose-dependent inhibition was observed for both</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Mabs 11E1 e 224G11.</span>Mabs 11E1 and 224G11.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000457] Para avaliação da formação de tubo em HUVEC, 25000 células incubadas 30 min com anticorpos a serem testados foram colocadas em lâminas com 48 poços revestidos com Matrigel. Então, HGF a 50 ng/ml foi adicionado e as lâminas foram incubadas a 37°C. O meio foi, então, coletado e CMFDA a 5 gM foi adicionado durante 15 min antes de observação microscópica.</span>[000457] To assess tube formation in HUVEC, 25,000 cells incubated for 30 min with antibodies to be tested were placed on slides with 48 wells coated with Matrigel. Then, 50 ng / ml HGF was added and the slides were incubated at 37 ° C. The medium was then collected and CMFDA at 5 gM was added for 15 min before microscopic observation.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000458] Os resultados mostrados na Figura 37 demonstram que, conforme esperado, o HGF induz à formação significativa de tubo. O anticorpo 9G4 introduzido como um controle de isotipo de IgG1, não teve qualquer efeito sobre a formação de tubo HGF-induzida, enquanto que 11E1 e 224G11 inibiram dramaticamente a formação de tubo.</span>[000458] The results shown in Figure 37 demonstrate that, as expected, HGF induces significant tube formation. The 9G4 antibody introduced as an IgG1 isotype control, had no effect on HGF-induced tube formation, whereas 11E1 and 224G11 dramatically inhibited tube formation.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 17: processo de humanização através de enxertagem de CDR do anticorpo 11E1</span>Example 17: humanization process by grafting CDR of antibody 11E1</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I - Humanização do domínio variável de cadeia leve</span>I - Humanization of the light chain variable domain</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Comparação da sequência nucleotídica da VL de 11E1 aos genes de linhagem germinativa de murino [000459] Como uma etapa preliminar, a sequência nucleotídica da VL de 11E1 foi comparada às sequências dos genes de linhagem germinativa de murino, parte do banco de dados IMGT (http://imgt.cines.fr).</span>Comparison of the nucleotide sequence of the 11E1 VL to the murine germline genes [000459] As a preliminary step, the nucleotide sequence of the 11E1 VL was compared to the sequences of the murine germline genes, part of the IMGT database (http : //imgt.cines.fr).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000460] Os genes de linhagem germinativa de murino IGKV4-79*01 e IGKJ4*01 com uma identidade de sequência de 98,58% para a região V e 97,22% para a região J, respectivamente, foram identificados. Com relação à identidade obtida, foi decidido usar diretamente as sequências de VL de 11E1 para buscar homologias humanas.</span>[000460] The murine germline genes IGKV4-79 * 01 and IGKJ4 * 01 with a sequence identity of 98.58% for region V and 97.22% for region J, respectively, have been identified. Regarding the obtained identity, it was decided to directly use the 11E1 VL sequences to search for human homologies.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000461] Esses alinhamentos são representados nas Figuras 38A</span>[000461] These alignments are represented in Figures 38A</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 117/146</span>Petition 870190095443, of 24/09/2019, p. 117/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">104/131 para o gene V e 38B para o gene J.</span>104/131 for gene V and 38B for gene J.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Comparação da sequência nucleotídica da VL de 11E1 aos genes de linhagem germinativa humana [000462] De forma a identificar o melhor candidato humano para a enxertagem de CDR, o gene de linhagem germinativa humana mostrando a melhor identidade com a VL de 11E1 foi buscado. Para essa finalidade, a sequência nucleotídica da VL de 11E1 foi alinhada às sequências do gene de linhagem germinativa humana, parte do banco de dados IMGT.</span>Comparison of the nucleotide sequence of the 11E1 VL to the human germline genes [000462] In order to identify the best human candidate for CDR grafting, the human germline gene showing the best identity with the 11E1 VL was sought. For this purpose, the nucleotide sequence of the 11E1 VL was aligned to the sequences of the human germline gene, part of the IMGT database.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000463] Os genes de linhagem germinativa humana IGKV3-7*02 e IGKV3D-7*01 com uma identidade de sequência para ambos os genes de linhagem germinativa de 69,86% para a região V foram identificados. O gene de linhagem germinativa humana IGKV3-7*02 é conhecido no banco de dados IMGT como uma ORF, o que significa que essa sequência é encontrada no genoma humano, mas pode apresentar alguns problemas de recombinação, levando a anticorpos naturais derivados de IGKV3-7*02 não funcionais. Assim, o gene de linhagem germinativa IGKV3D-7*01 foi selecionado como a região V humana receptora para a VL de murino de CDRs de 11E1.</span>[000463] Human germline genes IGKV3-7 * 02 and IGKV3D-7 * 01 with a sequence identity for both germline genes of 69.86% for region V have been identified. The human germline gene IGKV3-7 * 02 is known in the IMGT database as an ORF, which means that this sequence is found in the human genome, but can present some recombination problems, leading to natural antibodies derived from IGKV3- 7 * 02 not functional. Thus, the germline gene IGKV3D-7 * 01 was selected as the recipient human V region for murine VL of 11E1 CDRs.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000464] Para a região J, o melhor escore de homologia foi primeiro obtido com um gene de linhagem germinativa humana IGKJ3*01 mostrando uma identidade de sequência de 78,38%. Mas um maior número de nucleotídeos consecutivos idênticos e uma melhor adaptação de aminoácido foram encontrados no alinhamento com o gene de linhagem germinativa humana IGKJ4*02 (identidade de sequência de 75,68%). Assim, o gene de linhagem germinativa IGKJ4*02 foi selecionado como região J humana receptora para a VL de murino de CDRs de 11E1.</span>[000464] For region J, the best homology score was first obtained with a human germline gene IGKJ3 * 01 showing a sequence identity of 78.38%. But a greater number of consecutive identical nucleotides and a better adaptation of the amino acid were found in alignment with the human germline gene IGKJ4 * 02 (sequence identity 75.68%). Thus, the germline gene IGKJ4 * 02 was selected as the human J region for the murine VL of 11E1 CDRs.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000465] Os alinhamentos são representados na Figuras 39A para a região V e 39B para a região J.</span>[000465] The alignments are represented in Figures 39A for region V and 39B for region J.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 118/146</span>Petition 870190095443, of 24/09/2019, p. 118/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">105/131 [000466] Para otimização da seleção, aqueles versados na técnica também poderiam fazer alinhamentos entre as sequências proteicas de forma a auxiliá-los na escolha.</span>105/131 [000466] To optimize the selection, those skilled in the art could also make alignments between protein sequences in order to assist them in choosing.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Versão humanizada de VL de 11E11 [000467] As etapas seguintes no processo de humanização consistem em ligação das sequências de genes de linhagem germinativa selecionados IGKV3D-7*01 e IGKJ4*02 e também das CDRs da VL de murino de 11E1 às frameworks dessas sequências de genes de linhagem germinativa.</span>Humanized version of 11E11 VL [000467] The next steps in the humanization process consist of linking the selected germline gene sequences IGKV3D-7 * 01 and IGKJ4 * 02 and also the CDRs of the 11E1 murine VL to the frameworks of these sequences of germline genes.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000468] Conforme representado na Figura 40, os resíduos em negrito na sequência VL de 11E1 correspondem aos trinta aminoácidos que se verificou serem diferentes entre o domínio VL de 11E1 e as frameworks humanas selecionadas (FR humana, isto é, IGKV3D-7*01 e IGKJ4*02).</span>[000468] As shown in Figure 40, the residues in bold in the 11E1 VL sequence correspond to the thirty amino acids that were found to be different between the 11E1 VL domain and the selected human frameworks (human FR, ie IGKV3D-7 * 01 and IGKJ4 * 02).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000469] Com relação a vários critérios, tais como sua participação conhecida na interface VH/VL, na ligação a antígeno ou na estrutura da CDR, as alterações de classe de aminoácido entre resíduos de murino e humanos, localização do resíduo na estrutura 3D do domínio variável, quatro dos trinta diferentes resíduos foram identificados como tendo sofrido eventual mutação. Esses quatro resíduos definidos mais importantes e mutações em suas contrapartes humanas sendo L4 de murino para M humana, Y40 para S, Y87 para F e T96 15 para P. Esses resíduos classificados como um são mostrados na Figura 40 como resíduos em negrito na sequência HZVL de 11E1, onde eles permaneceram de murino.</span>[000469] With respect to several criteria, such as their known participation in the VH / VL interface, in the antigen binding or in the CDR structure, the changes in the amino acid class between murine and human residues, location of the residue in the 3D structure of the variable domain, four of the thirty different residues were identified as having undergone eventual mutation. These four most important defined residues and mutations in their human counterparts being murine L4 for human M, Y40 for S, Y87 for F and T96 15 for P. These residues classified as one are shown in Figure 40 as residues in bold in the HZVL sequence of 11E1, where they remained a murine.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000470] Naturalmente, os resíduos mencionados acima a serem testados não são limitados, mas devem ser considerados como mutações preferenciais.</span>[000470] Naturally, the residues mentioned above to be tested are not limited, but must be considered as preferential mutations.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000471] Com o auxílio de um modelo molecular, outras mutações poderiam ser identificadas. Podem ser mencionados os seguintes</span>[000471] With the aid of a molecular model, other mutations could be identified. The following can be mentioned</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 119/146</span>Petition 870190095443, of 24/09/2019, p. 119/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">106/131 resíduos classificados como dois, isto é, resíduos 24 (S/R), 53 (W/L), (I/T), 67 (L/R), 86 (S/D), 95 (Q/E), 99 (A/F) ou 121 (E/D) sobre os quais mutações também poderiam ser consideradas em outra modalidade preferida.</span>106/131 waste classified as two, that is, waste 24 (S / R), 53 (W / L), (I / T), 67 (L / R), 86 (S / D), 95 (Q / E), 99 (A / F) or 121 (E / D) on which mutations could also be considered in another preferred modality.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000472] Naturalmente, os resíduos mencionados acima a serem eventualmente testados não são limitados, mas devem ser considerados como mutações preferenciais. Em outra modalidade preferida, todos os dezoito outros resíduos classificados como três entre os trinta diferentes aminoácidos poderiam ser reconsiderados.</span>[000472] Naturally, the residues mentioned above to be tested are not limited, but should be considered as preferential mutations. In another preferred embodiment, all eighteen other residues classified as three out of thirty different amino acids could be reconsidered.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000473] Todas as mutações mencionadas acima serão testadas individualmente ou de acordo com várias combinações.</span>[000473] All the mutations mentioned above will be tested individually or according to various combinations.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000474] Figura 40 representa a VL humanizada de E11E1 implementada com as mutações mencionadas acima claramente identificadas. O número sob cada mutação proposta corresponde à classificação na qual a referida mutação será feita.</span>[000474] Figure 40 represents the humanized V11 of E11E1 implemented with the mutations mentioned above clearly identified. The number under each proposed mutation corresponds to the classification in which that mutation will be made.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">II - Humanização do domínio variável de cadeia pesada</span>II - Humanization of the heavy chain variable domain</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Comparação da sequência nucleotídica da VH de 11E1 aos genes de linhagem germinativa de murino [000475] Como uma etapa preliminar, a sequência nucleotídica da VH de 11E1 foi comparada às sequências dos genes de linhagem germinativa de murino, parte do banco de dados IMGT (http://imgt.cines.fr).</span>Comparison of the 11E1 VH nucleotide sequence to the murine germline genes [000475] As a preliminary step, the 11E1 VH nucleotide sequence was compared to the sequences of the murine germline genes, part of the IMGT database (http : //imgt.cines.fr).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000476] Os genes de linhagem germinativa de murino IGHV1-7*01, IGHD4-1*01 e IGHJ3*01 com uma identidade de sequência de 94,10% para a região V, 66,67% para a região D e 100% para a região J, respectivamente, foram identificados. Com relação à identidade obtida, foi decidido usar diretamente as sequências de VH de 11E1 para buscar homologias humanas.</span>[000476] The murine germline genes IGHV1-7 * 01, IGHD4-1 * 01 and IGHJ3 * 01 with a sequence identity of 94.10% for region V, 66.67% for region D and 100 % for region J, respectively, were identified. Regarding the obtained identity, it was decided to directly use the 11E1 VH sequences to search for human homologies.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000477] Esses alinhamentos são representados nas Figuras 41A para o gene V, 41B para o gene D e 41C para o gene J.</span>[000477] These alignments are represented in Figures 41A for gene V, 41B for gene D and 41C for gene J.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 120/146</span>Petition 870190095443, of 24/09/2019, p. 120/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">107/131</span>107/131</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Comparação da sequência nucleotídica da VH de 11E1 aos genes de linhagem germinativa humana [000478] De forma a identificar o melhor candidato humano para a enxertagem de CDR, o gene de linhagem germinativa humana mostrando a melhor identidade com a VH de 11E1 foi buscado. Para essa finalidade, a sequência nucleotídica da VH de 11E1 foi alinhada às sequências do gene de linhagem germinativa humana, parte do banco de dados IMGT. Para otimização da seleção, alinhamentos entre as sequências proteicas foram feitos para buscar melhores homologias. Esses dois métodos complementares levam à identificação de duas possíveis sequências V receptoras humanas para uma VH de murino de CDRs de 11E1. Alinhamento nucleotídico proporciona o gene de linhagem germinativa humana IGHV1-2*02 com uma identidade de sequência de 75,69%, enquanto que o alinhamento protéico proporciona o gene de linhagem germinativa humana IGHV146*01 com uma identidade de sequência de 71,10%.</span>Comparison of the 11E1 VH nucleotide sequence to the human germline genes [000478] In order to identify the best human candidate for CDR grafting, the human germline gene showing the best identity with the 11E1 VH was sought. For this purpose, the 11E1 VH nucleotide sequence was aligned with the human germline gene sequences, part of the IMGT database. To optimize the selection, alignments between protein sequences were made to seek better homologies. These two complementary methods lead to the identification of two possible human V receptor sequences for a murine VH of 11E1 CDRs. Nucleotide alignment provides the human germline gene IGHV1-2 * 02 with a sequence identity of 75.69%, while protein alignment provides the human germline gene IGHV146 * 01 with a sequence identity of 71.10% .</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000479] É notável que a região D pertence estritamente à região CDR3 no domínio VH. O processo de humanização é baseado em uma abordagem de enxertagem de CDR. Análise dos D-genes humanos mais próximos não é útil nessa estratégia.</span>[000479] It is notable that region D belongs strictly to the CDR3 region in the VH domain. The humanization process is based on a CDR grafting approach. Analysis of the closest human D-genes is not useful in this strategy.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000480] Buscas por homologias para a região J levam à identificação do gene de linhagem germinativa humana IGHJ4*03 com uma identidade de sequência de 80,85%.</span>[000480] Searches for homologies for region J lead to the identification of the human germline gene IGHJ4 * 03 with a sequence identity of 80.85%.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000481] Buscando por similaridades globais e alinhamentos de sequência, o gene de linhagem germinativa V humana IGHV1-46*01 e o gene de linhagem germinativa J humana IGHJ4*03 foram, assim, selecionados como sequências humanas receptoras para a VH de murino de CDRs de 11E1.</span>[000481] Searching for global similarities and sequence alignments, the human V germline gene IGHV1-46 * 01 and the human J germline gene IGHJ4 * 03 were thus selected as human sequences for murine VH 11E1 CDRs.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000482] Os alinhamentos são representados na Figuras 42A para a região V e 42B para a região J.</span>[000482] The alignments are represented in Figures 42A for region V and 42B for region J.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 121/146</span>Petition 870190095443, of 24/09/2019, p. 121/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">108/131</span>108/131</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Versão humanizada de VH de 11H1 [000483] As etapas seguintes no processo de humanização consistem em ligação das sequências dos genes de linhagem germinativa selecionados IGHV 1-46*01 e IGHJ4*03 e também das CDRs da VH de murino de 11E1 às frameworks dessas sequências de genes de linhagem germinativa.</span>Humanized version of 11H1 VH [000483] The next steps in the humanization process consist of linking the sequences of the selected germline genes IGHV 1-46 * 01 and IGHJ4 * 03 and also of the CDRs of the murine VH of 11E1 to the frameworks of these germline gene sequences.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000484] Conforme representado na Figura 43, os resíduos em negrito na sequência VH de 11E1 correspondem aos vinte e seis aminoácidos que se verificou serem diferentes entre o domínio VH de 11E1 e as frameworks humanas selecionadas (FR humana, isto é, IGHV1-46*01 e 10 IGHJ4*03).</span>[000484] As shown in Figure 43, the residues in bold in the 11H1 VH sequence correspond to the twenty-six amino acids that were found to be different between the 11E1 VH domain and the selected human frameworks (human FR, ie, IGHV1-46 * 01 and 10 IGHJ4 * 03).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000485] Com relação a vários critérios, tais como sua participação conhecida na interface VH/VL, na ligação a antígeno ou na estrutura da CDR, as alterações de classe de aminoácido entre resíduos de murino e humanos, localização do resíduo na estrutura 3D do domínio variável, cinco dos vinte e seis diferentes resíduos foram identificados como tendo sofrido eventual mutação. Esses cinco resíduos definidos mais importantes e mutações em suas contrapartes humanas sendo N40 de murino para H humana, Y55 para I, D66 para S, A80 para R e K82 para T. Esses resíduos classificados como um são mostrados na Figura 43 como resíduos em negrito na sequência HZVH de 11E1, onde eles permaneceram de murino.</span>[000485] With respect to several criteria, such as their known participation in the VH / VL interface, in the antigen binding or in the CDR structure, changes in the amino acid class between murine and human residues, location of the residue in the 3D structure of the variable domain, five of the twenty-six different residues were identified as having undergone eventual mutation. These five most important defined residues and mutations in their human counterparts being N40 from murine to human H, Y55 to I, D66 to S, A80 to R and K82 to T. These residues classified as one are shown in Figure 43 as residues in bold in the 11E1 HZVH sequence, where they remained murine.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000486] Naturalmente, os resíduos mencionados acima a serem testados não são limitados, mas devem ser considerados como mutações preferenciais.</span>[000486] Naturally, the residues mentioned above to be tested are not limited, but must be considered as preferential mutations.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000487] Com o auxílio de um modelo molecular, outras mutações poderiam ser identificadas. Podem ser mencionados os seguintes resíduos classificados como dois, isto é, resíduos 53 (I/M), 71 (L/F), 76 (A/V), 78 (L/M) e 87 (A/V) sobre os quais mutações também poderiam ser consideradas em outra modalidade preferida.</span>[000487] With the aid of a molecular model, other mutations could be identified. The following wastes classified as two can be mentioned, that is, residues 53 (I / M), 71 (L / F), 76 (A / V), 78 (L / M) and 87 (A / V) on which mutations could also be considered in another preferred modality.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 122/146</span>Petition 870190095443, of 24/09/2019, p. 122/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">109/131 [000488] Naturalmente, os resíduos mencionados acima a serem eventualmente testados não são limitados, mas devem ser considerados como mutações preferenciais. Em outra modalidade preferida, todos os dezesseis outros resíduos classificados como três dentre os vinte-seis diferentes aminoácidos poderiam ser reconsiderados.</span>109/131 [000488] Of course, the residues mentioned above to be tested are not limited, but should be considered as preferential mutations. In another preferred embodiment, all sixteen other residues classified as three out of twenty-six different amino acids could be reconsidered.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000489] Todas as mutações mencionadas acima serão testadas individualmente ou de acordo com várias combinações.</span>[000489] All mutations mentioned above will be tested individually or according to various combinations.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000490] A Figura 43 representa a VH humanizada VH de 11E1 implementada com as mutações mencionadas acima claramente identificadas. O número sob cada mutação proposta corresponde à classificação na qual a referida mutação será feita.</span>[000490] Figure 43 represents the humanized VH of 11E1 implemented with the mutations mentioned above clearly identified. The number under each proposed mutation corresponds to the classification in which that mutation will be made.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 18: efeito de Mabs purificados sobre a fosforilação de c-met [000491] No exemplo 3, o efeito de Mabs anti-c-Met sobre a fosforilação foi ensaiado com sobrenadantes dosados de cada hibridoma a ser avaliado. O teste foi realizado novamente com Mabs 11E1 e 224G11 purificados que foram avaliados em uma concentração final de 30 pg/ml (a 200 nM) ou em uma faixa de dose de 0,0015 a 30 pg/ml (a 0,01-200 nM) de forma a determinar a IC50 de cada anticorpo. O protocolo usado é o mesmo conforme aquele descrito no exemplo 3. [000492] Os resultados de 3 experimentos independentes são apresentados na Figura 44 e demonstram que, uma vez purificados, 11E1 e 224G11 não mostraram efeito agonista quando adicionados isoladamente à células A549 e, respectivamente, um efeito antagonista de 87 e 75% na presença de HGF. Conforme esperado, o Mab 5D5 introduzido como um controle positivo agonista, mostrou um efeito agonista significativo (58%) quando adicionado isoladamente e apenas um efeito antagonista moderado (39%) na presença de HGF. Com relação aos cálculos de EC50, 11E1 e 224G11 tinham IC50s nanomolares.</span>Example 18: effect of purified Mabs on phosphorylation of c-met [000491] In example 3, the effect of anti-c-Met Mabs on phosphorylation was assayed with dosed supernatants from each hybridoma to be evaluated. The test was performed again with purified Mabs 11E1 and 224G11 that were evaluated at a final concentration of 30 pg / ml (at 200 nM) or in a dose range of 0.0015 to 30 pg / ml (at 0.01-200 nM) in order to determine the IC 50 of each antibody. The protocol used is the same as that described in example 3. [000492] The results of 3 independent experiments are shown in Figure 44 and demonstrate that, once purified, 11E1 and 224G11 did not show an agonist effect when added alone to A549 cells and, respectively, an antagonistic effect of 87 and 75% in the presence of HGF. As expected, Mab 5D5 introduced as a positive agonist control, showed a significant agonist effect (58%) when added alone and only a moderate antagonist effect (39%) in the presence of HGF. Regarding the EC50 calculations, 11E1 and 224G11 had nanomolar IC50s.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 123/146</span>Petition 870190095443, of 24/09/2019, p. 123/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">110/131</span>110/131</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 19: combinação in vivo de 224G11 e Navelbine® sobre o modelo de xenoenxerto NCI-H441 [000493] Células NCI-H441 da ATCC foram rotineiramente cultivadas em meio RPMI 1640, FCS a 10%, L-Glutamina a 1%. As células foram divididas dois dias antes de enxertagem, estando na fase exponencial de crescimento. Dez milhões de células NCI-H441 foram enxertadas em camundongos nus atímicos. Cinco dias após implante, os tumores eram mensuráveis e os animais foram divididos em 6 grupos de 6 camundongos com tamanho comparável do tumor. Os camundongos foram tratados i.p. com uma dose de carregamento de 2 mg de Mab 224G11 /camundongo e, então, duas vezes por semana com 1 mg de anticorpo/camundongo até o Dia 38 ou com 3 injeções de Navelbine® (D5, D12, D19) a 8 mg/kg. Um terceiro grupo administrado com o tratamento combinado também foi incluído. Navelbine® foi fornecido através de injeções i.p. O volume do tumor foi medido duas vezes por semana e calculado através da fórmula: π/6 X comprimento X largura X altura e os pesos dos animais foram monitorados a cada dia durante o período de tratamento com Navelbine®. Análise estatística foi realizada em cada tempo medido usando um t-teste ou um teste de Mann-Whitney. Nesse experimento, o volume médio do tumor de grupos tratados com uma única modalidade é reduzido em 72%, 76% e 99,8% para 224G11, Navelbine® e Navelbine® + 224G11, respectivamente, no dia 41 pós-primeira injeção. No dia 41, a terapia combinada melhorou significativamente o crescimento de tumor comparado com tratamentos com uma única terapia (p &lt; 0,041 comparado com Navelbine® apenas e p &lt; 0,002 comparado com 224G11 apenas no dia 41), 4 de 6 camundongos estando sem tumores no grupo com a terapia combinada. Os resultados são representados na Figura 45.</span>Example 19: in vivo combination of 224G11 and Navelbine® on the NCI-H441 xenograft model [000493] ATCC NCI-H441 cells were routinely cultured in RPMI 1640 medium, 10% FCS, 1% L-Glutamine. The cells were divided two days before grafting, being in the exponential growth phase. Ten million NCI-H441 cells were grafted onto athymic nude mice. Five days after implantation, the tumors were measurable and the animals were divided into 6 groups of 6 mice of comparable tumor size. The mice were treated i.p. with a loading dose of 2 mg of Mab 224G11 / mouse and then twice a week with 1 mg of antibody / mouse until Day 38 or with 3 injections of Navelbine® (D5, D12, D19) at 8 mg / kg. A third group administered with the combined treatment was also included. Navelbine® was supplied through i.p. The tumor volume was measured twice a week and calculated using the formula: π / 6 X length X width X height and the weights of the animals were monitored each day during the treatment period with Navelbine®. Statistical analysis was performed at each time measured using a t-test or a Mann-Whitney test. In this experiment, the average tumor volume of groups treated with a single modality is reduced by 72%, 76% and 99.8% to 224G11, Navelbine® and Navelbine® + 224G11, respectively, on day 41 after the first injection. On day 41, the combination therapy significantly improved tumor growth compared to treatments with a single therapy (p &lt;0.041 compared to Navelbine® only and p &lt;0.002 compared to 224G11 only on day 41), 4 of 6 mice being tumor free in the group with combination therapy. The results are shown in Figure 45.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000494] Esses resultados foram confirmados 50 dias após o final</span>[000494] These results were confirmed 50 days after the end</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 124/146</span>Petition 870190095443, of 24/09/2019, p. 124/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">111/131 dos tratamento (D88), onde 66% dos camundongos que receberam o tratamento combinado permaneceram livres dos tumores.</span>111/131 of the treatments (D88), where 66% of the mice that received the combined treatment remained tumor free.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 20: combinação in vivo de 224G11 e Doxorubicina sobre o modelo de xenoenxerto NCI-H441 [000495] Células NCI-H441 da ATCC foram rotineiramente cultivadas em meio RPMI 1640, FCS a 10%, L-Glutamina a 1%. As células foram divididas dois dias antes de enxertagem, estando na fase exponencial de crescimento. Dez milhões de células NCI-H441 foram enxertadas em camundongos nus atímicos. Cinco dias após implante, os tumores eram mensuráveis e os animais foram divididos em grupos de 6 camundongos com tamanho comparável do tumor. Os camundongos foram tratados i.p. com uma dose de carregamento de 2 mg de Mab 224G11/camundongo e, então, duas vezes por semana com 1 mg de anticorpo/camundongo ou com 4 injeções de Doxorubicina (D5, D12, D19, D26) a 5 mg/kg. Um terceiro grupo administrado com o tratamento combinado também foi incluído. Doxorubicina foi fornecida através de injeções i.v. O volume do tumor foi medido duas vezes por semana e calculado através da fórmula: π/6 X comprimento X largura X altura e os pesos dos animais foram monitorados a cada dia durante o período de tratamento com Doxorubicina. Análise estatística foi realizada em cada tempo medido usando um t-teste ou um teste de Mann-Whitney. As terapias únicas e o tratamento combinado mostraram atividade antitumor significativa comparado com o grupo de controle (p &lt; 0,002 do D11 ao D39). Os resultados são representados na Figura 46.</span>Example 20: in vivo combination of 224G11 and Doxorubicin on the NCI-H441 xenograft model [000495] ATCC NCI-H441 cells were routinely cultured in RPMI 1640 medium, 10% FCS, 1% L-Glutamine. The cells were divided two days before grafting, being in the exponential growth phase. Ten million NCI-H441 cells were grafted onto athymic nude mice. Five days after implantation, the tumors were measurable and the animals were divided into groups of 6 mice of comparable tumor size. The mice were treated i.p. with a loading dose of 2 mg of Mab 224G11 / mouse and then twice a week with 1 mg of antibody / mouse or with 4 injections of Doxorubicin (D5, D12, D19, D26) at 5 mg / kg. A third group administered with the combined treatment was also included. Doxorubicin was provided through i.v. injections. The volume of the tumor was measured twice a week and calculated using the formula: π / 6 X length X width X height and the weights of the animals were monitored each day during the treatment period with Doxorubicin. Statistical analysis was performed at each time measured using a t-test or a Mann-Whitney test. Single therapies and combined treatment showed significant antitumor activity compared to the control group (p &lt;0.002 from D11 to D39). The results are shown in Figure 46.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000496] Tratamento combinado também demonstra uma atividade anticrescimento de tumor significativa comparado com o tratamento com uma única modalidade entre D11 e D39, indicando que há um benefício em combinar Doxorubicina com um tratamento anti-c-Met.</span>[000496] Combined treatment also demonstrates significant tumor anti-growth activity compared to treatment with a single modality between D11 and D39, indicating that there is a benefit in combining Doxorubicin with an anti-c-Met treatment.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 21: combinação in vivo de 224G11 e Docetaxel sobre o</span>Example 21: in vivo combination of 224G11 and Docetaxel on</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 125/146</span>Petition 870190095443, of 24/09/2019, p. 125/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">112/131 modelo de xenoenxerto NCI-H441 [000497] Células NCI-H441 da ATCC foram rotineiramente cultivadas em meio RPMI 1640, FCS a 10%, L-Glutamina a 1%. As células foram divididas dois dias antes de enxertagem, estando na fase exponencial de crescimento. Dez milhões de células NCI-H441 foram enxertadas em camundongos nus atímicos. Cinco dias após implante, os tumores eram mensuráveis e os animais foram divididos em grupos de 6 camundongos com tamanho comparável do tumor. Os camundongos foram tratados i.p. com uma dose de carregamento de 2 mg de Mab 224G11/camundongo e, então, duas vezes por semana com 1 mg de anticorpo/camundongo ou com 4 injeções de Docetaxel (D5, D12, D19, D26) a 7,5 mg/kg. Um terceiro grupo administrado com o tratamento combinado também foi incluído. Docetaxel foi fornecido através de injeções. O volume do tumor foi medido duas vezes por semana e calculado através da fórmula: π/6 X comprimento X largura X altura e os pesos dos animais foram monitorados a cada dia durante o período de tratamento com Docetaxel. Análise estatística foi realizada em cada tempo medido usando um t-teste ou um teste de Mann-Whitney. As terapias únicas e o tratamento combinado mostraram atividade antitumor significativa comparado com o grupo de controle (p &lt; 0,002 do D11 ao D35). Os resultados são representados na Figura 47.</span>112/131 NCI-H441 xenograft model [000497] ATCC NCI-H441 cells were routinely cultured in RPMI 1640 medium, 10% FCS, 1% L-Glutamine. The cells were divided two days before grafting, being in the exponential growth phase. Ten million NCI-H441 cells were grafted onto athymic nude mice. Five days after implantation, the tumors were measurable and the animals were divided into groups of 6 mice of comparable tumor size. The mice were treated i.p. with a loading dose of 2 mg of Mab 224G11 / mouse and then twice a week with 1 mg of antibody / mouse or with 4 injections of Docetaxel (D5, D12, D19, D26) at 7.5 mg / kg . A third group administered with the combined treatment was also included. Docetaxel was supplied through injections. The tumor volume was measured twice a week and calculated using the formula: π / 6 X length X width X height and the weights of the animals were monitored each day during the period of treatment with Docetaxel. Statistical analysis was performed at each time measured using a t-test or a Mann-Whitney test. Single therapies and combined treatment showed significant antitumor activity compared to the control group (p &lt;0.002 from D11 to D35). The results are shown in Figure 47.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000498] Tratamento combinado também demonstra uma atividade anticrescimento de tumor significativa comparado com o tratamento com uma única modalidade entre D18 e D35, indicando que há um benefício em combinar Docetaxel com um tratamento anti-c-Met.</span>[000498] Combined treatment also demonstrates significant tumor anti-growth activity compared to treatment with a single modality between D18 and D35, indicating that there is a benefit in combining Docetaxel with an anti-c-Met treatment.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 22: combinação in vivo de 224G11 e Temozolomida sobre o modelo de xenoenxerto U87MG [000499] Células U87-MG da ATCC foram rotineiramente cultivadas em meio DMEM, FCS a 10%, L-Glutamina a 1%. As células foram divididas dois dias antes de enxertagem, estando na fase exponencial</span>Example 22: In vivo combination of 224G11 and Temozolomide on the U87MG xenograft model [000499] ATCC U87-MG cells were routinely cultured in DMEM, 10% FCS, 1% L-Glutamine. The cells were divided two days before grafting, being in the exponential phase</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 126/146</span>Petition 870190095443, of 24/09/2019, p. 126/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">113/131 de crescimento. Cinco milhões de células U87-MG foram enxertadas em camundongos nus atímicos. Dezenove dias após implante, os tumores eram mensuráveis e os animais foram divididos em grupos de 6 camundongos com tamanho comparável do tumor. Os camundongos foram tratados i.p. com uma dose de carregamento de 2 mg de Mab 224G11/camundongo e, então, duas vezes por semana com 1 mg de anticorpo/camundongo ou com 3 injeções de Temozolomida (D19, D26, D33) a 5 mg/kg. Um terceiro grupo administrado com o tratamento combinado também foi incluído. Temozolomida foi fornecida através de injeções. O volume do tumor foi medido duas vezes por semana e calculado através da fórmula: π/6 X comprimento X largura X altura e os pesos dos animais foram monitorados a cada dia durante o período de tratamento com Temozolomida. Análise estatística foi realizada em cada tempo medido usando um t-teste ou um teste de Mann-Whitney. As terapias únicas e o tratamento combinado mostraram atividade antitumor significativa comparado com o grupo de controle (p &lt; 0,002 do D22 ao D32 (onde camundongos de controle foram sacrificados por razões éticas)). Os resultados são representados na Figura 48.</span>113/131 of growth. Five million U87-MG cells were grafted onto athymic nude mice. Nineteen days after implantation, the tumors were measurable and the animals were divided into groups of 6 mice of comparable tumor size. The mice were treated i.p. with a loading dose of 2 mg of Mab 224G11 / mouse and then twice a week with 1 mg of antibody / mouse or with 3 injections of Temozolomide (D19, D26, D33) at 5 mg / kg. A third group administered with the combined treatment was also included. Temozolomide was supplied through injections. The tumor volume was measured twice a week and calculated using the formula: π / 6 X length X width X height and the weights of the animals were monitored each day during the treatment period with Temozolomide. Statistical analysis was performed at each time measured using a t-test or a Mann-Whitney test. Single therapies and combined treatment showed significant antitumor activity compared to the control group (p &lt;0.002 from D22 to D32 (where control mice were sacrificed for ethical reasons)). The results are shown in Figure 48.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000500] Tratamento combinado também demonstra uma atividade anticrescimento de tumor significativa comparado com o tratamento com uma única (P &lt; 0,002 do dia 22 ao dia 43 (onde camundongos de controle foram sacrificados por razões éticas) para Temozolomida e do dia 29 ao dia 53 (último dia de tratamento) para 224G11. Tomados juntos, esses dados indicam que há um benefício em combinar Temozolomida com um tratamento anti-c-Met.</span>[000500] Combined treatment also demonstrates significant tumor anti-growth activity compared to treatment with a single one (P &lt;0.002 from day 22 to day 43 (where control mice were sacrificed for ethical reasons) for Temozolomide and day 29 to day 53 (last day of treatment) for 224G11 Taken together, these data indicate that there is a benefit in combining Temozolomide with an anti-c-Met treatment.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 23: formação de esferoide [000501] Conforme já descrito no Exemplo 9 para outros Mabs, nós avaliamos a capacidade do Mab 224G11 de inibir o crescimento de tumor in vitro no modelo de esferoide U87-MG. Para essa finalidade,</span>Example 23: spheroid formation [000501] As already described in Example 9 for other Mabs, we evaluated the ability of Mab 224G11 to inhibit tumor growth in vitro in the U87-MG spheroid model. For this purpose,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 127/146</span>Petition 870190095443, of 24/09/2019, p. 127/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">114/131 células U87-MG crescidas como uma monocamada foram soltas através de tripsina-EDTA e resuspensas em meio de cultura de células completo. Os esferoides foram iniciados através de inoculação de 625 células à poços únicas de lâminas de fundo redondo com 96 poços em DMEM-FCS a 2,5%. Para impedir a adesão celular a um substrato, as lâminas foram pré-revestidas com poliHEMA em etanol a 95% e secas ao ar em temperatura ambiente. As lâminas foram incubadas sob condições padrões de cultura a 37°C, 5% de CO2 em incubadoras umidificadas. Anticorpos monoclonais purificados (10 gg/ml) foram adicionados após 4 e 10 dias de cultura de esferoide. Os esferoides foram mantidos em cultura durante 17 dias. Então, o crescimento de esferoide foi monitorado através de medição da área de esferoides usando um módulo de medição automática do software Axio Vision. A área foi expressa em gm<sup class="style-scope patent-text">2</sup>. 8-16 esferoides foram avaliados para cada condição. O tamanho do esferoide foi medido antes de adição de anticorpos, após 10 dias de cultura e após 17 dias de cultura.</span>114/131 U87-MG cells grown as a monolayer were released via trypsin-EDTA and resuspended in complete cell culture medium. The spheroids were started by inoculating 625 cells into single wells of 96-well round-bottom slides in 2.5% DMEM-FCS. To prevent cell adhesion to a substrate, the slides were pre-coated with polyHEMA in 95% ethanol and air-dried at room temperature. The slides were incubated under standard culture conditions at 37 ° C, 5% CO2 in humidified incubators. Purified monoclonal antibodies (10 gg / ml) were added after 4 and 10 days of spheroid culture. The spheroids were kept in culture for 17 days. Then, spheroid growth was monitored by measuring the spheroid area using an automatic measurement module from the Axio Vision software. The area was expressed in gm <sup class="style-scope patent-text">2</sup> . 8-16 spheroids were assessed for each condition. The spheroid size was measured before adding antibodies, after 10 days of culture and after 17 days of culture.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000502] Nessas condições, esferoides homogêneos foram obtidos e nenhuma diferença estatística foi observada antes de adição de anticorpos (Figura 49A).</span>[000502] Under these conditions, homogeneous spheroids were obtained and no statistical difference was observed before adding antibodies (Figure 49A).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000503] Conforme ilustrado nas Figuras 49B-49D, o controle de isotipo 9G4 não teve efeito sobre o crescimento de esferoides após 10 ou 17 dias de cultura. Enquanto que a adição de 5D5 não teve um grande efeito sobre o tamanho de esferoide, a adição de 224G11 e 11E1 inibiu acentuadamente o crescimento de tumor.</span>[000503] As shown in Figures 49B-49D, the 9G4 isotype control had no effect on spheroid growth after 10 or 17 days of culture. While the addition of 5D5 did not have a great effect on the spheroid size, the addition of 224G11 and 11E1 markedly inhibited tumor growth.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 24: atividade in vitro de formas quiméricas e humanizadas de 224G11 no ensaio de fosfo-c-Met [000504] De forma a comparar a eficácia in vitro de formas de murino, quiméricas e humanizadas em um ensaio funcional, sobrenadantes de cultura resultantes do hibridoma 224G11 e células HEK293 transfectadas foram dosados e testados conforme descrito no</span>Example 24: in vitro activity of chimeric and humanized forms of 224G11 in the phospho-c-Met assay [000504] In order to compare the in vitro efficacy of murine, chimeric and humanized forms in a functional assay, culture supernatants resulting from the hybridoma 224G11 and transfected HEK293 cells were assayed and tested as described in</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 128/146</span>Petition 870190095443, of 24/09/2019, p. 128/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">115/131</span>115/131</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 3. Os dados resumidos na Figura 50 mostraram os resultados esperados para o anticorpo de murino não purificado, conforme já descrito na Figura 6B. Os anticorpos quiméricos e humanizados não purificados mostraram uma atividade comparável, quer quando adicionados isoladamente (Figura 50A) ou quando incubados na presença de HGF (Figura 50B).</span>Example 3. The data summarized in Figure 50 showed the expected results for the unpurified murine antibody, as already described in Figure 6B. Chimeric and non-purified humanized antibodies showed comparable activity, either when added alone (Figure 50A) or when incubated in the presence of HGF (Figure 50B).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 25: determinação de constantes de afinidade (KD) de anticorpos anti-c-Met através de análise Biacore [000505] A afinidade de ligação de anticorpos 11E1 e 224G11 purificados foi investigada através do BIAcore X usando o Domínio Extracelular de c-Met recombinante (ECD) fundido a um domínio Fc de IgG1 (R&amp;D Systems) como antígeno (MW = 129 kDa). Uma vez que as proteínas de fusão c-Met-Fc e anticorpos são compostos bivalentes, fragmentos Fab dos mAbs 11E1 e 224G11 (MW = 50 kDa) foram gerados através de clivagem com papaína, purificados e usados nesse ensaio para evitar interferência com o parâmetro avidez. Para o ensaio, um anticorpo de captura anti-Tag de histidina foi revestido sobre lascas sensoras CM5. O tampão de operação foi HBS-EP, a taxa de fluxo foi de 30 pl/min e o teste foi realizado a 25°C. Antígeno cMet solúvel (ECD_M1)2-Fc-(HHHHHH)2 foi capturado sobre a lasca sensora (em torno de 270 RU) e os anticorpos a serem testados foram usados em solução como analitos. A lasca sensora foi regenerada usando tampão de Glicina, HCl, pH de 1,5 sobre ambas as células de fluxo durante meio minuto.</span>Example 25: determination of affinity constants (KD) of anti-c-Met antibodies using Biacore analysis [000505] The binding affinity of purified 11E1 and 224G11 antibodies was investigated using BIAcore X using the recombinant c-Met Extracellular Domain (ECD) fused to an IgG1 Fc domain (R&amp;D Systems) as an antigen (MW = 129 kDa). Since the c-Met-Fc fusion proteins and antibodies are divalent compounds, Fab fragments of mAbs 11E1 and 224G11 (MW = 50 kDa) were generated through cleavage with papain, purified and used in this assay to avoid interference with the parameter greed. For the assay, an anti-histidine tag capture antibody was coated on CM5 sensor chips. The operating buffer was HBS-EP, the flow rate was 30 pl / min and the test was performed at 25 ° C. Soluble cMet antigen (ECD_M1) 2-Fc- (HHHHHH) 2 was captured on the sensor chip (around 270 RU) and the antibodies to be tested were used in solution as analytes. The sensor chip was regenerated using Glycine buffer, HCl, pH 1.5 over both flow cells for half a minute.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000506] A Figura 51 ilustra o princípio dessa análise. Os parâmetros cinéticos resultantes são resumidos na tabela 4 a seguir. Eles indicam que ambos os anticorpos anti-c-Met 11E1 e 224G11 se ligam à proteína de fusão c-Met-Fc recombinante com afinidades comparáveis, oscilando de cerca de 40 pM.</span>[000506] Figure 51 illustrates the principle of this analysis. The resulting kinetic parameters are summarized in table 4 below. They indicate that both anti-c-Met-11E1 and 224G11 antibodies bind to recombinant c-Met-Fc fusion protein with comparable affinities, ranging from about 40 pM.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 129/146</span>Petition 870190095443, of 24/09/2019, p. 129/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">116/131</span>116/131</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabela 4</span>Table 4</span>
  </p>
  <p class="style-scope patent-text">
    <tables class="style-scope patent-text">
      <patent-tables class="style-scope patent-text">
        <tgroup cols="5" class="style-scope patent-text">
          
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text"> </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Kon1
X 10-<sup class="style-scope patent-text">6</sup>
[1/M.s]</span>Kon1 X 10- <sup class="style-scope patent-text">6</sup> [1 / Ms]</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Kon1
X 10-<sup class="style-scope patent-text">6</sup>
[1/M.s]</span>Kon1 X 10- <sup class="style-scope patent-text">6</sup> [1 / Ms]</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Meia-vida
[h]</span>
Half life
[H]</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
K [pM]</span>
K [pM]</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Fab de 11E1</span>
11E1 Fab</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
1,13 ± 0,01</span>
1.13 ± 0.01</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
4,68 ± 0,001</span>
4.68 ± 0.001</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
4,1</span>
4.1</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
41,4 ± 0,5</span>
41.4 ± 0.5</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Fab de 224G11</span>
224G11 Fab</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
2,04 ± 0,01</span>
2.04 ± 0.01</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
7,79 ± 0,40</span>
7.79 ± 0.40</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
2,5</span>
2.5</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
34,8 ± 1,9</span>
34.8 ± 1.9</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Exemplo 26: atividad</span>
Example 26: activity</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
e in vivo de 224G11 sobre células M</span>
and in vivo 224G11 on M cells</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
DA-MB-231</span>
DA-MB-231</span>
              </entry>
            </row>
          
        </tgroup>
      </patent-tables>
    </tables>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">coimplantadas com células MRC5 como fonte de HGF humano em camundongos nus atímicos [000507] Células MDA-MB-213 e MRC5 da ATCC foram cultivadas em meio DMEM, FCS a 10%, L-Glutamina a 1%. As células foram divididas dois dias antes de enxertagem, estando na fase exponencial de crescimento. Cinco milhões de células MDA-MB-231 e 500 000 células MRC5 foram coinjetadas s.c. a camundongos nus atímicos. Doze dias após implante, os tumores eram mensuráveis e os animais foram divididos em grupos de 6 camundongos com tamanho de tumor comparável. Os camundongos foram tratados i.p. com uma dose de carregamento de 2 mg de Mab 224G11/camundongo e, então, duas vezes por semana com 1 mg de anticorpo/camundongo. O volume do tumor foi medido duas vezes por semana e calculado através da fórmula: π/6 X comprimento X largura X altura.</span>coimplanted with MRC5 cells as a source of human HGF in athymic nude mice [000507] ATCC MDA-MB-213 and MRC5 cells were cultured in DMEM, 10% FCS, 1% L-Glutamine. The cells were divided two days before grafting, being in the exponential growth phase. Five million MDA-MB-231 cells and 500,000 MRC5 cells were co-injected s.c. to athymic nude mice. Twelve days after implantation, the tumors were measurable and the animals were divided into groups of 6 mice with comparable tumor size. The mice were treated i.p. with a loading dose of 2 mg of Mab 224G11 / mouse and then twice a week with 1 mg of antibody / mouse. The tumor volume was measured twice a week and calculated using the formula: π / 6 X length X width X height.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000508] Os resultados descritos na Figura 52 mostraram uma diferença significativa no crescimento médio dos tumores de camundongos tratados com 224G11 comparado com aqueles do grupo de controle.</span>[000508] The results described in Figure 52 showed a significant difference in the average growth of the tumors of mice treated with 224G11 compared to those in the control group.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 27: elementos complementares sobre a humanização de anticorpos 227H1, 11E1 e 224G11</span>Example 27: complementary elements on the humanization of 227H1, 11E1 and 224G11 antibodies</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Procedimento Geral [000509] Humanização de anticorpos anti-cMet foi realizada independentemente para cada cadeia e sequencialmente, com relação</span>General Procedure [000509] Humanization of anti-cMet antibodies was performed independently for each chain and sequentially, with respect to</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 130/146</span>Petition 870190095443, of 24/09/2019, p. 130/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">117/131 aos aminoácidos analisados em cada domínio variável. O processo de humanização foi avaliado em uma primeira tentativa em um ensaio de ligação ELISA à Fc-cMet recombinante; as atividades de ligação dos anticorpos humanizados sendo comparadas ao anticorpo quimérico recombinante. Em uma segunda tentativa, os anticorpos humanizados antianti-cMet foram avaliados com relação às suas capacidades de deslocar a ligação de Fc-cMet sobre HGF recombinante revestido sobre plástico; esse ensaio de competição permite a comparação direta de versões de murino, quiméricas e humanizadas dos anticorpos antianti-cMet.</span>117/131 to the amino acids analyzed in each variable domain. The humanization process was evaluated in a first attempt in an ELISA binding assay to recombinant Fc-cMet; the binding activities of the humanized antibodies being compared to the recombinant chimeric antibody. In a second attempt, the humanized anti-cMet antibodies were evaluated for their ability to displace the Fc-cMet binding over recombinant plastic-coated HGF; this competition assay allows direct comparison of chimeric, humanized and murine versions of the anti-cMet antibodies.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000510] Nas Figuras 53 e 54 são exemplificadas as atividades antiligação à c-Met típicas dos anticorpos monoclonais de murino 227H1, 11E1 e 224G11.</span>[000510] Figures 53 and 54 exemplify the c-Met anti-binding activities typical of 227H1, 11E1 and 224G11 murine monoclonal antibodies.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000511] A Figura 53 mostra as atividade antiligação direta à c-Met de anticorpos de murino purificados detectados. Nesse ensaio, anticorpos monoclonais de murino anti-cMet mostram diferentes atividades antiligação à c-Met, mas ainda dependentes de dose.</span>[000511] Figure 53 shows the direct anti-binding activity to c-Met of purified murine antibodies detected. In that assay, murine anti-cMet monoclonal antibodies show different anti-binding activities to c-Met, but are still dose dependent.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000512] A Figura 54 mostra as atividades de competição de ligação HGF-cMet de anticorpos purificados de murino. O ensaio de competição revela diferenças confiáveis entre esses anticorpos monoclonais antianti-cMet, com uma atividade competitiva moderada, não completa, mas confiável para o anticorpo monoclonal 11E1, enquanto que os anticorpos de murino 224G11 e 227H1 mostram um padrão similar de atividades competitivas, com um máximo de 100% de deslocamento de ligação ao HGF em uma alta concentração de anticorpo. O anticorpo monoclonal 224G11 mostrou o melhor valor de IC50.</span>[000512] Figure 54 shows the HGF-cMet binding competition activities of purified murine antibodies. The competition assay reveals reliable differences between these anti-cMet monoclonal antibodies, with a moderate, not complete, but reliable competitive activity for monoclonal antibody 11E1, whereas murine antibodies 224G11 and 227H1 show a similar pattern of competitive activities, with a maximum of 100% HGF binding displacement at a high antibody concentration. The monoclonal antibody 224G11 showed the best IC50 value.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000513] É notável que as atividades de ligação direta dos anticorpos de murino não refletem suas propriedades competitivas de ligação ao HGF intrínsecas.</span>[000513] It is notable that the direct binding activities of murine antibodies do not reflect their intrinsic competitive HGF binding properties.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 131/146</span>Petition 870190095443, of 24/09/2019, p. 131/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">118/131 [000514] Esses dois ensaios foram usados para caracterizar as versões quiméricas e humanizadas recombinantes dos anticorpos antianti-cMet de murino. Para essa finalidade, resumidamente, domínios variáveis antianti-cMet, seja de murino ou humanizados, foram clonados em vetores de expressão da série pCONplus da Lonza e anticorpos recombinantes IgG1/K-derivados foram expressos em células CHO. Os sobrenadantes de cultura foram concentrados e extensivamente submetidos à diálise contra PBS e, então, dosados com relação às concentrações de anticorpos expressos e diretamente usados para analisar as atividades antiligação à c-Met correspondentes. Ensaios de ligação direta e competição-HGF foram avaliados para melhor caracterizar as versões quiméricas ou humanizadas recombinantes.</span>118/131 [000514] These two assays were used to characterize the chimeric and humanized recombinant versions of the murine antianti-cMet antibodies. For this purpose, in summary, antianti-cMet variable domains, whether murine or humanized, were cloned into Lonza's pCONplus series expression vectors and recombinant IgG1 / K-derived antibodies were expressed in CHO cells. Culture supernatants were concentrated and extensively subjected to dialysis against PBS and then dosed with respect to the concentrations of expressed antibodies and directly used to analyze the corresponding c-Met anti-binding activities. Direct binding and HGF competition assays were evaluated to better characterize the chimeric or humanized recombinant versions.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 27-1: humanização do domínio variável de cadeia pesada de 227H1 [000515] De forma a identificar o melhor candidato humano para a enxertagem de CDR, o gene de linhagem germinativa humana mostrando a melhor identidade com a sequência VH de 227H1 de murino foi buscado. Com o auxílio do banco de dados IMGT, o gene de linhagem germinativa V humana IGHV1-2*02 e o gene de linhagem germinativa J humana IGHJ4*01 foram, assim, selecionados como sequências humanas receptoras para a VH de murino de CDRs de 227H1.</span>Example 27-1: humanization of the 227H1 heavy chain variable domain [000515] In order to identify the best human candidate for CDR grafting, the human germline gene showing the best identity with the murine 227H1 VH sequence was sought. With the aid of the IMGT database, the human V germline gene IGHV1-2 * 02 and the human J germline gene IGHJ4 * 01 were thus selected as human sequences for the 227H1 CDR murine VH .</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000516] A Figura 55 representa um alinhamento de aminoácido do domínio VH de 227H1 de murino com a estrutura principal selecionada. Na fileira FR humana, apenas o aminoácido que se verificou ser diferente do domínio VH do 227H1 de murino é representado. As fileiras HZ3VH, HZ2VH e HZ1VH correspondem às versões humanizadas implementadas do domínio VH de 227H1 com as mutações mencionadas acima (fileira trocado por) claramente</span>[000516] Figure 55 represents an amino acid alignment of the murine 227H1 VH domain with the selected backbone. In the human FR row, only the amino acid that was found to be different from the murine 227H1 VH domain is represented. The rows HZ3VH, HZ2VH and HZ1VH correspond to the implemented humanized versions of the VH domain of 227H1 with the mutations mentioned above (row replaced by) clearly</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 132/146</span>Petition 870190095443, of 24/09/2019, p. 132/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">119/131 identificadas. O número sob cada mutação proposta corresponde à classificação na qual a referida mutação será feita.</span>119/131 identified. The number under each proposed mutation corresponds to the classification in which that mutation will be made.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000517] Em uma primeira série de experimentos, nós construímos e analisamos as atividades antiligação à c-Met das três versões humanizadas do domínio VH de 227H1 de murino quando expresso em combinação à cadeia leve quimérica do 227H1. Os resultados obtidos a partir do ensaio antiligação direta à c-Met são mostrados na Figura 56. Nesse experimento, nenhuma diferença nas capacidades de ligação dos anticorpos recombinantes quiméricos ou parcialmente humanizados 227H1-derivados testados foi observada. Nesse ponto, 26 dos 32 aminoácidos que se verificou serem diferentes entre um domínio VH de 227H1 de murino e a estrutura principal selecionada foram analisados e se descobriu não serem relevantes para a atividade antiligação à c-Met do domínio VH humanizado do 227H1, quando combinado com a cadeia leve quimérica.</span>[000517] In a first series of experiments, we constructed and analyzed the c-Met anti-binding activities of the three humanized versions of the murine 227H1 VH domain when expressed in combination with the 227H1 chimeric light chain. The results obtained from the direct anti-binding assay to c-Met are shown in Figure 56. In this experiment, no difference in the binding capabilities of the 227H1-derived chimeric or partially humanized recombinant antibodies was observed. At that point, 26 of the 32 amino acids that were found to be different between a murine 227H1 VH domain and the selected main structure were analyzed and found not to be relevant to the c-Met anti-binding activity of the humanized 227H1 VH domain, when combined with the chimeric light chain.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000518] Em conjunto com uma análise por mutagênese dirigida ao sítio dos últimos seis resíduos de murino na versão humanizada HZ1VH do domínio VH de 227H1, nós construímos uma versão totalIMGT humanizada original HZ4VH e testamos suas propriedades antiligação à c-Met. Os resultados são fornecidos na Figura 57 para o ensaio de ligação direta e na Figura 58 para o ensaio de competição de ligação ao HGF. É notável que ambas as versões quiméricas e humanizadas recombinantes de 227H1 mostram uma melhor atividade competitiva do que o anticorpo de murino de origem.</span>[000518] In conjunction with a site-directed mutagenesis analysis of the last six murine residues in the humanized version HZ1VH of the VH domain of 227H1, we constructed an original humanized total IMGT version HZ4VH and tested its anti-binding properties to c-Met. The results are provided in Figure 57 for the direct binding assay and in Figure 58 for the HGF binding competition assay. It is notable that both the chimeric and humanized recombinant versions of 227H1 show better competitive activity than the original murine antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000519] Todavia, dado os dados experimentais obtidos com relação às propriedades antiligação à c-Met do domínio VH humanizado totalIMGT do 227H1, a sequência de aminoácido resultante representada na Figura 59 foi selecionada e uma análise bioinformática foi, então, realizada para avaliar o nível de humanidade do assim denominado domínio variável HZ VH humanizado do 227H1.</span>[000519] However, given the experimental data obtained with respect to the anti-binding properties to the c-Met of the humanized VH totalIMGT domain of 227H1, the resulting amino acid sequence represented in Figure 59 was selected and a bioinformatics analysis was then performed to evaluate the level of humanity of the so-called humanized HZ VH variable domain of 227H1.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 133/146</span>Petition 870190095443, of 24/09/2019, p. 133/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">120/131 [000520] Para essa finalidade, uma comparação simples das sequências de estrutura principal com o banco de dados humano foi realizada usando as ferramentas IMGT. Dado o nível de humanização que nós obtivemos durante esse processo, dos 89 aminoácidos analisados correspondendo aos resíduos de estrutura principal, se descobriu que 89 eram confiáveis com uma origem humana. Apenas resíduos das CDRs podem ser diferentes mas, se assim, são diferentes do gene de linhagem germinativa humana correspondente e estão, obviamente, em posições hipervariáveis. Baseado no sistema de numeração IMGT e ferramentas de análise de homologia, nós primeiro humanizamos totalmente um domínio variável de anticorpo originário de murino.</span>120/131 [000520] For this purpose, a simple comparison of the main structure sequences with the human database was performed using the IMGT tools. Given the level of humanization that we obtained during this process, of the 89 amino acids analyzed corresponding to the main structure residues, 89 were found to be reliable with a human origin. Only CDR residues can be different, but if so, they are different from the corresponding human germline gene and are obviously in hypervariable positions. Based on the IMGT numbering system and homology analysis tools, we first fully humanized a variable domain of murine antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 27-2:hHumanização de anticorpo monoclonal 11E1</span>Example 27-2: hHumanization of monoclonal antibody 11E1</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I - Humanização do domínio variável de cadeia pesada de 11E1 [000521] De forma a identificar o melhor candidato humano para a enxertagem de CDR, o gene de linhagem germinativa humana mostrando a melhor identidade com a sequência VH de 11E1 de murino foi buscado. Com o auxílio do banco de dados IMGT, o gene de linhagem germinativa V humana IGHV1-46*01 e o gene de linhagem germinativa J humana IGHJ4*03 foram, assim, selecionados como sequências humanas receptoras para a VH de murino de CDRs de 11E1.</span>I - Humanization of the 11E1 heavy chain variable domain [000521] In order to identify the best human candidate for CDR grafting, the human germline gene showing the best identity with the murine 11E1 VH sequence was sought. With the aid of the IMGT database, the human V germline gene IGHV1-46 * 01 and the human J germline gene IGHJ4 * 03 were thus selected as human sequences for CDE 11R murine VH .</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000522] A Figura 60 representa um alinhamento de aminoácido do domínio VH de 11E1 de murino com a estrutura principal humana selecionada. Na fileira FR humana, apenas o aminoácido que se verificou ser diferente do domínio VH de 11E1 de murino é representado. As fileiras HZ VH3, HZ VH2 e HZ VH1 correspondem às versões humanizadas implementadas do domínio VH de 11E1 com as mutações mencionadas acima (fileira trocado por) claramente</span>[000522] Figure 60 represents an amino acid alignment of the murine 11E1 VH domain with the selected human backbone. In the human FR row, only the amino acid that was found to be different from the murine 11E1 VH domain is represented. The rows HZ VH3, HZ VH2 and HZ VH1 correspond to the implemented humanized versions of the 11H1 VH domain with the mutations mentioned above (row replaced by) clearly</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 134/146</span>Petition 870190095443, of 24/09/2019, p. 134/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">121/131 identificadas. O número sob cada mutação proposta corresponde à classificação na qual a referida mutação será feita.</span>121/131 identified. The number under each proposed mutation corresponds to the classification in which that mutation will be made.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000523] Em uma primeira série de experimentos, construíu-se e analisamos as atividades antiligação à c-Met das três primeiras versões humanizadas do domínio VH de 11E1 quando expresso em combinação com a cadeia leve quimérica de 11E1. Os resultados obtidos a partir do ensaio antiligação direta à c-Met são mostrados na Figura 61. Nesse experimento, uma capacidade de ligação similar dos anticorpos recombinantes quiméricos ou parcialmente humanizados 11E1-derivados testados foi observada. Nesse ponto, 19 dos 24 aminoácidos que se verificou serem diferentes entre o domínio VH de 11E1 de murino e a estrutura principal humana selecionada foram analisados e se verificou não serem relevantes para a atividade antiligação à c-Met do domínio VH de 11E1 humanizado, quando combinado com a cadeia leve quimérica.</span>[000523] In a first series of experiments, the c-Met anti-binding activities of the first three humanized versions of the 11E1 VH domain were constructed and analyzed when expressed in combination with the 11E1 chimeric light chain. The results obtained from the direct anti-binding assay to c-Met are shown in Figure 61. In this experiment, a similar binding capacity of the 11E1-derived chimeric or partially humanized recombinant antibodies was observed. At that point, 19 of the 24 amino acids that were found to be different between the murine 11E1 VH domain and the selected human backbone were analyzed and found not to be relevant for the c-Met anti-binding activity of the humanized 11E1 VH domain when combined with the chimeric light chain.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">II - Humanização do domínio variável de cadeia leve de 11E1 [000524] De forma a identificar o melhor candidato humano para a enxertagem de CDR, o gene de linhagem germinativa humana mostrando a melhor identidade com a sequência VL de 11E1 de murino foi buscado. Com o auxílio do banco de dados IMGT, o gene de linhagem germinativa V humana IGKV3D-7*01 e o gene de linhagem germinativa J humana IGKJ4*01 foram, assim, selecionados como sequências humanas receptoras para a VL de murino de CDRs de 11E1.</span>II - Humanization of the 11E1 light chain variable domain [000524] In order to identify the best human candidate for CDR grafting, the human germline gene showing the best identity with the murine 11E1 VL sequence was sought. With the aid of the IMGT database, the human V germline gene IGKV3D-7 * 01 and the human J germline gene IGKJ4 * 01 were thus selected as human receptor sequences for the murine VL of 11E1 CDRs .</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000525] A Figura 62 representa um alinhamento de aminoácido do domínio VL de 11E1 de murino com a estrutura principal humana selecionada. Na fileira Fr humana, apenas o aminoácido que se verificou ser diferente do domínio VL de 11E1 de murino é representado. As fileiras HZ VL3, HZ VL2 e HZ VL1 correspondem às</span>[000525] Figure 62 represents an amino acid alignment of the murine 11E1 VL domain with the selected human backbone. In the human Fr row, only the amino acid that was found to be different from the murine 11E1 VL domain is represented. The rows HZ VL3, HZ VL2 and HZ VL1 correspond to the</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 135/146</span>Petition 870190095443, of 24/09/2019, p. 135/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">122/131 versões humanizadas implementadas do domínio VL de 11E1 com as mutações mencionadas acima (fileira trocado por) claramente identificadas. O número sob cada mutação proposta corresponde à classificação na qual a referida mutação será feita.</span>122/131 humanized versions implemented from the 11E1 VL domain with the mutations mentioned above (row replaced by) clearly identified. The number under each proposed mutation corresponds to the classification in which that mutation will be made.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000526] Em uma primeira série de experimentos, nós construímos e analisamos as atividades antiligação à c-Met das três primeiras versões humanizadas do domínio VL 11E1 de murino quando expresso em combinação com a cadeia pesada quimérica do 11E1. Os resultados obtidos a partir do ensaio antiligação direta à c-Met são mostrados na Figura 63. Nesse experimento, nós observamos capacidades de ligação similares dos anticorpos recombinantes quiméricos ou parcialmente humanizados 11E1-derivados testados. Nesse ponto, 26 dos 30 aminoácidos que se verificou serem diferentes entre o domínio VL de 11E1 de murino e a estrutura principal humana selecionada foram analisados e não se verificou serem relevantes para a atividade antiligação à c-Met do domínio VL humanizado de 11E1, quando combinado com a cadeia pesada quimérica.</span>[000526] In a first series of experiments, we constructed and analyzed the c-Met anti-binding activities of the first three humanized versions of the murine VL 11E1 domain when expressed in combination with the 11E1 chimeric heavy chain. The results obtained from the direct anti-binding assay to c-Met are shown in Figure 63. In this experiment, we observed similar binding capabilities of the 11E1-derived chimeric or partially humanized recombinant antibodies. At that point, 26 of the 30 amino acids that were found to be different between the murine 11E1 VL domain and the selected human main structure were analyzed and were not found to be relevant to the c-Met anti-binding activity of the humanized 11E1 VL domain when combined with the chimeric heavy chain.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">III - Humanização do anticorpo 11E1 [000527] Nesse estágio de humanização do anticorpo monoclonal 11E1, a sequência de anticorpo humanizado resultante teórica contém apenas cinco resíduos fora de CDRs provenientes do domínio VH de murino de origem e quatro resíduos fora das CDRs provenientes da sequência VL de murino de origem (veja Figura 60, fileira HZ VH1 e Figura 62, fileira HZ VL1). Então, foi decidido caracterizar imediatamente a versão humanizada de cadeias leve e pesada combinada do anticorpo 11E1. Os resultados são fornecidos na Figura 64 para o ensaio antiligação direta à c-Met.</span>III - Humanization of the 11E1 antibody [000527] At this stage of humanization of the monoclonal antibody 11E1, the resulting theoretical humanized antibody sequence contains only five residues outside the CDRs from the murine VH domain of origin and four residues outside the CDRs from the VL sequence of murine origin (see Figure 60, row HZ VH1 and Figure 62, row HZ VL1). Then, it was decided to immediately characterize the combined humanized light and heavy chain version of the 11E1 antibody. The results are provided in Figure 64 for the direct anti-binding assay to c-Met.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000528] Nesse experimento, foi observado capacidades de ligação similares para os anticorpos recombinantes quiméricos ou humanizados 11E1-derivados testados. Análise de propriedades</span>[000528] In this experiment, similar binding capabilities were observed for the 11E1-derived chimeric or humanized recombinant antibodies tested. Property analysis</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 136/146</span>Petition 870190095443, of 24/09/2019, p. 136/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">123/131 competitivas de ligação ao HGF e análise por mutagênese dirigida ao sítio da contribuição dos nove resíduos de murino à esquerda que restaram foram realizadas independentemente ou em combinação nessa versão pré-humanizada VH1/VL1 selecionada do anticorpo monoclonal 11E1.</span>123/131 competitive HGF binding and site-directed mutagenesis analysis of the contribution of the remaining nine murine residues on the left were performed independently or in combination on this pre-humanized VH1 / VL1 version of the 11E1 monoclonal antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 27-3: humanização de anticorpo monoclonal 224G11</span>Example 27-3: humanization of monoclonal antibody 224G11</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I - Humanização de domínio variável de cadeia pesada de 224G11 [000529] De forma a identificar o melhor candidato humano para a enxertagem de CDR, o gene de linhagem germinativa humana mostrando a melhor identidade com a sequência VH de 224G11 de murino foi buscado.</span>I - Humanization of 224G11 heavy chain variable domain [000529] In order to identify the best human candidate for CDR grafting, the human germline gene showing the best identity with the murine 224G11 VH sequence was sought.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000530] Com relação à alta homologia de sequência entre as sequências de domínio VH de 224G11 e 227H1 e conforme confirmado através do uso de ferramentas do banco de dados IMGT, o mesmo gene de linhagem germinativa V humana IGHV1-2*02 e gene de linhagem germinativa J humana IGHJ4*01 foram, assim, selecionados como sequências humanas receptoras para a VH de murino de CDRs de 224G11 .</span>[000530] Regarding the high sequence homology between the VH domain sequences of 224G11 and 227H1 and as confirmed through the use of tools from the IMGT database, the same human germline gene IGHV1-2 * 02 and gene of germline human J IGHJ4 * 01 were thus selected as human sequences for murine VH of 224G11 CDRs.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000531] Baseado nessa alta homologia, foi decidido transferir diretamente as informações de humanização obtidas a partir de humanização do domínio VH de 227H1 (veja Exemplo 27) e, então, criou-se uma versão humanizada total-IMGT, conforme representado na Figura 65, a qual representa um alinhamento de aminoácido dos domínios VH de 227H1 e 224G11 de murino com as frameworks selecionadas. Na fileira FR humana, apenas o aminoácido que se verificou ser diferente do domínio VH de 224G11 de murino é representado. A fileira HZ VH0 corresponde à versão humanizada total-IMGT do domínio VH de 224G11, conforme obtido para o domínio HZ VH de 227H1 total-IMGT.</span>[000531] Based on this high homology, it was decided to directly transfer the humanization information obtained from humanization of the 227H1 VH domain (see Example 27) and, then, a full humanized version-IMGT was created, as shown in Figure 65 , which represents an amino acid alignment of the murine 227H1 and 224G11 VH domains with the selected frameworks. In the human FR row, only the amino acid that was found to be different from the murine 224G11 VH domain is represented. The HZ VH0 row corresponds to the humanized total-IMGT version of the 224G11 VH domain, as obtained for the 227H1 total-IMGT HZ VH domain.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 137/146</span>Petition 870190095443, of 24/09/2019, p. 137/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">124/131 [000532] A versão humanizada total-IMGT do domínio VH do 224G11 de murino foi, então, construída e suas atividades antiligação à c-Met foram analisadas, quando expresso em combinação com a cadeia leve quimérica de 224G11. Os resultados obtidos a partir do ensaio antiligação direta à c-Met são mostrados na Figura 66, enquanto que a Figura 67 ilustra o ensaio de competição de ligação ao HGF. Dado os dados experimentais obtidos com relação às propriedades antiligação à c-Met do domínio VH de 224G11 humanizado total-IMGT, a sequência de aminoácido resultante, conforme representado na Figura 65, foi selecionada e uma análise bioinformática foi, então, realizada para avaliar o nível de humanidade do assim denominado domínio HZ VH0 de 224G11.</span>124/131 [000532] The humanized total-IMGT version of the murine 224G11 VH domain was then constructed and its anti-binding activities to c-Met were analyzed, when expressed in combination with the 224G11 chimeric light chain. The results obtained from the direct anti-binding assay to c-Met are shown in Figure 66, while Figure 67 illustrates the HGF binding competition assay. Given the experimental data obtained regarding the anti-binding properties to the c-Met of the VH domain of humanized total 224G11-IMGT, the resulting amino acid sequence, as represented in Figure 65, was selected and a bioinformatics analysis was then performed to evaluate the level of humanity of the so-called HZ VH0 domain of 224G11.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000533] Dada a estratégia de humanização aplicada aqui, pode-se referir ao Exemplo 27 para a análise de humanidade da sequência HZ VHO de 224G11. Conforme descrito para a humanização do domínio VH de 227H1, nós confirmamos a confiabilidade do sistema de numeração IMGT e ferramentas de análise de homologia e também demonstramos a possibilidade de transferência da estratégia de humanização entre anticorpos sob os limites de sua homologia intrínseca.</span>[000533] Given the humanization strategy applied here, we can refer to Example 27 for the humanity analysis of the HZ VHO sequence of 224G11. As described for the humanization of the 227H1 VH domain, we confirm the reliability of the IMGT numbering system and homology analysis tools and also demonstrate the possibility of transferring the humanization strategy between antibodies under the limits of their intrinsic homology.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">II - Humanização do domínio variável de cadeia leve de 224G11 [000534] De forma a identificar o melhor candidato humano para a enxertagem de CDR, o gene de linhagem germinativa humana mostrando a melhor identidade com a sequência VL de 224G11 de murino foi buscado. Com o auxílio de ferramentas de análise do banco de dados IMGT, duas possíveis regiões V humanas receptoras para a VL de murino de CDRs de 224G11 foram identificadas. Assim, duas estratégias de humanização foram planejadas para o domínio VL de 224G11. A primeira corresponde a um experimento inicial para uma</span>II - Humanization of the 224G11 light chain variable domain [000534] In order to identify the best human candidate for CDR grafting, the human germline gene showing the best identity with the murine 224G11 VL sequence was sought. With the aid of analysis tools from the IMGT database, two possible human V receptor regions for the murine VL of 224G11 CDRs were identified. Thus, two humanization strategies were planned for the VL domain of 224G11. The first corresponds to an initial experiment for a</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 138/146</span>Petition 870190095443, of 24/09/2019, p. 138/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">125/131 estrutura principal humana com um comprimento de CDR1 mais curto (IGKV3-11*01), a segunda com um comprimento de CDR1 mais longo (IGKV4-1*01).</span>125/131 human main structure with a shorter CDR1 length (IGKV3-11 * 01), the second with a longer CDR1 length (IGKV4-1 * 01).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000535] A Figura 68 representa um alinhamento de aminoácido do domínio VL de 224G11 de murino com as duas frameworks selecionadas. Nas fileiras de FR Hu-FR mais curta e mais longa, apenas o aminoácido que se verificou ser diferente do domínio VL de 224G11 de murino é representado. As fileiras HZ VL3 e HZ VL6 correspondem às versões humanizadas básicas do domínio VL de 224G11 com as mutações mencionadas acima (fileira classificação) claramente identificadas. O número sob cada mutação proposta corresponde à classificação na qual a referida mutação será feita, quer a CDR1-estrutura principal mais curta ou mais longa seja selecionada.</span>[000535] Figure 68 represents an amino acid alignment of the murine 224G11 VL domain with the two selected frameworks. In the rows of shorter and longer FR Hu-FR, only the amino acid that was found to be different from the murine 224G11 VL domain is represented. The rows HZ VL3 and HZ VL6 correspond to the basic humanized versions of the 224G11 VL domain with the mutations mentioned above (classification row) clearly identified. The number under each proposed mutation corresponds to the classification in which the referred mutation will be made, whether the shortest or longest CDR1-main structure is selected.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000536] Em um primeiro conjunto de experimentos, as duas versões humanizadas básicas do domínio VL de 224G11 de murino foram construídas e suas atividades antiligação à c-Met foram analisadas, quando expresso em combinação com a cadeia pesada quimérica de 224G11. Os resultados obtidos a partir do ensaio antiligação direta à cMet são mostrados na Figura 69. Nesse experimento, uma atividade antiligação à c-Met similar foi observada para as versões quiméricas e HZ VL6 (CDR1 mais longa), enquanto que quase nenhuma ligação foi detectada para o anticorpo recombinante 224G11-derivado HZ VL3 (CDR1 mais curta).</span>[000536] In a first set of experiments, the two basic humanized versions of the murine 224G11 VL domain were constructed and their anti-binding activities to c-Met were analyzed, when expressed in combination with the 224G11 chimeric heavy chain. The results obtained from the direct anti-binding assay to cMet are shown in Figure 69. In this experiment, a similar anti-binding activity to c-Met was observed for the chimeric and HZ VL6 (longer CDR1) versions, while almost no link was detected for the recombinant HZ VL3-derived 224G11 antibody (shorter CDR1).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000537] Em um segundo conjunto de experimentos, nós construímos e analisamos as atividades antiligação à c-Met das versões humanizadas implementadas do domínio VH HZ VL6-derivado de 224G11 quando expresso em combinação com a cadeia pesada quimérica de 224G11. Duas formas humanizadas adicionais foram analisadas; na versão HZ VL5, os sete resíduos do terceiro grupo</span>[000537] In a second set of experiments, we built and analyzed the anti-binding activities to the c-Met of the humanized versions implemented from the V4 HZ VL6-derived domain of 224G11 when expressed in combination with the 224G11 chimeric heavy chain. Two additional humanized forms were analyzed; in the HZ VL5 version, the seven residues of the third group</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 139/146</span>Petition 870190095443, of 24/09/2019, p. 139/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">126/131 (classificação 3) são humanizados e, na versão HZ VL4, os quatro resíduos à esquerda no primeiro grupo (resíduos de classificação 1) apenas permaneceram de murino. Os resultados obtidos a partir do ensaio antiligação direta à c-Met são mostrados na Figura 70. Nesse experimento, nenhuma diferença nas capacidades de ligação dos anticorpos recombinantes parcialmente humanizados ou quiméricos 224G11-derivados testados foi observada. Nesse ponto, 18 dos 22 aminoácidos que se verificou serem diferentes entre o domínio VL de 224G11 de murino e a estrutura principal CDR1 mais longa foram analisados e não se verificou serem relevantes para a atividade antiligação à c-Met do domínio VL do 224G11 humanizado, quando combinado com a cadeia pesada quimérica.</span>126/131 (classification 3) are humanized and, in the HZ VL4 version, the four residues on the left in the first group (classification 1 residues) only remained murine. The results obtained from the direct anti-binding assay to c-Met are shown in Figure 70. In this experiment, no difference in the binding capabilities of the partially humanized or chimeric 224G11-derived chimeric antibodies was observed. At that point, 18 of the 22 amino acids that were found to be different between the murine 224G11 VL domain and the longer CDR1 main structure were analyzed and were not found to be relevant to the c-Met anti-binding activity of the humanized 224G11 VL domain, when combined with the chimeric heavy chain.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000538] Então, foi testada a versão humanizada HZ VL4 do domínio VL de 224G11 no ensaio de competição de ligação ao HGF. Conforme mostrado na Figura 71, os resultados obtidos demonstram a atividade competitiva similar dos anticorpos derivados de 224G11 humanizados HZ VL4 e quiméricos recombinante e de murino.</span>[000538] Then, the humanized HZ VL4 version of the 224G11 VL domain was tested in the HGF binding competition trial. As shown in Figure 71, the results obtained demonstrate the similar competitive activity of antibodies derived from humanized 224G11 HZ VL4 and recombinant and murine chimeric.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000539] Nesse estágio da humanização do domínio VL de 224G11, a sequência resultante contém apenas quatro resíduos fora das CDRs provenientes da sequência de origem de murino. Conforme mostrado na Figura 72, esses quatro resíduos §-rotulados são L4, M39, H40 e R84.</span>[000539] At this stage of the humanization of the 224G11 VL domain, the resulting sequence contains only four residues outside the CDRs from the murine source sequence. As shown in Figure 72, these four §-labeled residues are L4, M39, H40 and R84.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000540] Baseado no sistema de numeração IMGT e ferramentas de análise de homologia, nós demonstramos que a estrutura principal mostrando diferenças estruturais em termos de comprimento de CDR ainda podem ser adequadas em um processo de humanização. Foi decidido caracterizar a versão humanizada de cadeias pesada e leve do anticorpo 224G11. Análise por mutagênese dirigida ao sítio da contribuição dos quatro resíduos de murino restantes foi, então, realizada quando expressa em combinação com uma versão</span>[000540] Based on the IMGT numbering system and homology analysis tools, we demonstrate that the main structure showing structural differences in terms of CDR length can still be suitable in a humanization process. It was decided to characterize the humanized heavy and light chain version of the 224G11 antibody. Site-directed mutagenesis analysis of the contribution of the remaining four murine residues was then performed when expressed in combination with a version</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 140/146</span>Petition 870190095443, of 24/09/2019, p. 140/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">127/131 humanizada VH0 da cadeia pesada.</span>127/131 humanized VH0 heavy chain.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">III - Humanização de anticorpo 224G11 [000541] Em uma primeira série de experimentos, nós construímos e analisamos as atividades antiligação à c-Met da versão totalmente humanizada do anticorpo 224G11. Essa versão recombinante abrange os domínios VH e VL VH0 e VL4 humanizados, respectivamente. Os resultados obtidos a partir do ensaio antiligação direta à c-Met são mostrados na Figura 73. Nesse experimento, descobriu-se que a atividade antiligação à c-Met do 224G11 totalmente humano era similar àquela das versões humanizada e quimérica recombinante de uma única cadeia do 224G11. Foi, então, testada a versão totalmente humanizada do domínio VL de 224G11 no ensaio de competição de ligação ao HGF. Os resultados obtidos conforme mostrado na Figura 74 demonstram a atividade competitiva similar dos anticorpos derivados de 224G11 totalmente humanizados e quiméricos recombinantes e de murino de origem.</span>III - Humanization of 224G11 antibody [000541] In a first series of experiments, we built and analyzed the c-Met anti-binding activities of the fully humanized version of the 224G11 antibody. This recombinant version covers the humanized VH and VL VH0 and VL4 domains, respectively. The results obtained from the direct anti-binding assay to c-Met are shown in Figure 73. In this experiment, it was discovered that the c-Met anti-binding activity of the fully human 224G11 was similar to that of the humanized and chimeric recombinant versions of a single chain of 224G11. The fully humanized version of the 224G11 VL domain was then tested in the HGF binding competition trial. The results obtained as shown in Figure 74 demonstrate the similar competitive activity of the fully humanized and recombinant chimeric and murine 224G11 antibodies of origin.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000542] Nesse estágio de humanização do anticorpo 224G11, a sequência resultante contém apenas quatro resíduos fora das CDRs provenientes da sequência do domínio variável de cadeia leve de origem de murino. Foram, então, analisados variantes únicos por mutagênese dirigida ao sítio do domínio VL4 humanizado quando expresso em combinação com uma versão humanizada VH0 da cadeia pesada. Conforme exemplificado na Figura 75 para o ensaio de ligação direta, nós identificamos resíduos relevantes potenciais entre os quatro testados, sendo M39 e H40.</span>[000542] At this stage of humanization of the 224G11 antibody, the resulting sequence contains only four residues outside the CDRs from the sequence of the murine light chain variable domain. Unique variants were then analyzed by mutagenesis directed to the humanized VL4 domain site when expressed in combination with a humanized VH0 heavy chain version. As shown in Figure 75 for the direct binding assay, we identified potential relevant residues among the four tested, being M39 and H40.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000543] Foi decidido analisar múltiplos mutantes do domínio VL HZ VL4 humanizado de 224G11 quando expresso em combinação com o domínio VH HZ VH0 humanizado de 224G11. Conforme mostrado na Figura 76 para o ensaio de ligação direta e na Figura 77 para o ensaio de competição de ligação ao HGF, múltiplos mutantes de aminoácido</span>[000543] It was decided to analyze multiple mutants of the humanized VL HZ VL4 domain of 224G11 when expressed in combination with the humanized VH HZ VH0 domain of 224G11. As shown in Figure 76 for the direct binding assay and Figure 77 for the HGF binding competition assay, multiple amino acid mutants</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 141/146</span>Petition 870190095443, of 24/09/2019, p. 141/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">128/131 do domínio VL4 foram analisados para identificar a melhor combinação humanizada. Baseado em análise de mutantes únicos, descobriu-se, sobre mutantes duplos e triplos que eles podem exibir as melhores atividades anti-cMet. O mutante VH0/VL4-2x corresponde ao domínio VH HZ VH0 de 224G11 expresso com o domínio VL HZ VL4 de 224G11 humanizado com a mutação dupla L4M/R84G. O mutante VH0/VL4-3x corresponde ao domínio VH HZ VH0 de 224G11 humanizado expresso com o domínio VL HZ VL4 de 224G11 humanizado com a mutação tripla L4M/M39L/R84G.</span>128/131 of the VL4 domain were analyzed to identify the best humanized combination. Based on analysis of single mutants, it has been discovered, on double and triple mutants, that they can exhibit the best anti-cMet activities. The VH0 / VL4-2x mutant corresponds to the 224G11 VH HZ VH0 domain expressed with the 224G11 VL HZ VL4 domain humanized with the L4M / R84G double mutation. The VH0 / VL4-3x mutant corresponds to the humanized 224G11 VH HZ VH0 domain expressed with the humanized 224G11 VL HZ VL4 domain with the L4M / M39L / R84G triple mutation.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[000544] Dados os dados experimentais obtidos com relação às propriedades antiligação à c-Met do anticorpo totalmente humanizado 224G11, a análise bioinformática das sequências de domínio variável pesado e leve foi, então, realizada para avaliar o nível de humanidade das melhores versões humanizadas VH0/VL4-2x e VH0/VL4-3x. Foi previamente demonstrado a humanização totalIMGT do domínio VH0 VH de 224G11. Com relação ao nível de humanidade das versões de domínio VL humanizadas VL4-2x e -3x de 224G11, elas contêm apenas resíduos de murino M39 e/ou H40. Esses dois resíduos chave potenciais estão localizados no final da CDR1, M39 sendo a âncora de CDR N-terminal. Dado o problema de comprimento da CDR que foi defrontado durante a humanização do domínio VL de 224G11 e considerando essas posições como parte da definição de Kabat da VL CDR1, o nível de humanidade do anticorpo 224G11 totalmente humanizado mostraria uma imunogenicidade fortemente reduzida em virtude dos resíduos de murino mínimos conservados.</span>[000544] Given the experimental data obtained with respect to the anti-binding properties of the fully humanized antibody 224G11, the bioinformatics analysis of the heavy and light variable domain sequences was then performed to assess the humanity level of the best humanized VH0 versions / VL4-2x and VH0 / VL4-3x. It was previously demonstrated the total humanization IMGT of the VH0 VH domain of 224G11. Regarding the level of humanity of the humanized VL domain versions VL4-2x and -3x of 224G11, they contain only M39 and / or H40 murine residues. These two potential key residues are located at the end of CDR1, M39 being the N-terminal CDR anchor. Given the CDR length problem that was encountered during the humanization of the 224G11 VL domain and considering these positions as part of the Kabat definition of VL CDR1, the humanity level of the fully humanized 224G11 antibody would show a strongly reduced immunogenicity due to the residues conserved minimum murine</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 142/146</span>Petition 870190095443, of 24/09/2019, p. 142/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">129/131</span>129/131</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">RECEBIDO NO CASO DE UM DEPÓSITO ORIGINAL emitido de acordo com a Regra 7.1 pela</span>RECEIVED IN CASE OF AN ORIGINAL DEPOSIT issued in accordance with Rule 7.1 by</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AUTORIDADE DEPOSITÁRIA INTERNACIONAL identificada na parte inferior desta página</span>INTERNATIONAL DEPOSITORY AUTHORITY identified at the bottom of this page</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">TRATADO DE BUDAPESTE SOBRE O RECONHECIMENTO INTERNACIONAL DO DEPÓSITO DE MICROORGANISMOS</span>BUDAPEST TREATY ON INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">PARA FINS DE PROCEDIMENTO DE PATENTE</span>FOR PURPOSE OF PATENT PROCEDURE</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FORMULÁRIO INTERNACIONAL</span>INTERNATIONAL FORM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">PARA</span>FOR</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Pierre Fabre Medicament</span>Pierre Fabre Medicament</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Institut de Recherche Pierre Fabre</span>Institut de Recherche Pierre Fabre</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Centre d’lmmunologie Pierre Fabre</span>Center d’lmmunologie Pierre Fabre</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5, avenue Napoléon III - BP 60497 74164 SAINT-JULIEN EN GENEVOIS</span>5, avenue Napoléon III - BP 60497 74164 SAINT-JULIEN EN GENEVOIS</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">NOME E ENDEREÇO</span>NAME AND ADDRESS</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DO</span>OF</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DEPOSITANTE</span>DEPOSITOR</span>
  </p>
  <p class="style-scope patent-text">
    <tables class="style-scope patent-text">
      <patent-tables class="style-scope patent-text">
        <tgroup cols="2" class="style-scope patent-text">
          
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
I. IDENTIFICAÇÃO DO MICROORGANISMO</span>
I. IDENTIFICATION OF MICROORGANISM</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Referência de identificação fornecida pelo DEPOSITANTE:
F50064-020(2bis)-224G11-Cl1A</span>
Identification reference provided by the DEPOSITOR:
F50064-020 (2is) -224G11-Cl1A</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Número de acesso fornecido pela
AUTORIDADE DEPOSITÁRIA INTERNACIONAL:
CNCM I-3731</span>
Access number provided by
INTERNATIONAL DEPOSITORY AUTHORITY:
CNCM I-3731</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
II. DESCRIÇÃO CIENTÍFICA E/OU DESIGNAÇÃO TAXONÔMICA PROPOSTA</span>
II. SCIENTIFIC DESCRIPTION AND / OR PROPOSED TAXONOMIC DESIGNATION</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
O microorganismo identificado sob I acima foi acompanhado por: [H uma descrição científica
uma designação taxonômmica proposta
(Marcar com um X onde aplicável)</span>
The microorganism identified under I above was accompanied by: [H a scientific description
a proposed taxonomic designation
(Mark with an X where applicable)</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
III. RECEBIMENTO E ACEITAÇÃO</span>
III. RECEIPT AND ACCEPTANCE</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
A presente Autoridade Depositária Internacional aceita o microorganismo identificado sob I acima, o qual foi recebido pela mesma em 14 de Março de 2007 (data do depósito original)<sup class="style-scope patent-text">1</sup> </span>This International Depositary Authority accepts the microorganism identified under I above, which was received by it on March 14, 2007 (date of original deposit) <sup class="style-scope patent-text">1</sup> </span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
IV. RECEBIMENTO DE SICLITAÇÃO PARA CONVERSÃO</span>
IV. RECEIVING SICLITATION FOR CONVERSION</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
O microorganismo identificado sob I acima foi recebido por essa Autoridade Depositária Internacional em (data do depósito original)
e uma solicitação para converter o depósito original em um depósito sob o Tratado de Budapeste foi recebida pela mesma em (data de recebimento da solicitação para conversão)</span>
The microorganism identified under I above was received by that International Depositary Authority on (date of original deposit)
and a request to convert the original deposit into a deposit under the Budapest Treaty was received by (date of receipt of the request for conversion)</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
V. AUTORIDADE DEPOSITÁRIA INTERNACIONAL</span>
V. INTERNATIONAL DEPOSITORY AUTHORITY</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Nome: COLLECTION NATIONALE
DE CULTURES DE MICROORGANISMES (CNCM)
Endereço: Institut Pasteur
25, rue du Docteur Roux
F-75724 Paris Cedex 15 (França)</span>
Name: COLLECTION NATIONALE
OF MICROORGANISM CULTURES (CNCM)
Address: Institut Pasteur
25, rue du Docteur Roux
F-75724 Paris Cedex 15 (France)</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Assinatura(s) da(s) pessoa(s) tendo o poder de representar a Autoridade Depositária Internacional ou do(s) oficial(is) autorizado(s):
Data:
&lt;signature&gt; Georges 'WAGENER
Paris, 25 de Abril de 2007</span>
Signature (s) of the person (s) having the power to represent the International Depositary Authority or authorized official (s):
Date:
&lt;signature&gt; Georges' WAGENER
Paris, April 25, 2007</span>
              </entry>
            </row>
          
        </tgroup>
      </patent-tables>
    </tables>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Onde a Regra 6.4(d) se aplica, tal data é a data na qual o estado de autoridade depositária internacional foi adquirido.</span>Where Rule 6.4 (d) applies, such date is the date on which the status of international depositary authority was acquired.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulário BP/4 (página única)</span>BP / 4 form (single page)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 143/146</span>Petition 870190095443, of 24/09/2019, p. 143/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">130/131</span>130/131</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">TRATADO DE BUDAPESTE SOBRE O RECONHECIMENTO INTERNACIONAL DE DEPÓSITO DE MICROORGANISMOS</span>BUDAPEST TREATY ON INTERNATIONAL RECOGNITION OF DEPOSIT OF MICROORGANISMS</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">PARA FINS DE PROCEDIMENTO DE PATENTE</span>FOR PURPOSE OF PATENT PROCEDURE</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FORMULÁRIO INTERNACIONAL</span>INTERNATIONAL FORM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">PARA</span>FOR</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Madame Nathalie CORVAIA</span>Madame Nathalie CORVAIA</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Madame Liliane GOETSCH</span>Madame Liliane GOETSCH</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Institut de Recherche Pierre Fabre</span>Institut de Recherche Pierre Fabre</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Centre d’lmmunologie Pierre Fabre</span>Center d’lmmunologie Pierre Fabre</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5, avenue Napoléon III - BP 60497 74164 SAINT-JULIEN EN GENEVOIS Cedex</span>5, avenue Napoléon III - BP 60497 74164 SAINT-JULIEN EN GENEVOIS Cedex</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">NOME E ENDEREÇO DA PARTE</span>PART NAME AND ADDRESS</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">À QUAL A DESCLARAÇÃO DE VIABILIDADE</span>TO WHICH THE STATEMENT OF FEASIBILITY</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">É FEITA</span>IS MADE</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DECLARAÇÃO DE VIABILIDADE</span>STATEMENT OF FEASIBILITY</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Emitida de acordo com a Regra 10.2 pela</span>Issued in accordance with Rule 10.2 by</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AUTORIDADE DEPOSITÁRIA INTERNACIONAL identificada na página seguinte</span>INTERNATIONAL DEPOSITORY AUTHORITY identified on the next page</span>
  </p>
  <p class="style-scope patent-text">
    <tables class="style-scope patent-text">
      <patent-tables class="style-scope patent-text">
        <tgroup cols="2" class="style-scope patent-text">
          
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
I. DEPOSITANTE</span>
I. DEPOSITOR</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
II. IDENTIFICAÇÃO DO MICROORGANISMO</span>
II. IDENTIFICATION OF MICROORGANISM</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Nome: PIERRE FABRE MEDICAMENT
Institut de Recherche Pierre Fabre Centre d’lmmunologie Pierre Fabre
Endereço: 5, avenue Napoléon III - BP 60497
74164 SAINT JULIEN EN GENEVOIS</span>
Name: PIERRE FABRE MEDICAMENT
Institut de Recherche Pierre Fabre Center d’lmmunologie Pierre Fabre
Address: 5, avenue Napoléon III - BP 60497
74164 SAINT JULIEN EN GENEVOIS</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Número de acesso fornecido pela
AUTORIDADE DEPOSITÁRIA INTERNACIONAL:
CNCM-3731
Data de depósito ou da transferência<sup class="style-scope patent-text">1</sup>
14 de Março de 2007</span>Access number provided by the INTERNATIONAL DEPOSITORY AUTHORITY: CNCM-3731 Date of deposit or transfer <sup class="style-scope patent-text">1</sup> March 14, 2007</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
III. DECLARAÇÃO DE VIABILIDADE</span>
III. STATEMENT OF FEASIBILITY</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
A viabilidade do microorganismo identificado sob II acima foi testada
em 26 de M arço de 2007 . Nessa data, o referido microorganismo era
Kl <sup class="style-scope patent-text">3</sup> viável
□ <sup class="style-scope patent-text">3</sup> não mais viável</span>The viability of the microorganism identified under II above was tested on March 26, 2007. On that date, said microorganism was viable Kl <sup class="style-scope patent-text">3</sup> □ <sup class="style-scope patent-text">3</sup> no longer viable</span>
              </entry>
            </row>
          
        </tgroup>
      </patent-tables>
    </tables>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <sup class="style-scope patent-text">1</sup> Indicar a data do depósito original ou, onde um novo depósito ou uma transferência foi feita, a data relevante mais recente (data do novo depósito ou data da transferência).</span> <sup class="style-scope patent-text">1</sup> Indicate the date of the original deposit or, where a new deposit or transfer was made, the most recent relevant date (date of new deposit or transfer date).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <sup class="style-scope patent-text">2</sup> Nos casos mencionados na Regra 10.2(a)(ii) e (iii), refira-se ao teste de viabilidade mais recente.</span> <sup class="style-scope patent-text">2</sup> In the cases mentioned in Rule 10.2 (a) (ii) and (iii), refer to the most recent feasibility test.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <sup class="style-scope patent-text">3</sup> Marcar com um X no quadro aplicável.</span> <sup class="style-scope patent-text">3</sup> Mark with an X in the applicable box.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulário BP/9 (primeria página)</span>BP / 9 form (first page)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 144/146</span>Petition 870190095443, of 24/09/2019, p. 144/146</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">131/131</span>131/131</span>
  </p>
  <p class="style-scope patent-text">
    <tables class="style-scope patent-text">
      <patent-tables class="style-scope patent-text">
        <tgroup cols="2" class="style-scope patent-text">
          
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
IV. CONDIÇÕES SOB AS QUAIS O TESTE DE VIABILIDADE FOI REALIZADO<sup class="style-scope patent-text">4</sup> </span>IV. CONDITIONS UNDER WHICH THE FEASIBILITY TEST HAS BEEN PERFORMED <sup class="style-scope patent-text">4</sup> </span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text"> </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
V. AUTORIDADE DEPOSITÁRIA INTERNACIONAL</span>
V. INTERNATIONAL DEPOSITORY AUTHORITY</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Nome:
COLLECTION NATIONALE
DE CULTURES DE MICROORGANISMES (CNCM)
Endereço: Institut Pasteur
25, rue du Docteur Roux
F-75724 Paris Cedex 15 (França)</span>
Name:
COLLECTION NATIONALE
OF MICROORGANISM CULTURES (CNCM)
Address: Institut Pasteur
25, rue du Docteur Roux
F-75724 Paris Cedex 15 (France)</span>
              </entry>
              <entry class="style-scope patent-text">
                <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Assinatura(s) da(s) pessoa(s) tendo o poder de representar a Autoridade Depositária Internacional ou do(s) oficial(is) autorizado(s):
Georges Wagener
&lt;assinatura&gt;
Data: Paris, 25 de Abril de 2007</span>
Signature (s) of the person (s) having the power to represent the International Depositary Authority or authorized official (s):
Georges Wagener
&lt;signature&gt;
Date: Paris, April 25, 2007</span>
              </entry>
            </row>
            <row class="style-scope patent-text">
              <entry class="style-scope patent-text"> </entry>
              <entry class="style-scope patent-text"> </entry>
            </row>
          
        </tgroup>
      </patent-tables>
    </tables>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <sup class="style-scope patent-text">4</sup> Preencher se a informação foi solicitada e se os resultados do teste foram negativos.</span> <sup class="style-scope patent-text">4</sup> Fill in if the information was requested and if the test results were negative.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulário BP/9 (segunda e última página)</span>BP / 9 form (second and last page)</span>
  </p>
</description>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
            <div class="flex flex-width style-scope patent-result">
              <section id="claims" class="style-scope patent-result">
                <h3 class="style-scope patent-result">
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Claims <span class="style-scope patent-result">(21)</span></div>
                    <div class="collapse style-scope patent-result">
                      Hide Dependent <iron-icon style="height: 15px; width: 15px;" icon="expand-less" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 8l-6 6 1.41 1.41L12 10.83l4.59 4.58L18 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </div>
                  </div>
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result"></div>
                    <div class="righthead style-scope patent-result">translated from Portuguese</div>
                  </div>
                </h3>
                <patent-text name="claims" enable-text-selection="" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><claims mxw-id="PCLM238814204" lang="EN" load-source="google" class="style-scope patent-text">
  <claim num="1" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">REIVINDICAÇÕES
    </span></span></claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1. Anticorpo isolado ou um de seus fragmentos divalentes ligados à c-Met, caracterizado pelo fato de que o anticorpo compreende uma cadeia pesada compreendendo CDR-H1, CDR-H2 e CDR-H3 compreendendo, respectivamente, a sequência de aminoácido SEQ ID Nos. 1, 2 e 3; e uma cadeia leve compreendendo CDR-L1, CDR-L2 e CDR-L3 compreendendo, respectivamente, a sequência de aminoácido SEQ ID Nos. 10, 11 e 12.</span>1. Isolated antibody or one of its divalent fragments linked to c-Met, characterized by the fact that the antibody comprises a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3 comprising, respectively, the amino acid sequence SEQ ID Nos . 1, 2 and 3; and a light chain comprising CDR-L1, CDR-L2 and CDR-L3 comprising, respectively, the amino acid sequence SEQ ID Nos. 10, 11 and 12.</span>
    </claim-text>
  </claim>
  <claim num="2" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2. Anticorpo ou um de seus fragmentos divalentes ligados à c-Met de acordo com a reivindicação 1, caracterizado pelo fato de que compreende uma cadeia pesada compreendendo a sequência de aminoácido SEQ ID No. 18 e uma cadeia leve compreendendo a sequência de aminoácido SEQ ID No. 21.</span>2. Antibody or one of its divalent fragments linked to c-Met according to claim 1, characterized in that it comprises a heavy chain comprising the amino acid sequence SEQ ID No. 18 and a light chain comprising the amino acid sequence SEQ ID No. 21.</span>
    </claim-text>
  </claim>
  <claim num="3" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">3. Hibridoma de murino capaz de secretar um anticorpo como definido na reivindicação 2, caracterizado pelo fato de que o referido hibridoma é o hibridoma de murino depositado no CNCM, Institut Pasteur, Paris, em 14 de Março de 2007 sob o número 1-3731.</span>3. Murine hybridoma capable of secreting an antibody as defined in claim 2, characterized by the fact that said hybridoma is the murine hybridoma deposited at the CNCM, Institut Pasteur, Paris, on March 14, 2007 under number 1-3731 .</span>
    </claim-text>
  </claim>
  <claim num="4" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">4. Anticorpo ou um de seus fragmentos divalentes ligados à c-Met de acordo com a reivindicação 1 ou 2, caracterizado pelo fato de que o referido anticorpo é um anticorpo monoclonal.</span>4. Antibody or one of its divalent fragments bound to c-Met according to claim 1 or 2, characterized in that said antibody is a monoclonal antibody.</span>
    </claim-text>
  </claim>
  <claim num="5" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5. Anticorpo ou um de seus fragmentos divalentes ligados à c-Met de acordo com a reivindicação 4, caracterizado pelo fato de que o referido anticorpo é um anticorpo quimérico, em que as regiões constantes de cadeia leve e cadeia pesada são derivadas de um anticorpo humano.</span>5. Antibody or one of its divalent fragments bound to c-Met according to claim 4, characterized in that said antibody is a chimeric antibody, in which the light and heavy chain constant regions are derived from an antibody human.</span>
    </claim-text>
  </claim>
  <claim num="6" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">6. Anticorpo ou um de seus fragmentos divalentes ligados à c-Met de acordo com qualquer uma das reivindicações 1 a 5, caracterizado pelo fato de que é capaz de ligar especificamente à c-Met.</span>6. Antibody or one of its divalent fragments bound to c-Met according to any one of claims 1 to 5, characterized by the fact that it is capable of binding specifically to c-Met.</span>
    </claim-text>
  </claim>
  <claim num="7" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">7. Anticorpo ou um de seus fragmentos divalentes ligados à c-Met de acordo com a reivindicação 6, caracterizado pelo fato de que</span>7. Antibody or one of its divalent fragments linked to c-Met according to claim 6, characterized by the fact that</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 6/146</span>Petition 870190095443, of 24/09/2019, p. 6/146</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2/4 é capaz de inibir a ativação dependente de ligante e independente de ligante de c-Met.</span>2/4 is able to inhibit ligand-dependent and ligand-independent activation of c-Met.</span>
    </claim-text>
  </claim>
  <claim num="8" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">8. Anticorpo ou um de seus fragmentos divalentes ligados à c-Met de acordo com a reivindicação 7, caracterizado pelo fato de que inibe a dimerização de c-Met.</span>8. Antibody or one of its divalent fragments linked to c-Met according to claim 7, characterized by the fact that it inhibits the dimerization of c-Met.</span>
    </claim-text>
  </claim>
  <claim num="9" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">9. Ácido nucleico isolado, caracterizado pelo fato de que é escolhido dos seguintes ácidos nucleicos:</span>9. Isolated nucleic acid, characterized by the fact that it is chosen from the following nucleic acids:</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">a) um ácido nucleico, DNA ou RNA, que codifica um anticorpo ou um de seus fragmentos divalentes ligados à c-Met como definido na reivindicação 1 ou 2;</span>a) a nucleic acid, DNA or RNA, which encodes an antibody or one of its divalent fragments linked to c-Met as defined in claim 1 or 2;</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">b) um ácido nucleico compreendendo uma sequência de DNA compreendendo a sequência SEQ ID No. 24 de CDR-H1, a sequência SEQ ID No. 25 de CDR-H2, a sequência SEQ ID No. 26 de CDR-H3 e a sequência SEQ ID No. 33 de CDR-L1, a sequência SEQ ID No. 34 de CDR-L2 e a sequência SEQ ID No. 35 de CDR-L3;</span>b) a nucleic acid comprising a DNA sequence comprising the CDR-H1 sequence SEQ ID No. 24, the CDR-H2 sequence SEQ ID No. 25, the CDR-H3 sequence SEQ ID No. 26 and the sequence SEQ CDR-L1 ID No. 33, CDR-L2 sequence SEQ ID No. 34 and CDR-L3 sequence SEQ ID No. 35;</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">c) um ácido nucleico compreendendo uma sequência de DNA compreendendo a sequência SEQ ID No. 41 de cadeia pesada e a sequência SEQ ID NO. 44 de cadeia leve;</span>c) a nucleic acid comprising a DNA sequence comprising the heavy chain SEQ ID No. 41 sequence and the SEQ ID NO sequence. 44 light chain;</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">d) os ácidos nucleicos de RNA correspondentes dos ácidos nucleicos como definidos em b) e/ou c); e</span>d) the corresponding RNA nucleic acids of the nucleic acids as defined in b) and / or c); and</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">e) os ácidos nucleicos complementares dos ácidos nucleicos como definidos em a), b) e c).</span>e) nucleic acids complementary to nucleic acids as defined in a), b) and c).</span>
    </claim-text>
  </claim>
  <claim num="10" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10. Vetor, caracterizado pelo fato de que compreende um ácido nucleico como definido na reivindicação 9.</span>10. Vector, characterized by the fact that it comprises a nucleic acid as defined in claim 9.</span>
    </claim-text>
  </claim>
  <claim num="11" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">11. Método para a produção de um anticorpo ou um de seus fragmentos divalentes ligados à c-Met como definido em qualquer uma das reivindicações 1, 2 e 4-8, caracterizado pelo fato de que o método compreende:</span>11. Method for the production of an antibody or one of its divalent fragments linked to c-Met as defined in any one of claims 1, 2 and 4-8, characterized by the fact that the method comprises:</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">a) cultura, em um meio e condições de cultura apropriados, de uma célula hospedeira que compreende um vetor como definido na</span>a) culture, in an appropriate medium and culture conditions, of a host cell comprising a vector as defined in</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 7/146</span>Petition 870190095443, of 24/09/2019, p. 7/146</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">3/4 reivindicação 10; e</span>3/4 claim 10; and</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">b) recuperação dos referidos anticorpos ou um de seus fragmentos divalentes ligados à c-Met do meio de cultura ou das referidas células cultivadas.</span>b) recovering said antibodies or one of their divalent fragments linked to c-Met from the culture medium or from said cultured cells.</span>
    </claim-text>
  </claim>
  <claim num="12" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">12. Anticorpo ou um de seus fragmentos divalentes ligados à c-Met de acordo com qualquer uma das reivindicações 1, 2 e 4 a 8 ou obtido pelo método como definido na reivindicação 11, caracterizado pelo fato de que é para uso como medicamento.</span>12. Antibody or one of its divalent fragments bound to c-Met according to any one of claims 1, 2 and 4 to 8 or obtained by the method as defined in claim 11, characterized by the fact that it is for use as a medicine.</span>
    </claim-text>
  </claim>
  <claim num="13" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">13. Composição, caracterizada pelo fato de que compreende, como um princípio ativo, um composto consistindo em um anticorpo ou um de seus fragmentos divalentes ligados à c-Met como definido em qualquer uma das reivindicações 1, 2 e 4 a 8, ou obtido pelo método como definido na reivindicação 11 ou produzido pelo hibridoma como definido na reivindicação 3.</span>13. Composition, characterized by the fact that it comprises, as an active ingredient, a compound consisting of an antibody or one of its divalent fragments linked to c-Met as defined in any one of claims 1, 2 and 4 to 8, or obtained by the method as defined in claim 11 or produced by the hybridoma as defined in claim 3.</span>
    </claim-text>
  </claim>
  <claim num="14" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">14. Composição de acordo com a reivindicação 13, caracterizada pelo fato de que compreende ainda um agente como um produto combinado para uso simultâneo, separado ou sequencial, e em que o referido agente é um anticorpo antitumoral.</span>Composition according to claim 13, characterized in that it further comprises an agent as a combined product for simultaneous, separate or sequential use, and wherein said agent is an anti-tumor antibody.</span>
    </claim-text>
  </claim>
  <claim num="15" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15. Composição de acordo com a reivindicação 13 ou 14, caracterizada pelo fato de que compreende pelo menos um agente como um produto combinado para uso simultâneo, separado ou sequencial, em que o referido agente é um agente citotóxico/cistostático.</span>Composition according to claim 13 or 14, characterized in that it comprises at least one agent as a combined product for simultaneous, separate or sequential use, wherein said agent is a cytotoxic / cystostatic agent.</span>
    </claim-text>
  </claim>
  <claim num="16" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">16. Composição de acordo com qualquer uma das reivindicações 13 a 15, caracterizada pelo fato de que pelo menos um dos referidos anticorpos ou um de seus fragmentos divalentes ligados à cMet, é conjugado com uma toxina celular e/ou um radioelemento.</span>16. Composition according to any one of claims 13 to 15, characterized in that at least one of said antibodies or one of its divalent fragments bound to cMet, is conjugated to a cellular toxin and / or a radio element.</span>
    </claim-text>
  </claim>
  <claim num="17" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">17. Composição de acordo com qualquer uma das reivindicações 13 a 16, caracterizada pelo fato de que é para uso como um medicamento.</span>17. Composition according to any of claims 13 to 16, characterized by the fact that it is for use as a medicament.</span>
    </claim-text>
  </claim>
  <claim num="18" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">18. Uso de um anticorpo ou um de seus fragmentos diva</span>18. Use of an antibody or one of its diva fragments</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Petição 870190095443, de 24/09/2019, pág. 8/146</span>Petition 870190095443, of 24/09/2019, p. 8/146</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">4/4 lentes ligados à c-Met como definido em qualquer uma das reivindicações 1, 2 e 4-8 ou obtido pelo método como definido na reivindicação 11, ou produzido pelo hibridoma como definido na reivindicação 3 ou de uma composição como definida em qualquer uma das reivindicações 13 a 16, caracterizado pelo fato de que é para o preparo de um medicamento para a prevenção ou para o tratamento de câncer.</span>4/4 lenses attached to c-Met as defined in any one of claims 1, 2 and 4-8 or obtained by the method as defined in claim 11, or produced by the hybridoma as defined in claim 3 or a composition as defined in any one of claims 13 to 16, characterized by the fact that it is for the preparation of a medication for the prevention or treatment of cancer.</span>
    </claim-text>
  </claim>
  <claim num="19" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">19. Uso de acordo com a reivindicação 18, caracterizado pelo fato de que o referido câncer é um câncer escolhido de câncer de próstata, osteosarcomas, câncer de pulmão, câncer de mama, câncer endometrial, glioblastoma ou câncer de cólon.</span>19. Use according to claim 18, characterized by the fact that said cancer is a cancer chosen from prostate cancer, osteosarcomas, lung cancer, breast cancer, endometrial cancer, glioblastoma or colon cancer.</span>
    </claim-text>
  </claim>
  <claim num="20" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20. Uso de acordo com a reivindicação 18 ou 19, caracterizado pelo fato de que o referido câncer é um câncer relacionado à ativação de c-Met selecionado dentre câncer que é dependente e/ou independente de HGF.</span>20. Use according to claim 18 or 19, characterized by the fact that said cancer is a cancer related to the activation of c-Met selected from cancer that is dependent and / or independent of HGF.</span>
    </claim-text>
  </claim>
  <claim num="21" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">21. Método de diagnóstico in vitro de enfermidades induzidas por uma superexpressão ou uma subexpressão do receptor de cMet começando a partir de uma amostra biológica na qual a presença anormal do receptor de c-Met é suspeita, caracterizado pelo fato de que o referido método compreende uma etapa em que a referida amostra biológica é contatada com o anticorpo ou um de seus fragmentos divalentes ligados à c-Met como definido em qualquer uma das reivindicações 1, 2 e 4-8, ou obtido pelo método como definido na reivindicação 11 ou produzido pelo hibridoma como definido na reivindicação 3, sendo possível que o referido anticorpo seja, se necessário, rotulado.</span>21. Method of in vitro diagnosis of diseases induced by an overexpression or an underexpression of the cMet receptor starting from a biological sample in which the abnormal presence of the c-Met receptor is suspected, characterized by the fact that the referred method comprises a step in which said biological sample is contacted with the antibody or one of its divalent fragments bound to c-Met as defined in any one of claims 1, 2 and 4-8, or obtained by the method as defined in claim 11 or produced by the hybridoma as defined in claim 3, it being possible that said antibody is, if necessary, labeled.</span>
    </claim-text>
  </claim>
</claims>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
          </div>

          <div class="footer style-scope patent-result">

            
            <h3 id="patentCitations" class="scroll-target style-scope patent-result">
              Patent Citations (33)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/DE2840250C2/en"><a id="link" href="#" class="style-scope state-modifier">DE2840250C2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1978-09-15</span>
                    <span class="td style-scope patent-result">1983-01-20</span>
                    <span class="td style-scope patent-result">Siemens AG, 1000 Berlin und 8000 München</span>
                    <span class="td style-scope patent-result">
  Circuit arrangement for a line-fed loudspeaker station
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4424200A/en"><a id="link" href="#" class="style-scope state-modifier">US4424200A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1979-05-14</span>
                    <span class="td style-scope patent-result">1984-01-03</span>
                    <span class="td style-scope patent-result">Nuc Med Inc.</span>
                    <span class="td style-scope patent-result">Method for radiolabeling proteins with technetium-99m 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4479930A/en"><a id="link" href="#" class="style-scope state-modifier">US4479930A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1982-07-26</span>
                    <span class="td style-scope patent-result">1984-10-30</span>
                    <span class="td style-scope patent-result">Trustees Of The University Of Massachusetts</span>
                    <span class="td style-scope patent-result">Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4816567A/en"><a id="link" href="#" class="style-scope state-modifier">US4816567A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1983-04-08</span>
                    <span class="td style-scope patent-result">1989-03-28</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Recombinant immunoglobin preparations 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4831175A/en"><a id="link" href="#" class="style-scope state-modifier">US4831175A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1986-09-05</span>
                    <span class="td style-scope patent-result">1989-05-16</span>
                    <span class="td style-scope patent-result">The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services</span>
                    <span class="td style-scope patent-result">Backbone polysubstituted chelates for forming a metal chelate-protein conjugate 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/IL162181A/en"><a id="link" href="#" class="style-scope state-modifier">IL162181A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1988-12-28</span>
                    <span class="td style-scope patent-result">2006-04-10</span>
                    <span class="td style-scope patent-result">Pdl Biopharma Inc</span>
                    <span class="td style-scope patent-result">A method of producing humanized immunoglubulin, and polynucleotides encoding the same 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5530101A/en"><a id="link" href="#" class="style-scope state-modifier">US5530101A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1988-12-28</span>
                    <span class="td style-scope patent-result">1996-06-25</span>
                    <span class="td style-scope patent-result">Protein Design Labs, Inc.</span>
                    <span class="td style-scope patent-result">Humanized immunoglobulins 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB8924581D0/en"><a id="link" href="#" class="style-scope state-modifier">GB8924581D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1989-11-01</span>
                    <span class="td style-scope patent-result">1989-12-20</span>
                    <span class="td style-scope patent-result">Pa Consulting Services</span>
                    <span class="td style-scope patent-result">Bleaching of hair 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB9014932D0/en"><a id="link" href="#" class="style-scope state-modifier">GB9014932D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1990-07-05</span>
                    <span class="td style-scope patent-result">1990-08-22</span>
                    <span class="td style-scope patent-result">Celltech Ltd</span>
                    <span class="td style-scope patent-result">Recombinant dna product and method 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1994004679A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1994004679A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1991-06-14</span>
                    <span class="td style-scope patent-result">1994-03-03</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Method for making humanized antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JPH05244982A/en"><a id="link" href="#" class="style-scope state-modifier">JPH05244982A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1991-12-06</span>
                    <span class="td style-scope patent-result">1993-09-24</span>
                    <span class="td style-scope patent-result">Sumitomo Chem Co Ltd</span>
                    <span class="td style-scope patent-result">Humanized b-b10 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5639641A/en"><a id="link" href="#" class="style-scope state-modifier">US5639641A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-09-09</span>
                    <span class="td style-scope patent-result">1997-06-17</span>
                    <span class="td style-scope patent-result">Immunogen Inc.</span>
                    <span class="td style-scope patent-result">Resurfacing of rodent antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6214344B1/en"><a id="link" href="#" class="style-scope state-modifier">US6214344B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1995-06-02</span>
                    <span class="td style-scope patent-result">2001-04-10</span>
                    <span class="td style-scope patent-result">Genetech, Inc.</span>
                    <span class="td style-scope patent-result">Hepatocyte growth factor receptor antagonists and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5686292A/en"><a id="link" href="#" class="style-scope state-modifier">US5686292A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1995-06-02</span>
                    <span class="td style-scope patent-result">1997-11-11</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Hepatocyte growth factor receptor antagonist antibodies and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/TR199902553T2/en"><a id="link" href="#" class="style-scope state-modifier">TR199902553T2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-04-14</span>
                    <span class="td style-scope patent-result">2000-03-21</span>
                    <span class="td style-scope patent-result">Micromet Gesellschaft F�R Biomedizinische Forschung Mbh</span>
                    <span class="td style-scope patent-result">
  New methods and uses for the production of antigen receptors against the human body.
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7563874B2/en"><a id="link" href="#" class="style-scope state-modifier">US7563874B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-08-31</span>
                    <span class="td style-scope patent-result">2009-07-21</span>
                    <span class="td style-scope patent-result">The Regents Of The University Of California</span>
                    <span class="td style-scope patent-result">Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20060057651A1/en"><a id="link" href="#" class="style-scope state-modifier">US20060057651A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-12-08</span>
                    <span class="td style-scope patent-result">2006-03-16</span>
                    <span class="td style-scope patent-result">Bowdish Katherine S</span>
                    <span class="td style-scope patent-result">Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2476776A1/en"><a id="link" href="#" class="style-scope state-modifier">CA2476776A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-02-21</span>
                    <span class="td style-scope patent-result">2003-09-04</span>
                    <span class="td style-scope patent-result">Duke University</span>
                    <span class="td style-scope patent-result">Reagents and treatment methods for autoimmune diseases 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/BRPI0407446A/en"><a id="link" href="#" class="style-scope state-modifier">BRPI0407446A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-02-13</span>
                    <span class="td style-scope patent-result">2006-01-31</span>
                    <span class="td style-scope patent-result">Pharmacia Corp</span>
                    <span class="td style-scope patent-result">
  C-met Antibodies for cancer treatment
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU2004252067B2/en"><a id="link" href="#" class="style-scope state-modifier">AU2004252067B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-05-09</span>
                    <span class="td style-scope patent-result">2012-04-12</span>
                    <span class="td style-scope patent-result">Duke University</span>
                    <span class="td style-scope patent-result">CD20-specific antibodies and methods of employing same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/HN2004000285A/en"><a id="link" href="#" class="style-scope state-modifier">HN2004000285A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-08-04</span>
                    <span class="td style-scope patent-result">2006-04-27</span>
                    <span class="td style-scope patent-result">Pfizer Prod Inc</span>
                    <span class="td style-scope patent-result">
  ANTIBODIES DIRECTED TO c-MET
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU2004298483A1/en"><a id="link" href="#" class="style-scope state-modifier">AU2004298483A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-12-11</span>
                    <span class="td style-scope patent-result">2005-06-30</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Methods and compositions for inhibiting c-met dimerization and activation 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/NZ552485A/en"><a id="link" href="#" class="style-scope state-modifier">NZ552485A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-08-05</span>
                    <span class="td style-scope patent-result">2009-11-27</span>
                    <span class="td style-scope patent-result">Genentech Inc</span>
                    <span class="td style-scope patent-result">Humanized anti-cmet antagonists 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20060094059A1/en"><a id="link" href="#" class="style-scope state-modifier">US20060094059A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-09-22</span>
                    <span class="td style-scope patent-result">2006-05-04</span>
                    <span class="td style-scope patent-result">Odyssey Thera, Inc.</span>
                    <span class="td style-scope patent-result">Methods for identifying new drug leads and new therapeutic uses for known drugs 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP5837730B2/en"><a id="link" href="#" class="style-scope state-modifier">JP5837730B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-02-10</span>
                    <span class="td style-scope patent-result">2015-12-24</span>
                    <span class="td style-scope patent-result">ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ</span>
                    <span class="td style-scope patent-result">
  Anti-interferon alpha monoclonal antibody and method of use
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8008443B2/en"><a id="link" href="#" class="style-scope state-modifier">US8008443B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-04-26</span>
                    <span class="td style-scope patent-result">2011-08-30</span>
                    <span class="td style-scope patent-result">Medimmune, Llc</span>
                    <span class="td style-scope patent-result">Modulation of antibody effector function by hinge domain engineering 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/NO345593B1/en"><a id="link" href="#" class="style-scope state-modifier">NO345593B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-07-18</span>
                    <span class="td style-scope patent-result">2021-05-03</span>
                    <span class="td style-scope patent-result">Amgen Inc</span>
                    <span class="td style-scope patent-result">
  Human anti-B7RP1 neutralizing antibodies
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2007016285A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2007016285A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-07-28</span>
                    <span class="td style-scope patent-result">2007-02-08</span>
                    <span class="td style-scope patent-result">Novartis Ag</span>
                    <span class="td style-scope patent-result">M-csf specific monoclonal antibody and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2368864T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2368864T3</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-02-06</span>
                    <span class="td style-scope patent-result">2011-11-23</span>
                    <span class="td style-scope patent-result">Metheresis Translational Research Sa</span>
                    <span class="td style-scope patent-result">
  ANTI-MET MONOCLONAL ANTIBODIES, THEIR FRAGMENTS AND VECTORS FOR THE TREATMENT OF CORRESPONDING TUMORS AND PRODUCTS.
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2007126799A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2007126799A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-03-30</span>
                    <span class="td style-scope patent-result">2007-11-08</span>
                    <span class="td style-scope patent-result">Novartis Ag</span>
                    <span class="td style-scope patent-result">Compositions and methods of use for antibodies of c-met 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2143441A1/en"><a id="link" href="#" class="style-scope state-modifier">EP2143441A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-07-08</span>
                    <span class="td style-scope patent-result">2010-01-13</span>
                    <span class="td style-scope patent-result">Pierre Fabre Medicament</span>
                    <span class="td style-scope patent-result">Combination of a  c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AR074439A1/en"><a id="link" href="#" class="style-scope state-modifier">AR074439A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-12-02</span>
                    <span class="td style-scope patent-result">2011-01-19</span>
                    <span class="td style-scope patent-result">Pf Medicament</span>
                    <span class="td style-scope patent-result">
  ANTI-CMET ANTIBODY (C-MET RECEIVER)
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2010064089A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2010064089A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-12-02</span>
                    <span class="td style-scope patent-result">2010-06-10</span>
                    <span class="td style-scope patent-result">Pierre Fabre Medicament</span>
                    <span class="td style-scope patent-result">Novel anti-cmet antibody 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                </div>
              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner, † Cited by third party</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="citedBy" class="scroll-target style-scope patent-result">
              Cited By (97)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2143441A1/en"><a id="link" href="#" class="style-scope state-modifier">EP2143441A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-07-08</span>
                    <span class="td style-scope patent-result">2010-01-13</span>
                    <span class="td style-scope patent-result">Pierre Fabre Medicament</span>
                    <span class="td style-scope patent-result">Combination of a  c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/PA8849001A1/en"><a id="link" href="#" class="style-scope state-modifier">PA8849001A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-11-21</span>
                    <span class="td style-scope patent-result">2010-06-28</span>
                    <span class="td style-scope patent-result">Lilly Co Eli</span>
                    <span class="td style-scope patent-result">
  C-MET ANTIBODIES
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9469691B2/en"><a id="link" href="#" class="style-scope state-modifier">US9469691B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-12-02</span>
                    <span class="td style-scope patent-result">2016-10-18</span>
                    <span class="td style-scope patent-result">Pierre Fabre Medicament</span>
                    <span class="td style-scope patent-result">Anti-cMET antibody 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20140112911A9/en"><a id="link" href="#" class="style-scope state-modifier">US20140112911A9</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-12-02</span>
                    <span class="td style-scope patent-result">2014-04-24</span>
                    <span class="td style-scope patent-result">Liliane Goetsch</span>
                    <span class="td style-scope patent-result">Novel anti-cmet antibody 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AR074439A1/en"><a id="link" href="#" class="style-scope state-modifier">AR074439A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-12-02</span>
                    <span class="td style-scope patent-result">2011-01-19</span>
                    <span class="td style-scope patent-result">Pf Medicament</span>
                    <span class="td style-scope patent-result">
  ANTI-CMET ANTIBODY (C-MET RECEIVER)
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8545839B2/en"><a id="link" href="#" class="style-scope state-modifier">US8545839B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-12-02</span>
                    <span class="td style-scope patent-result">2013-10-01</span>
                    <span class="td style-scope patent-result">Pierre Fabre Medicament</span>
                    <span class="td style-scope patent-result">Anti-c-Met antibody 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20110124368A/en"><a id="link" href="#" class="style-scope state-modifier">KR20110124368A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-04-07</span>
                    <span class="td style-scope patent-result">2011-11-16</span>
                    <span class="td style-scope patent-result">로슈 글리카트 아게</span>
                    <span class="td style-scope patent-result">Bispecific anti-erbb-2/anti-c-met antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20110124369A/en"><a id="link" href="#" class="style-scope state-modifier">KR20110124369A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-04-07</span>
                    <span class="td style-scope patent-result">2011-11-16</span>
                    <span class="td style-scope patent-result">로슈 글리카트 아게</span>
                    <span class="td style-scope patent-result">Bispecific anti-erbb-3/anti-c-met antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2287197A1/en"><a id="link" href="#" class="style-scope state-modifier">EP2287197A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-08-21</span>
                    <span class="td style-scope patent-result">2011-02-23</span>
                    <span class="td style-scope patent-result">Pierre Fabre Medicament</span>
                    <span class="td style-scope patent-result">Anti-cMET antibody and its use for the detection and the diagnosis of cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR101671378B1/en"><a id="link" href="#" class="style-scope state-modifier">KR101671378B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-10-30</span>
                    <span class="td style-scope patent-result">2016-11-01</span>
                    <span class="td style-scope patent-result">삼성전자 주식회사</span>
                    <span class="td style-scope patent-result">c-Met specific antibodies and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR101748707B1/en"><a id="link" href="#" class="style-scope state-modifier">KR101748707B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-11-27</span>
                    <span class="td style-scope patent-result">2017-06-20</span>
                    <span class="td style-scope patent-result">삼성전자주식회사</span>
                    <span class="td style-scope patent-result">c-Met specific antibodies and diagnosis kit for cancer using thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2545077B1/en"><a id="link" href="#" class="style-scope state-modifier">EP2545077B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-03-10</span>
                    <span class="td style-scope patent-result">2018-10-31</span>
                    <span class="td style-scope patent-result">Genmab A/S</span>
                    <span class="td style-scope patent-result">Monoclonal antibodies against c-met 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2808344A1/en"><a id="link" href="#" class="style-scope state-modifier">EP2808344A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-06-01</span>
                    <span class="td style-scope patent-result">2014-12-03</span>
                    <span class="td style-scope patent-result">Monash University</span>
                    <span class="td style-scope patent-result">Antibodies directed to the receptor tyrosine kinase c-Met 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2402370A1/en"><a id="link" href="#" class="style-scope state-modifier">EP2402370A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-06-29</span>
                    <span class="td style-scope patent-result">2012-01-04</span>
                    <span class="td style-scope patent-result">Pierre Fabre Médicament</span>
                    <span class="td style-scope patent-result">Novel antibody for the diagnosis and/or prognosis of cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20130315895A1/en"><a id="link" href="#" class="style-scope state-modifier">US20130315895A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-07-01</span>
                    <span class="td style-scope patent-result">2013-11-28</span>
                    <span class="td style-scope patent-result">Takeda Pharmaceutical Company Limited</span>
                    <span class="td style-scope patent-result">COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/RU2013114360A/en"><a id="link" href="#" class="style-scope state-modifier">RU2013114360A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-08-31</span>
                    <span class="td style-scope patent-result">2014-10-10</span>
                    <span class="td style-scope patent-result">Дженентек, Инк.</span>
                    <span class="td style-scope patent-result">
  BIOMARKERS AND TREATMENT METHODS
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2611928B1/en"><a id="link" href="#" class="style-scope state-modifier">EP2611928B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-09-03</span>
                    <span class="td style-scope patent-result">2016-04-27</span>
                    <span class="td style-scope patent-result">Academia Sinica</span>
                    <span class="td style-scope patent-result">Anti-c-met antibody and methods of use thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US11644471B2/en"><a id="link" href="#" class="style-scope state-modifier">US11644471B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-09-30</span>
                    <span class="td style-scope patent-result">2023-05-09</span>
                    <span class="td style-scope patent-result">Ablynx N.V.</span>
                    <span class="td style-scope patent-result">Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2621953B1/en"><a id="link" href="#" class="style-scope state-modifier">EP2621953B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-09-30</span>
                    <span class="td style-scope patent-result">2017-04-05</span>
                    <span class="td style-scope patent-result">Ablynx N.V.</span>
                    <span class="td style-scope patent-result">Biological materials related to c-met 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2012175741A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2012175741A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-06-23</span>
                    <span class="td style-scope patent-result">2012-12-27</span>
                    <span class="td style-scope patent-result">Ablynx Nv</span>
                    <span class="td style-scope patent-result">Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/RU2608644C2/en"><a id="link" href="#" class="style-scope state-modifier">RU2608644C2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-11-03</span>
                    <span class="td style-scope patent-result">2017-01-23</span>
                    <span class="td style-scope patent-result">арДЖЕН-ИКС Н.В.</span>
                    <span class="td style-scope patent-result">ANTI c-Met RECEPTOR PROTEIN ANTIBODIES 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20130121886A/en"><a id="link" href="#" class="style-scope state-modifier">KR20130121886A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-11-24</span>
                    <span class="td style-scope patent-result">2013-11-06</span>
                    <span class="td style-scope patent-result">글락소 그룹 리미티드</span>
                    <span class="td style-scope patent-result">Multispecific antigen binding proteins targeting hgf 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR101444837B1/en"><a id="link" href="#" class="style-scope state-modifier">KR101444837B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-06-03</span>
                    <span class="td style-scope patent-result">2014-09-30</span>
                    <span class="td style-scope patent-result">한국생명공학연구원</span>
                    <span class="td style-scope patent-result">c-Met-targeting full agonist human antibody with HGF activity and usage thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9573992B2/en"><a id="link" href="#" class="style-scope state-modifier">US9573992B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-06-23</span>
                    <span class="td style-scope patent-result">2017-02-21</span>
                    <span class="td style-scope patent-result">Ablynx N.V.</span>
                    <span class="td style-scope patent-result">Serum albumin binding proteins 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/SG194932A1/en"><a id="link" href="#" class="style-scope state-modifier">SG194932A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-06-30</span>
                    <span class="td style-scope patent-result">2013-12-30</span>
                    <span class="td style-scope patent-result">Genentech Inc</span>
                    <span class="td style-scope patent-result">Anti-c-met antibody formulations 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2748197A2/en"><a id="link" href="#" class="style-scope state-modifier">EP2748197A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-08-26</span>
                    <span class="td style-scope patent-result">2014-07-02</span>
                    <span class="td style-scope patent-result">Merrimack Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Tandem fc bispecific antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/BR112014006419A2/en"><a id="link" href="#" class="style-scope state-modifier">BR112014006419A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-09-19</span>
                    <span class="td style-scope patent-result">2018-08-07</span>
                    <span class="td style-scope patent-result">Genentech Inc</span>
                    <span class="td style-scope patent-result">
  Methods to Treat a Cancer Patient, Kit and Article
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2758430A4/en"><a id="link" href="#" class="style-scope state-modifier">EP2758430A4</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-09-20</span>
                    <span class="td style-scope patent-result">2015-06-03</span>
                    <span class="td style-scope patent-result">Lilly Co Eli</span>
                    <span class="td style-scope patent-result">Anti-c-met antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2850261C/en"><a id="link" href="#" class="style-scope state-modifier">CA2850261C</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-09-30</span>
                    <span class="td style-scope patent-result">2021-04-20</span>
                    <span class="td style-scope patent-result">Ablynx Nv</span>
                    <span class="td style-scope patent-result">C-met immunoglobulin single variable domains 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9346884B2/en"><a id="link" href="#" class="style-scope state-modifier">US9346884B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-09-30</span>
                    <span class="td style-scope patent-result">2016-05-24</span>
                    <span class="td style-scope patent-result">Ablynx N.V.</span>
                    <span class="td style-scope patent-result">Biological materials related to c-Met 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR101865223B1/en"><a id="link" href="#" class="style-scope state-modifier">KR101865223B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-10-05</span>
                    <span class="td style-scope patent-result">2018-06-08</span>
                    <span class="td style-scope patent-result">삼성전자주식회사</span>
                    <span class="td style-scope patent-result">Anti c-Met humanized antibody and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20130036993A/en"><a id="link" href="#" class="style-scope state-modifier">KR20130036993A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-10-05</span>
                    <span class="td style-scope patent-result">2013-04-15</span>
                    <span class="td style-scope patent-result">삼성전자주식회사</span>
                    <span class="td style-scope patent-result">Antibodies specifically binding to epitope in sema domain of c-met 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20130037153A/en"><a id="link" href="#" class="style-scope state-modifier">KR20130037153A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-10-05</span>
                    <span class="td style-scope patent-result">2013-04-15</span>
                    <span class="td style-scope patent-result">삼성전자주식회사</span>
                    <span class="td style-scope patent-result">Anti c-met antibody and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9926364B2/en"><a id="link" href="#" class="style-scope state-modifier">US9926364B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-11-03</span>
                    <span class="td style-scope patent-result">2018-03-27</span>
                    <span class="td style-scope patent-result">Argen-X N.V.</span>
                    <span class="td style-scope patent-result">Chimeric human-llama antigens and methods of use 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU2012340826A1/en"><a id="link" href="#" class="style-scope state-modifier">AU2012340826A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-11-21</span>
                    <span class="td style-scope patent-result">2014-05-29</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Purification of anti-c-met antibodies 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2785741A1/en"><a id="link" href="#" class="style-scope state-modifier">EP2785741A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-12-02</span>
                    <span class="td style-scope patent-result">2014-10-08</span>
                    <span class="td style-scope patent-result">Cancer Research Technology Limited</span>
                    <span class="td style-scope patent-result">Antibodies against hgf - receptor and uses 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR101910601B1/en"><a id="link" href="#" class="style-scope state-modifier">KR101910601B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-12-22</span>
                    <span class="td style-scope patent-result">2018-10-23</span>
                    <span class="td style-scope patent-result">삼성전자주식회사</span>
                    <span class="td style-scope patent-result">Deimmunized anti c-Met humanized antibody and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2013130565A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2013130565A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-02-29</span>
                    <span class="td style-scope patent-result">2013-09-06</span>
                    <span class="td style-scope patent-result">The Brigham And Women's Hosptial, Inc.</span>
                    <span class="td style-scope patent-result">Neutralizing antibody for epstein barr virus associated disease 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2013152252A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2013152252A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-04-06</span>
                    <span class="td style-scope patent-result">2013-10-10</span>
                    <span class="td style-scope patent-result">OSI Pharmaceuticals, LLC</span>
                    <span class="td style-scope patent-result">Combination anti-cancer therapy 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2013192594A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2013192594A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-06-21</span>
                    <span class="td style-scope patent-result">2013-12-27</span>
                    <span class="td style-scope patent-result">Sorrento Therapeutics Inc.</span>
                    <span class="td style-scope patent-result">Antigen binding proteins that bind c-met 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR101938699B1/en"><a id="link" href="#" class="style-scope state-modifier">KR101938699B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-07-23</span>
                    <span class="td style-scope patent-result">2019-01-16</span>
                    <span class="td style-scope patent-result">삼성전자주식회사</span>
                    <span class="td style-scope patent-result">Use of LRIG1 as a biomarker for identifying a subject for application of anti-c-Met antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR101938698B1/en"><a id="link" href="#" class="style-scope state-modifier">KR101938698B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-07-23</span>
                    <span class="td style-scope patent-result">2019-01-16</span>
                    <span class="td style-scope patent-result">삼성전자주식회사</span>
                    <span class="td style-scope patent-result">Use of Cbl as a biomarker for identifying a subject for application of anti c-Met antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10413620B2/en"><a id="link" href="#" class="style-scope state-modifier">US10413620B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-08-17</span>
                    <span class="td style-scope patent-result">2019-09-17</span>
                    <span class="td style-scope patent-result">The Regents Of The University Of Colorado, A Body Corporate</span>
                    <span class="td style-scope patent-result">Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU2013302441B2/en"><a id="link" href="#" class="style-scope state-modifier">AU2013302441B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-08-17</span>
                    <span class="td style-scope patent-result">2018-05-10</span>
                    <span class="td style-scope patent-result">The Regents Of The University Of Colorado, A Body Corporate</span>
                    <span class="td style-scope patent-result">Compositions and methods for detecting complement activation 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP5614733B2/en"><a id="link" href="#" class="style-scope state-modifier">JP5614733B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-09-05</span>
                    <span class="td style-scope patent-result">2014-10-29</span>
                    <span class="td style-scope patent-result">Jsr株式会社</span>
                    <span class="td style-scope patent-result">
  Screening method for substances that affect epithelial maintenance of cells
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ME03486B/en"><a id="link" href="#" class="style-scope state-modifier">ME03486B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-10-12</span>
                    <span class="td style-scope patent-result">2020-01-20</span>
                    <span class="td style-scope patent-result">Medimmune Ltd</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines and conjugates thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20150259430A1/en"><a id="link" href="#" class="style-scope state-modifier">US20150259430A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-11-05</span>
                    <span class="td style-scope patent-result">2015-09-17</span>
                    <span class="td style-scope patent-result">Mab Discovery Gmbh</span>
                    <span class="td style-scope patent-result">Method for the production of multispecific antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2727941A1/en"><a id="link" href="#" class="style-scope state-modifier">EP2727941A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-11-05</span>
                    <span class="td style-scope patent-result">2014-05-07</span>
                    <span class="td style-scope patent-result">MAB Discovery GmbH</span>
                    <span class="td style-scope patent-result">Method for the production of multispecific antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2014074907A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2014074907A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-11-09</span>
                    <span class="td style-scope patent-result">2014-05-15</span>
                    <span class="td style-scope patent-result">Indi Molecular, Inc.</span>
                    <span class="td style-scope patent-result">C-met-specific capture agents, compositions, and methods of using and making 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR101911048B1/en"><a id="link" href="#" class="style-scope state-modifier">KR101911048B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-01-29</span>
                    <span class="td style-scope patent-result">2018-10-24</span>
                    <span class="td style-scope patent-result">삼성전자주식회사</span>
                    <span class="td style-scope patent-result">Pharmaceutical composition for combination therapy containing p53 activator and c-Met inhibitor 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2016509045A/en"><a id="link" href="#" class="style-scope state-modifier">JP2016509045A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-02-22</span>
                    <span class="td style-scope patent-result">2016-03-24</span>
                    <span class="td style-scope patent-result">エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト</span>
                    <span class="td style-scope patent-result">
  How to treat cancer and prevent drug resistance
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2016510755A/en"><a id="link" href="#" class="style-scope state-modifier">JP2016510755A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-03-06</span>
                    <span class="td style-scope patent-result">2016-04-11</span>
                    <span class="td style-scope patent-result">メリマック ファーマシューティカルズ インコーポレーティッド</span>
                    <span class="td style-scope patent-result">
  Anti-C-MET Tandem Fc Bispecific Antibody
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN105209077B/en"><a id="link" href="#" class="style-scope state-modifier">CN105209077B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-03-13</span>
                    <span class="td style-scope patent-result">2019-06-11</span>
                    <span class="td style-scope patent-result">麦迪穆有限责任公司</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines Zhuo and its conjugate 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR102049990B1/en"><a id="link" href="#" class="style-scope state-modifier">KR102049990B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-03-28</span>
                    <span class="td style-scope patent-result">2019-12-03</span>
                    <span class="td style-scope patent-result">삼성전자주식회사</span>
                    <span class="td style-scope patent-result">Fusion protein comprising anti-c-Met antibody and VEGF binding fragment 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR102139607B1/en"><a id="link" href="#" class="style-scope state-modifier">KR102139607B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-04-01</span>
                    <span class="td style-scope patent-result">2020-07-30</span>
                    <span class="td style-scope patent-result">삼성전자주식회사</span>
                    <span class="td style-scope patent-result">Pharmaceutical composition for combination therapy containing anti-c-Met antibody and FGFR inhibitor 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR102089591B1/en"><a id="link" href="#" class="style-scope state-modifier">KR102089591B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-07-29</span>
                    <span class="td style-scope patent-result">2020-03-18</span>
                    <span class="td style-scope patent-result">삼성전자주식회사</span>
                    <span class="td style-scope patent-result">Anti-EGFR scFv fragment and Bispecific anti-c-Met/anti-EGFR antibodies comprising the same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2015031614A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2015031614A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-08-28</span>
                    <span class="td style-scope patent-result">2015-03-05</span>
                    <span class="td style-scope patent-result">Abbvie Inc.</span>
                    <span class="td style-scope patent-result">Soluble cmet assay 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2015031626A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2015031626A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-08-28</span>
                    <span class="td style-scope patent-result">2015-03-05</span>
                    <span class="td style-scope patent-result">Abbvie Inc.</span>
                    <span class="td style-scope patent-result">Soluble cmet assay 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2015051159A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2015051159A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-10-02</span>
                    <span class="td style-scope patent-result">2015-04-09</span>
                    <span class="td style-scope patent-result">The Rockefeller University</span>
                    <span class="td style-scope patent-result">Amyloid protofibril antibodies and methods of use thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9717715B2/en"><a id="link" href="#" class="style-scope state-modifier">US9717715B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-11-15</span>
                    <span class="td style-scope patent-result">2017-08-01</span>
                    <span class="td style-scope patent-result">Samsung Electronics Co., Ltd.</span>
                    <span class="td style-scope patent-result">Method of combination therapy using an anti-C-Met antibody 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN107002119A/en"><a id="link" href="#" class="style-scope state-modifier">CN107002119A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-03-24</span>
                    <span class="td style-scope patent-result">2017-08-01</span>
                    <span class="td style-scope patent-result">豪夫迈·罗氏有限公司</span>
                    <span class="td style-scope patent-result">Treatment of cancer and the former and associating that HGF is expressed using C MET antagonists 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20170005016A/en"><a id="link" href="#" class="style-scope state-modifier">KR20170005016A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-05-23</span>
                    <span class="td style-scope patent-result">2017-01-11</span>
                    <span class="td style-scope patent-result">제넨테크, 인크.</span>
                    <span class="td style-scope patent-result">Mit biomarkers and methods using the same 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10188746B2/en"><a id="link" href="#" class="style-scope state-modifier">US10188746B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-09-10</span>
                    <span class="td style-scope patent-result">2019-01-29</span>
                    <span class="td style-scope patent-result">Medimmune Limited</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines and conjugates thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/IL250902B/en"><a id="link" href="#" class="style-scope state-modifier">IL250902B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-09-16</span>
                    <span class="td style-scope patent-result">2022-08-01</span>
                    <span class="td style-scope patent-result">Symphogen As</span>
                    <span class="td style-scope patent-result">Anti-met antibodies and compositions 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2018503596A/en"><a id="link" href="#" class="style-scope state-modifier">JP2018503596A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-10-03</span>
                    <span class="td style-scope patent-result">2018-02-08</span>
                    <span class="td style-scope patent-result">アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ</span>
                    <span class="td style-scope patent-result">
  Antibodies against pathological forms of TDP-43 and uses thereof
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2016053610A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2016053610A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-10-03</span>
                    <span class="td style-scope patent-result">2016-04-07</span>
                    <span class="td style-scope patent-result">Academia Sinica</span>
                    <span class="td style-scope patent-result">Antibodies against pathological forms of tdp-43 and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US11035860B2/en"><a id="link" href="#" class="style-scope state-modifier">US11035860B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-11-20</span>
                    <span class="td style-scope patent-result">2021-06-15</span>
                    <span class="td style-scope patent-result">Stichting Katholieke Universiteit</span>
                    <span class="td style-scope patent-result">Auto-active and intracellular mutant of MET 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10398774B2/en"><a id="link" href="#" class="style-scope state-modifier">US10398774B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-12-09</span>
                    <span class="td style-scope patent-result">2019-09-03</span>
                    <span class="td style-scope patent-result">INSERM (Institut National de la Santé et de la Recherche Médicale)</span>
                    <span class="td style-scope patent-result">Human monoclonal antibodies against AXL 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2016097313A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2016097313A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-12-19</span>
                    <span class="td style-scope patent-result">2016-06-23</span>
                    <span class="td style-scope patent-result">Ablynx N.V.</span>
                    <span class="td style-scope patent-result">Cysteine linked nanobody dimers 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2016135041A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2016135041A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-02-26</span>
                    <span class="td style-scope patent-result">2016-09-01</span>
                    <span class="td style-scope patent-result">INSERM (Institut National de la Santé et de la Recherche Médicale)</span>
                    <span class="td style-scope patent-result">Fusion proteins and antibodies comprising thereof for promoting apoptosis 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20180057595A1/en"><a id="link" href="#" class="style-scope state-modifier">US20180057595A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-03-16</span>
                    <span class="td style-scope patent-result">2018-03-01</span>
                    <span class="td style-scope patent-result">Celldex Therapeutics, Inc.</span>
                    <span class="td style-scope patent-result">Anti-MET Antibodies and Methods of Use Thereof 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10273305B2/en"><a id="link" href="#" class="style-scope state-modifier">US10273305B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-04-02</span>
                    <span class="td style-scope patent-result">2019-04-30</span>
                    <span class="td style-scope patent-result">Ablynx N.V.</span>
                    <span class="td style-scope patent-result">Bispecific CXCR4-CD4 polypeptides with potent anti-HIV activity 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/TW201709932A/en"><a id="link" href="#" class="style-scope state-modifier">TW201709932A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-06-12</span>
                    <span class="td style-scope patent-result">2017-03-16</span>
                    <span class="td style-scope patent-result">西雅圖遺傳學公司</span>
                    <span class="td style-scope patent-result">CD123 antibodies and conjugates thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2017062496A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2017062496A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-10-05</span>
                    <span class="td style-scope patent-result">2017-04-13</span>
                    <span class="td style-scope patent-result">University Of Virginia Patent Foundation</span>
                    <span class="td style-scope patent-result">Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2019500011A/en"><a id="link" href="#" class="style-scope state-modifier">JP2019500011A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-11-03</span>
                    <span class="td style-scope patent-result">2019-01-10</span>
                    <span class="td style-scope patent-result">メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ</span>
                    <span class="td style-scope patent-result">
  Bispecific antibodies with enhanced tumor selectivity and inhibition and uses thereof
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US11046782B2/en"><a id="link" href="#" class="style-scope state-modifier">US11046782B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-03-30</span>
                    <span class="td style-scope patent-result">2021-06-29</span>
                    <span class="td style-scope patent-result">Musc Foundation For Research Development</span>
                    <span class="td style-scope patent-result">Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/LT3458102T/en"><a id="link" href="#" class="style-scope state-modifier">LT3458102T</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-05-17</span>
                    <span class="td style-scope patent-result">2020-08-25</span>
                    <span class="td style-scope patent-result">Abbvie Biotherapeutics Inc.</span>
                    <span class="td style-scope patent-result">Anti-cmet antibody drug conjugates and methods for their use 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/TW201811824A/en"><a id="link" href="#" class="style-scope state-modifier">TW201811824A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-07-06</span>
                    <span class="td style-scope patent-result">2018-04-01</span>
                    <span class="td style-scope patent-result">美商西建公司</span>
                    <span class="td style-scope patent-result">Antibodies with low immunogenicity and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2019534882A/en"><a id="link" href="#" class="style-scope state-modifier">JP2019534882A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-10-11</span>
                    <span class="td style-scope patent-result">2019-12-05</span>
                    <span class="td style-scope patent-result">メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ</span>
                    <span class="td style-scope patent-result">
  Antibody-drug conjugates with immune-mediated therapeutics
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/TWI782930B/en"><a id="link" href="#" class="style-scope state-modifier">TWI782930B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-11-16</span>
                    <span class="td style-scope patent-result">2022-11-11</span>
                    <span class="td style-scope patent-result">美商再生元醫藥公司</span>
                    <span class="td style-scope patent-result">Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2018129029A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2018129029A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-01-04</span>
                    <span class="td style-scope patent-result">2018-07-12</span>
                    <span class="td style-scope patent-result">Immunogen, Inc.</span>
                    <span class="td style-scope patent-result">Met antibodies and immunoconjugates and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2019018538A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2019018538A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-07-20</span>
                    <span class="td style-scope patent-result">2019-01-24</span>
                    <span class="td style-scope patent-result">H. Lee Moffitt Cancer Center And Research Institute, Inc.</span>
                    <span class="td style-scope patent-result">Recombinant cd123-binding antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2019117691A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2019117691A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-12-15</span>
                    <span class="td style-scope patent-result">2019-06-20</span>
                    <span class="td style-scope patent-result">경북대학교 산학협력단</span>
                    <span class="td style-scope patent-result">Peptides binding to cd44v6 and use thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR102194025B1/en"><a id="link" href="#" class="style-scope state-modifier">KR102194025B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-12-15</span>
                    <span class="td style-scope patent-result">2020-12-22</span>
                    <span class="td style-scope patent-result">경북대학교 산학협력단</span>
                    <span class="td style-scope patent-result">CD44v6 binding peptide and use thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN112040769B/en"><a id="link" href="#" class="style-scope state-modifier">CN112040769B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-03-24</span>
                    <span class="td style-scope patent-result">2023-05-16</span>
                    <span class="td style-scope patent-result">瑞泽恩制药公司</span>
                    <span class="td style-scope patent-result">Genetically modified non-human animals, methods of manufacture and use for producing therapeutic antibodies against peptide-MHC complexes 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/MX2020012418A/en"><a id="link" href="#" class="style-scope state-modifier">MX2020012418A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-05-23</span>
                    <span class="td style-scope patent-result">2021-04-28</span>
                    <span class="td style-scope patent-result">Adc Therapeutics Sa</span>
                    <span class="td style-scope patent-result">Molecular adjuvant. 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2020014306A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2020014306A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-07-10</span>
                    <span class="td style-scope patent-result">2020-01-16</span>
                    <span class="td style-scope patent-result">Immunogen, Inc.</span>
                    <span class="td style-scope patent-result">Met antibodies and immunoconjugates and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN109541221B/en"><a id="link" href="#" class="style-scope state-modifier">CN109541221B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-10-24</span>
                    <span class="td style-scope patent-result">2022-03-22</span>
                    <span class="td style-scope patent-result">益善生物技术股份有限公司</span>
                    <span class="td style-scope patent-result">c-Met specific antibody, composition and kit 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN114340684A/en"><a id="link" href="#" class="style-scope state-modifier">CN114340684A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-09-16</span>
                    <span class="td style-scope patent-result">2022-04-12</span>
                    <span class="td style-scope patent-result">瑞泽恩制药公司</span>
                    <span class="td style-scope patent-result">Radiolabeled MET binding proteins for immunopet imaging 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20230372528A1/en"><a id="link" href="#" class="style-scope state-modifier">US20230372528A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-10-16</span>
                    <span class="td style-scope patent-result">2023-11-23</span>
                    <span class="td style-scope patent-result">University Of Georgia Research Foundation, Inc.</span>
                    <span class="td style-scope patent-result">Glycoconjugates 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2022126416A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2022126416A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-12-16</span>
                    <span class="td style-scope patent-result">2022-06-23</span>
                    <span class="td style-scope patent-result">武汉友芝友生物制药股份有限公司</span>
                    <span class="td style-scope patent-result">Anti-bcma antibody, preparation method therefor and application thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN112679614B/en"><a id="link" href="#" class="style-scope state-modifier">CN112679614B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-01-15</span>
                    <span class="td style-scope patent-result">2022-08-16</span>
                    <span class="td style-scope patent-result">广东安普泽生物医药股份有限公司</span>
                    <span class="td style-scope patent-result">Antibody for specifically binding RANKL targeted therapeutic drug and application thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB202102396D0/en"><a id="link" href="#" class="style-scope state-modifier">GB202102396D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-02-19</span>
                    <span class="td style-scope patent-result">2021-04-07</span>
                    <span class="td style-scope patent-result">Adc Therapeutics Sa</span>
                    <span class="td style-scope patent-result">Molecular adjuvant 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN112946279A/en"><a id="link" href="#" class="style-scope state-modifier">CN112946279A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-03-17</span>
                    <span class="td style-scope patent-result">2021-06-11</span>
                    <span class="td style-scope patent-result">扬州大学</span>
                    <span class="td style-scope patent-result">Method for detecting serum biomarkers of cervical cancer patient by using sandwich SERS (surface enhanced Raman scattering) immunosensor based on oil-water interface self-assembly 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/UY39743A/en"><a id="link" href="#" class="style-scope state-modifier">UY39743A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-04-29</span>
                    <span class="td style-scope patent-result">2022-11-30</span>
                    <span class="td style-scope patent-result">Abbvie Inc</span>
                    <span class="td style-scope patent-result">
  ANTI-C-MET ANTIBODY AND DRUG CONJUGATES
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/TW202334429A/en"><a id="link" href="#" class="style-scope state-modifier">TW202334429A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-10-01</span>
                    <span class="td style-scope patent-result">2023-09-01</span>
                    <span class="td style-scope patent-result">中央研究院</span>
                    <span class="td style-scope patent-result">Antibody specific to spike protein of sars-cov-2 and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20230279080A1/en"><a id="link" href="#" class="style-scope state-modifier">US20230279080A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-12-27</span>
                    <span class="td style-scope patent-result">2023-09-07</span>
                    <span class="td style-scope patent-result">Academia Sinica</span>
                    <span class="td style-scope patent-result">Antibody specific to spike protein of sars-cov-2 and uses thereof 
     </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>

              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner, † Cited by third party, ‡ Family to family citation</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="similarDocuments" class="scroll-target style-scope patent-result">
              Similar Documents
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication</span>
                    <span class="th style-scope patent-result">Publication Date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8871909B2/en"><a id="link" href="#" class="style-scope state-modifier">US8871909B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-10-28</span>
                    <span class="td style-scope patent-result">Antibodies inhibiting c-Met dimerization and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU2016228280B2/en"><a id="link" href="#" class="style-scope state-modifier">AU2016228280B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-02-21</span>
                    <span class="td style-scope patent-result">Novel antibodies inhibiting c-met dimerization, and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU2014200630B2/en"><a id="link" href="#" class="style-scope state-modifier">AU2014200630B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-10-06</span>
                    <span class="td style-scope patent-result">Novel antibodies inhibiting c-met dimerization, and uses thereof 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="relatedApplications" class="scroll-target style-scope patent-result">Priority And Related Applications</h3>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="appsClaimingPriority" class="scroll-target style-scope patent-result">
              Applications Claiming Priority (4)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US92978907P<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2007-07-12</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2014681A1/en"><a id="link" href="#" class="style-scope state-modifier">EP07301231A</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2007-07-12</span>
                    <span class="td style-scope patent-result">Novel antibodies inhibiting c-met dimerization, and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US2063908P<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2008-01-11</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2009007427A2/en"><a id="link" href="#" class="style-scope state-modifier">PCT/EP2008/059026</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2008-07-10</span>
                    <span class="td style-scope patent-result">Novel antibodies inhibiting c-met dimerization, and uses thereof 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="legalEvents" class="scroll-target style-scope patent-result">
              Legal Events
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Date</span>
                    <span class="th style-scope patent-result">Code</span>
                    <span class="th style-scope patent-result">Title</span>
                    <span class="th style-scope patent-result">Description</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2017-03-28</span>
                    <span class="td nowrap style-scope patent-result">B07D</span>
                    <span class="td nowrap style-scope patent-result">Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]</span>
                    <span class="td style-scope patent-result">
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2018-04-17</span>
                    <span class="td nowrap style-scope patent-result">B07E</span>
                    <span class="td nowrap style-scope patent-result">Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]</span>
                    <span class="td style-scope patent-result">
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2018-04-24</span>
                    <span class="td nowrap style-scope patent-result">B06F</span>
                    <span class="td nowrap style-scope patent-result">Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]</span>
                    <span class="td style-scope patent-result">
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2018-09-04</span>
                    <span class="td nowrap style-scope patent-result">B06T</span>
                    <span class="td nowrap style-scope patent-result">Formal requirements before examination [chapter 6.20 patent gazette]</span>
                    <span class="td style-scope patent-result">
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2019-07-02</span>
                    <span class="td nowrap style-scope patent-result">B06A</span>
                    <span class="td nowrap style-scope patent-result">Patent application procedure suspended [chapter 6.1 patent gazette]</span>
                    <span class="td style-scope patent-result">
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2019-11-26</span>
                    <span class="td nowrap style-scope patent-result">B09A</span>
                    <span class="td nowrap style-scope patent-result">Decision: intention to grant [chapter 9.1 patent gazette]</span>
                    <span class="td style-scope patent-result">
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2020-01-21</span>
                    <span class="td nowrap style-scope patent-result">B16A</span>
                    <span class="td nowrap style-scope patent-result">Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/01/2020,  OBSERVADAS AS CONDICOES LEGAIS.</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2021-05-25</span>
                    <span class="td nowrap style-scope patent-result">B16C</span>
                    <span class="td nowrap style-scope patent-result">Correction of notification of the grant [chapter 16.3 patent gazette]</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/07/2008  OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <div id="notices" class="vertical layout center style-scope patent-result">
              
                <span class="style-scope patent-result">Data provided by IFI CLAIMS Patent Services</span>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
          </div>
          <div class="bottombar style-scope patent-result">
            <bottom-bar class="style-scope patent-result"><template is="dom-if" class="style-scope bottom-bar"></template>
</bottom-bar>
          </div>
        </div>
      </div>
      <template is="dom-if" class="style-scope patent-result"></template>
    </div>
  </patent-result>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
  </result-container>
        </div>
      </div>
    
        </div>
      </div>
      <search-footer class="style-scope search-ui">
    
    

    <div id="footer" class="vertical layout center style-scope search-footer">
        <span class="links style-scope search-footer">
          <overlay-tooltip positioning-target="#footerAbout" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Learn more about data coverage, search syntax and other features.
    </div>
  </overlay-tooltip>
          <a id="footerAbout" data-proto="ABOUT" href="https://support.google.com/faqs/answer/6390996" target="_blank" class="style-scope search-footer">About</a>
          <overlay-tooltip positioning-target="#footerFeedback" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Send feedback about technical issues or feature requests for Google Patents.
    </div>
  </overlay-tooltip>
          <a id="footerFeedback" data-proto="SEND_FEEDBACK" href="#" onclick="sendFeedback();" class="style-scope search-footer">Send Feedback</a>
          <a data-proto="PUBLIC_DATASETS" href="https://console.cloud.google.com/marketplace/product/google_patents_public_datasets/google-patents-public-data" target="_blank" class="style-scope search-footer">Public Datasets</a>
          <a data-proto="TERMS" href="https://www.google.com/policies/terms/" target="_blank" class="style-scope search-footer">Terms</a>
          <a data-proto="PRIVACY_POLICY" href="https://www.google.com/privacy/privacy-policy.html" target="blank" class="style-scope search-footer">Privacy Policy</a>
          <a data-proto="SEARCH_HELP" href="https://support.google.com/websearch/" target="_blank" class="style-scope search-footer">Help</a>
        </span>
    </div>
  </search-footer>
    </div>

  </search-ui>
  </search-result>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <paper-toast id="toast" duration="3000" class="style-scope search-app x-scope paper-toast-0" aria-hidden="true" style="outline: none; display: none;">
    

    <span id="label" class="style-scope paper-toast"></span>
    
      <div id="noticeContent" class="style-scope search-app"></div>
    
  </paper-toast>
  </search-app>
    <script type="text/javascript" src="//www.gstatic.com/feedback/api.js"></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/js/help/prod/service/lazy.min.js"></script>
    <script type="text/javascript">
      if (window.help && window.help.service) {
        helpApi = window.help.service.Lazy.create(0, {apiKey: 'AIzaSyDTEI_0tLX4varJ7bwK8aT-eOI5qr3BmyI', locale: 'en-US'});
        window.requestedSurveys = new Set();
        window.requestSurvey = function(triggerId) {
          if (window.requestedSurveys.has(triggerId)) {
            return;
          }
          window.requestedSurveys.add(triggerId);
          helpApi.requestSurvey({
            triggerId: triggerId,
            enableTestingMode: false,
            callback: (requestSurveyCallbackParam) => {
              if (!requestSurveyCallbackParam.surveyData) {
                return;
              }
              helpApi.presentSurvey({
                productData: {
                  productVersion: window.version,
                  customData: {
                    "experiments": "",
                  },
                },
                surveyData: requestSurveyCallbackParam.surveyData,
                colorScheme: 1,
                customZIndex: 10000,
              });
            }
          });
        };

        window.requestSurvey('YXTwAsvoW0kedxbuTdH0RArc9VhT');
      }
    </script>
    <script src="/sw/null_loader.js"></script>
  

<iframe id="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.1968303812" name="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.1968303812" style="width: 1px; height: 1px; position: absolute; top: -100px; display: none;" src="https://scone-pa.clients6.google.com/static/proxy.html?usegapi=1&amp;jsh=m%3B%2F_%2Fscs%2Fabc-static%2F_%2Fjs%2Fk%3Dgapi.lb.en.IKZeRvoAYNY.O%2Fam%3DAAAQ%2Fd%3D1%2Frs%3DAHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw%2Fm%3D__features__#parent=https%3A%2F%2Fpatents.google.com&amp;rpctoken=656656419" tabindex="-1" aria-hidden="true"></iframe><iron-a11y-announcer>
    
    <div class="style-scope iron-a11y-announcer" aria-live="polite"></div>
  </iron-a11y-announcer></body></html>